

PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0097022P.	PR	2121	CCCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAATGTTGGTCTCCACCACTG	2180	
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.	PR	2653	CCCTTTCTCTCCCACTCTCTTGACACATTTTAATAAATAAGGCTTGGCTTCTGAACCTA	2712	
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.	PR	2181	NCTCCCAA	2240	
PR	02-JUN-1998;	98US-0087603P.	PR	26-AUG-1998;	98US-0097955P.	PR	2713	CAA	2772	
PR	02-JUN-1998;	98US-0087753P.	PR	26-AUG-1998;	98US-0097971P.	PR	QY	2241	AA 2242	
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0097974P.	PR	DB	2773	AA 2774	
PR	03-JUN-1998;	98US-0088025P.	PR	01-SEP-1998;	98US-0098014P.	PR	QY	2181	NCTCCCAA	2240
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098716P.	PR	DB	2713	CAA	2772
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098723P.	PR	QY	2181	NCTCCCAA	2240
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098803P.	PR	DB	2713	CAA	2772
PR	03-JUN-1998;	98US-0088202P.	PR	02-SEP-1998;	98US-0098821P.	PR	QY	2181	NCTCCCAA	2240
PR	05-JUN-1998;	98US-0088211P.	PR	02-SEP-1998;	98US-0098843P.	PR	DB	2713	CAA	2772
PR	05-JUN-1998;	98US-0088217P.	PR	09-SEP-1998;	98US-0099602P.	PR	QY	2181	NCTCCCAA	2240
PR	09-JUN-1998;	98US-0088653P.	PR	10-SEP-1998;	98US-0099741P.	PR	DB	2713	CAA	2772
PR	10-JUN-1998;	98US-0088738P.	PR	10-SEP-1998;	98US-0099754P.	PR	QY	2181	NCTCCCAA	2240
PR	10-JUN-1998;	98US-0088740P.	PR	10-SEP-1998;	98US-0099763P.	PR	DB	2713	CAA	2772
PR	10-JUN-1998;	98US-0088811P.	PR	10-SEP-1998;	98US-0099812P.	PR	QY	2181	NCTCCCAA	2240
PR	10-JUN-1998;	98US-0088824P.	PR	15-SEP-1998;	98US-0100388P.	PR	DB	2713	CAA	2772
PR	10-JUN-1998;	98US-0088825P.	PR	16-SEP-1998;	98US-0100662P.	PR	QY	2181	NCTCCCAA	2240
PR	11-JUN-1998;	98US-0088826P.	PR	16-SEP-1998;	98US-0100664P.	PR	DB	2713	CAA	2772
PR	11-JUN-1998;	98US-0088861P.	PR	16-SEP-1998;	98US-0101751P.	PR	QY	2181	NCTCCCAA	2240
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100683P.	PR	DB	2713	CAA	2772
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100684P.	PR	QY	2181	NCTCCCAA	2240
PR	12-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100919P.	PR	DB	2713	CAA	2772
PR	12-JUN-1998;	98US-0089090P.	PR	17-SEP-1998;	98US-0100930P.	PR	QY	2181	NCTCCCAA	2240
PR	16-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0100849P.	PR	DB	2713	CAA	2772
PR	16-JUN-1998;	98US-0089512P.	PR	18-SEP-1998;	98US-0101014P.	PR	QY	2181	NCTCCCAA	2240
PR	16-JUN-1998;	98US-0089514P.	PR	18-SEP-1998;	98US-0101068P.	PR	DB	2713	CAA	2772
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101471P.	PR	QY	2181	NCTCCCAA	2240
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101472P.	PR	DB	2713	CAA	2772
PR	17-JUN-1998;	98US-0089533P.	PR	23-SEP-1998;	98US-0101475P.	PR	QY	2181	NCTCCCAA	2240
PR	18-JUN-1998;	98US-0089908P.	PR	23-SEP-1998;	98US-0101477P.	PR	DB	2713	CAA	2772
PR	19-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101738P.	PR	QY	2181	NCTCCCAA	2240
PR	22-JUN-1998;	98								

PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087603P.
PR 02-JUN-1998; 98US-0087753P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090686P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.

PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTACCACCTCTTCCCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTTCTCCCATCTCTTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAAA 2240

Db 2713 CAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 701
ACF00491

us-10-036-342-56.rng

Wed Feb 16 11:37:55 2005

ID AC000491 standard; cDNA; 2846 BP.
XX AC000491;
XX DT 19-SEP-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003054456-A1.
XX PD 20-MAR-2003.
XX PF 27-JUN-2002; 2002US-00184638.
XX PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069435P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.

Db 2653 CCTTTCTCCCTCCCATCTCTGTACACATTTTAAATAAATAAGGGTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 703

ACF14567 standard; cDNA; 2846 BP.

AC ACF14567;

XX 02-OCT-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnerability; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003054457-A1.

XX 20-MAR-2003.

XX 01-JUL-2002; 2002US-00187752.

XX 05-APR-1999; 99US-0127706P.

PR 01-MAR-2000; 2000WO-US0005601.

PR 28-FEB-2001; 2001WO-US0005520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-540605/51.

DR P-PSDB; ABR93774.

XX New secreted and transmembrane polypeptides and nucleic acids encoding

PT the polypeptides, useful in gene therapy, in identifying chromosomes, as

PT chromosome markers, and in generating probes.

XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides

CC (ABR93690-93994) and nucleic acids encoding them (ACF14483-ACF14787). The

CC invention also relates to sequences at least 80% identical to the PRO

CC nucleic acid and polypeptide sequences of the invention, a recombinant

CC vectors and host cells comprising a PRO nucleic acid, a method for the

CC recombinant production of a PRO polypeptide, antibodies against a PRO

CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

CC acids encoding PRO polypeptides of the invention were initially

CC identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA

CC libraries containing sequences of interest were identified using

CC oligonucleotides based on the consensus sequences, and cDNA clones were

CC isolated and characterised. The PRO polypeptides are useful for

CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which

CC enhanced TNF-alpha release would be beneficial. They are also useful for

CC stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage

CC disorders such as arthritis and sports injuries. The PRO polypeptides may

CC be used in a method for detecting the presence of a tumour (e.g., an

CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate

CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

CC method involves comparing the level of expression of the PRO polypeptide

CC in test and control samples, where a higher level of expression of PRO

CC polypeptide in the test sample as compared to the control sample is

CC indicative of the presence of a tumour. The PRO polypeptides are

CC additionally useful for in drug screening to identify agonists and

CC antagonists of PRO polypeptides. PRO nucleic acids are useful as

CC hybridisation probes (for isolation of antisense RNA and DNA and in gene

CC gene mapping, in the generation of antisense RNA and DNA and in gene

CC therapy. The nucleic acids can also be used for mapping genes encoding

CC PRO polypeptides, for genetic analysis of individuals with genetic

CC disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of

CC therapeutically useful compounds. Sequences ACF14483-ACF14787 represent

CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the

CC invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Qy Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Db Best Local Similarity 71.3%; Pred. No. 0.00023;

Qy Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

2121 CCTTTCCTTTACACATCTCTTCTCTTTATCTTATTAATAAATGTTGGTCTCCACACTG 2180

2653 CCTTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGGTTGGCTTCTGAACCTA 2712

2181 NCTCCCAA 2240

2713 CAAAAAATAA 2772

2241 AA 2242

2773 AA 2774

RESULT 704

ACF22342

ID ACF22342 standard; cDNA; 2846 BP.

XX ACF22342;

XX 19-SEP-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnerability; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003059883-A1.

XX 27-MAR-2003.

XX 19-JUL-2002; 2002US-00199308.

XX 29-SEP-1998; 98US-0102331P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 28-FEB-2001; 2001WO-US0005520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-555482/52.
 DR P-PSDB; ABM01817.
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, or for preparing a medicament for treating a condition
 PT that is responsive to the PRO polypeptide or anti-PRO antibody.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX
 CC The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM01733-ABM02037) and nucleic acids encoding them (ACF22258-ACF22562).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF2258-ACF22562 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CTTTGTCTTACCACTCTTCTTTATCTATTATTAATAATGTGTCTCCACCACTG 2180
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2653 CTTTTCCTCCCATCTCTTGTCACACATTTTAATAATAAAGGTGGCTTCTGTA 2712
 Qy 2181 NCTCCAAAAA||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2713 CAAAAA||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Qy 2241 AA 2242
 Db 2773 AA 2774
 RESULT 705

ACF78919
 ID ACF78919 standard; cDNA; 2846 BP.
 XX
 AC ACF78919;
 XX
 DT 06-NOV-2003 (first entry)
 XX
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 DE
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnary; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003049764-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 18-JUL-2002; 2002US-00199665.
 XX
 PR 31-MAR-1998; 98US-0080194P.
 PR 08-MAR-1999; 99WO-US005028.
 PR 25-AUG-1999; 99US-00380138.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI; 2003-585113/55.
 P-PSDB; ABM78240.
 XX
 PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 CC
 CC The invention relates to human PRO secreted/transmembrane polypeptides
 CC and nucleic acids encoding them, the invention also provides recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF2258-ACF22562 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX

therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. The present sequence appears in the exemplification of the specification. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCCTTTTAATCTATTATAAAAAAGTTGCGTCTCCACCACCTG 2180
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 2653 CCITTTCTCTCCCACATCTCTGTACACATTTTAAATAAATGAAGGTTGGCTTCTGAACA 2712
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2181 NCTCCCCAAA 2240
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

DB 2713 CAIAA 2772
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2241 AA 2242
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

DB 2773 AA 2774
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 706
ACFL1640
ID ACFL1640 standard; cDNA; 2846 BP.

XX
AC FL1640;
XX
XX
XX 09-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX
FN US2003073177-A1.
XX
XX 17-APR-2003.
XX
XX 12-JUL-2002; 2002US-00194365.
PF
XX 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 98US-00254311.
PR 08-MAR-1999; 98WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.

PR	01-JUL-1998;	98US-0091360P.	PR	15-SEP-1999;	99WO-US021090.
PR	01-JUL-1998;	98US-0091544P.	PR	15-SEP-1999;	99WO-US021547.
PR	02-JUL-1998;	98US-0091478P.	PR	08-OCT-1999;	99US-0158663P.
PR	02-JUL-1998;	98US-0091519P.	PR	30-NOV-1999;	99WO-US028313.
PR	02-JUL-1998;	98US-0091626P.	PR	01-DEC-1999;	99WO-US028301.
PR	02-JUL-1998;	98US-0091628P.	PR	16-DEC-1999;	99WO-US028634.
PR	02-JUL-1998;	98US-0091633P.	PR	16-DEC-1999;	99WO-US030095.
PR	02-JUL-1998;	98US-0091646P.	PR	05-DEC-1999;	99WO-US030911.
PR	02-JUL-1998;	98US-0091673P.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-JUL-1998;	98US-0091878P.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-JUL-1998;	98US-0091982P.	PR	11-FEB-2000;	2000WO-US003565.
PR	09-JUL-1998;	98US-0092182P.	PR	18-FEB-2000;	2000WO-US004341.
PR	10-JUL-1998;	98US-0092472P.	PR	22-FEB-2000;	2000WO-US004414.
PR	20-JUL-1998;	98US-0093339P.	PR	24-FEB-2000;	2000WO-US004914.
PR	30-JUL-1998;	98US-0094651P.	PR	24-FEB-2000;	2000WO-US005004.
PR	04-AUG-1998;	98US-0095282P.	PR	02-MAR-2000;	2000WO-US005841.
PR	04-AUG-1998;	98US-0095285P.	PR	10-MAR-2000;	2000WO-US006319.
PR	04-AUG-1998;	98US-0095301P.	PR	15-MAR-2000;	2000WO-US006884.
PR	04-AUG-1998;	98US-0095302P.	PR	20-MAR-2000;	2000WO-US007377.
PR	04-AUG-1998;	98US-0095318P.	PR	30-MAR-2000;	2000WO-US008439.
PR	04-AUG-1998;	98US-0095321P.	PR	15-MAY-2000;	2000WO-US013358.
PR	04-AUG-1998;	98US-0095325P.	PR	17-MAY-2000;	2000WO-US013705.
PR	10-AUG-1998;	98US-0095916P.	PR	22-MAY-2000;	2000WO-US014042.
PR	10-AUG-1998;	98US-0095929P.	PR	30-MAY-2000;	2000WO-US014941.
PR	10-AUG-1998;	98US-0096012P.	PR	02-JUN-2000;	2000WO-US015264.
PR	11-AUG-1998;	98US-0096143P.	PR	23-JUN-2000;	2000US-0213637P.
PR	11-AUG-1998;	98US-0096146P.	PR	28-JUL-2000;	2000WO-US020710.
PR	12-AUG-1998;	98US-0096329P.	PR	11-AUG-2000;	2000WO-US022031.
PR	17-AUG-1998;	98US-0096757P.	PR	23-AUG-2000;	2000WO-US023522.
PR	17-AUG-1998;	98US-0096766P.	Query Match 3.0%; Score 66.6; DB 9; Length 2846;		
PR	17-AUG-1998;	98US-0096768P.	Best Local Similarity 71.3%; Pred. No. 0.00023;		
PR	17-AUG-1998;	98US-0096773P.	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
PR	17-AUG-1998;	98US-0096791P.			
PR	17-AUG-1998;	98US-0096867P.	QY	2121 CCTTTCCTTACACATCTTCTCTTTATCTTATTATATAAAATGTTGGTCTCCACACTG	2180
PR	17-AUG-1998;	98US-0096891P.	DB	2653 CCTTTCTCTCCCTCTCTTGTACACATTTTAAATAAAGGTTGCTTCTGACTA	2712
PR	17-AUG-1998;	98US-0096894P.	QY	2181 NCTCCCAA	2240
PR	17-AUG-1998;	98US-0096895P.	DB	2713 CAAA	2772
PR	17-AUG-1998;	98US-0096897P.	QY	2241 AA 2242	
PR	17-AUG-1998;	98US-0097022P.	DB	2773 AA 2774	
PR	19-AUG-1998;	98US-0097141P.	RESULT 708		
PR	20-AUG-1998;	98US-0097218P.	ACF51597		
PR	24-AUG-1998;	98US-0097661P.	ID	ACF51597 standard; cDNA; 2846 BP.	
PR	26-AUG-1998;	98US-0097952P.	XX	ACF51597;	
PR	26-AUG-1998;	98US-0097954P.	XX	07-OCT-2003 (first entry)	
PR	26-AUG-1998;	98US-0097955P.	DT	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
PR	26-AUG-1998;	98US-0097971P.	XX	Human; PRO; secreted protein; transmembrane protein;	
PR	26-AUG-1998;	98US-0097978P.	XX	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;	
PR	26-AUG-1998;	98US-0097979P.	XX	chondrocyte; proliferation; differentiation; cartilage disorder;	
PR	26-AUG-1998;	98US-0098014P.	XX	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;	
PR	31-AUG-1998;	98US-0098525P.	XX	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;	
PR	16-SEP-1998;	98US-0100634P.	XX	liver; drug screening; transgenic animal; genetic analysis;	
PR	16-SEP-1998;	98WO-US019330.	XX	antiarthritic; vulnery; gene therapy; gene; ss.	
PR	17-SEP-1998;	98WO-US019437.	OS	Homo sapiens.	
PR	17-SEP-1998;	98WO-US021141.	XX	US2003064442-A1.	
PR	07-OCT-1998;	98WO-US025108.	PN	03-APR-2003.	
PR	01-DEC-1998;	98US-0113296P.	PD	02-JUL-2002; 2002US-00187738.	
PR	22-DEC-1998;	99WO-US000106.	PF		
PR	05-JAN-1999;	99WO-US005028.	XX		
PR	08-MAR-1999;	99US-0123957P.	XX		
PR	12-MAR-1999;	99WO-US012252.	XX		
PR	02-JUN-1999;	99US-0141037P.	XX		
PR	07-JUL-1999;	99US-0143048P.	XX		
PR	20-JUL-1999;	99US-0144758P.	XX		
PR	26-JUL-1999;	99US-0145698P.	XX		
PR	28-JUL-1999;	99US-0146222P.	XX		
PR	17-AUG-1999;	99US-0149396P.	XX		


```
PR 29-SEP-1998; 98US-0102240P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PL, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-596615/56.
DR P-PSDB; ABM27555.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for diagnosing, preventing and/or treating tumors, such as
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM27471-ABM27775) and nucleic acids encoding them (ACF51513-ACF51817).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterized. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF51513-ACF51817 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CTTTGGCTTACCACTCTCTTCCTTTATCTATTATAAATAATGTGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2181 NCTCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
```

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 709

ACF33520

ID ACF33520 standard; cDNA; 2846 BP.

AC ACF33520;

XX 23-SEP-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003064450-A1.

XX 03-APR-2003.

XX 16-JUL-2002; 2002US-00196744.

XX 30-OCT-1998; 98US-0106464P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 18-FEB-2000; 2000WO-US004342.

XX 24-AUG-2000; 2000WO-US023328.

XX 01-DEC-2000; 2000WO-US032678.

XX 28-FEB-2001; 2001WO-US006520.

XX 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-596615/56.

XX P-PSDB; ABM13156.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.,
XX cancer.

Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides
XX and nucleic acids encoding them, the invention also provides recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterized. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may

OS	Homo sapiens.
XX	
XX	US2003068731-A1.
XX	
XX	10-APR-2003.
XX	
XX	18-JUL-2002; 2002US-00199667.
PF	
XX	
PR	17-DEC-1997; 97US-0069870P.
PR	01-DEC-1998; 98WO-US025108.
PR	03-MAR-1999; 99US-00254311.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	
XX	(GETH) GENENTECH INC.
PA	
XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI	
XX	

RESULT 711	
ACF37555	
ID	ACF37555 standard; cDNA; 2846 BP.
XX	
XX	ACF37555;
XX	
XX	AC
XX	AC
XX	
XX	07-OCT-2003 (first entry)
XX	
XX	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE	
XX	
XX	Human; PRO; secreted protein; transmembrane protein;
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; proliferation; differentiation; cartilage disorder;
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW	liver; drug screening; transgenic animal; genetic analysis;
KW	antiarthritic; vulnuary; gene therapy; gene; ss.
XX	
XX	
OS	Homo sapiens.

XX US2003068683-A1.
PN 10-APR-2003.
XX 27-JUN-2002; 2002US-00184633.
XX 18-SEP-1997; 97US-0059263P.
PR 17-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069333P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098803P.

PR	02-SEP-1998;	98US-0098821P.	OS	Homo sapiens.
PR	02-SEP-1998;	98US-0098843P.	XX	
PR	03-SEP-1998;	98US-0099602P.	PN	US2003068754-A1.
PR	10-SEP-1998;	98US-0099741P.	XX	
PR	10-SEP-1998;	98US-0099754P.	PD	10-APR-2003.
PR	10-SEP-1998;	98US-0099763P.	XX	
PR	10-SEP-1998;	98US-0099812P.	PF	26-JUL-2002; 2002US-00206910.
PR	12-SEP-1998;	98US-0100388P.	XX	
PR	12-SEP-1998;	98US-0100662P.	PR	21-MAR-2000; 2000US-0191314P.
PR	16-SEP-1998;	98US-0100864P.	PR	28-FEB-2001; 2001WO-US006520.
PR	16-SEP-1998;	98US-0101751P.	PR	15-JAN-2002; 2002US-00052586.
PR	16-SEP-1998;	98WO-US019330.	XX	
PR	17-SEP-1998;	98US-0100683P.	PA	(GETH) GENENTECH INC.
PR	17-SEP-1998;	98US-0100684P.	XX	
PR	17-SEP-1998;	98US-0100919P.	PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PR	17-SEP-1998;	98US-0100930P.	PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PR	18-SEP-1998;	98US-0100849P.	XX	
PR	18-SEP-1998;	98US-0101014P.	DR	WPI; 2003-615901/58.
PR	18-SEP-1998;	98US-0101068P.	DR	P-PSDB; ABM08276.
PR	23-SEP-1998;	98US-0101471P.	XX	
PR	23-SEP-1998;	98US-0101472P.	PT	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
PR	23-SEP-1998;	98US-0101475P.	PT	PRO827, useful in molecular biology, chromosome and gene mapping, in
PR	23-SEP-1998;	98US-0101477P.	PT	generating antisense RNA and DNA, and in gene therapy.
PR	24-SEP-1998;	98US-0101738P.	XX	
PR	24-SEP-1998;	98US-0101739P.	PS	Claim 2; Fig 169; 700pp; English.
PR	24-SEP-1998;	98US-0101743P.	XX	
PR	24-SEP-1998;	98US-0101922P.	CC	The invention relates to human PRO secreted/transmembrane polypeptides
PR	25-SEP-1998;	98US-0101786P.	CC	(ABM08192-ABM08496) and nucleic acids encoding them (ACF28456-ACF28760).
PR	29-SEP-1998;	98US-0102207P.	CC	The invention also relates to sequences at least 80% identical to the PRO
PR	29-SEP-1998;	98US-0102240P.	CC	nucleic acid and polypeptide sequences of the invention, recombinant
PR	29-SEP-1998;	98US-0102330P.	CC	vectors and host cells comprising a PRO nucleic acid, a method for the
PR	29-SEP-1998;	98US-0102331P.	CC	recombinant production of a PRO polypeptide, antibodies against a PRO
PR	30-SEP-1998;	98US-0102487P.	CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
PR	30-SEP-1998;	98US-0102570P.	CC	acids encoding PRO polypeptides of the invention were initially
PR	30-SEP-1998;	98US-0102571P.	CC	identified via homology screening using consensus sequences based on the
PR	01-OCT-1998;	98US-0102684P.	CC	extracellular domain sequences from known secreted proteins. Human cDNA
PR	01-OCT-1998;	98US-0102687P.	CC	libraries containing sequences of interest were identified using
			CC	oligonucleotides based on the consensus sequences, and cDNA clones were
			CC	isolated and characterised. The PRO polypeptides are useful for
			CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
			CC	human blood and may thus be used in the treatment of conditions in which
			CC	enhanced TNF-alpha release would be beneficial. They are also useful for
			CC	stimulating the proliferation or differentiation of chondrocytes and as
			CC	disorders such as arthritis and sports injuries. The PRO polypeptides may
			CC	be used in a method for detecting the presence of a tumour (e.g., an
			CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
			CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
			CC	method involves comparing the level of expression of the PRO polypeptide
			CC	in test and control samples, where a higher level of expression of PRO
			CC	polypeptide in the test sample as compared to the control sample is
			CC	indicative of the presence of a tumour. The PRO polypeptides are
			CC	additionally useful for in drug screening to identify agonists and
			CC	antagonists of PRO polypeptides. PRO nucleic acids are useful as
			CC	hybridisation probes for isolation of cDNA molecules), in chromosome and
			CC	gene mapping, in the generation of antisense RNA and DNA and in gene
			CC	therapy. The nucleic acids can also be used for mapping genes encoding
			CC	PRO polypeptides, for genetic analysis of individuals with genetic
			CC	disorders, and for generating either transgenic animals or knock-out
			CC	animals which are useful in the development and screening of
			CC	therapeutically useful compounds. Sequences ACF28456-ACF28760 represent
			CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
			CC	invention. Note: The sequence data for this patent is also available in
			CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html
			CC	
			XX	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
			SQ	
				Query Match 3.0%; Score 66.6; DB 9; Length 2846;
				Best Local Similarity 71.3%; Pred. No. 0.00023;
				Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY	2121	CGTTTGGTTTACCACTCTTCTTTATCTATTATTAATAAATGTTGCTCTCCACCACTG 2180		
Db	2653	CGTTTCTCTCCCACTCTTGTACACATTTTATAAATAGCGTTGGCTCTCGACTA 2712		
QY	2181	NCTCCCAAA 2240		
Db	2713	CAA 2772		
QY	2241	AA 2242		
Db	2773	AA 2774		
				RESULT 712
				ACF28540
ID		ACF28540 standard; cDNA; 2846 BP.		
XX				
AC		ACF28540;		
XX				
DT		20-SEP-2003 (first entry)		
XX				
DE		Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		
XX				
KW		Human; PRO; secreted protein; transmembrane protein;		
KW		extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		
KW		chondrocyte; proliferation; differentiation; cartilage disorder;		
KW		bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;		
KW		adrenal tumour; lung; colon; breast; prostate; kidney; rectum;		
KW		liver; drug screening; transgenic animal; genetic analysis;		
XX		antiarthritic; vulnery; gene therapy; gene; ss.		

enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF75151-ACF75455 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTATTAATAAATGTTGGTCCACACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAATGAGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAAAAATAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 715

ACF61056
ID ACF61056 standard; cDNA; 2846 BP.
XX ACF61056;
AC ACF61056;
XX 10-OCT-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003096358-A1.
XX 22-MAY-2003.
PD 24-JUL-2002; 2002US-00202941.
PF 29-SEP-1998; 98US-0102240P.
XX 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.

PR 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PU, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-670131/63.
DR P-PSDB; ABM33776.

Three hundred and five nucleic acids encoding PRO polypeptides, useful for the manufacture of a medicament for diagnosing or treating tumor or for tissue typing.

Claim 2; Fig 169; 706pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides (ABM33692-ABM33996) and nucleic acids encoding them (ACF60972-ACF61276). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF60972-ACF61276 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTATTAATAAATGTTGGTCCACACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAATGAGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAAAAATAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF4128-ACF4432 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTGGTCTCCACACATG 2180
DB 2653 CTTTTCCTTCCCATCTCTTGTCACACATTTTATAATAAATAAGGCTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAA 2240
DB 2713 CAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 717
ACH08454
ID ACH08454 standard; cDNA; 2846 BP.
XX ACH08454;
XX ACH08454;
DT 10-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
XX Homo sapiens.
XX US2003049756-A1.
XX 13-MAR-2003.
XX 19-JUL-2002; 2002US-00198768.
XX 26-JUN-1998; 98US-00105413.
XX 16-SEP-1998; 98WO-US019330.
XX 07-OCT-1998; 98US-00168978.
XX 07-OCT-1998; 98WO-US021141.
XX 06-NOV-1998; 98US-00187368.
XX 01-DEC-1998; 98WO-US025108.
XX 07-DEC-1998; 98US-00202054.
XX 03-MAR-1999; 99US-00254311.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 01-SEP-1999; 99WO-US020111.
XX 15-SEP-1999; 99WO-US021090.
XX 18-OCT-1999; 99US-00403297.

CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF4128-ACF4432 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTGGTCTCCACACATG 2180
DB 2653 CTTTTCCTTCCCATCTCTTGTCACACATTTTATAATAAATAAGGCTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAA 2240
DB 2713 CAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 717
ACH08454
ID ACH08454 standard; cDNA; 2846 BP.
XX ACH08454;
XX ACH08454;
DT 10-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
XX Homo sapiens.
XX US2003104556-A1.
XX 05-JUN-2003.
XX 26-JUL-2002; 2002US-00206918.
XX 05-JUN-2000; 2000US-0209832P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-670251/63.
XX P-PSDB; ABM20235.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
XX colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM20151-ABM20455) and nucleic acids encoding them (ACF4128-ACF4432).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX indicative of the presence of a tumour. The PRO polypeptides are
XX additionally useful for in drug screening to identify agonists and

PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000WO-US064484.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019632.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918595.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard AL, Godowski PJ;
XX Gurney AL, Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-677930/64.
DR P-PSDB; ABO48727.

PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT colon, breast, prostate, rectal, cervical or liver tumors.

XX Claim 2; Fig 169; 701pp; English.

XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for

CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGGCTTTACCACTCTTTCTTTATCTATTATAAATAATGTTGCTCCACCACTG 2180

DB 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAATAATGAGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAA 2240

DB 2713 CAAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 718

ID ACD39420 standard; DNA; 2846 BP.

XX AC ACD39420;

XX 04-SEP-2003 (first entry)

XX Human PRO 1344 PCR primer #1.

XX Human; ss; PRO; secreted protein; transmembrane protein; antidiabetic;
XX cytosolic; antirheumatic; antiarthritic; antiulcer; neuroprotective;
XX antiinflammatory; antibacterial; immunosuppressive; gene therapy;
XX diabetes; cancer; rheumatoid arthritis; ulcers;
XX amyotrophic lateral sclerosis; inflammatory condition; septic shock.

XX Homo sapiens.

XX US2003017982-A1.

XX 23-JAN-2003.

XX 16-NOV-2001; 2001US-00990441.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WO-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066770P.

XX 25-FEB-1998; 98US-0075945P.

XX 20-MAR-1998; 98US-0078910P.

XX 28-APR-1998; 98US-0083322P.

XX 07-MAY-1998; 98US-0084600P.

XX 28-MAY-1998; 98US-0087106P.

XX 02-JUN-1998; 98US-0087607P.

XX 02-JUN-1998; 98US-0087609P.

XX 02-JUN-1998; 98US-0087759P.

XX 03-JUN-1998; 98US-0087827P.

XX 04-JUN-1998; 98US-0088021P.

XX 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088036P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 16-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0113296P.
PR 01-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0123957P.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0123957P.
PR 23-JUN-1999; 98US-014037P.
PR 07-JUL-1999; 98US-014037P.
PR 20-JUL-1999; 98US-014037P.
PR 20-JUL-1999; 98US-014037P.
PR 26-JUL-1999; 98US-014037P.
PR 28-JUL-1999; 98US-014037P.
PR 17-AUG-1999; 98US-014037P.
PR 15-SEP-1999; 98US-014037P.
PR 15-SEP-1999; 98US-014037P.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 16-DEC-1999; 98US-0158663P.
PR 16-DEC-1999; 98US-0158663P.
PR 20-DEC-1999; 98US-0158663P.
PR 05-JAN-2000; 98US-0158663P.
PR 06-JAN-2000; 98US-0158663P.
PR 11-FEB-2000; 98US-0158663P.
PR 18-FEB-2000; 98US-0158663P.
PR 22-FEB-2000; 98US-0158663P.
PR 24-FEB-2000; 98US-0158663P.

PR	17-JUN-1998;	98US-0089598P;
PR	17-JUN-1998;	98US-0089653P;
PR	18-JUN-1998;	98US-0089908P;
PR	19-JUN-1998;	98US-0089952P;
PR	21-JUN-1998;	98US-0090246P;
PR	22-JUN-1998;	98US-0090252P;
PR	22-JUN-1998;	98US-0090254P;
PR	24-JUN-1998;	98US-0090429P;
PR	24-JUN-1998;	98US-0090435P;
PR	24-JUN-1998;	98US-0090444P;
PR	24-JUN-1998;	98US-0090461P;
PR	25-JUN-1998;	98US-0090535P;
PR	25-JUN-1998;	98US-0090540P;
PR	25-JUN-1998;	98US-0090676P;
PR	25-JUN-1998;	98US-0090678P;
PR	25-JUN-1998;	98US-0090688P;
PR	25-JUN-1998;	98US-0090690P;
PR	25-JUN-1998;	98US-0090694P;
PR	25-JUN-1998;	98US-0090695P;
PR	25-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-0090862P;
PR	26-JUN-1998;	98US-0090863P;
PR	26-JUN-1998;	98US-0091010P;
PR	01-JUL-1998;	98US-0091355P;
PR	01-JUL-1998;	98US-0091359P;
PR	02-JUL-1998;	98US-0091478P;
PR	02-JUL-1998;	98US-0091486P;
PR	02-JUL-1998;	98US-0091626P;
PR	02-JUL-1998;	98US-0091628P;
PR	02-JUL-1998;	98US-0091632P;
PR	04-JUL-1998;	98US-0094006P;
PR	04-AUG-1998;	98US-0095282P;
PR	10-AUG-1998;	98US-0095998P;
PR	10-AUG-1998;	98US-0096012P;
PR	10-AUG-1998;	98US-0096012P;
PR	17-AUG-1998;	98US-0096757P;
PR	17-AUG-1998;	98US-0096766P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096897P;
PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;
PR	18-AUG-1998;	98US-0096959P;
PR	18-AUG-1998;	98US-0097022P;
PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;
PR	26-AUG-1998;	98US-0097955P;
PR	26-AUG-1998;	98US-0097971P;
PR	26-AUG-1998;	98US-0097974P;
PR	26-AUG-1998;	98US-0098014P;
PR	01-SEP-1998;	98US-0098716P;
PR	01-SEP-1998;	98US-0098723P;
PR	02-SEP-1998;	98US-0098803P;
PR	02-SEP-1998;	98US-0098821P;
PR	09-SEP-1998;	98US-0098843P;
PR	10-SEP-1998;	98US-0098960P;
PR	10-SEP-1998;	98US-0099741P;
PR	10-SEP-1998;	98US-0099754P;
PR	10-SEP-1998;	98US-0099763P;
PR	10-SEP-1998;	98US-0099812P;
PR	15-SEP-1998;	98US-0100389P;
PR	16-SEP-1998;	98US-0100662P;
PR	16-SEP-1998;	98US-0100664P;
PR	16-SEP-1998;	98US-0100751P;
PR	16-SEP-1998;	98US-0100751P;
PR	17-SEP-1998;	98US-0100683P;
PR	17-SEP-1998;	98US-0100684P;
PR	17-SEP-1998;	98US-0100919P;
PR	17-SEP-1998;	98US-0100930P;
PR	18-SEP-1998;	98US-0100849P;
PR	18-SEP-1998;	98US-0101014P;
PR	18-SEP-1998;	98US-0101068P;
PR	23-SEP-1998;	98US-0101471P;
PR	23-SEP-1998;	98US-0101472P;

PR 25-AUG-1999; 99US-00380142.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US021090.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 01-DEC-1999; 99WO-US028301.
 PR 30-DEC-1999; 99WO-US028551.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00866028.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 30-JUL-2001; 2001US-00918585.
 PR 06-AUG-2001; 2001US-00924419.
 PR 13-AUG-2001; 2001US-00929404.
 PR 16-AUG-2001; 2001US-00931836.
 PR 28-AUG-2001; 2001US-00941992.
 PR 29-AUG-2001; 2001WO-US027099.
 PR 04-SEP-2001; 2001US-00946374.
 PR 15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PU, Gurney AL;
 Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-479637/45.
 P-PSDB; ABO15434.

New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 in gene therapy, chromosome identification, tissue typing, or as
 hybridization probes in chromosome and gene mapping.

Claim 2; Fig 169; 707pp; English.

The invention discloses human nucleic acids encoding secreted and
 transmembrane (PRO) polypeptides, with or without their associated signal
 peptide. Also disclosed is an antibody that specifically binds to the PRO
 polypeptide. A method for stimulating the release of tumour necrosis
 factor alpha (TNF-alpha) from human blood by contacting the blood with a
 PRO polypeptide, a method for stimulating the proliferation or
 differentiation of chondrocyte cells by contacting the cells with a PRO
 polypeptide, a method for detecting the presence of a tumour in a mammal
 and an oligonucleotide probe derived from any of the PRO nucleotide

CC sequences. The nucleotide sequences are useful as probes, in chromosome
 and gene mapping, in generating antisense RNA and DNA, in preparing PRO
 CC polypeptides by recombinant techniques and in gene therapy (e.g. for
 CC replacement of defective gene). The PRO polypeptides are useful as
 CC molecular weight markers for protein electrophoresis purposes, for
 CC chromosome identification, as chromosome markers, as therapeutic agents,
 CC for stimulating the release of TNF-alpha from human blood, for
 CC stimulating the proliferation or differentiation of chondrocytes and
 CC detecting the presence, prevention and/or treatment of a tumour, such as
 CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
 CC The PRO polypeptides and nucleic acids may also be used diagnostically
 CC for tissue typing. The sequence presented is a cDNA encoding one of the
 CC PRO polypeptides of the invention. Note: The sequence data for this
 CC patent can also be obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTTATTAATAAATGTGTCTCCACACTG 2180
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2653 CCTTTCTCTCCCATCTCTTGTACACATTTTATAAATAAGGCTTGGCTTCTGAAC 2712
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 QY 2181 NCTCCCAA 2240
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2713 CAAA 2772
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 QY 2241 AA 2242
 |||||
 Db 2773 AA 2774

RESULT 721

ACF06728

ID ACF06728 standard; cDNA; 2846 BP.

AC ACF06728;

XX 13-SEP-2003 (first entry)

Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

Human; PRO; secreted protein; transmembrane protein;
 extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 chondrocyte; proliferation; differentiation; cartilage disorder;
 bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 liver; drug screening; transgenic animal; genetic analysis;
 antiarthritic; vulnery; gene therapy; gene; ss.

OS Homo sapiens.

PN US2003040065-A1.

XX 27-FEB-2003.

PF 26-JUN-2002; 2002US-00183017.

XX 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066146P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 17-DEC-1997; 97US-0069425P.
PR 18-DEC-1997; 97US-0069870P.
PR 10-MAR-1998; 97US-0068017P.
PR 11-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 20-MAR-1998; 98US-0077886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 03-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.

PR	21-NOV-1997;	97US-00661200
PR	24-NOV-1997;	97US-00664566
PR	24-NOV-1997;	97US-0066772P
PR	11-DEC-1997;	97US-0069335P
PR	12-DEC-1997;	97US-0069425P
PR	12-DEC-1997;	97US-0069870P
PR	18-DEC-1997;	97US-0068017P
PR	10-MAR-1998;	98US-0077450P
PR	11-MAR-1998;	98US-0077632P
PR	11-MAR-1998;	98US-0077649P
PR	20-MAR-1998;	98US-0078086P
PR	27-MAR-1998;	98US-0078393P
PR	27-MAR-1998;	98US-0079564P
PR	27-MAR-1998;	98US-0079786P
PR	31-MAR-1998;	98US-0080107P
PR	31-MAR-1998;	98US-0080194P
PR	01-APR-1998;	98US-0080327P
PR	01-APR-1998;	98US-0080333P
PR	08-APR-1998;	98US-0081049P
PR	08-APR-1998;	98US-0081070P
PR	09-APR-1998;	98US-0081195P
PR	15-APR-1998;	98US-0081838P
PR	21-APR-1998;	98US-0082568P
PR	22-APR-1998;	98US-0082569P
PR	22-APR-1998;	98US-0082704P
PR	28-APR-1998;	98US-0082797P
PR	28-APR-1998;	98US-0083322P
PR	29-APR-1998;	98US-0083495P
PR	29-APR-1998;	98US-0083496P
PR	29-APR-1998;	98US-0083499P
PR	29-APR-1998;	98US-0083559P
PR	05-MAY-1998;	98US-0084366P
PR	06-MAY-1998;	98US-0084414P
PR	07-MAY-1998;	98US-0084639P
PR	07-MAY-1998;	98US-0084640P
PR	15-MAY-1998;	98US-0084643P
PR	15-MAY-1998;	98US-0085579P
PR	15-MAY-1998;	98US-0085580P
PR	15-MAY-1998;	98US-0085582P
PR	15-MAY-1998;	98US-0085700P
PR	18-MAY-1998;	98US-0086023P
PR	22-MAY-1998;	98US-0086392P
PR	22-MAY-1998;	98US-0086486P
PR	28-MAY-1998;	98US-0087098P
PR	28-MAY-1998;	98US-0087208P
PR	02-JUN-1998;	98US-0087609P
PR	02-JUN-1998;	98US-0087759P
PR	03-JUN-1998;	98US-0087827P
PR	04-JUN-1998;	98US-0088025P
PR	04-JUN-1998;	98US-0088028P
PR	04-JUN-1998;	98US-0088029P
PR	04-JUN-1998;	98US-0088033P
PR	04-JUN-1998;	98US-0088326P
PR	05-JUN-1998;	98US-0088167P
PR	05-JUN-1998;	98US-0088202P
PR	05-JUN-1998;	98US-0088212P
PR	05-JUN-1998;	98US-0088217P
PR	09-JUN-1998;	98US-0088655P
PR	10-JUN-1998;	98US-0088722P
PR	10-JUN-1998;	98US-0088738P
PR	10-JUN-1998;	98US-0088740P
PR	10-JUN-1998;	98US-0088811P
PR	10-JUN-1998;	98US-0088824P
PR	10-JUN-1998;	98US-0088825P
PR	11-JUN-1998;	98US-0088826P
PR	11-JUN-1998;	98US-0088861P
PR	11-JUN-1998;	98US-0088863P
PR	11-JUN-1998;	98US-0088876P
PR	12-JUN-1998;	98US-0089090P
PR	12-JUN-1998;	98US-0089105P
PR	16-JUN-1998;	98US-0089315P
PR	16-JUN-1998;	98US-0089314P
PR	17-JUN-1998;	98US-0089538P

```
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090522P.
PR 22-JUN-1998; 98US-0090524P.
PR 22-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090335P.
PR 25-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0099812P.
PR 16-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0103571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0103571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTTACCACTCTTTCTCTTTTATCTATTATAAAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGACTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
DB 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 723
ACD22788
ID ACD22788 standard; cDNA; 2846 BP.
XX AC ACD22788;
XX DT 25-AUG-2003 (first entry)
XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX OS Homo sapiens.
XX PN US2003040077-A1.
XX PD 27-FEB-2003.
XX PF 16-JUL-2002; 2002US-00196745.
XX PR 18-SEP-1997; 97US-0059263P.
XX PR 18-SEP-1997; 97US-0059266P.
XX PR 18-SEP-1997; 97US-0062250P.
XX PR 21-OCT-1997; 97US-0063486P.
XX PR 24-OCT-1997; 97US-0063120P.
XX PR 24-OCT-1997; 97US-0063121P.
XX PR 28-OCT-1997; 97US-0063540P.
XX PR 28-OCT-1997; 97US-0063541P.
XX PR 28-OCT-1997; 97US-0063544P.
XX PR 28-OCT-1997; 97US-0063564P.
XX PR 29-OCT-1997; 97US-0063734P.
XX PR 31-OCT-1997; 97US-0063870P.
XX PR 31-OCT-1997; 97US-0064103P.
```


PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069333P.
PR 12-DEC-1997; 97US-0069423P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078933P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083493P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087603P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088653P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089103P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.

```
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CTTTGGTTTACCACTCTTCTTTTATCTTATTAATAAAAGTTGGTCTCCACCACTG 2180
Db 2653 CTTTTCCTTCCCATCTCTGTACACATTTTATAATAAATGAGGTGGTCTCTGAAC 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 724
ACF41488
ID ACF41488 standard; cDNA; 2846 BP.
XX AC ACF41488;
XX DT 06-NOV-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US200304928-A1.
XX PD 06-MAR-2003.
XX PF 28-JUN-2002; 2002US-00184620.
XX PF 18-SEP-1997; 97US-0059263P.
XX PF 18-SEP-1997; 97US-0059266P.
XX PF 17-OCT-1997; 97US-0062250P.
XX PF 21-OCT-1997; 97US-0063486P.
XX PF 24-OCT-1997; 97US-0063120P.
XX PF 24-OCT-1997; 97US-0063120P.
XX PF 28-OCT-1997; 97US-0063540P.
XX PF 28-OCT-1997; 97US-0063541P.
XX PF 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081938P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
```

PR	12-JUN-1998,	98US-00890908,
PR	12-JUN-1998,	98US-00891052P,
PR	16-JUN-1998,	98US-00895112P,
PR	16-JUN-1998,	98US-00895141P,
PR	17-JUN-1998,	98US-0089538P,
PR	17-JUN-1998,	98US-0089538P,
PR	17-JUN-1998,	98US-0089598P,
PR	17-JUN-1998,	98US-00896533P,
PR	18-JUN-1998,	98US-0089908P,
PR	19-JUN-1998,	98US-0089952P,
PR	21-JUN-1998,	98US-0090246P,
PR	22-JUN-1998,	98US-0090252P,
PR	22-JUN-1998,	98US-0090254P,
PR	24-JUN-1998,	98US-0090429P,
PR	24-JUN-1998,	98US-0090435P,
PR	24-JUN-1998,	98US-0090444P,
PR	24-JUN-1998,	98US-0090461P,
PR	24-JUN-1998,	98US-0090535P,
PR	24-JUN-1998,	98US-0090540P,
PR	25-JUN-1998,	98US-0090676P,
PR	25-JUN-1998,	98US-0090678P,
PR	25-JUN-1998,	98US-0090688P,
PR	25-JUN-1998,	98US-0090690P,
PR	25-JUN-1998,	98US-0090694P,
PR	25-JUN-1998,	98US-0090695P,
PR	25-JUN-1998,	98US-0090696P,
PR	26-JUN-1998,	98US-009105413,
PR	26-JUN-1998,	98US-009105413,
PR	26-JUN-1998,	98US-0090862P,
PR	26-JUN-1998,	98US-0090863P,
PR	26-JUN-1998,	98US-0091010P,
PR	01-JUL-1998,	98US-0091359P,
PR	01-JUL-1998,	98US-0091544P,
PR	02-JUL-1998,	98US-0091478P,
PR	02-JUL-1998,	98US-0091486P,
PR	02-JUL-1998,	98US-0091626P,
PR	02-JUL-1998,	98US-0091628P,
PR	02-JUL-1998,	98US-0091632P,
PR	24-JUL-1998,	98US-0094006P,
PR	04-AUG-1998,	98US-0095282P,
PR	10-AUG-1998,	98US-0095990P,
PR	10-AUG-1998,	98US-0096012P,
PR	17-AUG-1998,	98US-0096757P,
PR	17-AUG-1998,	98US-0096766P,
PR	17-AUG-1998,	98US-0096867P,
PR	17-AUG-1998,	98US-0096891P,
PR	17-AUG-1998,	98US-0096897P,
PR	18-AUG-1998,	98US-0096949P,
PR	18-AUG-1998,	98US-0096953P,
PR	18-AUG-1998,	98US-0096955P,
PR	26-AUG-1998,	98US-00975022P,
PR	26-AUG-1998,	98US-0097522P,
PR	26-AUG-1998,	98US-0097954P,
PR	26-AUG-1998,	98US-0097955P,
PR	26-AUG-1998,	98US-0097971P,
PR	26-AUG-1998,	98US-0097974P,
PR	26-AUG-1998,	98US-0098014P,
PR	01-SEP-1998,	98US-0098716P,
PR	01-SEP-1998,	98US-0098723P,
PR	02-SEP-1998,	98US-0098803P,
PR	02-SEP-1998,	98US-0098821P,
PR	02-SEP-1998,	98US-0098843P,
PR	09-SEP-1998,	98US-00996022P,
PR	10-SEP-1998,	98US-0099741P,
PR	10-SEP-1998,	98US-009754P,
PR	10-SEP-1998,	98US-0097563P,
PR	10-SEP-1998,	98US-0098812P,
PR	15-SEP-1998,	98US-0100388P,
PR	16-SEP-1998,	98US-0100662P,
PR	16-SEP-1998,	98US-0100664P,
PR	16-SEP-1998,	98US-0101751P,
PR	16-SEP-1998,	98WO-U019330,
PR	17-SEP-1998,	98US-0100683P,
PR	17-SEP-1998,	98US-0100684P,
PR	17-SEP-1998,	98US-0100919P,
PR	17-SEP-1998,	98US-0100930P,

PR	18-SEP-1998;	98US-01100849P
PR	18-SEP-1998;	98US-01101014P
PR	18-SEP-1998;	98US-01101068P
PR	23-SEP-1998;	98US-01101471P
PR	23-SEP-1998;	98US-01101472P
PR	23-SEP-1998;	98US-01101475P
PR	23-SEP-1998;	98US-01101477P
PR	24-SEP-1998;	98US-01101738P
PR	24-SEP-1998;	98US-01101739P
PR	24-SEP-1998;	98US-01101743P
PR	25-SEP-1998;	98US-01101932P
PR	25-SEP-1998;	98US-01101786P
PR	29-SEP-1998;	98US-01022040P
PR	29-SEP-1998;	98US-01022070P
PR	29-SEP-1998;	98US-01023310P
PR	29-SEP-1998;	98US-01023331P
PR	30-SEP-1998;	98US-01024487P
PR	30-SEP-1998;	98US-01025707P
PR	30-SEP-1998;	98US-01102571P
PR	01-OCT-1998;	98US-01102684P
PR	01-OCT-1998;	98US-01102687P

	Query Match	3.0%	Score 66.6;	DB 9;	Length 2846;
	Best Local Similarity	71.3%;	Pred. No. 0.00023;		
	Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;
Qy	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTGGTCTCCACCACCTG	2180		
Db	2653	CCTTTTCTTTCCCATCTCTCTGTACACATTTTAAATAAATAGGGTGGCTTCTGAACATA	2712		
Qy	2181	NCTCCCAA	2240		
Db	2713	CAAA	2772		

RESULT 725

ADA06519
ID ADA06519 standard; cDNA; 2846 BP.

XX
AC
ADA06519:XX
DT 29-JAN-2004 (revised)

DT	06-NOV-2003	(first entry)
DI	23-OCT-2004	(revised)

XX

DE Human secreted/transmembrane PRO polypeptide cDNA #65.

ss; gene; human; tissue typing; cardiac insufficiency disorder;
angiogenesis; wound healing; tumour; immune response; retinal disorder;
retinal injury; sight loss; age-related macular degeneration; AMD;
kidney disorder; mesangial cell function; Berger disease; nephropathy;
dermatitis; herpeticiform; Crohn's disease; sports injury; arthritis

OS Homo sapiens.

PN US2003049638-A1.

PD 13-MAR-2003.

16-NOV-2001; 2001US-00991157.

PR 16-JUN-1997; 97US-0049787P.

PR 05-NOV-1997; 97WO-US020069;

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1999; 99US-007591EP

EX 23-FEB-1998; 580S-0073543E;
PR 20-MAR-1998; 98US-0078910P;

PR 28-APR-1998; 98US-0083322P.

PR	02-JUL-1998;	98US-00916333P
PR	02-JUL-1998;	98US-0091664P
PR	02-JUL-1998;	98US-00916673P
PR	02-JUL-1998;	98US-0091978P
PR	07-JUL-1998;	98US-00919822P
PR	07-JUL-1998;	98US-00921832P
PR	09-JUL-1998;	98US-0092472P
PR	10-JUL-1998;	98US-0093339P
PR	20-JUL-1998;	98US-00934651P
PR	30-JUL-1998;	98US-00952822P
PR	04-AUG-1998;	98US-00952853P
PR	04-AUG-1998;	98US-0095301P
PR	04-AUG-1998;	98US-00953302P
PR	04-AUG-1998;	98US-0095318P
PR	04-AUG-1998;	98US-0095321P
PR	04-AUG-1998;	98US-0095325P
PR	04-AUG-1998;	98US-0095916P
PR	10-AUG-1998;	98US-0095923P
PR	10-AUG-1998;	98US-0096012P
PR	11-AUG-1998;	98US-0096146P
PR	11-AUG-1998;	98US-0096329P
PR	13-AUG-1998;	98US-0096413P
PR	13-AUG-1998;	98US-0096757P
PR	17-AUG-1998;	98US-0096766P
PR	17-AUG-1998;	98US-0096768P
PR	17-AUG-1998;	98US-0096773P
PR	17-AUG-1998;	98US-0096791P
PR	17-AUG-1998;	98US-0096867P
PR	17-AUG-1998;	98US-0096891P
PR	17-AUG-1998;	98US-0096894P
PR	17-AUG-1998;	98US-0096895P
PR	17-AUG-1998;	98US-0096897P
PR	18-AUG-1998;	98US-0096949P
PR	18-AUG-1998;	98US-0096950P
PR	18-AUG-1998;	98US-0096959P
PR	18-AUG-1998;	98US-0096960P
PR	18-AUG-1998;	98US-0097022P
PR	19-AUG-1998;	98US-0097141P
PR	20-AUG-1998;	98US-0097218P
PR	24-AUG-1998;	98US-00979661P
PR	26-AUG-1998;	98US-0097952P
PR	26-AUG-1998;	98US-0097954P
PR	26-AUG-1998;	98US-0097955P
PR	26-AUG-1998;	98US-0097971P
PR	26-AUG-1998;	98US-0097974P
PR	26-AUG-1998;	98US-0097978P
PR	26-AUG-1998;	98US-0097979P
PR	26-AUG-1998;	98US-0097986P
PR	26-AUG-1998;	98US-0098014P
PR	31-AUG-1998;	98US-0098525P
PR	31-AUG-1998;	98US-0100634P
PR	16-SEP-1998;	98WO-US0019330
PR	17-SEP-1998;	98US-0100858P
PR	17-SEP-1998;	98WO-US019437
PR	17-OCT-1998;	98WO-US021141
PR	01-DEC-1998;	98WO-US025108
PR	22-DEC-1998;	98US-0113296P
PR	05-JAN-1999;	99WO-US000106
PR	08-MAR-1999;	99WO-US005028
PR	12-MAR-1999;	99US-0123957P
PR	02-JUN-1999;	99WO-US012252
PR	23-JUN-1999;	99US-0141037P
PR	07-JUL-1999;	99US-0143048P
PR	20-JUL-1999;	99US-0144758P
PR	26-JUL-1999;	99US-0146569P
PR	28-JUL-1999;	99US-0146222P
PR	17-AUG-1999;	99US-0149396P
PR	15-SEP-1999;	99WO-US020190
PR	15-SEP-1999;	99WO-US021547
PR	08-OCT-1999;	99US-0158663P
PR	30-NOV-1999;	99WO-US028313
PR	01-DEC-1999;	99WO-US028301
PR	01-DEC-1999;	99WO-US028634

PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US0003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 15-MAY-2000; 2000WO-US013358.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-JUN-2000; 2000WO-US0213637P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. NO. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTACCACCTCTTCTTTATCTATTATTAATAAATGTTGCTCCACCCTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCAAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 726

ADA39212

ID ADA39212 standard; cDNA; 2846 BP.

XX AC ADA39212;

DT 20-NOV-2003 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein PRO1344.

XX KW PRO; secreted protein; transmembrane protein;
 KW hypertrophy of neonatal heart; angiogenesis;
 KW vascular endothelial growth factor; VEGF-stimulated proliferation;
 KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
 KW c-fos induction; adipocyte cell; chondrocyte differentiation;
 KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
 KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;
 KW rod photoreceptor cell.

XX OS Homo sapiens.

XX FN US2003059782-A1.

XX PD 27-MAR-2003.

XX PF 15-NOV-2001; 2001US-00997628.

XX PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088023P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088036P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 05-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 16-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 19-JUN-1998; 98US-0089947P.
 PR 19-JUN-1998; 98US-0089948P.
 PR 19-JUN-1998; 98US-0089952P.
 PR 22-JUN-1998; 98US-0090246P.
 PR 22-JUN-1998; 98US-0090252P.
 PR 22-JUN-1998; 98US-0090254P.
 PR 23-JUN-1998; 98US-0090349P.
 PR 23-JUN-1998; 98US-0090355P.
 PR 24-JUN-1998; 98US-0090429P.
 PR 24-JUN-1998; 98US-0090431P.
 PR 24-JUN-1998; 98US-0090435P.
 PR 24-JUN-1998; 98US-0090444P.
 PR 24-JUN-1998; 98US-0090445P.
 PR 24-JUN-1998; 98US-0090472P.
 PR 24-JUN-1998; 98US-0090535P.
 PR 24-JUN-1998; 98US-0090540P.
 PR 24-JUN-1998; 98US-0090542P.
 PR 24-JUN-1998; 98US-0090557P.
 PR 25-JUN-1998; 98US-0090676P.
 PR 25-JUN-1998; 98US-0090678P.
 PR 25-JUN-1998; 98US-0090690P.
 PR 25-JUN-1998; 98US-0090694P.
 PR 25-JUN-1998; 98US-0090695P.
 PR 25-JUN-1998; 98US-0090696P.
 PR 26-JUN-1998; 98US-0090862P.
 PR 26-JUN-1998; 98US-0090863P.
 PR 01-JUL-1998; 98US-0091360P.
 PR 01-JUL-1998; 98US-0091544P.
 PR 02-JUL-1998; 98US-0091478P.

PR 02-JUL-1998;	98US-0091519P.
PR 02-JUL-1998;	98US-0091626P.
PR 02-JUL-1998;	98US-0091628P.
PR 02-JUL-1998;	98US-0091633P.
PR 02-JUL-1998;	98US-0091646P.
PR 02-JUL-1998;	98US-0091673P.
PR 02-JUL-1998;	98US-0091978P.
PR 07-JUL-1998;	98US-0091982P.
PR 07-JUL-1998;	98US-0091982P.
PR 09-JUL-1998;	98US-0092182P.
PR 10-JUL-1998;	98US-0092472P.
PR 20-JUL-1998;	98US-0093339P.
PR 30-JUL-1998;	98US-0094511P.
PR 04-AUG-1998;	98US-0095282P.
PR 04-AUG-1998;	98US-0095285P.
PR 04-AUG-1998;	98US-0095301P.
PR 04-AUG-1998;	98US-0095302P.
PR 04-AUG-1998;	98US-0095318P.
PR 04-AUG-1998;	98US-0095321P.
PR 04-AUG-1998;	98US-0095321P.
PR 10-AUG-1998;	98US-0095916P.
PR 10-AUG-1998;	98US-0095929P.
PR 10-AUG-1998;	98US-0096012P.
PR 11-AUG-1998;	98US-0096143P.
PR 11-AUG-1998;	98US-0096146P.
PR 12-AUG-1998;	98US-0096329P.
PR 17-AUG-1998;	98US-0096757P.
PR 17-AUG-1998;	98US-0096766P.
PR 17-AUG-1998;	98US-0096768P.
PR 17-AUG-1998;	98US-0096773P.
PR 17-AUG-1998;	98US-0096791P.
PR 17-AUG-1998;	98US-0096867P.
PR 17-AUG-1998;	98US-0096891P.
PR 17-AUG-1998;	98US-0096894P.
PR 17-AUG-1998;	98US-0096895P.
PR 17-AUG-1998;	98US-0096897P.
PR 18-AUG-1998;	98US-0096949P.
PR 18-AUG-1998;	98US-0096950P.
PR 18-AUG-1998;	98US-0096959P.
PR 18-AUG-1998;	98US-0096960P.
PR 18-AUG-1998;	98US-0097022P.
PR 19-AUG-1998;	98US-0097141P.
PR 20-AUG-1998;	98US-0097218P.
PR 24-AUG-1998;	98US-0097661P.
PR 26-AUG-1998;	98US-0097952P.
PR 26-AUG-1998;	98US-0097954P.
PR 26-AUG-1998;	98US-0097955P.
PR 26-AUG-1998;	98US-0097971P.
PR 26-AUG-1998;	98US-0097974P.
PR 26-AUG-1998;	98US-0097978P.
PR 26-AUG-1998;	98US-0097979P.
PR 26-AUG-1998;	98US-0097986P.
PR 26-AUG-1998;	98US-0098014P.
PR 31-AUG-1998;	98US-0098525P.
PR 16-SEP-1998;	98US-0100634P.
PR 16-SEP-1998;	98WO-US019330.
PR 17-SEP-1998;	98US-0100858P.
PR 17-SEP-1998;	98WO-US019437.
PR 07-OCT-1998;	98WO-US021141.
PR 01-DEC-1998;	98WO-US025108.
PR 22-DEC-1998;	98US-0113296P.
PR 05-JAN-1999;	98WO-US000106.
PR 08-MAR-1999;	98WO-US005028.
PR 12-MAR-1999;	98US-0123957P.
PR 02-JUN-1999;	98WO-US012252.
PR 23-JUN-1999;	98US-0141037P.
PR 07-JUL-1999;	98US-0143048P.
PR 20-JUL-1999;	98US-0144758P.
PR 26-JUL-1999;	98US-0145698P.
PR 28-JUL-1999;	98US-0146222P.
PR 17-AUG-1999;	98US-0149396P.
PR 15-SEP-1999;	98WO-US021090.
PR 15-SEP-1999;	98WO-US021547.
PR 08-OCT-1999;	98US-0158663P.
PR 02-JUL-1998;	98US-0091519P.
PR 02-JUL-1998;	98US-0091626P.
PR 02-JUL-1998;	98US-0091628P.
PR 02-JUL-1998;	98US-0091633P.
PR 02-JUL-1998;	98US-0091646P.
PR 02-JUL-1998;	98US-0091673P.
PR 07-JUL-1998;	98US-0091978P.
PR 07-JUL-1998;	98US-0091982P.
PR 09-JUL-1998;	98US-0092182P.
PR 10-JUL-1998;	98US-0092472P.
PR 20-JUL-1998;	98US-0093339P.
PR 30-JUL-1998;	98US-0094511P.
PR 04-AUG-1998;	98US-0095282P.
PR 04-AUG-1998;	98US-0095285P.
PR 04-AUG-1998;	98US-0095301P.
PR 04-AUG-1998;	98US-0095302P.
PR 04-AUG-1998;	98US-0095318P.
PR 04-AUG-1998;	98US-0095321P.
PR 04-AUG-1998;	98US-0095321P.
PR 10-AUG-1998;	98US-0095916P.
PR 10-AUG-1998;	98US-0095929P.
PR 10-AUG-1998;	98US-0096012P.
PR 11-AUG-1998;	98US-0096143P.
PR 11-AUG-1998;	98US-0096146P.
PR 12-AUG-1998;	98US-0096329P.
PR 17-AUG-1998;	98US-0096757P.
PR 17-AUG-1998;	98US-0096766P.
PR 17-AUG-1998;	98US-0096768P.
PR 17-AUG-1998;	98US-0096773P.
PR 17-AUG-1998;	98US-0096791P.
PR 17-AUG-1998;	98US-0096867P.
PR 17-AUG-1998;	98US-0096891P.
PR 17-AUG-1998;	98US-0096894P.
PR 17-AUG-1998;	98US-0096895P.
PR 17-AUG-1998;	98US-0096897P.
PR 18-AUG-1998;	98US-0096949P.
PR 18-AUG-1998;	98US-0096950P.
PR 18-AUG-1998;	98US-0096959P.
PR 18-AUG-1998;	98US-0096960P.
PR 18-AUG-1998;	98US-0097022P.
PR 19-AUG-1998;	98US-0097141P.
PR 20-AUG-1998;	98US-0097218P.
PR 24-AUG-1998;	98US-0097661P.
PR 26-AUG-1998;	98US-0097952P.
PR 26-AUG-1998;	98US-0097954P.
PR 26-AUG-1998;	98US-0097955P.
PR 26-AUG-1998;	98US-0097971P.
PR 26-AUG-1998;	98US-0097974P.
PR 26-AUG-1998;	98US-0097978P.
PR 26-AUG-1998;	98US-0097979P.
PR 26-AUG-1998;	98US-0097986P.
PR 26-AUG-1998;	98US-0098014P.
PR 31-AUG-1998;	98US-0098525P.
PR 16-SEP-1998;	98US-0100634P.
PR 16-SEP-1998;	98WO-US019330.
PR 17-SEP-1998;	98US-0100858P.
PR 17-SEP-1998;	98WO-US019437.
PR 07-OCT-1998;	98WO-US021141.
PR 01-DEC-1998;	98WO-US025108.
PR 22-DEC-1998;	98US-0113296P.
PR 05-JAN-1999;	98WO-US000106.
PR 08-MAR-1999;	98WO-US005028.
PR 12-MAR-1999;	98US-0123957P.
PR 02-JUN-1999;	98WO-US012252.
PR 23-JUN-1999;	98US-0141037P.
PR 07-JUL-1999;	98US-0143048P.
PR 20-JUL-1999;	98US-0144758P.
PR 26-JUL-1999;	98US-0145698P.
PR 28-JUL-1999;	98US-0146222P.
PR 17-AUG-1999;	98US-0149396P.
PR 15-SEP-1999;	98WO-US021090.
PR 15-SEP-1999;	98WO-US021547.
PR 08-OCT-1999;	98US-0158663P.
PR 30-NOV-1999;	99WO-US028313.
PR 01-DEC-1999;	99WO-US028301.
PR 01-DEC-1999;	99WO-US028634.
PR 16-DEC-1999;	99WO-US030095.
PR 20-DEC-1999;	99WO-US030911.
PR 05-JAN-2000;	2000WO-US000219.
PR 06-JAN-2000;	2000WO-US000376.
PR 11-FEB-2000;	2000WO-US0003565.
PR 18-FEB-2000;	2000WO-US004341.
PR 22-FEB-2000;	2000WO-US004414.
PR 24-FEB-2000;	2000WO-US004914.
PR 02-MAR-2000;	2000WO-US005004.
PR 10-MAR-2000;	2000WO-US005841.
PR 15-MAR-2000;	2000WO-US006319.
PR 20-MAR-2000;	2000WO-US006884.
PR 30-MAR-2000;	2000WO-US007377.
PR 15-MAY-2000;	2000WO-US008439.
PR 17-MAY-2000;	2000WO-US013358.
PR 22-MAY-2000;	2000WO-US013705.
PR 30-MAY-2000;	2000WO-US014042.
PR 02-JUN-2000;	2000WO-US014941.
PR 23-JUN-2000;	2000WO-US015264.
PR 23-JUN-2000;	2000US-0213637P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;	
Best Local Similarity 71.3%; Pred. No. 0.00023;	
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
QY 2121 CCTTTGCTTTACCACTCTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACACTG 2180	
DB 2653 CCTTTTCTTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACATA 2712	
QY 2181 NCTCCCAA 2240	
DB 2713 CAAAAAATAA 2772	
QY 2241 AA 2242	
DB 2773 AA 2774	
RESULT 727	
ACF07035	
ID ACF07035 standard; cDNA; 2846 BP.	
XX ACF07035;	
XX ACF07035;	
DT 06-SEP-2003 (first entry)	
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
DE Human; PRO; secreted protein; transmembrane protein;	
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;	
KW chondrocyte; proliferation; differentiation; cartilage disorder;	
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;	
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;	
KW liver; drug screening; transgenic animal; genetic analysis;	
KW antiarthritic; vulnery; gene therapy; gene; ss.	
XX Homo sapiens.	
XX US2003049746-A1.	
XX 13-MAR-2003.	
XX 15-JUL-2002; 2002US-00195885.	
XX 04-APR-2000; 2000US-0194449P.	
XX 28-FEB-2001; 2001WO-US006520.	
XX 15-JAN-2002; 2002US-00052586.	
XX (GETH) GENENTECH INC.	
XX	

disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. The present sequence appears in the exemplification of the specification. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

2121 CCTTTGCTTTACCACTCTTCTCTTTATCTATTATAAATAAGTTCCTCCACCACTG 2180
 2553 CCTTTTCTCTCCCATCTCTGTACACATTTAATAAATAAGGTTGGCTTCTGAAC 2172
 2181 NCTCCCAA 2240
 2713 CAAA 2772

2241 AA 2242
 2773 AA 2774

RESULT 729
 ACD46089
 ID ACD46089 standard; cDNA; 2846 BP.
 AC ACD46089;
 XX
 XX
 13-SEP-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein (PRO) cDNA #85.
 XX
 KW Human; Gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
 XX
 OS Homo sapiens.
 XX
 PN US2003064459-A1.
 XX
 XX 03-APR-2003.
 XX
 PF 18-JUL-2002; 2002US-00199456.
 XX
 XX 25-JUN-1998; 98US-0090678P.
 XX 02-JUN-1999; 99WO-US012252.
 XX 25-AUG-1999; 99US-00380137.
 XX 28-FEB-2001; 2001WO-US006520.
 XX 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-605861/57.
 XX P-PSDB; ABO28199.
 XX
 XX New secreted and transmembrane PRO polypeptides, useful in gene therapy,
 PT stimulating the release of tumor necrosis factor-alpha, stimulating the
 PT proliferation or differentiation of chondrocyte cells and detecting the
 PT presence of a tumor.
 XX
 XX Claim 2; Fig 169; 700pp; English.
 XX
 CC The invention discloses human nucleic acids encoding secreted and
 CC transmembrane (PRO) polypeptides, with or without their associated signal
 CC peptide. Also disclosed is an antibody that specifically binds to the PRO

polypeptide, a method for stimulating the release of tumour necrosis factor alpha (TNF-alpha) from human blood by contacting the blood with a PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

2121 CCTTTGCTTTACCACTCTTCTCTTTATCTATTATAAATAAGTTCCTCCACCACTG 2180
 2653 CCTTTTCTCTCCCATCTCTGTACACATTTAATAAATAAGGTTGGCTTCTGAAC 2172
 2181 NCTCCCAA 2240
 2713 CAAA 2772

2241 AA 2242
 2773 AA 2774

RESULT 730
 ACF46992
 ID ACF46992 standard; cDNA; 2846 BP.
 XX
 AC ACF46992;
 XX
 XX 08-OCT-2003 (first entry)
 XX
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX
 DE Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003068757-A1.
 XX
 XX 10-APR-2003.
 PD
 XX 25-JUL-2002; 2002US-00206913.
 PF
 XX 05-APR-1999; 99US-0127706P.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-605928/57.
DR P-PSDB; ABM22980.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
PT PRO927, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM22896-ABM23200) and nucleic acids encoding them (ACF46908-ACF47212).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF46908-ACF47212 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTATTATTAATGTTGCTCCACCACTG 2180
Db 2653 CTTTTCTTCCCTCCCTCTTGTACACATTTTAAATAAAGGTTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 731
ACF54360

ACF54360 standard; cDNA; 2846 BP.
ACF54360;
10-OCT-2003 (first entry)
Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; proliferation; differentiation; cartilage disorder;
bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss.
Homo sapiens.
US2003068723-A1.
10-APR-2003.
18-JUL-2002; 2002US-00199307.
04-JUN-1998; 98US-0088028P.
02-JUN-1999; 99WO-US012252.
25-AUG-1999; 99US-00380137.
28-FEB-2001; 2001WO-US006520.
15-JAN-2002; 2002US-00052586.
(GETH) GENENTECH INC.
Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-615886/58.
P-PSDB; ABM30300.
New secreted and transmembrane PRO nucleic acid, useful for the
manufacture of a medicament for diagnosing or treating tumors or for
tissue typing.
Claim 2; Fig 169; 700pp; English.
The invention relates to human PRO secreted/transmembrane polypeptides
(ABM30216-ABM30520) and nucleic acids encoding them (ACF54276-ACF54580).
The invention also relates to sequences at least 80% identical to the PRO
nucleic acid and polypeptide sequences of the invention, recombinant
vectors and host cells comprising a PRO nucleic acid, a method for the
recombinant production of a PRO polypeptide, antibodies against a PRO
polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
acids encoding PRO polypeptides of the invention were initially
identified via homology screening using consensus sequences based on the
extracellular domain sequences from known secreted proteins. Human cDNA
libraries containing sequences of interest were identified using
oligonucleotides based on the consensus sequences, and cDNA clones were
isolated and characterised. The PRO polypeptides are useful for
stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
human blood and may thus be used in the treatment of conditions in which
enhanced TNF-alpha release would be beneficial. They are also useful for
stimulating the proliferation or differentiation of chondrocytes and as
disorders such as arthritis and sports injuries. The PRO polypeptides may
be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are
additionally useful for in drug screening to identify agonists and
antagonists of PRO polypeptides. PRO nucleic acids are useful as
hybridisation probes (for isolation of cDNA molecules), in chromosome and

CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF54276-ACF54580 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACTCTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCCCACTCTCTGTACACATTTTAAATAAGGTTGGTCTCTGAACCTA 2712

QY 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 732
ACF45764
ID ACF45764 standard; cDNA; 2846 BP.
XX
AC ACF45764;
XX
09-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003068741-A1.
XX
XX 10-APR-2003.
XX
XX 23-JUL-2002; 2002US-00201854.
XX
XX 03-NOV-1998; 98US-0106919P.
XX
XX 01-SEP-1999; 99WO-US020111.
XX
XX 18-OCT-1999; 99US-00403297.
XX
XX 28-FEB-2001; 2001WO-US006520.
XX
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-615893/58.
XX
XX P-PSDB; ABM21760.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
XX PRO827, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX

PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM21676-ABM21980) and nucleic acids encoding them (ACF45680-ACF45984).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF45680-ACF45984 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACTCTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCCCACTCTCTGTACACATTTTAAATAAGGTTGGTCTCTGAACCTA 2712

QY 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 733
ACF45457
ID ACF45457 standard; cDNA; 2846 BP.
XX
XX ACF45457;
XX
XX 09-OCT-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX

bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnerability; gene therapy; gene; ss.

Homo sapiens.

US2003068744-A1.

10-APR-2003.

23-JUL-2002;

17-NOV-1998: 98US-0108779P.

01-SEP-1999, 33WC-03020111:
18-OCT-1999: 99US-00403297:

20-SEP-2001; 2001NOV-0000000000
15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-615895/58.

100-443887-1

new isolated nucleic acid encoding a secreted and transmembrane protein polypeptide e.g. PRO1079 or PRO827, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2: Fig 169: 706pp: English.

The invention relates to human PRO secreted/transmembrane polypeptides (ACF45371-ABW21675) and nucleic acids encoding them (ACF45373-ACF45677). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor- α (TNF- α) from human blood and may thus be used in the treatment of conditions in which enhanced TNF- α release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF45373-ACF45677 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	2653	Db
	CGTTTGGCTTTACCACTCTTTCCCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG	CTTTTCTTTCCCACTCTCTGGTACACATTTTAATAAATAAGGGTTGGCTCTGAACCTA	2180

Qy	2181	NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2240
Dc	2713	CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2772

Qv 2241 AA 2242

2773 2774 2775

RESULT 734

ID ACF38476 standard: cDNA: 2846 bp.

AC ACF38476:

08-OCT-2003 (first entry)

DE Human secreted polypeptide PRO1344-encoding cDNA, SEO ID NO:169.

KW Human; BRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor- α ; TNF- α ; TNF- α ;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnervary; gene therapy; gene; ss.

OS Homo sapiens.

PN US2003068766-A1.

PD 10-APR-2003.

29-JUL-2002; 2002US-00207917.

PR 25-APR-2000; 2000US-0199550P.

15-JAN-2002; 2002US-00052586.

PA (GETH) GENENTECH INC.

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-615907/58.

XX
XX
XXXXX,

PT acids, useful in gene therapy, chromosome identification, tissue typing,
PT or as hybridization probes in chromosome and gene mapping

PS Claim 2; Fig 169; 699pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides (ABM15207-ABM1551) and nucleic acids encoding them (ACF386599-ACF39603). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins Human CDNA

libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF38699-ACF39603 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTATCTATTATAAAATGTTGGTCTCCACACTG 2180
DB 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTATAAAATAGGTTGGTCTTGAACTA 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 735
ACD89537
ID ACD89537 standard; cDNA; 2846 BP.
XX ACD89537;
AC ACD89537;
DT 08-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
XX US2003068694-A1.
XX 10-APR-2003.
XX 09-JUL-2002; 2002US-00192009.
XX 05-JUN-2000; 2000US-0209832P.
PR 28-FEB-2001; 2001WO-US006520.

15-JAN-2002; 2002US-00052586.
(GETH) GENENTECH INC.
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-625462/59.
DR P-PSDB; ABO41061.
XX New PRO nucleic acid, useful for the manufacture of a medicament for
diagnosing or treating tumor or for tissue typing.
XX Claim 2; Fig 169; 699pp; English.
XX The invention discloses human nucleic acids encoding secreted and
transmembrane (PRO) polypeptides, with or without their associated signal
peptide. Also disclosed is an antibody that specifically binds to the PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor alpha (TNF-alpha) from human blood by contacting the blood with a
PRO polypeptide, a method for stimulating the proliferation or
differentiation of chondrocyte cells by contacting the cells with a PRO
polypeptide, a method for detecting the presence of a tumour in a mammal
and an oligonucleotide probe derived from any of the PRO nucleotide
sequences. The nucleotide sequences are useful as probes, in chromosome
and gene mapping, in generating antisense RNA and DNA, in preparing PRO
polypeptides by recombinant techniques and in gene therapy (e.g. for
replacement of defective gene). The PRO polypeptides are useful as
molecular weight markers for protein electrophoresis purposes, for
chromosome identification, as chromosome markers, as therapeutic agents,
for stimulating the release of TNF-alpha from human blood, for
stimulating the proliferation or differentiation of chondrocytes and
detecting the presence, prevention and/or treatment of a tumour, such as
adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
The PRO polypeptides and nucleic acids may also be used diagnostically
for tissue typing. The sequence presented is a cDNA encoding one of the
PRO polypeptides of the invention. Note: The sequence data for this
patent can also be obtained in electronic format directly from USPTO at
seqdata.uspto.gov/sequence.html

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTATCTATTATAAAATGTTGGTCTCCACACTG 2180
DB 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTATAAAATAGGTTGGTCTTGAACTA 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 736
ACD85239
ID ACD85239 standard; cDNA; 2846 BP.
XX ACD85239;
AC ACD85239;
DT 05-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.


```

PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625469/59.
XX P-PSDB; ABO37401.
XX
XX New isolated and secreted PRO nucleic acids, useful for the manufacture
XX of a medicament for diagnosed or treating tumors or for tissue typing.
XX
XX Claim 2; Fig 169; 701pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a
XX PRO polypeptide, a method for stimulating the proliferation or
XX differentiation of chondrocyte cells by contacting the cells with a PRO
XX polypeptide, a method for detecting the presence of a tumour in a mammal
XX and an oligonucleotide probe derived from any of the PRO nucleotide
XX sequences. The nucleotide sequences are useful as probes, in chromosome
XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO
XX polypeptides by recombinant techniques and in gene therapy (e.g. for
XX replacement of defective gene). The PRO polypeptides are useful as
XX molecular weight markers for protein electrophoresis purposes, for
XX chromosome identification, as chromosome markers, as therapeutic agents,
XX for stimulating the release of TNF-alpha from human blood, for
XX stimulating the proliferation or differentiation of chondrocytes and
XX detecting the presence, prevention and/or treatment of a tumour, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
XX The PRO polypeptides and nucleic acids may also be used diagnostically
XX for tissue typing. The sequence presented is a cDNA encoding one of the
XX PRO polypeptides of the invention. Note: The sequence data for this
XX patent can also be obtained in electronic format directly from USPTO at
XX seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX QY 2121 CCTTTCCTTACCACCTCTTCTTCTTATCTATTAATAAAATGTTGGTCTCCACCACTG 2180
XX DB 2653 CCTTTCCTTCCCACTCTCTGTACACATTTTAATAAATAGGTTGGCTTCTGACTA 2712
XX
XX QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
XX DB 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
XX
XX QY 2241 AA 2242
XX DB 2773 AA 2774
XX
XX RESULT 738

```

```

ACF75849
ID ACF75849 standard; cDNA; 2846 BP.
XX
XX AC ACF75849;
XX
XX DT 06-NOV-2003 (first entry)
XX
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX KW Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX
XX OS Homo sapiens.
XX
XX PN US2003104544-A1.
XX
XX PD 05-JUN-2003.
XX
XX PF 09-JUL-2002; 2002US-00192007.
XX
XX PR 03-MAR-2000; 2000US-0187202P.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-658682/52.
XX P-PSDB; ABM75191.
XX
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
XX molecular biology; chromosome and gene mapping, in generating antisense
XX RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM75107-ABM75411) and nucleic acids encoding them (ACF75765-ACF76069).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX indicative of the presence of a tumour. The PRO polypeptides are
XX additionally useful for in drug screening to identify agonists and
XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA and in gene

```



```
XX OS Homo sapiens.
XX PN US2003049760-A1.
XX PD 13-MAR-2003.
XX PF 19-JUL-2002; 2002US-00199310.
XX PR 05-JUN-1998; 98US-0088202P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 15-JAN-2002; 2002US-00052586.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-669839/63.
XX DR P-PSDB; ABO46226.
XX PT Three hundred and five nucleic acids encoding PRO polypeptides, useful in
XX PT gene therapy, or for preparing a medicament for treating a condition that
XX PT is responsive to the PRO polypeptide or anti-PRO antibody.
XX PS Claim 2; Fig 169; 700pp; English.
XX CC The present invention relates to the isolation of novel human PRO
XX CC polypeptides, and the polynucleotide sequences encoding them. The PRO
XX CC polypeptides are secreted and transmembrane proteins. The PRO
XX CC polynucleotide sequences are useful in molecular biology as hybridisation
XX CC probes, in chromosome and gene mapping, in generating antisense RNA and
XX CC DNA, and in gene therapy. The PRO polypeptides are useful as
XX CC pharmaceuticals, diagnostics, biosensors or bioreactors for the detection
XX CC of tumours. They are also useful for stimulating the release of tumour
XX CC necrosis factor (TNF)-alpha from human blood, or for stimulating the
XX CC proliferation or differentiation of chondrocyte cells. The anti-PRO
XX CC antibodies may be used in diagnostic assays for PRO polypeptides, or for
XX CC the affinity purification of PRO polypeptides from recombinant cell
XX CC culture or natural sources. ACH05552-ACH05856 represent cDNA sequences
XX CC encoding the human PRO polypeptides of the invention. Note: The sequence
XX CC data for this patent was obtained in electronic format directly from the
XX CC USPTO web site at seqdata.uspto.gov/psipdbEntry.html
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTTACCACCTCTTTCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTGACACATTTTAATAAAATAAGGTTGGTCTTGAACCTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 741
ID ADA82604
XX ID ADA82604 standard; cDNA; 2846 BP.
XX AC ADA82604;
XX DT 20-NOV-2003 (first entry)
XX
```

Human secreted/transmembrane protein (PRO) cDNA #85.

Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha; tumour necrosis factor alpha; chondrocyte cell; gene therapy; tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.

Homo sapiens.

US2003049755-A1.

13-MAR-2003.

18-JUL-2002; 2002US-00198765.

08-APR-1998; 98US-0081070P.

08-MAR-1999; 99WO-US005028.

25-AUG-1999; 99US-00380138.

28-FEB-2001; 2001WO-US006520.

15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-708321/67.

P-PSDB; ADA82605.

New secreted and transmembrane polypeptides, designated PRO polypeptides, and their encoding nucleic acids, useful for diagnosing, preventing or treating tumors, such as adrenal, lung, colon, breast, and prostate tumors.

Claim 2; Fig 169; 700pp; English.

The invention discloses human nucleic acids encoding secreted and transmembrane (PRO) polypeptides, with or without their associated signal peptide. Also disclosed is an antibody that specifically binds to the PRO polypeptide, a method for stimulating the release of tumour necrosis factor alpha (TNF-alpha) from human blood by contacting the blood with a PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846; Best Local Similarity 71.3%; Pred. No. 0.00023; Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTTACCACCTCTTTCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTGACACATTTTAATAAAATAAGGTTGGTCTTGAACCTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 741

ADA82604

ID ADA82604 standard; cDNA; 2846 BP.

XX ADA82604;

XX DT 20-NOV-2003 (first entry)

XX

Db 2713 CAAAAA... 2772
 Qy 2241 AA 2242
 Db 2773 AA 2774
 RESULT 742
 ADB85610
 ID ADB85610 standard; cDNA; 2846 BP.
 XX ADB85610;
 AC
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neurotrophin; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
 XX
 OS Homo sapiens.
 XX
 PN US2003049735-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 01-MAY-2002; 2002US-00063518.
 XX
 XX 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 22-AUG-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-585111/55.
 DR P-PSDB; ADB85611.
 XX
 PT New PRO polypeptide, useful in diagnosing and treating disorders that
 PT affect glucose or free fatty acids in skeletal muscle, such as diabetes,
 XX hypoinsulinemia or hyperinsulinemia.
 PS Disclosure; Fig 37; 235pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neurotrophins and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTTATTAATAAATGTTGCTCCACCTG 2180
 Db 2853 CCTTTCTCTCCCATCTCTTGATACATTTTATAAATAAGGTTGCTTCTGAAC 2712
 Qy 2181 NCTCCCAA 2240
 Db 2713 CAAAAA... 2772
 Qy 2241 AA 2242
 Db 2773 AA 2774

RESULT 743

ADB96238
 ID ADB96238 standard; cDNA; 2846 BP.

XX ADB96238;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Human PRO polynucleotide #65.
 XX
 KW Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
 KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;
 KW haemoglobin-associated disorder; thalassaemia; endothelial cell growth;
 KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
 KW antidiabetic; antanaemic; cytostatic; cardiant; vulnerary;
 KW antiinflammatory; anorectic.
 XX
 OS Homo sapiens.
 XX
 PN US2003054403-A1.
 XX
 PD 20-MAR-2003.

XX
PR 15-NOV-2001; 2001US-00997559.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0065311P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088266P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088714P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 18-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 02-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.

PR	23-JUN-1999;	99US-0141037P.	XX	10-APR-2003.	
PR	07-JUL-1999;	99US-0143048P.	XX	20-JUN-2002;	2002US-00176746.
PR	20-JUL-1999;	99US-0144758P.	XX	18-SEP-1997;	97US-0059263P.
PR	26-JUL-1999;	99US-0145698P.	PR	17-OCT-1997;	97US-0059266P.
PR	28-JUL-1999;	99US-0146222P.	PR	21-OCT-1997;	97US-0062250P.
PR	17-AUG-1999;	99US-0149396P.	PR	24-OCT-1997;	97US-0063486P.
PR	15-SEP-1999;	99WO-US021090.	PR	24-OCT-1997;	97US-0063120P.
PR	15-SEP-1999;	99WO-US0211547.	PR	28-OCT-1997;	97US-0063540P.
PR	08-OCT-1999;	99US-0158663P.	PR	28-OCT-1997;	97US-0063541P.
PR	30-NOV-1999;	99WO-US028313.	PR	29-OCT-1997;	97US-0063734P.
PR	01-DEC-1999;	99WO-US028301.	PR	31-OCT-1997;	97US-0063870P.
PR	16-DEC-1999;	99WO-US028634.	PR	31-OCT-1997;	97US-0064103P.
PR	20-DEC-1999;	99WO-US030095.	PR	13-NOV-1997;	97US-0065311P.
PR	05-JAN-2000;	2000WO-US000219.	PR	21-NOV-1997;	97US-0066120P.
PR	06-JAN-2000;	2000WO-US000376.	PR	24-NOV-1997;	97US-0066466P.
PR	11-FEB-2000;	2000WO-US000365.	PR	24-NOV-1997;	97US-0066772P.
PR	18-FEB-2000;	2000WO-US004341.	PR	11-DEC-1997;	97US-0069335P.
PR	22-FEB-2000;	2000WO-US004414.	PR	12-DEC-1997;	97US-0069425P.
PR	24-FEB-2000;	2000WO-US004914.	PR	17-DEC-1997;	97US-0069870P.
PR	24-FEB-2000;	2000WO-US005004.	PR	18-DEC-1997;	97US-0068017P.
PR	02-MAR-2000;	2000WO-US005841.	PR	10-MAR-1998;	98US-0077450P.
PR	10-MAR-2000;	2000WO-US006319.	PR	11-MAR-1998;	98US-0077632P.
PR	15-MAR-2000;	2000WO-US006884.	PR	11-MAR-1998;	98US-0077649P.
PR	20-MAR-2000;	2000WO-US007377.	PR	20-MAR-1998;	98US-0078886P.
PR	30-MAR-2000;	2000WO-US008439.	PR	27-MAR-1998;	98US-0078939P.
PR	15-MAY-2000;	2000WO-US013358.	PR	27-MAR-1998;	98US-0079664P.
PR	17-MAY-2000;	2000WO-US013705.	PR	27-MAR-1998;	98US-0079786P.
PR	22-MAY-2000;	2000WO-US014042.	PR	31-MAR-1998;	98US-0080107P.
PR	30-MAY-2000;	2000WO-US014941.	PR	31-MAR-1998;	98US-0080194P.
PR	02-JUN-2000;	2000WO-US015264.	PR	01-APR-1998;	98US-0080327P.
PR	23-JUN-2000;	2000US-0213637P.	PR	01-APR-1998;	98US-0080333P.
PR	28-JUL-2000;	2000WO-US020710.	PR	08-APR-1998;	98US-0081049P.
PR	11-AUG-2000;	2000WO-US022031.	PR	08-APR-1998;	98US-0081070P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;					98US-0081195P.
Best Local Similarity 71.3%; Pred. No. 0.00023;					98US-0081838P.
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;					98US-0082568P.
Qy	2121	CGTTTGGTTTACCACTCTTCTTTTATTAATAAATAATGTCCTCCACCACTG	2180	15-APR-1998;	98US-0082569P.
Db	2653	CGTTTCTCTCCCATCTTGTACACATTTTATAAATAAGGGTGGCTCTGAACTA	2712	21-APR-1998;	98US-0082704P.
Qy	2181	NCTCCCAAA	2240	22-APR-1998;	98US-0082797P.
Db	2713	CAAA	2772	28-APR-1998;	98US-0083322P.
Qy	2241	AA 2242		29-APR-1998;	98US-0083495P.
Db	2773	AA 2774		29-APR-1998;	98US-0083496P.
RESULT 744					98US-0083499P.
ACF55895					98US-0083559P.
ID	ACF55895 standard; cDNA; 2846 BP.				98US-0084366P.
XX	ACF55895;				98US-0084414P.
XX	ACF55895;				98US-0084639P.
DT	04-DEC-2003 (first entry)				98US-0084640P.
XX	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.				98US-0084643P.
DE	Human; PRO; secreted protein; transmembrane protein;				98US-0085579P.
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;				98US-0085580P.
KW	chondrocyte; proliferation; differentiation; cartilage disorder;				98US-0086023P.
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;				98US-0086486P.
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;				98US-0087098P.
KW	liver; drug screening; transgenic animal; genetic analysis;				98US-0087208P.
KW	antiarthritic; vulnery; gene therapy; gene; ss.				98US-0087599P.
OS	Homo sapiens.				98US-0088025P.
XX	US2003068680-A1.				98US-0088028P.
PN					98US-0088033P.
					98US-0088326P.
					98US-0088167P.

PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.
PR	10-JUN-1998;	98US-0088861P.
PR	11-JUN-1998;	98US-0088863P.
PR	11-JUN-1998;	98US-0088876P.
PR	12-JUN-1998;	98US-0089090P.
PR	12-JUN-1998;	98US-0089105P.
PR	16-JUN-1998;	98US-0089512P.
PR	17-JUN-1998;	98US-0089538P.
PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089635P.
PR	18-JUN-1998;	98US-0089908P.
PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090446P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090688P.
PR	25-JUN-1998;	98US-0090690P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090695P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-00105413.
PR	26-JUN-1998;	98US-0090862P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091486P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.
PR	02-JUL-1998;	98US-0091632P.
PR	24-JUL-1998;	98US-0094006P.
PR	04-AUG-1998;	98US-0095282P.
PR	10-AUG-1998;	98US-0095998P.
PR	10-AUG-1998;	98US-0096012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096756P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096881P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98US-0101933P.
PR	16-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	01-OCT-1998;	98US-0102687P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;		
Best Local Similarity 71.3%; Pred. No. 0.00023;		
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
QY	2121	CGTTTGGCTTTACCACTCTTTCTTTTCTTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
Db	2653	CGTTTCTCTCCCATCTCTTGACATTTTAATAAATAAGGTTGGCTTCTGACTA 2712
QY	2181	NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
Db	2713	CAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY	2241	AA 2242
Db	2773	AA 2774
RESULT 745		
ACF55281		
ID	ACF55281 standard; cDNA; 2846 BP.	
XX		
AC	ACF55281;	
XX		
DT	04-DEC-2003 (first entry)	
XX		
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
XX		
KW	Human; PRO; secreted protein; transmembrane protein;	
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;	
KW	chondrocyte; proliferation; differentiation; cartilage disorder;	
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;	
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;	
KW	liver; drug screening; transgenic animal; genetic analysis;	
KW	antiarthritic; vulnery; gene therapy; gene; ss.	
XX		
OS	Homo sapiens.	
XX		

liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss;
Homo sapiens.

US2003068713-A1.

10-APR-2003.

17-JUL-2002; 2002US-00197696.

29-OCT-1997; 97US-0063734P.

16-SEP-1998; 98WO-US019330.

25-AUG-1999; 99US-00380139.

28-FEB-2001; 2001WO-US006520.

15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-605917/57.

P-PSDB; ABM32435.

New PRO nucleic acid, useful for the manufacture of a medicament for
diagnosing or treating tumor or for tissue typing.

Claim 2; Fig 169; 703pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides
(ABM32351-ABM32655) and nucleic acids encoding them (ACF56425-ACF56729).
The invention also relates to sequences at least 80% identical to the PRO
nucleic acid and polypeptide sequences of the invention, recombinant
vectors and host cells comprising a PRO nucleic acid, a method for the
recombinant production of a PRO polypeptide, antibodies against a PRO
polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
acids encoding PRO polypeptides of the invention were initially
identified via homology screening using consensus sequences based on the
extracellular domain sequences from known secreted proteins. Human cDNA
libraries containing sequences of interest were identified using
oligonucleotides based on the consensus sequences, and cDNA clones were
isolated and characterised. The PRO polypeptides are useful for
stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
human blood and may thus be used in the treatment of conditions in which
enhanced TNF-alpha release would be beneficial. They are also useful for
stimulating the proliferation or differentiation of chondrocytes and as
such may be used in the treatment of various bone and/or cartilage
disorders such as arthritis and sports injuries. The PRO polypeptides may
be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are
additionally useful for in drug screening to identify agonists and
antagonists of PRO polypeptides. PRO nucleic acids are useful as
hybridisation probes (for isolation of cDNA molecules), in chromosome and
gene mapping, in the generation of antisense RNA and DNA and in gene
therapy. The nucleic acids can also be used for mapping genes encoding
PRO polypeptides, for genetic analysis of individuals with genetic
disorders, and for generating either transgenic animals or knock-out
animals which are useful in the development and screening of
therapeutically useful compounds. Sequences ACF56425-ACF56729 represent
cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTTCTTTATCTTTATTAATAAATGTTGCTCCCACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTTTGACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 749

ADB68289
ID ADB68289 standard; cDNA; 2846 BP.

AC ADB68289;

DT 04-DEC-2003 (first entry)

XX XX Human PRO1344 cDNA.

XX PRO; cytostatic; cancer; diabetes; hyperinsulinaemia; hypoinsulinaemia;
XX sports-related joint problem; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; tissue typing; gene therapy; transgenic; human; ss;
XX gene.

OS Homo sapiens.

XX US2003065161-A1.

XX 03-APR-2003.

XX 03-MAY-2002; 2002US-00063594.

XX 06-DEC-2001; 2001US-00006867.

XX (GETH) GENENTECH INC.

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-531738/50.

XX N-PSDB; ADB68290.

XX Novel secreted and transmembrane polypeptide, designated PRO1270, useful
XX for therapeutic and diagnostic purposes, for tissue typing and
XX identifying modulators of therapeutic use.
XX Example 4; Fig 37; 413pp; English.

XX The invention relates to a novel isolated PRO polypeptide. The
XX polypeptide of the invention demonstrates cytostatic activity and may be
XX useful during the preparation of a composition for diagnosing or treating
XX cancer, diabetes, hyperinsulinaemia, hypoinsulinaemia and sports-related
XX joint problems, including articular cartilage defects, osteoarthritis and
XX rheumatoid arthritis. Furthermore, the polypeptides may be utilised
XX during tissue typing, gene therapy and the production of transgenic
XX animals. The current sequence is that of the human PRO cDNA of the
XX invention.

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

XX Query Match 3.0%; Score 66.6; DB 10; Length 2846;

XX Best Local Similarity 71.3%; Pred. No. 0.00023;

XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCTTTATCTTTATTAATAAATGTTGCTCCCACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTTTGACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615903/58.
XX P-PSDB; ABM31520.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
XX PRO827, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM31436-ABM31740) and nucleic acids encoding them (ACF5504-ACF5508).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX additionally useful for in drug screening to identify agonists and
XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA and in gene
XX therapy. The nucleic acids can also be used for mapping genes encoding
XX PRO polypeptides, for genetic analysis of individuals with genetic
XX disorders, and for generating either transgenic animals or knock-out
XX animals which are useful in the development and screening of
XX therapeutically useful compounds. Sequences ACF5504-ACF5508 represent
XX cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTTTATCTATTATTAATAAATGTTGGTCCACCACTG 2180
Db 2653 CTTTTCTTCCCATCTCTTGTACACATTTTATAAATGAAGGTTGGCTTCGAAC 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 752
ACF54974
ID ACF54974 standard; cDNA; 2846 BP.
XX

AC ACF54974;
XX
XX 04-DEC-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX
XX Homo sapiens.
XX
XX US2003068771-A1.
XX
XX 10-APR-2003.
XX
XX 29-JUL-2002; 2002US-00208021.
XX
XX 14-MAR-2000; 2000US-0189320P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski P, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-615908/58.
XX P-PSDB; ABM30910.
XX
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for stimulating the release of tumor necrosis factor (TNF) alpha from
XX human blood and for stimulating the proliferation or differentiation of
XX chondrocyte cells.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM30826-ABM31130) and nucleic acids encoding them (ACF54890-ACF55194).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX indicative of the presence of a tumour. The PRO polypeptides are
XX additionally useful for in drug screening to identify agonists and
XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA and in gene
XX therapy. The nucleic acids can also be used for mapping genes encoding
XX PRO polypeptides, for genetic analysis of individuals with genetic

CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF54890-ACF55194 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAAATAAAATAAGGGTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAA 2240
Db 2713 CAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 753
ADB90913
ID ADB90913 standard; cDNA; 2846 BP.
XX
AC ADB90913;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX
OS Homo sapiens.
XX
PN US2003083473-A1.
XX
PD 01-MAY-2003.
XX
PF 03-MAY-2002; 2002US-00063595.
XX
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-786922/74.
DR P-PSDB; ADB90914.
XX
PT New antibody that binds a secreted and transmembrane polypeptide (PRO)
PT for treating cancer and for diagnostic assays and affinity purification
PT of PRO.
XX
PS Disclosure; Fig 37; 408pp; English.
XX
CC The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and

CC transmembrane PRO polypeptide.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAAATAAAATAAGGGTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAA 2240
Db 2713 CAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 754
ADC57710
ID ADC57710 standard; cDNA; 2846 BP.
XX
AC ADC57710;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #65.
XX
KW Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;
KW haemoglobin-associated disorder; thalassemia; endothelial cell growth;
KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
KW anti-diabetic; antianemic; cytostatic; cardiant; vulnary;
KW antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003027754-A1.
XX
PD 06-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990438.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.

[illegible]

```
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096896P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98WO-US012252.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 28-JUL-1999; 98US-0145698P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Oy 2121 CCITTTGCTTTACCACTCTTTCCTTTTATCTATTATAAAAAATGTGTCTCCCACTG 2180
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCITTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGCTTCTGAAC 2712
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Oy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Oy 2241 AA 2242
|||
Db 2773 AA 2774

RESULT 756
ADCl1941
ID ADCl1941 standard; cDNA; 2846 BP.
XX AC ADCl1941;
XX DT 18-DEC-2003 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein PRO1344.
XX KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX OS Homo sapiens.
XX SS US2003049681-A1.
XX PN 13-MAR-2003.
XX PD 15-NOV-2001; 2001US-00997514.
XX PF 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 24-NOV-1997; 97US-0066770P.
XX PR 25-FEB-1998; 98US-0075945P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 07-MAY-1998; 98US-0084600P.
XX PR 28-MAY-1998; 98US-0087106P.
XX PR 02-JUN-1998; 98US-0087607P.
XX PR 02-JUN-1998; 98US-0087609P.
XX PR 03-JUN-1998; 98US-0087827P.
XX PR 04-JUN-1998; 98US-0088021P.
XX PR 04-JUN-1998; 98US-0088025P.
XX PR 04-JUN-1998; 98US-0088026P.
XX PR 04-JUN-1998; 98US-0088028P.
XX PR 04-JUN-1998; 98US-0088029P.
XX PR 04-JUN-1998; 98US-0088030P.
XX PR 04-JUN-1998; 98US-0088033P.
XX PR 04-JUN-1998; 98US-0088326P.
```

PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-008876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089588P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 18-JUN-1998; 98US-0089601P.
PR 18-JUN-1998; 98US-0089807P.
PR 18-JUN-1998; 98US-0089808P.
PR 19-JUN-1998; 98US-0089847P.
PR 19-JUN-1998; 98US-0089848P.
PR 19-JUN-1998; 98US-0089852P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 04-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98WO-US012252.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.

```

PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015284.
PR 23-JUN-2000; 2000WO-US013637P.

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTCTTCTTTATCTTTATTAATAAATGTGTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGCTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

```

RESULT 757

```

ID ADC06993 standard; cDNA; 2846 BP.
XX
AC ADC06993;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO1344 cDNA.
XX

```

```

KW PRO; cytostatic; cancer; diabetes; hyperinsulinaemia; hypoinsulinaemia;
KW sports-related joint problem; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; tissue typing; gene therapy; transgenic; human; ss;
KW gene.
XX
OS Homo sapiens.
XX

```

```

XX US2003060602-A1.
XX
XX 27-MAR-2003.
XX
XX 02-MAY-2002; 2002US-00063563.
XX
XX 30-DEC-1998; 98KR-00062142.
XX
XX 08-MAR-1999; 99WO-US005028.
XX
XX 14-MAY-1999; 99US-00311832.
XX
XX 14-MAY-1999; 99WO-US010733.
XX
XX 25-AUG-1999; 99US-00380137.
XX
XX 25-AUG-1999; 99US-00380138.
XX
XX 25-AUG-1999; 99US-00380139.
XX
XX 25-AUG-1999; 99US-00380142.
XX
XX 15-SEP-1999; 99US-00397342.
XX
XX 18-OCT-1999; 99US-00403297.
XX
XX 12-NOV-1999; 99US-00423844.
XX
XX 30-DEC-1999; 99WO-US031274.
XX
XX 18-FEB-2000; 2000WO-US004341.
XX
XX 01-MAR-2000; 2000WO-US005601.
XX
XX 02-MAR-2000; 2000WO-US005841.
XX
XX 21-MAR-2000; 2000WO-US007532.
XX
XX 22-MAY-2000; 2000WO-US014042.
XX
XX 02-JUN-2000; 2000WO-US015264.
XX
XX 22-AUG-2000; 2000US-00644848.
XX
XX 24-AUG-2000; 2000WO-US023328.
XX
XX 18-SEP-2000; 2000US-0064610.
XX
XX 18-SEP-2000; 2000US-00665350.
XX
XX 08-NOV-2000; 2000US-00709238.
XX
XX 10-NOV-2000; 2000WO-US030873.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 20-DEC-2000; 2000US-00747259.
XX

```

```

PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-596569/56.
XX N-PSDB; ADC06994.
XX
XX New PRO polypeptide, useful for preparing a composition for diagnosing or
XX treating cancer or for tissue typing.
XX
XX Example 4; Fig 37; 234pp; English.
XX
XX The invention relates to a novel isolated PRO polypeptide. The
XX polypeptide of the invention demonstrates cytostatic activity and may be
XX useful during the preparation of a composition for diagnosing or treating
XX cancer, diabetes, hyperinsulinaemia, hypoinsulinaemia and sports-related
XX joint problems, including articular cartilage defects, osteoarthritis and
XX rheumatoid arthritis. Furthermore, the polypeptides may be utilised
XX during tissue typing, gene therapy and the production of transgenic
XX animals. The current sequence is that of the human PRO cDNA of the
XX invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

```

```

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTCTTCTTTATCTTTATTAATAAATGTGTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGCTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

```

RESULT 758

```

ID ADC56363
ID ADC56363 standard; cDNA; 2846 BP.
XX
AC ADC56363;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human PRO polynucleotide #65.
XX
XX Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
XX pancreatic beta-cell; insulin deficiency; diabetes mellitus;
XX haemoglobin-associated disorder; thalassaemia; endothelial cell growth;
XX cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
XX antidiabetic; antianaemic; cytostatic; cardiant; vulnerary;
XX antiinflammatory; anorectic.
XX
XX Homo sapiens.
XX

```

US2003064375-A1.

PR 08-MAR-1999; 99WO-US0050328.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US028634.
PR 20-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCTTTATTAATAAAATGTTGCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAGGTTGGCTTCTGA 2712

Qy 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 759
ADCl172
ID ADCl172 standard; cDNA; 2846 BP.
XX
AC ADCl172;
XX
DT 18-DEC-2003 (first entry)
XX
DE cDNA sequence encoding a PRO polypeptide (SeqID 37).
XX
KW PRO; gene; ss; cytostatic; gene therapy; cancer; recombinant DNA library.
XX
OS Mammalia.
XX
PN US2003065143-A1.
XX
PD 03-APR-2003.
XX

PF 02-MAY-2002; 2002US-00063555.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00844848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 08-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032878.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-596635/56.
DR P-PSDB; ADCl1713.
XX
PT New secreted and transmembrane PRO polypeptides, useful for preparing a
XX composition for diagnosing or treating cancer or for tissue typing.
XX
PS Disclosure; Fig 37; 236pp; English.
XX
XX This invention relates to novel isolated, secreted and transmembrane PRO
XX polypeptides. Specifically, it refers to native receptor and membrane
XX bound proteins which were identified from the screening of mammalian
XX recombinant DNA libraries. The PRO proteins described in the present
XX invention have been shown to have important and varied industrial
XX applications as biosensors, diagnostics and bioreactors, as well as for
XX tissue typing. Furthermore, they have cytostatic activity and via gene
XX therapy routes can be useful for the preparation of compositions for the
XX diagnosis or treatment of cancer. This polynucleotide sequence is a cDNA
XX sequence encoding a PRO polypeptide of the invention.
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCTTTATTAATAAAATGTTGCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAGGTTGGCTTCTGA 2712

PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090895P.
PR 25-JUN-1998; 98US-0090896P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095331P.
PR 04-AUG-1998; 98US-0095335P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.

PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US003376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY

2121 CCTTGGCTTTACCACCTCTTTCCTTTATCTTATTATATAAAATGTTGGTCTCCACCACCTG 2180

```

Db      2653 CCTTTCTCCCTCCCTCTCTGTACACATTTTAAATAAAGGTGGCTTCTCAACTA 2712
QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db      2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY      2241 AA 2242
Db      2773 AA 2774

RESULT 762
ADCI14870
ID      ADCI14870 standard; cDNA; 2846 BP.
XX
AC      ADCI14870;
XX
DT      18-DEC-2003 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW      ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW      affinity purification; secreted and transmembrane protein.
XX
XX      Homo sapiens.
XX
OS      US2003073208-A1.
XX
PN      17-APR-2003.
XX
PD      02-MAY-2002; 2002US-00063538.
XX
PR      30-DEC-1998; 98KR-00062142.
PR      08-MAR-1999; 99WO-US005028.
PR      14-MAY-1999; 99US-00311832.
PR      14-MAY-1999; 99WO-US010733.
PR      25-AUG-1999; 99US-00380137.
PR      25-AUG-1999; 99US-00380138.
PR      25-AUG-1999; 99US-00380139.
PR      25-AUG-1999; 99US-00380142.
PR      15-SEP-1999; 99US-00397342.
PR      18-OCT-1999; 99US-00403297.
PR      12-NOV-1999; 99US-00423844.
PR      30-DEC-1999; 99WO-US031274.
PR      18-FEB-2000; 2000WO-US004341.
PR      01-MAR-2000; 2000WO-US005601.
PR      02-MAR-2000; 2000WO-US005841.
PR      21-MAR-2000; 2000WO-US007532.
PR      22-MAY-2000; 2000WO-US014042.
PR      02-JUN-2000; 2000WO-US015264.
PR      22-AUG-2000; 2000US-00644848.
PR      24-AUG-2000; 2000WO-US023328.
PR      18-SEP-2000; 2000US-00664610.
PR      18-SEP-2000; 2000US-00665350.
PR      08-NOV-2000; 2000US-00709238.
PR      10-NOV-2000; 2000WO-US030873.
PR      01-DEC-2000; 2000WO-US032678.
PR      20-DEC-2000; 2000US-00747259.
PR      20-DEC-2000; 2000WO-US034956.
PR      28-FEB-2001; 2001WO-US006520.
PR      22-MAR-2001; 2001US-00816744.
PR      10-MAY-2001; 2001US-00854208.
PR      10-MAY-2001; 2001US-00854280.
PR      30-MAY-2001; 2001US-00870574.
PR      01-JUN-2001; 2001WO-US017800.
PR      05-JUN-2001; 2001US-00874503.
PR      29-JUN-2001; 2001US-00869599.
PR      18-JUL-2001; 2001US-00908837.
PR      06-DEC-2001; 2001US-00068687.
XX
XX      (GETH ) GENENTECH INC.
XX

```

```

PI      Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI      Grimaldi JC, Gurney AL, Watanabe CK, Wood WL;
XX
DR      WPI; 2003-743815/70.
DR      P-PSDB; ADCI14871.
XX
PT      Novel isolated secreted and transmembrane PRO1277 polypeptide useful in
PT      the preparation of a medicament for treating a condition responsive to
PT      PRO polypeptides, as a therapeutic agent e.g. a vaccine, and as a
PT      molecular weight marker.
XX
PS      Disclosure; SEQ ID NO 37; 237pp; English.
XX
CC      The invention describes an antibody that specifically binds to a PRO
CC      polypeptide having a fully defined amino acid sequence given in the
CC      specification. The antibody is useful in identifying PRO polypeptides
CC      useful for various industrial applications, including pharmaceuticals,
CC      diagnostics, biosensors and bioreactors. The antibody is also used for
CC      affinity purification of PRO polypeptides from recombinant cell culture
CC      or natural sources. The antibody, PRO polypeptide, or its agonists or
CC      antagonists, may be used for preparing a medicament for diagnosing or
CC      treating a condition responsive to the antibody, PRO polypeptide, or its
CC      agonists or antagonists. This sequence encodes a novel human secreted and
CC      transmembrane PRO polypeptide.
XX
SQ      Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY      2121 CCTTGTCTTACCACACTCTTCTTTATCTTTATTAATAAATGTTGTCTCCACACTG 2180
Db      2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTGGCTTCTCAACTA 2712
QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db      2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY      2241 AA 2242
Db      2773 AA 2774

RESULT 763
ADCS2365
ID      ADCS2365 standard; cDNA; 2846 BP.
XX
AC      ADCS2365;
XX
XX      18-DEC-2003 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW      ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW      affinity purification; secreted and transmembrane protein.
XX
OS      Homo sapiens.
XX
PN      US2003138882-A1.
XX
PD      24-JUL-2003.
XX
XX      08-MAY-2002; 2002US-00063735.
XX
PR      30-DEC-1998; 98KR-00062142.
PR      08-MAR-1999; 99WO-US005028.
PR      14-MAY-1999; 99US-00311832.
PR      14-MAY-1999; 99WO-US010733.
PR      25-AUG-1999; 99US-00380137.
PR      25-AUG-1999; 99US-00380138.
PR      25-AUG-1999; 99US-00380139.
PR      25-AUG-1999; 99US-00380142.
PR

```

Wed Feb 16 11:37:55 2005

```
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005941.
PR 21-MAR-2000; 2000WO-US007532.
PR 02-MAY-2000; 2000WO-US014042.
PR 22-AUG-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 28-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-829699/77.
XX P-FSDB; ADC52366.
XX
XX Novel isolated secreted and transmembrane PRO1774 cDNA sequence, used as
XX hybridization probes, and useful for diagnosing rectal tumors.
XX
XX Disclosure; SEQ ID NO 37; 410pp; English.
XX
XX The invention describes an antibody that specifically binds to a PRO
XX polypeptide having a fully defined amino acid sequence given in the
XX specification. The antibody is useful in identifying PRO polypeptides
XX useful for various industrial applications, including pharmaceuticals,
XX diagnostics, biosensors and bioreactors. The antibody is also used for
XX affinity purification of PRO polypeptides from recombinant cell culture
XX or natural sources. The antibody, PRO polypeptide, or its agonists or
XX antagonists, may be used for preparing a medicament for diagnosing or
XX treating a condition responsive to the antibody, PRO polypeptide, or its
XX agonists or antagonists. This sequence encodes a novel human secreted and
XX transmembrane PRO polypeptide.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 10; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX QY 2121 CTTTTCCTTACCACTCTTCTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
XX DB 2653 CTTTTCCTTCCCACTCTTGTACACATTTTAAATAATAGGCTTGGCTTCTGACTA 2712
XX
XX QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
XX DB 2713 CAABAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
XX
XX QY 2241 AA 2242
XX DB 2773 AA 2774
```

RESULT 764
ADC14530
ID ADC14530 standard; cDNA; 2846 BP.
XX
AC ADC14530;
XX
DT 18-DEC-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX human; secreted and transmembrane protein; PRO; neurotropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease;
KW gene; ss.
XX
OS Homo sapiens.
XX
PN US2003082546-A1.
XX
PD 01-MAY-2003.
XX
PF 28-AUG-2001; 2001US-00941992.
XX
PR 06-NOV-1996; 96US-00743698.
PR 16-JUN-1997; 97US-0049787P.
PR 16-JUN-1997; 97US-00876698.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97US-00965056.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.

PR	17-JUN-1998,	98US-00856000,
PR	17-JUN-1998,	98US-00856031,
PR	18-JUN-1998,	98US-00898801P,
PR	18-JUN-1998,	98US-00899070P,
PR	18-JUN-1998,	98US-00899080P,
PR	19-JUN-1998,	98US-00899472P,
PR	19-JUN-1998,	98US-00899480P,
PR	19-JUN-1998,	98US-00899520P,
PR	22-JUN-1998,	98US-0090246P,
PR	22-JUN-1998,	98US-0090252P,
PR	23-JUN-1998,	98US-0090254P,
PR	23-JUN-1998,	98US-0090254P,
PR	23-JUN-1998,	98US-0090355P,
PR	23-JUN-1998,	98US-0090355P,
PR	24-JUN-1998,	98US-0090429P,
PR	24-JUN-1998,	98US-0090431P,
PR	24-JUN-1998,	98US-0090435P,
PR	24-JUN-1998,	98US-0090444P,
PR	24-JUN-1998,	98US-0090445P,
PR	24-JUN-1998,	98US-0090472P,
PR	24-JUN-1998,	98US-0090535P,
PR	24-JUN-1998,	98US-0090540P,
PR	24-JUN-1998,	98US-0090542P,
PR	24-JUN-1998,	98US-0090557P,
PR	25-JUN-1998,	98US-0090676P,
PR	25-JUN-1998,	98US-0090678P,
PR	25-JUN-1998,	98US-0090690P,
PR	25-JUN-1998,	98US-0090694P,
PR	25-JUN-1998,	98US-0090695P,
PR	25-JUN-1998,	98US-0090696P,
PR	26-JUN-1998,	98US-00105413,
PR	26-JUN-1998,	98US-0090862P,
PR	26-JUN-1998,	98US-0090863P,
PR	01-JUL-1998,	98US-0091360P,
PR	01-JUL-1998,	98US-0091544P,
PR	02-JUL-1998,	98US-0091478P,
PR	02-JUL-1998,	98US-0091519P,
PR	02-JUL-1998,	98US-0091626P,
PR	02-JUL-1998,	98US-0091628P,
PR	02-JUL-1998,	98US-0091633P,
PR	02-JUL-1998,	98US-0091646P,
PR	02-JUL-1998,	98US-0091673P,
PR	07-JUL-1998,	98US-0091978P,
PR	07-JUL-1998,	98US-0091982P,
PR	09-JUL-1998,	98US-0092182P,
PR	10-JUL-1998,	98US-0092472P,
PR	20-JUL-1998,	98US-0093301P,
PR	30-JUL-1998,	98US-0093329P,
PR	04-AUG-1998,	98US-0094651P,
PR	04-AUG-1998,	98US-0095282P,
PR	04-AUG-1998,	98US-0095285P,
PR	04-AUG-1998,	98US-0095301P,
PR	04-AUG-1998,	98US-0095302P,
PR	04-AUG-1998,	98US-0095318P,
PR	04-AUG-1998,	98US-0095321P,
PR	04-AUG-1998,	98US-0095325P,
PR	10-AUG-1998,	98US-0095329P,
PR	10-AUG-1998,	98US-0095757P,
PR	10-AUG-1998,	98US-0095929P,
PR	11-AUG-1998,	98US-0096012P,
PR	11-AUG-1998,	98US-0096143P,
PR	11-AUG-1998,	98US-0096146P,
PR	12-AUG-1998,	98US-0096329P,
PR	17-AUG-1998,	98US-0096757P,
PR	17-AUG-1998,	98US-0096766P,
PR	17-AUG-1998,	98US-0096768P,
PR	17-AUG-1998,	98US-0096773P,
PR	17-AUG-1998,	98US-0096791P,
PR	17-AUG-1998,	98US-0096867P,
PR	17-AUG-1998,	98US-0096891P,
PR	17-AUG-1998,	98US-0096894P,
PR	17-AUG-1998,	98US-0096895P,
PR	17-AUG-1998,	98US-0096897P,
PR	18-AUG-1998,	98US-0096949P,
PR	18-AUG-1998,	98US-0096950P,
PR	18-AUG-1998,	98US-0096959P,

PR	18-AUG-1998;	98US-00963602P
PR	18-AUG-1998;	98US-00970222P
PR	19-AUG-1998;	98US-00971141P
PR	20-AUG-1998;	98US-00972181P
PR	20-AUG-1998;	98US-00976661P
PR	26-AUG-1998;	98US-00979522P
PR	26-AUG-1998;	98US-00979542P
PR	26-AUG-1998;	98US-00979555P
PR	26-AUG-1998;	98US-0097971P
PR	26-AUG-1998;	98US-0097974P
PR	26-AUG-1998;	98US-0097977P
PR	26-AUG-1998;	98US-0097978P
PR	26-AUG-1998;	98US-0097979P
PR	26-AUG-1998;	98US-0097986P
PR	26-AUG-1998;	98US-00980144P
PR	31-AUG-1998;	98US-00985252P
PR	16-SEP-1998;	98US-0100634P
PR	17-SEP-1998;	98US-0100858P
PR	17-SEP-1998;	98US-01009193P
PR	07-OCT-1998;	98US-00169978
PR	07-OCT-1998;	98US-00502114P
PR	06-NOV-1998;	98US-00187368
PR	01-DEC-1998;	98US-005025108
PR	07-DEC-1998;	98US-00502054
PR	22-DEC-1998;	98US-00218517
PR	22-DEC-1998;	98US-00113296P
PR	05-JAN-1999;	99WO-US0000106
PR	03-FEB-1999;	99WO-US0030911
PR	03-MAR-1999;	99US-00254311
PR	08-MAR-1999;	99WO-US0050268
PR	09-MAR-1999;	99US-00254460
PR	12-MAR-1999;	99US-00267213
PR	12-MAR-1999;	99US-0123357P
PR	12-APR-1999;	99US-00284291
PR	23-JUN-1999;	99WO-US0012252
PR	23-JUN-1999;	99US-01141037P
PR	07-JUL-1999;	99US-01143048P
PR	20-JUL-1999;	99US-0144758P
PR	26-JUL-1999;	99US-0145698P
PR	28-JUL-1999;	99US-0146222P
PR	17-AUG-1999;	99US-0149396P
PR	25-AUG-1999;	99US-00380137
PR	25-AUG-1999;	99US-00380138
PR	25-AUG-1999;	99US-00380139
PR	15-SEP-1999;	99WO-US021090
PR	15-SEP-1999;	99WO-US021547
PR	08-OCT-1999;	99US-0158663P
PR	08-OCT-1999;	99US-0043296
PR	12-NOV-1999;	99US-00423844
PR	30-NOV-1999;	99WO-US028313
PR	01-DEC-1999;	99WO-US028301
PR	16-DEC-1999;	99WO-US028634
PR	05-JAN-2000;	99WO-US003095
PR	06-JAN-2000;	2000WO-US000219
PR	11-FEB-2000;	2000WO-US000376
PR	11-FEB-2000;	2000WO-US003565
PR	18-FEB-2000;	2000WO-US004341

Query Match	3.0%;	Score 66.6;	DB 10;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches 87:	Conservative	0;	Mismatches 35;	Indels 0;

Oy	2121	CCTTTGTTTACCACTCTTTTCCTTTTATCTATTATAAAAAATGTTGGTCTCCACCACACTG	2180
		{ }	
Dδ	2653	CCTTTTCTTTCCCCTCTCTTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACATA	2712
		{ }	
Oy	2181	NCTCCCCAAA	2240
		{ }	
Dδ	2713	CARAAA	2772
		{ }	
Oy	2241	AA 2242	
		{ }	
Dδ	2773	AA 2774	
		{ }	

RESULT 765

ADD08062

ID ADD08062 standard; cDNA; 2846 BP.

XX AC ADD08062;

XX DT 01-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX KW Human; secreted protein; transmembrane protein; PRO;

KW neonatal heart hypertrophy; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW rod photoreceptor cell; c-fos induction; adipocyte;

KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;

KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;

KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;

KW polycystic kidney disease; renal tumour; neurodegenerative disorder;

KW Parkinson's disease; Alzheimer's disease; gene therapy;

KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;

KW antidiabetic; antianaemic; cytosstatic; neuroprotective;

KW antiparkinsonian; gene; ss.

XX OS Homo sapiens.

XX PN US2003068623-A1.

XX DD 10-APR-2003.

XX FF 14-NOV-2001; 2001US-00993469.

XX PP 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0085186P.

XX PR 13-NOV-1997; 97US-0085311P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

XX PR 04-JUN-1998; 98US-0088025P.

XX PR 04-JUN-1998; 98US-0088026P.

XX PR 04-JUN-1998; 98US-0088028P.

XX PR 04-JUN-1998; 98US-0088029P.

XX PR 04-JUN-1998; 98US-0088030P.

XX PR 04-JUN-1998; 98US-0088033P.

XX PR 04-JUN-1998; 98US-0088036P.

XX PR 05-JUN-1998; 98US-0088167P.

XX PR 05-JUN-1998; 98US-0088202P.

XX PR 05-JUN-1998; 98US-0088212P.

XX PR 05-JUN-1998; 98US-0088217P.

XX PR 09-JUN-1998; 98US-0088655P.

XX PR 10-JUN-1998; 98US-0088734P.

XX PR 10-JUN-1998; 98US-0088738P.

XX PR 10-JUN-1998; 98US-0088742P.

XX PR 10-JUN-1998; 98US-0088810P.

XX PR 10-JUN-1998; 98US-0088824P.

XX PR 10-JUN-1998; 98US-0088826P.

XX PR 11-JUN-1998; 98US-0088858P.

XX PR 11-JUN-1998; 98US-0088861P.

XX PR 11-JUN-1998; 98US-0088876P.

XX PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 23-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090515P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-009057P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0092182P.
PR 09-JUL-1998; 98US-0092472P.
PR 10-JUL-1998; 98US-0093399P.
PR 20-JUL-1998; 98US-0094651P.
PR 30-JUL-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.

	Query Match	3.0%;	Score 66.6;	DB 10;	Length 2846;
	Best Local Similarity	71.3%;	Pred. No. 0.00023;		
	Matches	87;	Conservative	0;	Gaps 0;
			Mismatches 35;	Indels	
Qy	2121	CGTTGCTTTACACACTCTTTCCCTTTTATCTTTATTAATAAAAAATGTTGGTCTCCACACACTG	2180		
Db	2653	CGTTTTCTTCCCACTCTTGTCACATTTTATAAAAAATAGGGTTGGCTTCTGAACATA	2712		
Qy	2181	NCTCCCAAAAAA AA	2240		
Db	2713	CAAAAAA AA	2772		
Qy	2241	AA	2242		

Db 2773 AA 2774

RESULT 767
ADD07529
ID ADD07529 standard; cDNA; 2846 BP.
XX
AC ADD07529;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW antiparkinsonian; gene; ss.
XX
OS Homo sapiens.
XX
FN US2002193299-A1.
XX
PD 19-DEC-2002.
XX
PF 19-NOV-2001; 2001US-00989735.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087108P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088023P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088328P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088828P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US015264.
PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
XX WPI; 2003-657230/62.
DR P-PSDB; ADD07530.
XX
XX Isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and
PT PRO1375, which stimulate proliferation of stimulated T-lymphocytes and
PT are thus therapeutically useful e.g. for enhancing immune response.
XX

PS Claim 2; SEQ ID NO 230; 659pp; English.

XX The invention relates to human secreted and transmembrane PRO
CC polypeptides and the polynucleotides encoding them. The PRO polypeptides
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
CC or bioreactors. They are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,
CC inducing proliferation and/or re-differentiation of chondrocytes, or
CC inducing pancreatic beta-cell precursor differentiation into mature
CC pancreatic beta-cells. They may therefore be useful in the treatment of
CC various insulin deficient states in mammals, including diabetes mellitus,
CC and in treating undesired endothelial cell growth, e.g., inhibiting
CC tumour growth. The sequences are also useful for treating mammalian
CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
CC renal dysplasia, polycystic kidney disease, renal tumours, and other
CC cancers such as those of the colon, lung and breast. PRO polypeptides or
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
CC a sample; to link a bioactive molecule to a cell; to modulate a
CC biological activity of a cell; as molecular weight markers for protein
CC electrophoresis purposes; for tissue typing; to prepare a medicament for
CC treating a condition responsive to the polypeptide or antibody, such as
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
CC disease); and in various diagnostic assays. The PRO polynucleotides can
CC be used as hybridisation probes, in chromosome and gene mapping, in
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
CC may also be used in preparing PRO polypeptides by recombinant techniques,
CC and in generating either transgenic animals or knock-out animals which,
CC in turn, are useful in the development and screening of therapeutically
CC useful reagents. This sequence represents a human PRO polynucleotide of
CC the invention. Note: The sequence data for this patent is also available
CC in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTACCACCTCTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTCCTTCCCACTCTCTGTACATTTTAAATAAGGTTGGTCTTCTGACTA 2712
QY 2181 NCTCCCAAA 2240
DB 2713 CAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 768

AD82420
ID ADC82420 standard; cDNA; 2846 BP.

XX AC ADC82420;

XX DT 01-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #65.

XX KW Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;
KW haemoglobin-associated disorder; thalassaemia; endothelial cell growth;
KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
KW antidiabetic; antianemic; cytostatic; cardiant; vulnerary;
KW antiinflammatory; anorectic.
XX OS Homo sapiens.

XX PN US2003059833-A1.
XX XX 27-MAR-2003.
XX PF 15-NOV-2001; 2001US-00997440.
XX PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 28-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.

PR	24-JUN-1998;	98US-0090542P.
PR	24-JUN-1998;	98US-0090557P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090690P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090699P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-0090862P.
PR	01-JUL-1998;	98US-0090863P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091519P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.
PR	02-JUL-1998;	98US-0091633P.
PR	02-JUL-1998;	98US-0091646P.
PR	02-JUL-1998;	98US-0091673P.
PR	07-JUL-1998;	98US-0091978P.
PR	07-JUL-1998;	98US-0091982P.
PR	09-JUL-1998;	98US-0092182P.
PR	10-JUL-1998;	98US-0092472P.
PR	20-JUL-1998;	98US-0093339P.
PR	30-JUL-1998;	98US-0094651P.
PR	04-AUG-1998;	98US-0095282P.
PR	04-AUG-1998;	98US-0095285P.
PR	04-AUG-1998;	98US-0095301P.
PR	04-AUG-1998;	98US-0095302P.
PR	04-AUG-1998;	98US-0095318P.
PR	04-AUG-1998;	98US-0095321P.
PR	04-AUG-1998;	98US-0095323P.
PR	10-AUG-1998;	98US-0095916P.
PR	10-AUG-1998;	98US-0095929P.
PR	10-AUG-1998;	98US-0096012P.
PR	11-AUG-1998;	98US-0096143P.
PR	11-AUG-1998;	98US-0096146P.
PR	12-AUG-1998;	98US-0096329P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096768P.
PR	17-AUG-1998;	98US-0096773P.
PR	17-AUG-1998;	98US-0096791P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096894P.
PR	17-AUG-1998;	98US-0096895P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096950P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0096960P.
PR	18-AUG-1998;	98US-0097022P.
PR	19-AUG-1998;	98US-0097141P.
PR	20-AUG-1998;	98US-0097218P.
PR	24-AUG-1998;	98US-0097661P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0097978P.
PR	26-AUG-1998;	98US-0097986P.
PR	26-AUG-1998;	98US-0098014P.
PR	31-AUG-1998;	98US-0098525P.
PR	16-SEP-1998;	98US-0100634P.
PR	16-SEP-1998;	98US-0100633P.
PR	17-SEP-1998;	98US-0100858P.
PR	17-SEP-1998;	98US-0100859P.
PR	07-OCT-1998;	98US-0100858P.
PR	01-DEC-1998;	98US-0100858P.
PR	22-DEC-1998;	98US-0113296P.

PR	05-JAN-1999;	99WO-US000106.
PR	20-FEB-1999;	99WO-US030911.
PR	08-MAR-1999;	99WO-US005028.
PR	12-MAR-1999;	99US-0123957P.
PR	02-JUN-1999;	99WO-US012252.
PR	23-JUN-1999;	99US-0141037P.
PR	07-JUL-1999;	99US-0143048P.
PR	20-JUL-1999;	99US-0144758P.
PR	26-JUL-1999;	99US-0145698P.
PR	28-JUL-1999;	99US-0146222P.
PR	17-AUG-1999;	99US-0149396P.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	08-OCT-1999;	99US-0158663P.
PR	30-NOV-1999;	99WO-US028313.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	16-DEC-1999;	99WO-US030095.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004514.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-2000;	2000WO-US013358.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-JUN-2000;	2000US-0213637P.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US0202031.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
Qy	2121	CCTTTGCTTTACCACTCTTTTCCTTTTATCTTTATTAATAAATAAATGTTGCTTCCCACTG	2180
Db	2653	CTTTTCCTTCCCATCTCTGTACACATTTTATAATAAAGGTTGGCTTCTGAACCTA	2712
Qy	2181	NTCCCAAA	2240
Db	2713	CAAA	2772
Qy	2241	AA 2242	
Db	2773	AA 2774	
RESULT 769			
ADD05642			
ID	ADD05642 standard; cDNA; 2846 BP.		
XX	AC ADD05642;		
XX	01-JAN-2004 (first entry)		
DT	Human secreted/transmembrane protein (PRO) cDNA #85.		
DE	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;		
XX	tumour necrosis factor alpha; chondrocyte cell; gene therapy;		
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;		
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.		
XX	Homo sapiens.		
OS			
XX			

PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090532P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 10-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.

PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0113296P.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0123957P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0149396P.
PR 30-NOV-1999; 98US-0158663P.
PR 08-OCT-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 16-DEC-1999; 98US-0158663P.
PR 20-DEC-1999; 98US-0158663P.
PR 05-JAN-2000; 98US-0158663P.
PR 06-JAN-2000; 98US-0158663P.
PR 11-FEB-2000; 98US-0158663P.
PR 18-FEB-2000; 98US-0158663P.
PR 22-FEB-2000; 98US-0158663P.
PR 24-FEB-2000; 98US-0158663P.
PR 24-FEB-2000; 98US-0158663P.
PR 02-MAR-2000; 98US-0158663P.
PR 10-MAR-2000; 98US-0158663P.
PR 15-MAR-2000; 98US-0158663P.
PR 20-MAR-2000; 98US-0158663P.
PR 30-MAR-2000; 98US-0158663P.
PR 15-MAY-2000; 98US-0158663P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATTTATTAATAAAATCTTCTCCACTG 2180
Db 2653 CCTTTTCTTTCCCACTCTTTGACATTTTATAATAAAGGTTGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 771
ADD06849
ID ADD06849 standard; cdna; 2846 BP.
XX


```
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091982P.
PR 07-JUL-1998; 98US-0091987P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-01019437.
PR 17-SEP-1998; 98US-01021141.
PR 01-DEC-1998; 98US-01025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0123957P.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0123957P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.

PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99US-0149396P.
PR 15-SEP-1999; 99US-0149396P.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99US-0158663P.
PR 01-DEC-1999; 99US-0158663P.
PR 01-DEC-1999; 99US-0158663P.
PR 16-DEC-1999; 99US-0158663P.
PR 20-DEC-1999; 99US-0158663P.
PR 05-JAN-2000; 2000US-0158663P.
PR 06-JAN-2000; 2000US-0158663P.
PR 11-FEB-2000; 2000US-0158663P.
PR 18-FEB-2000; 2000US-0158663P.
PR 22-FEB-2000; 2000US-0158663P.
PR 24-FEB-2000; 2000US-0158663P.
PR 24-FEB-2000; 2000US-0158663P.
PR 02-MAR-2000; 2000US-0158663P.
PR 10-MAR-2000; 2000US-0158663P.
PR 15-MAR-2000; 2000US-0158663P.
PR 20-MAR-2000; 2000US-0158663P.
PR 30-MAR-2000; 2000US-0158663P.
PR 15-MAY-2000; 2000US-0158663P.
PR 17-MAY-2000; 2000US-0158663P.
PR 22-MAY-2000; 2000US-0158663P.
PR 30-MAY-2000; 2000US-0158663P.
PR 02-JUN-2000; 2000US-0158663P.
PR 23-JUN-2000; 2000US-0158663P.
PR 28-JUL-2000; 2000US-0158663P.
PR 11-AUG-2000; 2000US-0158663P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CTTTCTTTTACCACTCTTTCTTTTATCTTATATAAAATGTTGGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CTTTCTTTTCTCCCACTCTCTGTACACATTTTAAATAAATAAGGTTGGTCTCTGAAC 2712
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 773
ADP55203
ID ADD55203 standard; cDNA; 2846 BP.
XX AC ADD55203;
XX DT 15-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #65.
XX KW Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
XX KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;
XX KW haemoglobin-associated disorder; thalassaemia; endothelial cell growth;
XX KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
XX KW antidiabetic; antianemic; cytostatic; cardiant; vulnery;
XX KW antiinflammatory; anorectic.
XX OS Homo sapiens.
XX PN US2003077593-A1.
XX PD 24-APR-2003.
XX PF 19-NOV-2001; 2001US-00989328.
XX
```

PR	16-JUN-1997;	97US-0049787P.	PR	25-JUN-1998;	98US-0090696P.
PR	17-OCT-1997;	97US-0022250P.	PR	26-JUN-1998;	98US-0090862P.
PR	05-NOV-1997;	97WO-US020069.	PR	26-JUN-1998;	98US-0090863P.
PR	12-NOV-1997;	97US-0065118P.	PR	01-JUL-1998;	98US-0091360P.
PR	24-NOV-1997;	97US-0065311P.	PR	01-JUL-1998;	98US-0091544P.
PR	25-FEB-1998;	98US-0066770P.	PR	02-JUL-1998;	98US-0091478P.
PR	20-MAR-1998;	98US-0075945P.	PR	02-JUL-1998;	98US-0091519P.
PR	28-APR-1998;	98US-0083332P.	PR	02-JUL-1998;	98US-0091626P.
PR	07-MAY-1998;	98US-00834600P.	PR	02-JUL-1998;	98US-0091628P.
PR	28-MAY-1998;	98US-0087106P.	PR	02-JUL-1998;	98US-0091633P.
PR	02-JUN-1998;	98US-0087607P.	PR	02-JUL-1998;	98US-0091646P.
PR	02-JUN-1998;	98US-0087609P.	PR	02-JUL-1998;	98US-0091673P.
PR	02-JUN-1998;	98US-0087759P.	PR	07-JUL-1998;	98US-0091978P.
PR	03-JUN-1998;	98US-0087827P.	PR	07-JUL-1998;	98US-0091982P.
PR	04-JUN-1998;	98US-0088021P.	PR	07-JUL-1998;	98US-0092182P.
PR	04-JUN-1998;	98US-0088025P.	PR	10-JUL-1998;	98US-0092472P.
PR	04-JUN-1998;	98US-0088026P.	PR	20-JUL-1998;	98US-0093339P.
PR	04-JUN-1998;	98US-0088028P.	PR	30-JUL-1998;	98US-0094651P.
PR	04-JUN-1998;	98US-0088029P.	PR	04-AUG-1998;	98US-0095282P.
PR	04-JUN-1998;	98US-0088030P.	PR	04-AUG-1998;	98US-0095285P.
PR	04-JUN-1998;	98US-0088033P.	PR	04-AUG-1998;	98US-0095301P.
PR	04-JUN-1998;	98US-0088326P.	PR	04-AUG-1998;	98US-0095302P.
PR	05-JUN-1998;	98US-0088167P.	PR	04-AUG-1998;	98US-0095318P.
PR	05-JUN-1998;	98US-0088202P.	PR	04-AUG-1998;	98US-0095321P.
PR	05-JUN-1998;	98US-0088212P.	PR	04-AUG-1998;	98US-0095325P.
PR	09-JUN-1998;	98US-0088217P.	PR	10-AUG-1998;	98US-0095916P.
PR	10-JUN-1998;	98US-0088655P.	PR	10-AUG-1998;	98US-0095929P.
PR	10-JUN-1998;	98US-0088734P.	PR	11-AUG-1998;	98US-0096012P.
PR	10-JUN-1998;	98US-0088738P.	PR	11-AUG-1998;	98US-0096143P.
PR	10-JUN-1998;	98US-0088742P.	PR	11-AUG-1998;	98US-0096146P.
PR	10-JUN-1998;	98US-0088810P.	PR	12-AUG-1998;	98US-0096329P.
PR	10-JUN-1998;	98US-0088824P.	PR	17-AUG-1998;	98US-0096757P.
PR	10-JUN-1998;	98US-0088826P.	PR	17-AUG-1998;	98US-0096766P.
PR	11-JUN-1998;	98US-0088858P.	PR	17-AUG-1998;	98US-0096768P.
PR	11-JUN-1998;	98US-0088861P.	PR	17-AUG-1998;	98US-0096773P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-AUG-1998;	98US-0096791P.
PR	12-JUN-1998;	98US-0089105P.	PR	17-AUG-1998;	98US-0096867P.
PR	16-JUN-1998;	98US-0089440P.	PR	17-AUG-1998;	98US-0096891P.
PR	16-JUN-1998;	98US-0089512P.	PR	17-AUG-1998;	98US-0096894P.
PR	16-JUN-1998;	98US-0089514P.	PR	17-AUG-1998;	98US-0096895P.
PR	17-JUN-1998;	98US-0089532P.	PR	17-AUG-1998;	98US-0096897P.
PR	17-JUN-1998;	98US-0089538P.	PR	18-AUG-1998;	98US-0096949P.
PR	17-JUN-1998;	98US-0089598P.	PR	18-AUG-1998;	98US-0096950P.
PR	17-JUN-1998;	98US-0089599P.	PR	18-AUG-1998;	98US-0096959P.
PR	17-JUN-1998;	98US-0089600P.	PR	18-AUG-1998;	98US-0096960P.
PR	17-JUN-1998;	98US-0089613P.	PR	18-AUG-1998;	98US-0097022P.
PR	18-JUN-1998;	98US-0089801P.	PR	19-AUG-1998;	98US-0097141P.
PR	18-JUN-1998;	98US-0089907P.	PR	20-AUG-1998;	98US-0097218P.
PR	18-JUN-1998;	98US-0089908P.	PR	20-AUG-1998;	98US-0097661P.
PR	19-JUN-1998;	98US-0089947P.	PR	26-AUG-1998;	98US-0097952P.
PR	19-JUN-1998;	98US-0089948P.	PR	26-AUG-1998;	98US-0097954P.
PR	19-JUN-1998;	98US-0089952P.	PR	26-AUG-1998;	98US-0097955P.
PR	22-JUN-1998;	98US-0090246			

```

PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACCTCTTCTTTATCTTTATTAATAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTTCCCATCTCTTGACACATTTTAAATAAAGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 774
ADD36041
ID ADD36041 standard; cDNA; 2846 BP.
XX AC
XX ADD36041;
XX AC
XX 15-JAN-2004 (first entry)
XX DE
XX Human PRO polynucleotide #65.
XX KW
XX Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
XX KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;
XX KW haemoglobin-associated disorder; thalassemia; endothelial cell growth;
XX KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
XX KW antidiabetic; antianaemic; cytostatic; cardiant; vulnery;
XX KW antiinflammatory; anorectic.
XX OS
XX Homo sapiens.
XX FN
XX US2003105298-A1.
XX PD
XX 05-JUN-2003.
XX PF
XX 03-MAY-2002; 2002US-00063580.
XX KW
XX 16-JUN-1998; 98US-0089514P.
XX PR
XX 02-JUN-1999; 99WO-US012252.
XX PR
XX 25-AUG-1999; 99US-00380137.

```

```

PR 24-AUG-2000; 2000WO-US023328.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-829362/77.
XX F-PSDB; ADD36042.
XX
XX New antibody that binds to a secreted and transmembrane polypeptide (PRO)
XX useful in diagnostic assays for PRO and as a PRO agonist or antagonist.
XX
XX Disclosure; Fig 37; 408pp; English.
XX
XX The invention describes an antibody that specifically binds to a PRO
XX polypeptide having a fully defined amino acid sequence given in the
XX specification. The antibody is useful in identifying PRO polypeptides
XX useful for various industrial applications, including pharmaceuticals,
XX diagnostics, biosensors and bioreactors. The antibody is also used for
XX affinity purification of PRO polypeptides from recombinant cell culture
XX or natural sources. The antibody, PRO polypeptide, or its agonists or
XX antagonists, may be used for preparing a medicament for diagnosing or
XX treating a condition responsive to the antibody, PRO polypeptide, or its
XX agonists or antagonists. This sequence encodes a novel human secreted and
XX transmembrane PRO polypeptide.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACCTCTTCTTTATCTTTATTAATAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTTCCCATCTCTTGACACATTTTAAATAAAGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 775
ADD56161
ID ADD56161 standard; cDNA; 2846 BP.
XX AC
XX ADD56161;
XX AC
XX 15-JAN-2004 (first entry)
XX DE
XX Human PRO polynucleotide #65.
XX KW
XX Human; PRO; gene; ss; pancreatic beta-cell precursor cell;
XX KW pancreatic beta-cell; insulin deficiency; diabetes mellitus;
XX KW haemoglobin-associated disorder; thalassemia; endothelial cell growth;
XX KW cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour;
XX KW antidiabetic; antianaemic; cytostatic; cardiant; vulnery;
XX KW antiinflammatory; anorectic.
XX OS
XX Homo sapiens.
XX FN
XX US2003077594-A1.
XX PD
XX 24-APR-2003.
XX PF
XX 14-NOV-2001; 2001US-00993583.
XX PR
XX 16-JUN-1997; 97US-0049787P.

```

PR 17-OCT-1997; 97US-0062350P.
PR 05-NOV-1997; 97WO-US00006P.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 30-JUL-1998; 98US-0093339P.
PR 04-AUG-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096857P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.

PR	16-JUN-1997;	97UTS-0043787P
PR	17-OCT-1997;	97UTS-0062250P
PR	05-NOV-1997;	97WNO-US020069
PR	12-NOV-1997;	97UTS-0065186P
PR	13-NOV-1997;	97UTS-0065311P
PR	23-NOV-1997;	97UTS-0066770P
PR	23-FEB-1998;	98UTS-0075945P
PR	20-MAR-1998;	98UTS-0078910P
PR	02-APR-1998;	98UTS-0083322P
PR	07-MAY-1998;	98UTS-0084600P
PR	28-MAY-1998;	98UTS-0087106P
PR	02-JUN-1998;	98UTS-0087607P
PR	02-JUN-1998;	98UTS-0087609P
PR	02-JUN-1998;	98UTS-0087759P
PR	03-JUN-1998;	98UTS-0087827P
PR	04-JUN-1998;	98UTS-0088021P
PR	04-JUN-1998;	98UTS-0088025P
PR	04-JUN-1998;	98UTS-0088026P
PR	04-JUN-1998;	98UTS-0088167P
PR	03-JUN-1998;	98UTS-0088202P
PR	05-JUN-1998;	98UTS-0088212P
PR	05-JUN-1998;	98UTS-0088217P
PR	09-JUN-1998;	98UTS-0088655P
PR	10-JUN-1998;	98UTS-0088734P
PR	10-JUN-1998;	98UTS-0088738P
PR	10-JUN-1998;	98UTS-0088742P
PR	10-JUN-1998;	98UTS-0088810P
PR	10-JUN-1998;	98UTS-0088824P
PR	10-JUN-1998;	98UTS-0088826P
PR	11-JUN-1998;	98UTS-0088858P
PR	11-JUN-1998;	98UTS-0088861P
PR	11-JUN-1998;	98UTS-0088876P
PR	12-JUN-1998;	98UTS-0089105P
PR	16-JUN-1998;	98UTS-0089440P
PR	16-JUN-1998;	98UTS-0089512P
PR	16-JUN-1998;	98UTS-0089532P
PR	17-JUN-1998;	98UTS-0089538P
PR	17-JUN-1998;	98UTS-0089598P
PR	17-JUN-1998;	98UTS-0089599P
PR	17-JUN-1998;	98UTS-0089600P
PR	17-JUN-1998;	98UTS-0089653P
PR	18-JUN-1998;	98UTS-0089801P
PR	18-JUN-1998;	98UTS-0089907P
PR	05-JAN-1999;	99WNO-US020313
PR	08-MAR-1999;	99WNO-US005106
PR	16-SEP-1998;	98WNO-US019330
PR	17-SEP-1998;	98WNO-US019437
PR	07-OCT-1998;	98WNO-US021141
PR	01-DEC-1998;	98WNO-US025108
PR	05-JAN-1999;	99WNO-US000528
PR	08-MAR-1999;	99WNO-US005068
PR	12-JUN-1999;	99WNO-US012252
PR	15-SEP-1999;	99WNO-US021090
PR	15-SEP-1999;	99WNO-US021547
PR	30-NOV-1999;	99WNO-US028313
PR	01-DEC-1999;	99WNO-US028301
PR	16-DEC-1999;	99WNO-US028634
PR	16-DEC-1999;	99WNO-US030095
PR	20-DEC-1999;	99WNO-US030911
PR	06-JAN-2000;	2000WNO-US000219
PR	06-JAN-2000;	2000WNO-US000376
PR	11-FEB-2000;	2000WNO-US003565
PR	18-FEB-2000;	2000WNO-US004341
PR	22-FEB-2000;	2000WNO-US004414
PR	24-FEB-2000;	2000WNO-US004914
PR	24-FEB-2000;	2000WNO-US005004
PR	02-MAR-2000;	2000WNO-US005841
PR	10-MAR-2000;	2000WNO-US006319

PR	17-JUN-1998;	98US-0089600P.	PR	19-AUG-1998;	98US-0097141P.	PR	17-AUG-1998;	98US-0089600P.	PR	19-AUG-1998;	98US-0097141P.
PR	17-JUN-1998;	98US-0089653P.	PR	20-AUG-1998;	98US-0097218P.	PR	20-AUG-1998;	98US-0089653P.	PR	20-AUG-1998;	98US-0097218P.
PR	17-JUN-1998;	98US-0089801P.	PR	24-AUG-1998;	98US-0097661P.	PR	24-AUG-1998;	98US-0089801P.	PR	24-AUG-1998;	98US-0097661P.
PR	18-JUN-1998;	98US-0089907P.	PR	26-AUG-1998;	98US-0097952P.	PR	26-AUG-1998;	98US-0089907P.	PR	26-AUG-1998;	98US-0097952P.
PR	18-JUN-1998;	98US-0089908P.	PR	26-AUG-1998;	98US-0097954P.	PR	26-AUG-1998;	98US-0089908P.	PR	26-AUG-1998;	98US-0097954P.
PR	18-JUN-1998;	98US-0089948P.	PR	26-AUG-1998;	98US-0097955P.	PR	26-AUG-1998;	98US-0089948P.	PR	26-AUG-1998;	98US-0097955P.
PR	19-JUN-1998;	98US-0089952P.	PR	26-AUG-1998;	98US-0097971P.	PR	26-AUG-1998;	98US-0089952P.	PR	26-AUG-1998;	98US-0097971P.
PR	22-JUN-1998;	98US-0090246P.	PR	26-AUG-1998;	98US-0097974P.	PR	26-AUG-1998;	98US-0090246P.	PR	26-AUG-1998;	98US-0097974P.
PR	22-JUN-1998;	98US-0090252P.	PR	26-AUG-1998;	98US-0097978P.	PR	26-AUG-1998;	98US-0090252P.	PR	26-AUG-1998;	98US-0097978P.
PR	22-JUN-1998;	98US-0090254P.	PR	26-AUG-1998;	98US-0097986P.	PR	26-AUG-1998;	98US-0090254P.	PR	26-AUG-1998;	98US-0097986P.
PR	23-JUN-1998;	98US-0090349P.	PR	26-AUG-1998;	98US-0098014P.	PR	26-AUG-1998;	98US-0090349P.	PR	26-AUG-1998;	98US-0098014P.
PR	23-JUN-1998;	98US-0090355P.	PR	31-AUG-1998;	98US-0098525P.	PR	31-AUG-1998;	98US-0090355P.	PR	31-AUG-1998;	98US-0098525P.
PR	24-JUN-1998;	98US-0090429P.	PR	16-SEP-1998;	98US-0100634P.	PR	16-SEP-1998;	98US-0090429P.	PR	16-SEP-1998;	98US-0100634P.
PR	24-JUN-1998;	98US-0090435P.	PR	16-SEP-1998;	98WO-US019330.	PR	16-SEP-1998;	98US-0090435P.	PR	16-SEP-1998;	98WO-US019330.
PR	24-JUN-1998;	98US-0090444P.	PR	17-SEP-1998;	98US-0100858P.	PR	17-SEP-1998;	98US-0090444P.	PR	17-SEP-1998;	98US-0100858P.
PR	24-JUN-1998;	98US-0090445P.	PR	17-SEP-1998;	98WO-US019437.	PR	17-SEP-1998;	98US-0090445P.	PR	17-SEP-1998;	98WO-US019437.
PR	24-JUN-1998;	98US-0090472P.	PR	07-OCT-1998;	98WO-US021141.	PR	07-OCT-1998;	98US-0090472P.	PR	07-OCT-1998;	98WO-US021141.
PR	24-JUN-1998;	98US-0090535P.	PR	01-DEC-1998;	98WO-US025108.	PR	01-DEC-1998;	98US-0090535P.	PR	01-DEC-1998;	98WO-US025108.
PR	24-JUN-1998;	98US-0090540P.	PR	22-DEC-1998;	98US-0113296P.	PR	22-DEC-1998;	98US-0090540P.	PR	22-DEC-1998;	98US-0113296P.
PR	24-JUN-1998;	98US-0090542P.	PR	05-JAN-1999;	99WO-US000106.	PR	05-JAN-1999;	98US-0090542P.	PR	05-JAN-1999;	99WO-US000106.
PR	24-JUN-1998;	98US-0090557P.	PR	20-FEB-1999;	99WO-US030911.	PR	20-FEB-1999;	98US-0090557P.	PR	20-FEB-1999;	99WO-US030911.
PR	25-JUN-1998;	98US-0090676P.	PR	08-MAR-1999;	99WO-US005028.	PR	08-MAR-1999;	98US-0090676P.	PR	08-MAR-1999;	99WO-US005028.
PR	25-JUN-1998;	98US-0090678P.	PR	12-MAR-1999;	99WO-US012252.	PR	12-MAR-1999;	98US-0090678P.	PR	12-MAR-1999;	99WO-US012252.
PR	25-JUN-1998;	98US-0090690P.	PR	02-JUN-1999;	99WO-US014037P.	PR	02-JUN-1999;	98US-0090690P.	PR	02-JUN-1999;	99WO-US014037P.
PR	25-JUN-1998;	98US-0090694P.	PR	23-JUN-1999;	99US-0143048P.	PR	23-JUN-1999;	98US-0090694P.	PR	23-JUN-1999;	99US-0143048P.
PR	25-JUN-1998;	98US-0090595P.	PR	07-JUL-1999;	99US-0144758P.	PR	07-JUL-1999;	98US-0090595P.	PR	07-JUL-1999;	99US-0144758P.
PR	25-JUN-1998;	98US-0090862P.	PR	26-JUL-1999;	99US-0145698P.	PR	26-JUL-1999;	98US-0090862P.	PR	26-JUL-1999;	99US-0145698P.
PR	26-JUN-1998;										

[illegible]

XX Disclosure; Fig 37; 387pp; English.

XX The invention describes an antibody that specifically binds to a PRO

CC polypeptide having a fully defined amino acid sequence given in the

CC specification. The antibody is useful in identifying PRO polypeptides

CC useful for various industrial applications, including pharmaceuticals,

CC diagnostics, biosensors and bioreactors. The antibody is also used for

CC affinity purification of PRO polypeptides from recombinant cell culture

CC or natural sources. The antibody, PRO polypeptide, or its agonists or

CC antagonists, may be used for preparing a medicament for diagnosing or

CC treating a condition responsive to the antibody, PRO polypeptide, or its

CC agonists or antagonists. This sequence encodes a novel human secreted and

CC transmembrane PRO polypeptide.

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTATTATATAAAATGTTGGTCTCCACCACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAAATAGGGTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAAAA AA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 781

ADG08595

ID ADG08595 standard; cDNA; 2846 BP.

AC ADG08595;

XX

DT 26-FEB-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

XX affinity purification; secreted and transmembrane protein.

XX Homo sapiens.

XX

XX US2003180793-A1.

XX

XX 25-SEP-2003.

XX

XX 02-MAY-2002; 2002US-00063546.

XX

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 18-OCT-1999; 99US-00403297.

XX 12-NOV-1999; 99US-00423844.

XX 30-DEC-1999; 99WO-US031274.

XX 18-FEB-2000; 2000WO-US004341.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005841.

XX 21-MAR-2000; 2000WO-US007532.

XX 22-MAY-2000; 2000WO-US014042.

XX 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX

XX (GETH) GENENTECH INC.

XX

XX Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX

XX WPI; 2003-787560/74.

DR P-PSDB; ADG08596.

XX

XX Novel antibody that binds to a PRO polypeptide, useful for treating in

PT cancer and in diagnostic assays, for e.g. detecting PRO expression in

PT specific cells, tissues, or serum.

XX

XX Disclosure; SEQ ID NO 37; 562pp; English.

XX

XX The invention describes an antibody that specifically binds to a PRO

CC polypeptide having a fully defined amino acid sequence given in the

CC specification. The antibody is useful in identifying PRO polypeptides

CC useful for various industrial applications, including pharmaceuticals,

CC diagnostics, biosensors and bioreactors. The antibody is also used for

CC affinity purification of PRO polypeptides from recombinant cell culture

CC or natural sources. The antibody, PRO polypeptide, or its agonists or

CC antagonists, may be used for preparing a medicament for diagnosing or

CC treating a condition responsive to the antibody, PRO polypeptide, or its

CC agonists or antagonists. This sequence encodes a novel human secreted and

CC transmembrane PRO polypeptide.

XX

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

SQ

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTATTATATAAAATGTTGGTCTCCACCACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAAATAGGGTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAAAA AA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 782

ADG02637

ID ADG02637 standard; cDNA; 2846 BP.

XX

XX ADG02637;

XX

XX 26-FEB-2004 (first entry)

XX

```

DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX
KW ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
KW secreted and transmembrane protein; PRO; chromosome mapping;
XX gene mapping; tumour.
XX
OS Homo sapiens.
XX
XX US2003207397-A1.
XX
XX 06-NOV-2003.
XX
XX 15-JUL-2002; 2002US-00195900.
XX
XX 14-MAR-2000; 2000US-0189320P.
XX
XX 28-FEB-2001; 2001WO-US006520.
XX
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-864790/80.
XX P-PSDB; ADG02638.
XX
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
XX particularly for treating e.g. lung or breast tumors, or arthritis in a
XX mammal.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO polypeptides
XX (secreted and transmembrane). The polynucleotide is useful in molecular
XX biology, including uses as hybridisation probes, in chromosome and gene
XX mapping, in generating antisense RNA and DNA, and in gene therapy. The
XX polynucleotide may also be used in preparing PRO polypeptides by
XX recombinant techniques, and in generating either transgenic animals or
XX knock-out animals which, in turn, are useful in the development and
XX screening of therapeutically useful reagents. The PRO polypeptide or the
XX antibody is used in preparing a medicament for treating a condition
XX responsive to the polypeptide or antibody, such as tumours, and in
XX various diagnostic assays. This sequence encodes a novel human secreted
XX and transmembrane PRO polypeptide.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 10; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX QY 2121 CCTTGGCTTTACCACTCTTCTTATTAATAAATAATGTTGCTCCACCACTG 2180
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 2653 CCTTTCTCTCCCACTCTTGTACACATTTTATAAATAAGGTTGGCTTCTGAAC 2712
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX QY 2241 AA 2242
XX |||||
XX Db 2773 AA 2774

RESULT 783
ADG01344
ID ADG01344 standard; cDNA; 2846 BP.
XX
XX AC ADG01344;
XX
XX 26-FEB-2004 (first entry)
XX
XX

```

```

DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX
KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
KW secreted and transmembrane protein; PRO; chromosome mapping;
XX gene mapping; tumour.
XX
XX OS Homo sapiens.
XX
XX PN US2003207399-A1.
XX
XX PD 06-NOV-2003.
XX
XX PF 24-JUL-2002; 2002US-00205506.
XX
XX PR 28-OCT-1998; 98US-0106033P.
XX
XX PR 01-SEP-1999; 99WO-US020111.
XX
XX PR 18-OCT-1999; 99US-00403297.
XX
XX PR 28-FEB-2001; 2001WO-US006520.
XX
XX PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX DR WPI; 2003-864792/80.
XX P-PSDB; ADG01345.
XX
XX PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
XX particularly for treating e.g. lung or breast tumors, or arthritis in a
XX mammal.
XX
XX PS Claim 2; SEQ ID NO 169; 700pp; English.
XX
XX CC The invention describes 305 nucleic acids encoding PRO polypeptides
XX (secreted and transmembrane). The polynucleotide is useful in molecular
XX biology, including uses as hybridisation probes, in chromosome and gene
XX mapping, in generating antisense RNA and DNA, and in gene therapy. The
XX polynucleotide may also be used in preparing PRO polypeptides by
XX recombinant techniques, and in generating either transgenic animals or
XX knock-out animals which, in turn, are useful in the development and
XX screening of therapeutically useful reagents. The PRO polypeptide or the
XX antibody is used in preparing a medicament for treating a condition
XX responsive to the polypeptide or antibody, such as tumours, and in
XX various diagnostic assays. This sequence encodes a novel human secreted
XX and transmembrane PRO polypeptide.
XX
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 10; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX QY 2121 CCTTGGCTTTACCACTCTTCTTATTAATAAATAATGTTGCTCCACCACTG 2180
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 2653 CCTTTCTCTCCCACTCTTGTACACATTTTATAAATAAGGTTGGCTTCTGAAC 2712
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX QY 2241 AA 2242
XX |||||
XX Db 2773 AA 2774

RESULT 784
ADP95519
ID ADP95519 standard; cDNA; 2846 BP.
XX
XX AC ADP95519;
XX
XX

```

DT 26-FEB-2004 (first entry)
 XX Novel human secreted and transmembrane protein PRO1344 cDNA.
 DE Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
 KW secreted and transmembrane protein; PRO; chromosome mapping;
 KW gene mapping; tumour.
 XX Homo sapiens.
 OS
 XX US2003207398-A1.
 PN
 XX 06-NOV-2003.
 PD
 XX 18-JUL-2002; 2002US-00198759.
 XX 22-APR-1998; 98US-0082704P.
 PR 08-MAR-1999; 99WO-US005028.
 PR 25-AUG-1999; 99US-00380138.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 PI WPI; 2003-864791/80.
 DR P-PSDB; ADF95216.
 XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
 XX for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
 PT particularly for treating e.g. lung or breast tumors, or arthritis in a
 PT mammal.
 XX Claim 2; SEQ ID NO 169; 700pp; English.
 PS The invention describes 305 nucleic acids encoding PRO polypeptides
 CC (secreted and transmembrane). The polynucleotide is useful in molecular
 CC biology, including uses as hybridisation probes, in chromosome and gene
 CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
 CC polynucleotide may also be used in preparing PRO polypeptides by
 CC recombinant techniques, and in generating either transgenic animals or
 CC knock-out animals which, in turn, are useful in the development and
 CC screening of therapeutically useful reagents. The PRO polypeptide or the
 CC antibody is used in preparing a medicament for treating a condition
 CC responsive to the polypeptide or antibody, such as tumours, and in
 CC various diagnostic assays. This sequence encodes a novel human secreted
 CC and transmembrane PRO polypeptide.
 XX Sequence 2846 BP; 768 A; 596 C; 745 G; 637 T; 0 U; 0 Other;
 SQ

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCCTTGGTTTACCACTCTTCCCTTTATCTATTATAAATGCTGCTCCACCACTG 2180
 DB 2653 CTTTCTTCCCTCCCATCTCTGTACACATTTTATAAATGCTGCTTCTGAACCTA 2712
 QY 2181 NCTCCCAA 2240
 DB 2713 CAAAAAATAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774

RESULT 785
 ADF95216
 ID ADF95216 standard; cDNA; 2846 BP.
 XX

AC ADF95216;
 XX 26-FEB-2004 (first entry)
 XX Novel human secreted and transmembrane protein PRO1344 cDNA.
 DE ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.
 XX Homo sapiens.
 OS
 XX US2003180795-A1.
 PN
 XX 25-SEP-2003.
 PD
 XX 07-MAY-2002; 2002US-00063662.
 XX 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 15-SEP-1999; 99US-00380142.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665150.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00854280.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX (GETH) GENENTECH INC.
 PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX WPI; 2003-787562/74.
 DR P-PSDB; ADF95217.
 XX Novel antibody that binds to a PRO polypeptide, useful for treating
 PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
 PT specific cells, tissues, or serum.
 XX Disclosure; SEQ ID NO 37; 562pp; English.
 PS The invention describes an antibody that specifically binds to a PRO
 CC polypeptide having a fully defined amino acid sequence given in the
 CC specification. The antibody is useful in identifying PRO polypeptides
 CC useful for various industrial applications, including pharmaceuticals,


```
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 02-JUL-1998; 98US-0094006P.
PR 04-JUL-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 24-SEP-1998; 98US-0101926P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 25-SEP-1998; 98US-0102330P.
PR 29-JUN-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCCTTTACACACTCTTTCTCTTTATCTTATATAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAAATAAATAAGGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 787
ADH24069
ID ADH24069 standard; cDNA; 2846 BP.
XX ADH24069;
AC ADH24069;
XX 11-MAR-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
KW antiarthritic; antidiabetic; cytostatic; vulnery; hyperglycaemic;
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW bone disorder; cartilage disorder; sports injury; arthritis;
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
XX chromosome identification; gene therapy; gene; ss; human.
OS Homo sapiens.
XX US2003180918-A1.
PN 25-SEP-2003.
XX 08-MAY-2002; 2002US-00063722.
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
```


PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 PI
 XX
 XX WPI; 2003-830993/77.
 DR P-PSDB; ADH24070.
 XX
 XX
 PT New isolated PRO polypeptide, useful for treating various bone and/or
 PT cartilage disorders, for example, sports injuries and arthritis.
 XX
 XX Disclosure; SEQ ID NO 37; 397pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
 CC specification. The PRO polypeptides are useful for treating various bone
 CC and/or cartilage disorders, for example, sports injuries and arthritis.
 CC They are also useful in the therapeutic treatment of disorders where
 CC either the stimulation or inhibition of glucose uptake by skeletal muscle
 CC would be beneficial, for example, diabetes or hyper- or hypo-
 CC insulinemia. They are also useful for treating pericyte-associated
 CC tumours and in wound healing. The anti-PRO antibody is useful for the
 CC preparation of a medicament useful in the treatment of cancer. The PRO
 CC polypeptides are also useful as molecular weight markers, or for
 CC chromosome identification. The PRO genes are useful as hybridisation
 CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 CC The PRO genes may also be used in gene therapy, particularly for
 CC replacing a defective gene. This sequence encodes a secreted and
 CC transmembrane PRO protein.
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CCTTGGCTTACCACTCTTCTTATTAATAAATGTTGCTTCCACCACTG 2180
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATGAGGTTGCTTCTGAACTA 2712
 Qy 2181 NCTCCCAA 2240
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2713 CAAAAAATAA 2772
 Qy 2241 AA 2242
 Db |||||
 2773 AA 2774
 RESULT 788
 ADH34095
 ID ADH34095 standard; cDNA; 2846 BP.
 XX
 AC ADH34095;
 XX

DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX
 KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.
 XX
 OS Homo sapiens.
 XX
 XX US2003180858-A1.
 PN
 XX 25-SEP-2003.
 PD
 XX 08-MAY-2002; 2002US-00063730.
 XX
 PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 30-DEC-1999; 99WO-US042384.
 PR 12-NOV-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00864610.
 PR 18-SEP-2000; 2000US-00865350.
 PR 08-NOV-2000; 2000WO-US079238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX
 XX (GETH) GENENTECH INC.
 FA
 XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 PI
 XX
 XX WPI; 2003-778508/73.
 DR P-PSDB; ADH34096.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in molecular biology, chromosome and gene mapping, in generating
 PT antisense RNA and DNA, in various diagnostic assays and in gene therapy.
 XX
 XX Disclosure; SEQ ID NO 37; 397pp; English.
 PS
 XX The invention describes an antibody that specifically binds to a PRO
 CC polypeptide having a fully defined amino acid sequence given in the
 CC specification. The antibody is useful in identifying PRO polypeptides
 CC useful for various industrial applications, including pharmaceuticals,
 CC diagnostics, biosensors and bioreactors. The antibody is also used for
 CC affinity purification of PRO polypeptides from recombinant cell culture

CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
 CC technology, in generating transgenic animals or knock-out animals which
 CC may be used in the development and screening of therapeutically useful
 CC reagents, in gene therapy, in chromosome identification, as anti-PRO
 CC markers and in generating probes. The PRO polypeptides, or anti-PRO
 CC antibodies, are useful for preparing a medicament for treating a
 CC condition which is responsive to the PRO polypeptides or anti-PRO
 CC antibodies. The PRO polypeptides are useful as molecular markers for
 CC protein electrophoresis, and in tissue typing. This sequence represents a
 CC human PRO polynucleotide of the invention. Note: The sequence data for
 CC this patent is also available in electronic format from USPTO at
 CC seqdata.uspto.gov/sequence.html.

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTTATCTTATTAATAAATCTGTCTCCACCTG 2180

Db 2653 CTTTCTCTCCCATCTCTGTACACATTTTATAAATAGGCTTCTGAACCTA 2712

QY 2181 NCTCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240

Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 792

ADG85303

ID ADG85303 standard; cDNA; 2846 BP.

XX ADG85303;

AC ADG85303;

XX 11-MAR-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1344 cDNA.

XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

XX affinity purification; secreted and transmembrane protein.

XX Homo sapiens.

XX US2003180904-A1.

XX 25-SEP-2003.

XX 02-MAY-2002; 2002US-00063565.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 18-SEP-1999; 99US-00397342.

XX 12-OCT-1999; 99US-00403297.

XX 30-DEC-1999; 99WO-US031274.

XX 18-FEB-2000; 2000WO-US004541.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005841.

XX 21-MAR-2000; 2000WO-US007532.

XX 22-MAY-2000; 2000WO-US014042.

XX 02-JUN-2000; 2000WO-US015264.

XX 22-AUG-2000; 2000WO-US064484.

XX 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX (GETH) GENENTECH INC.

PA Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-830990/77.

DR P-PSDB; ADG85304.

XX New isolated PRO polypeptide, useful for treating various bone and/or

PT cartilage disorders, for example, sports injuries and arthritis.

XX Disclosure; SEQ ID NO 37; 397pp; English.

XX The invention describes an antibody that specifically binds to a PRO

CC polypeptide having a fully defined amino acid sequence given in the

CC specification. The antibody is useful in identifying PRO polypeptides

CC useful for various industrial applications, including pharmaceuticals,

CC diagnostics, biosensors and bioreactors. The antibody is also used for

CC affinity purification of PRO polypeptides from recombinant cell culture

CC or natural sources. The antibody, PRO polypeptide, or its agonists or

CC antagonists, may be used for preparing a medicament for diagnosing or

CC treating a condition responsive to the antibody, PRO polypeptide, or its

CC agonists or antagonists. This sequence encodes a novel human secreted and

CC transmembrane PRO polypeptide.

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

SQ

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTTATCTTATTAATAAATCTGTCTCCACCTG 2180

Db 2653 CTTTCTCTCCCATCTCTGTACACATTTTATAAATAGGCTTCTGAACCTA 2712

QY 2181 NCTCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240

Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 793

ADH24579

ID ADH24579 standard; cDNA; 2846 BP.

XX ADH24579;

AC ADH24579;

XX 11-MAR-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1344 cDNA.

XX antiarthritic; antidiabetic; cytostatic; vulnerary; hyperglycaemic;

CC method for stimulating proliferation or differentiation of chondrocyte
 CC cells and a method for detecting the presence of a tumour in a mammal
 CC comprising comparing the level of expression of any PRO polypeptide,
 CC given in the specification, in a test sample of cells taken from the
 CC mammal with a control sample of normal cells of the same cell type, where
 CC a higher level of expression of the PRO polypeptide in the test sample as
 CC compared to the control sample indicates the presence of a tumour in the
 CC mammal. The polynucleotides are useful as hybridisation probes in
 CC chromosome and gene mapping or in generating antisense RNA and DNA, for
 CC preparing PRO polypeptides, in assays to identify other proteins or
 CC molecules involved in binding reactions, to generate transgenic animals
 CC or knockout animals, which in turn are useful in the development and
 CC screening of therapeutically useful reagents, for chromosome
 CC identification and in tissue typing. The PRO polypeptides and
 CC polynucleotides are also useful in gene therapy and as molecular weight
 CC markers for protein electrophoresis. The anti-PRO antibodies may be used
 CC in diagnostic assays for PRO or for the affinity purification of PRO from
 CC recombinant cell culture or natural sources. This sequence represents a
 CC human PRO polynucleotide of the invention.

XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CTTTGGCTTTACCACTCTTCCTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180

DB 2653 CTTTCTCTTCCCATCTCTGTACACATTTAATAAATAGGTTGGCTTCGAACTA 2712

QY 2181 NCTCCCAA 2240

DB 2713 CAAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 796

ADH37605

ID ADH37605 standard; cDNA; 2846 BP.

AC ADH37605;

XX 11-MAR-2004 (first entry)

DT Human secreted and transmembrane protein PRO1344 cDNA.

XX PRO; cytostatic; antidiabetic; antiarthritic; osteopathic; antirheumatic;

KW secreted and transmembrane polypeptide; cancer; gene therapy; ss; gene;

KW human.

XX Homo sapiens.

OS US2003181648-A1.

XX 25-SEP-2003.

XX 03-MAY-2002; 2002US-00063615.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 18-OCT-1999; 99US-00403297.

XX 12-NOV-1999; 99US-00423844.

XX 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 24-AUG-2000; 2000US-00644848.

PR 18-SEP-2000; 2000US-0064610.

PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.

XX (GETH) GENENTECH INC.

PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-787567/74.

DR P-PSDB; ADH37606.

XX New antibody that binds to a PRO polypeptide, useful in diagnostic assays

PT for PRO, or in preparing a medicament for treating a condition that is

PT responsive to the PRO polypeptide or anti-PRO antibody, e.g. cancer or

PT diabetes.

XX Example 4; SEQ ID NO 37; 396pp; English.

PS This invention describes novel human PRO polypeptides and the

XX polynucleotides encoding them which have cytostatic, antidiabetic,

CC antiarthritic, osteopathic and antirheumatic activity. Specifically,

CC claimed are secreted and transmembrane polypeptides, e.g. PRO180, PRO218,

CC PRO263, PRO295, PRO874, PRO300, PRO1864, PRO1822, PRO1063 or PRO1773

CC polypeptide. The PRO polypeptides or anti-PRO antibodies are useful for

CC preparing a medicament for treating a condition that is responsive to the

CC PRO polypeptide or anti-PRO antibody e.g. cancer, diabetes,

CC osteoarthritis or rheumatoid arthritis. PRO nucleotide sequences may be

CC used as hybridisation probes in chromosome and gene mapping or in

CC generating antisense RNA and DNA. The PRO nucleic acids are also useful

CC in preparing PRO polypeptides, in assays to identify other proteins or

CC molecules involved in binding reaction, in generating transgenic animals

CC or knockout animals, which in turn are useful in the development and

CC screening of therapeutically useful reagents, for chromosome

CC identification and tissue typing. The PRO polypeptides and nucleic acid

CC molecules are also useful in gene therapy, and as molecular weight

CC markers for protein electrophoresis purposes. Anti-PRO antibodies may be

CC used in diagnostic assays for PRO, or for the affinity purification of

CC PRO from recombinant cell culture or natural sources. This sequence

CC encodes a PRO polypeptide described in the disclosure of the invention.

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

SQ Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CTTTGGCTTTACCACTCTTCCTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180

DB 2653 CTTTCTCTTCCCATCTCTGTACACATTTAATAAATAGGTTGGCTTCGAACTA 2712

PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.

(GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

WPI; 2003-830992/77.
 P-FSDB; ADH24240.

New isolated PRO polypeptide, useful for treating various bone and/or
 cartilage disorders, for example, sports injuries and arthritis.

Disclosure; SEQ ID NO 37; 397pp; English.

The invention describes an isolated PRO (secreted and transmembrane)
 polypeptide comprising the 642 amino acid sequence (S1) defined in the
 specification. The PRO polypeptides are useful for treating various bone
 and/or cartilage disorders, for example, sports injuries and arthritis.
 They are also useful in the therapeutic treatment of disorders where
 either the stimulation or inhibition of glucose uptake by skeletal muscle
 would be beneficial, for example, diabetes or hyper- or hypo-
 insulinemia. They are also useful for treating pericyte-associated
 tumours and in wound healing. The anti-PRO antibody is useful for the
 preparation of a medicament useful in the treatment of cancer. The PRO
 polypeptides are also useful as molecular weight markers, or for
 chromosome identification. The PRO genes are useful as hybridisation
 probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 The PRO genes may also be used in gene therapy, particularly for
 replacing a defective gene. This sequence encodes a secreted and
 transmembrane PRO protein.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCTCTCTTCTTTATCTATTATTAATAAATGTGTCTCCACCTG 2180
 Db CTTTTCCTCCCTCTCTGTGACATTTTAATAAATAGGCTTCTGAACTA 2712
 QY 2181 NCTCCCAA 2240
 Db 2713 CAA 2772

QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 799
 ADH38533
 ID ADH38533 standard; cDNA; 2846 BP.
 XX
 AC ADH38533;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX
 KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neurotrophin; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
 OS Homo sapiens.
 XX
 PN US2003181643-A1.
 XX
 PD 25-SEP-2003.
 XX
 PF 03-MAY-2002; 2002US-00063596.
 XX
 PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 18-SEP-2000; 2000US-00709238.
 PR 08-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX
 DR WPI; 2003-787565/74.

OY 2241 AA 2242
 DB 2773 AA 2774

RESULT 801

ADH29462
 ID ADH29462 standard; cDNA; 2846 BP.

AC ADH29462;

DT 11-MAR-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1344 cDNA.

XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.

XX Homo sapiens.

XX US2003180860-A1.

XX 25-SEP-2003.

XX 08-MAY-2002; 2002US-00063736.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 18-OCT-1999; 99US-00403297.

XX 12-NOV-1999; 99US-00423844.

XX 30-DEC-1999; 99WO-US031274.

XX 18-FEB-2000; 2000WO-US004341.

XX 01-MAR-2000; 2000WO-US005601.

XX 21-MAR-2000; 2000WO-US005841.

XX 02-MAR-2000; 2000WO-US005841.

XX 21-MAR-2000; 2000WO-US007532.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 12-OCT-1999; 99US-00403297.

PT New isolated PRO polypeptide, useful for treating various bone and/or

PT cartilage disorders, for example, sports injuries and arthritis.

PS Disclosure; SEQ ID NO 37; 397pp; English.

XX The invention describes an antibody that specifically binds to a PRO
 CC polypeptide having a fully defined amino acid sequence given in the
 CC specification. The antibody is useful in identifying PRO polypeptides
 CC useful for various industrial applications, including pharmaceuticals,
 CC diagnostics, biosensors and bioreactors. The antibody is also used for
 CC affinity purification of PRO polypeptides from recombinant cell culture
 CC or natural sources. The antibody, PRO polypeptide, or its agonists or
 CC antagonists, may be used for preparing a medicament for diagnosing or
 CC treating a condition responsive to the antibody, PRO polypeptide, or its
 CC agonists or antagonists. This sequence encodes a novel human secreted and
 CC transmembrane PRO polypeptide.

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

OY 2121 CCTTGTCTTACCACTCTTTCTTTTATCTATTATTAATAAAATGTGTCTCCACCTG 2180

DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACCTA 2712

OY 2181 NCTCCCAA 2240

DB 2713 CAAAAAATAA 2772

OY 2241 AA 2242

DB 2773 AA 2774

RESULT 802

ADH27578

ID ADH27578 standard; cDNA; 2846 BP.

XX ADH27578;

XX 11-MAR-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.

XX Homo sapiens.

XX US2003180906-A1.

XX 25-SEP-2003.

XX 03-MAY-2002; 2002US-00063591.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 12-OCT-1999; 99US-00403297.

XX 30-DEC-1999; 99WO-US031274.

XX 18-FEB-2000; 2000WO-US004341.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005841.

XX 21-MAR-2000; 2000WO-US007532.

(GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

WPI; 2003-830989/77.

P-ESDB; ADH29463.

PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000WO-US0644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.

(GETH) GENENTECH INC.

XX Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI,
PI
XX WPI: 2003-875157/81.
XX P-PSDB; ADH53515.

XX New isolated PRO polypeptide, useful for treating various bone and/or
XX cartilage disorders, for example, sports injuries and arthritis.

XX Disclosure; SEQ ID NO 37; 397pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neuropeptides or hormones) which are received and interpreted by diverse
XX cell receptors or transmembrane bound proteins. These membrane bound proteins
XX and receptors may be of use as pharmaceutical and diagnostic agents, such
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytostatic activities through the
XX stimulation of chondrocytes. The nucleic acids of the invention may be
XX useful for the manufacture of a medicament for diagnosing or treating a
XX tumour in a mammal. In addition, they may be useful for measuring or
XX detecting the expression of a tumour associated gene. The present
XX sequence is a cDNA sequence which encodes a human PRO protein of the
XX invention.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGGTTTACCACCTCTTTCTTTTATTAATAAATAATGTTGCTCTCCACCTG 2180
DB 2653 CCTTTTCTTCTCCCATCTCTTGTACACATTTAATAAATAAGGTTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 807
ADH53684
ID ADH53684 standard; cDNA; 2846 BP.
XX
AC ADH53684;
XX
DT 25-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX human; PRO; membrane bound protein; membrane bound receptor;
XX cell proliferation; cell migration; cell differentiation;
XX mitogenic factor; survival factor; cytotoxic factor;
XX differentiation factor; neuropeptide; hormone; cell receptor;
XX receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.
XX
XX US2003181641-A1.
XX
PD 25-SEP-2003.
XX
PF 03-MAY-2002; 2002US-00063589.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR-28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH) GENENTECH INC.
XX
XX Raton DL, Filvaroff E, Gerritson ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-875161/81.
DR P-PSDB; ADH53685.
XX
XX New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
XX Disclosure; SEQ ID NO 37; 396pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neurotrophins and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC act as receptors for a variety of extracellular signals, such as growth
CC factors, differentiation factors, neurotrophins, hormones, cell receptors;
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred.No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACCTTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATGAGGTGCTTCTGAACATA 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAAAAATAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.
OS US2003181638-A1.
PN 25-SEP-2003.
XX
XX 03-MAY-2002; 2002US-00063579.
XX
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 22-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH) GENENTECH INC.
XX
XX Raton DL, Filvaroff E, Gerritson ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-875158/81.
DR P-PSDB; ADH52021.
XX
XX New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
XX Disclosure; SEQ ID NO 37; 397pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neurotrophins and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC act as receptors for a variety of extracellular signals, such as growth
CC factors, differentiation factors, neurotrophins, hormones, cell receptors;
XX

AD125385
ID AD125385 standard; cDNA; 2846 BP.
AC
XX AD125385;
XX
DT 15-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX ss: gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
KW
XX
XX OS Homo sapiens.
XX
XX US2003181696-A1.
XX
XX
XX PD 25-SEP-2003.
XX
XX PF 02-MAY-2002; 2002US-00063536.
XX
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 25-AUG-1999; 99US-00397342.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000WO-US016744.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US016744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00865959.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-875175/81.
XX P-PSDB; AD125386.
XX
XX New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
XX Disclosure; SEQ ID NO 37; 397pp; English.
XX
XX The invention relates to a novel PRO (secreted and transmembrane protein)
CC polypeptide, and the polynucleotide sequence encoding it. Also included

are a vector comprising the novel nucleic acid and a host cell comprising
the vector. The polynucleotide sequence is useful in molecular biology as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
may also be used in preparing the PRO polypeptide by recombinant
techniques, and in generating either transgenic or knock-out animals
which, in turn, are useful in the development and screening of
therapeutically useful reagents. The PRO polynucleotide sequence is
useful in preparing a medicament for treating a condition responsive to
the polypeptide or antibody, such as tumours, and in various diagnostic
assays. The specification also discloses other PRO proteins and the
polynucleotide sequences encoding them. The present sequence encodes a
PRO protein.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACACTG 2180
DB 2653 CCTTTCTTCCCATCTCTTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
DB 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 811
ADH90178
ID ADH90178 standard; cDNA; 2846 BP.
XX
XX AC ADH90178;
XX
XX DT 15-APR-2004 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX KW ss: gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX
XX OS Homo sapiens.
XX
XX PN US2003181698-A1.
XX
XX PD 25-SEP-2003.
XX
XX PF 07-MAY-2002; 2002US-00063638.
XX
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00664848.

PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001WO-US0874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.

XX (GETH) GENENTECH INC.

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

DR WPI; 2003-875177/81.
 DR P-PSDB; ADH90179.

XX New isolated PRO polypeptide, useful for treating various bone and/or
 PT cartilage disorders, for example, sports injuries and arthritis.

XX Disclosure; SEQ ID NO 37; 397pp; English.

XX The invention relates to a novel PRO (secreted and transmembrane protein)
 CC polypeptide, and the polynucleotide sequence encoding it. Also included
 CC are a vector comprising the novel nucleic acid and a host cell comprising
 CC the vector. The polynucleotide sequence is useful in molecular biology as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
 CC may also be used in preparing the PRO polypeptide by recombinant
 CC techniques, and in generating either transgenic or knock-out animals
 CC which, in turn, are useful in the development and screening of
 CC therapeutically useful reagents. The PRO polynucleotide sequence is
 CC useful in preparing a medicament for treating a condition responsive to
 CC the polypeptide or antibody, such as tumours, and in various diagnostic
 CC assays. The specification also discloses other PRO proteins and the
 CC polynucleotide sequences encoding them. The present sequence encodes a
 CC PRO protein.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGTCTTACCTCTTCTTTATCTATTATAATAAATGTTGCTCCACCACTG 2180

Db 2653 CTTTCTCTCCCATCTCTGTACACATTTTATAATAAATGTTGCTCTCGAATA 2712

Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240

Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 812

ID AD125555

XX AD125555 standard; cDNA; 2846 BP.

AC AD125555;

XX

DT 15-APR-2004 (first entry)
 XX Novel human secreted and transmembrane protein PRO1344 cDNA.
 DE
 XX ss: gene; human; PRO: pharmaceutical, diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.
 KW
 XX Homo sapiens.
 OS
 XX US2003181669-A1.
 PN
 XX 25-SEP-2003.
 PD
 XX 02-MAY-2002; 2002US-00063570.
 PF
 XX 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.

XX (GETH) GENENTECH INC.

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-811661/76.
 XX P-PSDB; ADI25556.

XX Novel antibody that binds to a PRO polypeptide, useful for treating
 FT cancer and in diagnostic assays, for e.g. detecting PRO expression in
 PT specific cells, tissues, or serum.

XX Disclosure; SEQ ID NO 37; 396pp; English.

XX The invention describes an antibody that specifically binds to a PRO
 CC polypeptide having a fully defined amino acid sequence given in the
 CC specification. The antibody is useful in identifying PRO polypeptides
 CC useful for various industrial applications, including pharmaceuticals,
 CC diagnostics, biosensors and bioreactors. The antibody is also used for
 CC affinity purification of PRO polypeptides from recombinant cell culture

KW antidiabetic; antianaemic; cytostatic; cardiant; vulnerary;
KW antinflammatory; anorectic.
XX Homo sapiens.
XX US2003050457-A1.
PN 13-MAR-2003.
PD
XX
PF 16-NOV-2001; 2001US-00991172.
XX
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US00086P.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087559P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090432P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.

```

PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020311.

Query Match          3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACCTCTTTCCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACGTG 2180
Db 2653 CCTTTTCCTCCCATCTCTGTACACATTTTAATAAAATAGGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
```

```

RESULT 815
AD103577
ID AD103577 standard; cDNA; 2846 BP.
XX
AC AD103577;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
KW cytosolic; vulnary; hyperglycaemic; hypoglycaemic; bone disorder;
KW cartilage disorder; sports injury; arthritis; hypoglycose; glucose uptake; diabetes;
KW
```

```

KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
KW gene.
XX
XX Homo sapiens.
OS
XX US2003181656-A1.
PN
XX
XX 25-SEP-2003.
PD
XX
XX 07-MAY-2002; 2002US-00063659.
PF
XX
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
PI WPI; 2003-875169/81.
XX P-PSDB; ADI03578.
XX
XX New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
PT
XX
XX Example 4; Fig 37; 397pp; English.
XX
XX This invention describes a novel human secreted and transmembrane PRO
CC polypeptide and the polynucleotides encoding it which have antiarthritic,
CC antidiabetic, cytostatic, vulnary, hyperglycaemic and hypoglycaemic
CC activity. The PRO polypeptides are useful for treating various bone
CC and/or cartilage disorders, for example, sports injuries and arthritis.
CC They are also useful in the therapeutic treatment of disorders where
CC either the stimulation or inhibition of glucose uptake by skeletal muscle
CC would be beneficial, for example, diabetes or hyper- or hypo-
CC insulinemia. They are also useful for treating pericyte-associated
CC tumours and in wound healing. An anti-PRO antibody is useful for the
CC preparation of a medicament useful in the treatment of cancer. The PRO
```

CC polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. ADI03541-ADI03708 represent the PRO
CC polynucleotides and polypeptides described in the disclosure of the
CC invention.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGGCTTTACCACTCTTTCTTTATCTTATTAATAAAATGTTGCTCCCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 816
ADI11934
ID ADI11934 standard; cDNA; 2846 BP.
XX AC ADI11934;
XX DT 22-APR-2004 (first entry)
XX DE Human PRO polynucleotide #19.
XX KW Human; PRO; gene; ss; cancer; affinity purification; cytostatic.
XX OS Homo sapiens.
XX PN US2003181686-A1.
XX PD 25-SEP-2003.
XX PF 03-MAY-2002; 2002US-00063584.
XX PR 06-DEC-2001; 2001US-00006867.
XX PA (GETH) GENENTECH INC.
XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;
XX PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX DR WPI; 2003-852271/79.
XX DR P-PSDB; ADI11935.

XX Novel antibody that binds to a PRO polypeptide, useful for treating
XX cancer and in diagnostic assays, for e.g. detecting PRO expression in
XX specific cells, tissues, or serum.
XX PS Disclosure; SEQ ID NO 37; 395pp; English.
XX The invention relates to an antibody that binds to a human PRO
XX polypeptide. The invention also relates to human PRO polynucleotides
XX encoding the PRO polypeptides of the invention. The antibody is
XX preferably a monoclonal or humanised antibody, or an antibody fragment,
XX and is used to treat cancer. The anti-PRO antibody can be used in
XX diagnostic assays, e.g. for detecting PRO expression in specific cells,
XX tissues or serum. The anti-PRO antibodies are also useful for the
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. This sequence represents a human PRO polynucleotide of the
XX invention.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGGCTTTACCACTCTTTCTTTATCTTATTAATAAAATGTTGCTCCCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 817
ADH90008
ID ADH90008 standard; cDNA; 2846 BP.
XX AC ADH90008;
XX DT 22-APR-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
XX OS affinity purification; secreted and transmembrane protein.
XX OS Homo sapiens.
XX PN US2003181697-A1.
XX PD 25-SEP-2003.
XX PF 02-MAY-2002; 2002US-00063562.
XX PR 30-DEC-1998; 98XR-00062142.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 14-MAY-1999; 99US-00311832.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 25-AUG-1999; 99US-00380138.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 25-AUG-1999; 99US-00380142.
XX PR 15-SEP-1999; 99US-00397342.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 12-NOV-1999; 99US-00423844.
XX PR 30-DEC-1999; 99WO-US031274.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 01-MAR-2000; 2000WO-US005601.
XX PR 21-MAR-2000; 2000WO-US005841.
XX PR 22-MAY-2000; 2000WO-US007532.
XX PR 02-JUN-2000; 2000WO-US014042.
XX PR 22-AUG-2000; 2000US-00644848.
XX PR 24-AUG-2000; 2000WO-US023328.
XX PR 18-SEP-2000; 2000US-00664610.
XX PR 18-SEP-2000; 2000US-00665350.
XX PR 08-NOV-2000; 2000US-00709238.
XX PR 10-NOV-2000; 2000WO-US030873.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 20-DEC-2000; 2000US-00747259.
XX PR 20-DEC-2000; 2000WO-US034956.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 22-MAR-2001; 2001US-00816744.
XX PR 10-MAY-2001; 2001US-00854208.
XX PR 30-MAY-2001; 2001US-00854280.
XX PR 30-MAY-2001; 2001US-00870574.

DB 2713 CAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 821
AD111594
ID AD111594 standard; cDNA; 2846 BP.
AC AD111594;
XX
DT 22-APR-2004 (first entry)
XX
DE Human PRO polynucleotide #19.
XX
KW Human; PRO; gene; ss; cancer; affinity purification; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003181684-A1.
XX
PD 25-SEP-2003.
XX
PF 07-MAY-2002; 2002US-00063660.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380137.
PR 15-SEP-1999; 99US-00397342.
PR 12-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00844848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-852269/79.
XX
P-PSDB; AD111595.

XX Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
PS Disclosure; SEQ ID NO 37; 396pp; English.
XX
CC The invention relates to an antibody that binds to a human PRO
CC polypeptide. The invention also relates to human PRO polynucleotides
CC encoding the PRO polypeptides of the invention. The antibody is
CC preferably a monoclonal or humanised antibody, or an antibody fragment,
CC and is used to treat cancer. The anti-PRO antibody can be used in
CC diagnostic assays, e.g. for detecting PRO expression in specific cells,
CC tissues or serum. The anti-PRO antibodies are also useful for the
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence represents a human PRO polynucleotide of the
CC invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACTCTTCTTTTATCTTATTAATAAAATGTGTCTCCCACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAAATAGGTTGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAA 2242
DB 2713 CAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 822
ADH98239
ID ADH98239 standard; cDNA; 2846 BP.
XX
AC ADH98239;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX
OS Homo sapiens.
XX
PN US2003181709-A1.
XX
PD 25-SEP-2003.
XX
PF 02-MAY-2002; 2002US-00063529.
XX
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-802903/75.
XX
P-PSDB; ADH98240.
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
PS Disclosure; SEQ ID NO 37; 397pp; English.
XX

CC The invention relates to a PRO (secreted and transmembrane protein)
CC polynucleotide appearing as ADH98283 encoding PRO polypeptide having
CC appearing as ADH98283. Also included are a vector comprising the novel
CC nucleic acid and a host cell comprising the vector. The polynucleotide is
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA, and in
CC gene therapy. The polynucleotide may also be used in preparing PRO
CC polypeptides by recombinant techniques, and in generating either
CC transgenic animals or knock-out animals which, in turn, are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polynucleotide is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. The specification discloses 84 PRO proteins
CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.
XX
SQ

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTTACCACTCTTCTCTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 823
ADH98579
ID ADH98579 standard; cDNA; 2846 BP.
XX
AC ADH98579;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
DE ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
KW
XX Homo sapiens.
OS
XX US2003181708-A1.
XX
XX 25-SEP-2003.
XX
XX 01-MAY-2002; 2002US-00063516.
XX
XX 06-DEC-2001; 2001US-00006867.
XX
XX (GETH) GENENTECH INC.
XX
XX Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
PI
XX WPI; 2003-787568/74.
DR P-FSDB; ADH98580.
XX
XX Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
PT
XX Disclosure; SEQ ID NO 37; 395pp; English.
PS
XX The invention relates to a PRO (secreted and transmembrane protein)
CC polynucleotide appearing as ADH98623 encoding PRO polypeptide having

CC appearing as ADH98623. Also included are a vector comprising the novel
CC nucleic acid and a host cell comprising the vector. The polynucleotide is
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA, and in
CC gene therapy. The polynucleotide may also be used in preparing PRO
CC polypeptides by recombinant techniques, and in generating either
CC transgenic animals or knock-out animals which, in turn, are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polynucleotide is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. The specification discloses 84 PRO proteins
CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.
XX
SQ

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTTACCACTCTTCTCTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 824
ADH98069
ID ADH98069 standard; cDNA; 2846 BP.
XX
AC ADH98069;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
DE ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
KW
XX Homo sapiens.
OS
XX US2003181673-A1.
XX
XX 25-SEP-2003.
XX
XX 03-MAY-2002; 2002US-00063597.
XX
XX 30-DEC-1998; 98KR-00062142.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 15-SEP-1999; 99US-00397342.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 30-DEC-1999; 99WO-US031274.
XX 18-FEB-2000; 2000WO-US004341.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 21-MAR-2000; 2000WO-US007532.
XX 22-MAY-2000; 2000WO-US014042.
XX 02-JUN-2000; 2000WO-US015264.
XX 22-AUG-2000; 2000WO-US014848.
XX 24-AUG-2000; 2000WO-US023328.

DT 07-JUL-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene therapy;
KW tumour necrosis factor-alpha release; TNF-alpha release;
KW chondrocyte proliferation; chondrocyte differentiation; tumour;
KW adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; gene; ss.
XX
OS Homo sapiens.
XX
XX
PN US2003032127-A1.
XX
XX 13-FEB-2003.
XX
XX 26-JUN-2002; 2002US-00183012.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082737P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 24-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.

PR 22-MAY-1998;	98US-0085486P.	PR 18-AUG-1998;	98US-0097022P.
PR 28-MAY-1998;	98US-0087098P.	PR 26-AUG-1998;	98US-0097952P.
PR 02-JUN-1998;	98US-0087208P.	PR 26-AUG-1998;	98US-0097954P.
PR 02-JUN-1998;	98US-0087609P.	PR 26-AUG-1998;	98US-0097955P.
PR 03-JUN-1998;	98US-0087759P.	PR 26-AUG-1998;	98US-0097971P.
PR 04-JUN-1998;	98US-0088025P.	PR 26-AUG-1998;	98US-0097974P.
PR 04-JUN-1998;	98US-0088028P.	PR 26-AUG-1998;	98US-0098014P.
PR 04-JUN-1998;	98US-0088029P.	PR 01-SEP-1998;	98US-0098716P.
PR 04-JUN-1998;	98US-0088033P.	PR 02-SEP-1998;	98US-0098723P.
PR 04-JUN-1998;	98US-0088326P.	PR 02-SEP-1998;	98US-0098803P.
PR 05-JUN-1998;	98US-0088167P.	PR 02-SEP-1998;	98US-0098821P.
PR 05-JUN-1998;	98US-0088202P.	PR 02-SEP-1998;	98US-0098843P.
PR 05-JUN-1998;	98US-0088217P.	PR 09-SEP-1998;	98US-0099602P.
PR 09-JUN-1998;	98US-0088211P.	PR 10-SEP-1998;	98US-0099741P.
PR 10-JUN-1998;	98US-0088655P.	PR 10-SEP-1998;	98US-0099763P.
PR 10-JUN-1998;	98US-0088722P.	PR 10-SEP-1998;	98US-0099812P.
PR 10-JUN-1998;	98US-0088738P.	PR 15-SEP-1998;	98US-0100388P.
PR 10-JUN-1998;	98US-0088740P.	PR 16-SEP-1998;	98US-0100662P.
PR 10-JUN-1998;	98US-0088811P.	PR 16-SEP-1998;	98US-0100664P.
PR 10-JUN-1998;	98US-0088824P.	PR 16-SEP-1998;	98US-0101751P.
PR 10-JUN-1998;	98US-0088825P.	PR 17-SEP-1998;	98US-0101933P.
PR 11-JUN-1998;	98US-0088826P.	PR 17-SEP-1998;	98US-0100683P.
PR 11-JUN-1998;	98US-0088861P.	PR 17-SEP-1998;	98US-0100684P.
PR 11-JUN-1998;	98US-0088863P.	PR 17-SEP-1998;	98US-0100919P.
PR 11-JUN-1998;	98US-0088876P.	PR 17-SEP-1998;	98US-0100930P.
PR 12-JUN-1998;	98US-0089090P.	PR 18-SEP-1998;	98US-0100849P.
PR 12-JUN-1998;	98US-0089105P.	PR 18-SEP-1998;	98US-0101014P.
PR 16-JUN-1998;	98US-0089511P.	PR 18-SEP-1998;	98US-0101058P.
PR 16-JUN-1998;	98US-0089514P.	PR 23-SEP-1998;	98US-0101471P.
PR 17-JUN-1998;	98US-0089538P.	PR 23-SEP-1998;	98US-0101472P.
PR 17-JUN-1998;	98US-0089598P.	PR 23-SEP-1998;	98US-0101475P.
PR 18-JUN-1998;	98US-0089653P.	PR 23-SEP-1998;	98US-0101477P.
PR 19-JUN-1998;	98US-0089908P.	PR 24-SEP-1998;	98US-0101738P.
PR 22-JUN-1998;	98US-0089952P.	PR 24-SEP-1998;	98US-0101739P.
PR 22-JUN-1998;	98US-0090246P.	PR 24-SEP-1998;	98US-0101743P.
PR 22-JUN-1998;	98US-0090252P.	PR 24-SEP-1998;	98US-0101922P.
PR 22-JUN-1998;	98US-0090254P.	PR 25-SEP-1998;	98US-0101786P.
PR 24-JUN-1998;	98US-0090429P.	PR 29-SEP-1998;	98US-0102207P.
PR 24-JUN-1998;	98US-0090435P.	PR 29-SEP-1998;	98US-0102240P.
PR 24-JUN-1998;	98US-0090444P.	PR 29-SEP-1998;	98US-0102330P.
PR 24-JUN-1998;	98US-0090446P.	PR 29-SEP-1998;	98US-0102331P.
PR 24-JUN-1998;	98US-0090533P.	PR 30-SEP-1998;	98US-0102487P.
PR 24-JUN-1998;	98US-0090540P.	PR 30-SEP-1998;	98US-0102570P.
PR 25-JUN-1998;	98US-0090676P.	PR 30-SEP-1998;	98US-0102571P.
PR 25-JUN-1998;	98US-0090678P.	PR 01-OCT-1998;	98US-0102684P.
PR 25-JUN-1998;	98US-0090688P.	PR 01-OCT-1998;	98US-0102687P.
PR 25-JUN-1998;	98US-0090690P.	PR 02-OCT-1998;	98US-0102965P.
PR 25-JUN-1998;	98US-0090695P.	PR 06-OCT-1998;	98US-0103258P.
PR 25-JUN-1998;	98US-0090696P.	PR 06-OCT-1998;	98US-0103449P.
PR 26-JUN-1998;	98US-00105413.	PR 07-OCT-1998;	98US-00168978.
PR 26-JUN-1998;	98US-0090862P.		
PR 26-JUN-1998;	98US-0090863P.		
PR 26-JUN-1998;	98US-0091010P.		
PR 01-JUL-1998;	98US-0091339P.		
PR 01-JUL-1998;	98US-0091544P.		
PR 02-JUL-1998;	98US-0091478P.		
PR 02-JUL-1998;	98US-0091486P.		
PR 02-JUL-1998;	98US-0091626P.		
PR 02-JUL-1998;	98US-0091628P.		
PR 02-JUL-1998;	98US-0091629P.		
PR 02-JUL-1998;	98US-0091632P.		
PR 02-JUL-1998;	98US-0094006P.		
PR 04-AUG-1998;	98US-0095282P.		
PR 10-AUG-1998;	98US-0095998P.		
PR 10-AUG-1998;	98US-0096012P.		
PR 17-AUG-1998;	98US-0096757P.		
PR 17-AUG-1998;	98US-0096766P.		
PR 17-AUG-1998;	98US-0096867P.		
PR 17-AUG-1998;	98US-0096891P.		
PR 17-AUG-1998;	98US-0096897P.		
PR 18-AUG-1998;	98US-0096949P.		
PR 18-AUG-1998;	98US-0096959P.		
Query Match 3.0%; Score 66.6; DB 10; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
Qy 2121	CCCTTGCTTTACCACTCTCTTCTTTATCTTTATTAATAAAATGTTGCTCTCCACACTG	2180	
Db 2653	CCCTTTCTCTCCCATCTCTGTACACATTTTATAAAATGAGGTGGCTTCTGAACATA	2712	
Qy 2181	NTCCCAA	2240	
Db 2713	CAAA	2772	
Qy 2241	AA 2242		
Db 2773	AA 2774		
RESULT 828			
ACC87592			
ID ACC87592 standard; cDNA; 2846 BP.			
XX			

AC ACC87592;
XX
XX
DT
XX
XX
DE 05-AUG-2003 (first entry)
XX
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
XX
OS Homo sapiens.
XX
XX
XX US2003027278-A1.
XX
XX
XX 06-FEB-2003.
XX
XX
XX 21-JUN-2002; 2002US-00176987.
XX
XX
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078886P.
XX 27-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081195P.
XX 13-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 28-APR-1998; 98US-0083322P.
XX 28-APR-1998; 98US-0083455P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 15-MAY-1998; 98US-0085579P.
XX
XX
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
XX 22-MAY-1998; 98US-0086486P.
XX 28-MAY-1998; 98US-0087098P.
XX 28-MAY-1998; 98US-0087208P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088326P.
XX 05-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088212P.
XX 05-JUN-1998; 98US-0088217P.
XX 09-JUN-1998; 98US-0088555P.
XX 10-JUN-1998; 98US-0088722P.
XX 10-JUN-1998; 98US-0088738P.
XX 10-JUN-1998; 98US-0088740P.
XX 10-JUN-1998; 98US-0088811P.
XX 10-JUN-1998; 98US-0088824P.
XX 10-JUN-1998; 98US-0088825P.
XX 10-JUN-1998; 98US-0088826P.
XX 11-JUN-1998; 98US-0088861P.
XX 11-JUN-1998; 98US-0088863P.
XX 11-JUN-1998; 98US-0088876P.
XX 12-JUN-1998; 98US-0089090P.
XX 12-JUN-1998; 98US-0089105P.
XX 16-JUN-1998; 98US-0089512P.
XX 16-JUN-1998; 98US-0089514P.
XX 17-JUN-1998; 98US-0089538P.
XX 17-JUN-1998; 98US-0089598P.
XX 17-JUN-1998; 98US-0089653P.
XX 18-JUN-1998; 98US-0089908P.
XX 19-JUN-1998; 98US-0089952P.
XX 22-JUN-1998; 98US-0090246P.
XX 22-JUN-1998; 98US-0090252P.
XX 22-JUN-1998; 98US-0090254P.
XX 24-JUN-1998; 98US-0090429P.
XX 24-JUN-1998; 98US-0090435P.
XX 24-JUN-1998; 98US-0090444P.
XX 24-JUN-1998; 98US-0090461P.
XX 24-JUN-1998; 98US-0090535P.
XX 24-JUN-1998; 98US-0090540P.
XX 25-JUN-1998; 98US-0090676P.
XX 25-JUN-1998; 98US-0090678P.
XX 25-JUN-1998; 98US-0090688P.
XX 25-JUN-1998; 98US-0090690P.
XX 25-JUN-1998; 98US-0090694P.
XX 25-JUN-1998; 98US-0090695P.
XX 25-JUN-1998; 98US-0090696P.
XX 26-JUN-1998; 98US-00105413.
XX 26-JUN-1998; 98US-0090862P.
XX 26-JUN-1998; 98US-0090863P.
XX 01-JUL-1998; 98US-0091010P.
XX 01-JUL-1998; 98US-0091359P.
XX 01-JUL-1998; 98US-0091544P.
XX 02-JUL-1998; 98US-0091478P.
XX 02-JUL-1998; 98US-0091486P.
XX 02-JUL-1998; 98US-0091626P.
XX 02-JUL-1998; 98US-0091628P.
XX 02-JUL-1998; 98US-0091632P.
XX 04-AUG-1998; 98US-0094006P.
XX 04-AUG-1998; 98US-0095282P.
XX 04-AUG-1998; 98US-0095598P.
XX 10-AUG-1998; 98US-0096012P.
XX 17-AUG-1998; 98US-0096757P.
XX 17-AUG-1998; 98US-0096766P.


```
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
```

```
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
```

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
QY 2121 CCTTGGCTTTACCACTCTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTGTGACACATTTTAAATAAAATAAGGGTTCGCTTCTGAACTA 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
    ||
Db 2773 AA 2774
```

RESULT 830
ACD04151

PR	17-AUG-1998;	98US-0096897P.	ABX77859	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.	ID	ABX77859 standard; cDNA; 2846 BP.
PR	18-AUG-1998;	98US-0096959P.	XX	
PR	18-AUG-1998;	98US-0097022P.	AC	ABX77859;
PR	26-AUG-1998;	98US-0097952P.	XX	
PR	26-AUG-1998;	98US-0097954P.	DT	14-APR-2003 (first entry)
PR	26-AUG-1998;	98US-0097955P.	XX	
PR	26-AUG-1998;	98US-0097971P.	XX	Human PRO polynucleotide #65.
PR	26-AUG-1998;	98US-0097974P.	DE	
PR	26-AUG-1998;	98US-0098014P.	KW	Human; PRO; gene; ss; cytostatic; tumour; cancer; breast; lung; stomach;
PR	01-SEP-1998;	98US-0098716P.	KW	liver; horse; cow; dog; sheep; pig; goat; rabbit; ADEPT;
PR	01-SEP-1998;	98US-0098723P.	KW	antibody-dependent enzyme mediated prodrug therapy.
PR	02-SEP-1998;	98US-0098803P.	XX	
PR	02-SEP-1998;	98US-0098821P.	XX	
PR	02-SEP-1998;	98US-0098843P.	OS	Homo sapiens.
PR	09-SEP-1998;	98US-0099602P.	XX	
PR	10-SEP-1998;	98US-0099741P.	PN	US2003027163-A1.
PR	10-SEP-1998;	98US-0099754P.	XX	
PR	10-SEP-1998;	98US-0099763P.	PD	06-FEB-2003.
PR	10-SEP-1998;	98US-0099812P.	XX	
PR	15-SEP-1998;	98US-0100388P.	PF	15-NOV-2001; 2001US-00997666.
PR	16-SEP-1998;	98US-0100662P.	XX	
PR	16-SEP-1998;	98US-0100664P.	XX	
PR	16-SEP-1998;	98US-0101751P.	PR	16-JUN-1997; 97US-0049787P.
PR	16-SEP-1998;	98WO-US019330.	PR	17-OCT-1997; 97US-0062250P.
PR	17-SEP-1998;	98US-0100683P.	PR	05-NOV-1997; 97WO-US020069.
PR	17-SEP-1998;	98US-0100684P.	PR	12-NOV-1997; 97US-0065186P.
PR	17-SEP-1998;	98US-0100919P.	PR	13-NOV-1997; 97US-0065311P.
PR	17-SEP-1998;	98US-0100930P.	PR	24-NOV-1997; 97US-0066770P.
PR	18-SEP-1998;	98US-0100849P.	PR	25-FEB-1998; 98US-0075945P.
PR	18-SEP-1998;	98US-0101014P.	PR	20-MAR-1998; 98US-0078910P.
PR	18-SEP-1998;	98US-0101068P.	PR	28-APR-1998; 98US-0083322P.
PR	23-SEP-1998;	98US-0101471P.	PR	07-MAY-1998; 98US-0084600P.
PR	23-SEP-1998;	98US-0101472P.	PR	28-MAY-1998; 98US-0087106P.
PR	23-SEP-1998;	98US-0101475P.	PR	02-JUN-1998; 98US-0087607P.
PR	23-SEP-1998;	98US-0101738P.	PR	02-JUN-1998; 98US-0087609P.
PR	24-SEP-1998;	98US-0101739P.	PR	02-JUN-1998; 98US-0087759P.
PR	24-SEP-1998;	98US-0101743P.	PR	03-JUN-1998; 98US-0088021P.
PR	24-SEP-1998;	98US-0101922P.	PR	04-JUN-1998; 98US-0088025P.
PR	25-SEP-1998;	98US-0101786P.	PR	04-JUN-1998; 98US-0088026P.
PR	29-SEP-1998;	98US-0102207P.	PR	04-JUN-1998; 98US-0088028P.
PR	29-SEP-1998;	98US-0102240P.	PR	04-JUN-1998; 98US-0088029P.
PR	29-SEP-1998;	98US-0102330P.	PR	04-JUN-1998; 98US-0088030P.
PR	29-SEP-1998;	98US-0102331P.	PR	04-JUN-1998; 98US-0088033P.
PR	30-SEP-1998;	98US-0102487P.	PR	05-JUN-1998; 98US-0088167P.
PR	30-SEP-1998;	98US-0102570P.	PR	05-JUN-1998; 98US-0088202P.
PR	30-SEP-1998;	98US-0102571P.	PR	05-JUN-1998; 98US-0088212P.
PR	01-OCT-1998;	98US-0102684P.	PR	05-JUN-1998; 98US-0088217P.
PR	01-OCT-1998;	98US-0102687P.	PR	09-JUN-1998; 98US-0088655P.
PR	02-OCT-1998;	98US-0102965P.	PR	10-JUN-1998; 98US-0088734P.
PR	06-OCT-1998;	98US-0103258P.	PR	10-JUN-1998; 98US-0088738P.
PR	06-OCT-1998;	98US-0103449P.	PR	10-JUN-1998; 98US-0088742P.
PR	07-OCT-1998;	98US-00168978.	PR	10-JUN-1998; 98US-0088810P.
Query Match 3.0%; Score 66.6; DB 10; Length 2846;				
Best Local Similarity 71.3%; Pred. No. 0.00023;				
Matches	87;	Conservative	0;	Mismatches 35; Indels 0; Gaps 0;
QY	2121	CCTTTGCTTACCACCTCTTTCCCTTTTATCTTATATAAAATGTTGGTCTCCACCACTG	2180	
Db	2653	CCTTTTCTTCCCATCTCTGTACACATTTTAATAAATAAGGTTGCTTCTGAAC	2712	
QY	2181	NCTCCCAA	2240	
Db	2713	CAA	2772	
QY	2241	AA 2242		
Db	2773	AA 2774		

RESULT 831

RESULT 832	17-JUN-1998;	98US-0089599P.
ABX80271	17-JUN-1998;	98US-0089600P.
ID	17-JUN-1998;	98US-0089653P.
XX	18-JUN-1998;	98US-0089801P.
XX	18-JUN-1998;	98US-0089907P.
XX	18-JUN-1998;	98US-0089908P.
XX	16-SEP-1998;	98WO-US019330.
DT	17-SEP-1998;	98WO-US019437.
XX	07-OCT-1998;	98WO-US021141.
DE	01-DEC-1998;	98WO-US025108.
XX	05-JAN-1999;	99WO-US000106.
KW	08-MAR-1999;	99WO-US005028.
KW	02-JUN-1999;	99WO-US012252.
KW	15-SEP-1999;	99WO-US021090.
KW	15-SEP-1999;	99WO-US021547.
KW	30-NOV-1999;	99WO-US028313.
KW	01-DEC-1999;	99WO-US028301.
KW	01-DEC-1999;	99WO-US028634.
KW	16-DEC-1999;	99WO-US030095.
KW	20-DEC-1999;	99WO-US030911.
XX	06-JAN-2000;	2000WO-US000219.
OS	06-JAN-2000;	2000WO-US000376.
XX	11-FEB-2000;	2000WO-US003565.
XX	18-FEB-2000;	2000WO-US004341.
XX	22-FEB-2000;	2000WO-US004414.
XX	24-FEB-2000;	2000WO-US004914.
XX	24-FEB-2000;	2000WO-US005004.
PF	02-MAR-2000;	2000WO-US005841.
XX	10-MAR-2000;	2000WO-US006319.
XX	15-MAR-2000;	2000WO-US006884.
XX	20-MAR-2000;	2000WO-US007377.
XX	30-MAR-2000;	2000WO-US008439.
XX	15-MAY-2000;	2000WO-US013358.
XX	17-MAY-2000;	2000WO-US013705.
XX	22-MAY-2000;	2000WO-US014042.
XX	30-MAY-2000;	2000WO-US014941.
XX	02-JUN-2000;	2000WO-US015264.
XX	28-JUL-2000;	2000WO-US020710.
XX	11-AUG-2000;	2000WO-US022031.
XX	23-AUG-2000;	2000WO-US023522.
XX	24-AUG-2000;	2000WO-US023328.
XX	08-NOV-2000;	2000WO-US030952.
XX	01-DEC-2000;	2000WO-US032678.
XX	28-FEB-2001;	2001WO-US006520.
XX	01-JUN-2001;	2001WO-US017800.
XX	20-JUN-2001;	2001WO-US019692.
XX	29-JUN-2001;	2001WO-US021066.
XX	09-JUL-2001;	2001WO-US021735.
XX	28-AUG-2001;	2001US-00941992.
XX	(GETH) GENENTECH INC.	
XX	Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DJ;	
XX	Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;	
PI	Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;	
PI	Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;	
PI	Zhang Z;	
XX	WPI; 2003-247083/24.	
DR	Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346	
XX	and PRO1375, which stimulate proliferation of stimulated T-lymphocytes	
XX	are therapeutically useful for enhancing immune response and in cancer	
XX	treatments.	
XX	Example 68; Page 245; 648pp; English.	
XX	The invention describes an isolated human PRO polypeptide. The PRO	
XX	polypeptides are useful in detecting PRO polypeptides in a sample, in	
XX	linking a bioactive molecule to a cell expressing a PRO polypeptide, and	
XX	in modulating at least one biological activity of a cell expressing a PRO	
XX	polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus	
XX	useful for treating cardiac insufficiency disorders. PRO1154 and PRO1156	

CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
 CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO819, PRO1126,
 CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
 CC useful for treating conditions or disorders where angiogenesis would be
 CC beneficial, e.g. wound healing and antagonist of this polypeptide are
 CC useful for treating cancerous tumours. PRO812 inhibits vascular
 CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
 CC cells and is thus useful for inhibiting endothelial cell growth in
 CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
 CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
 CC stimulated T-lymphocytes and are therapeutically useful for enhancing
 CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
 CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
 CC rod photoreceptor cells) and therefore are useful for treating retinal
 CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
 CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,
 CC and therefore are useful for treating kidney disorders associated with
 CC decreased mesangial cell function such as Berger disease or other
 CC nephropathies associated with dermatitis, herpeticiformis or Crohn's
 CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
 CC proliferation and/or redifferentiation of chondrocytes in culture and are
 CC thus useful for treating sports injuries, and arthritis. This sequence
 CC represents a primer used in the isolation of DNA encoding novel human PRO
 CC polypeptides
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 33; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTCTTCCTTTATCTTATTAATAAATGTTGCTCCCACTG 2180
 |||||
 Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAGGTTGCTTCTGACTA 2712
 |||||

Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
 |||||
 Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
 |||||

Qy 2241 AA 2242
 ||
 Db 2773 AA 2774

RESULT 833
 ACA69177
 ID ACA69177 standard; cDNA; 2846 BP.
 XX
 AC ACA69177;
 XX
 DT 26-JUN-2003 (first entry)
 XX
 DE Human cDNA encoding secreted/transmembrane protein PRO1344.
 XX
 KW Human; ss; gene; PRO; secreted protein; transmembrane protein;
 KW cardiac insufficiency disorders; angiogenesis; wound healing;
 KW cancerous tumour; immune response; retinal disorder; sight loss;
 KW retinitis pigmentosa; age-related macular degeneration; AMD;
 KW kidney disorder; Berger disease; nephropathy; dermatitis; herpeticiformis;
 KW Crohn's disease; sports injury; arthritis.
 XX
 OS Homo sapiens.
 XX
 XX
 PN US2003032023-A1.
 XX
 PD 13-FEB-2003.
 XX
 XX 14-NOV-2001; 2001US-00990711.
 XX
 XX 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97WO-US020069.
 PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088036P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 16-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 19-JUN-1998; 98US-0089947P.
 PR 19-JUN-1998; 98US-0089948P.
 PR 19-JUN-1998; 98US-0089952P.
 PR 22-JUN-1998; 98US-0090246P.
 PR 22-JUN-1998; 98US-0090252P.
 PR 22-JUN-1998; 98US-0090254P.
 PR 23-JUN-1998; 98US-0090349P.
 PR 23-JUN-1998; 98US-0090355P.
 PR 24-JUN-1998; 98US-0090429P.
 PR 24-JUN-1998; 98US-0090431P.
 PR 24-JUN-1998; 98US-0090435P.
 PR 24-JUN-1998; 98US-0090444P.
 PR 24-JUN-1998; 98US-0090445P.
 PR 24-JUN-1998; 98US-0090472P.
 PR 24-JUN-1998; 98US-0090535P.
 PR 24-JUN-1998; 98US-0090540P.
 PR 24-JUN-1998; 98US-0090542P.
 PR 24-JUN-1998; 98US-0090557P.
 PR 25-JUN-1998; 98US-0090676P.
 PR 25-JUN-1998; 98US-0090678P.
 PR 25-JUN-1998; 98US-0090690P.
 PR 25-JUN-1998; 98US-0090694P.
 PR 25-JUN-1998; 98US-0090695P.
 PR 25-JUN-1998; 98US-0090696P.
 PR 26-JUN-1998; 98US-0090862P.
 PR 26-JUN-1998; 98US-0090863P.
 PR 01-JUL-1998; 98US-0091360P.

[illegible]

PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0069333P.
PR 12-DEC-1997; 97US-0069428P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0069801P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 28-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 02-JUN-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088862P.
PR 11-JUN-1998; 98US-0088863P.
PR 17-SEP-1998; 98US-0100684P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 02-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096857P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-00999812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.

```
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102310P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102571P.
PR 30-SEP-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 01-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103395P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTTCCTTTTATCTTATATAAAAAATGGTCTCCACCACTG 2180
Dd ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712
Dd ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
Dd ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
Dd ||
QY 2773 AA 2774

RESULT 835
ACA90327
ID ACA90327 standard; cDNA; 2846 BP.
AC ACA90327;
AC ACA90327;
XX 11-AUG-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE
DE Human; Gene therapy; tissue typing; tumour; chondrocyte proliferation;
KW chondrocyte differentiation; tumour necrosis factor-alpha release; ss;
KW affinity purification; gene.
XX
XX Homo sapiens.
XX
XX US2003036147-A1.
XX
XX 20-FEB-2003.
XX
XX 02-JUL-2002; 2002US-00187741.
XX
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.

97US-0063121P.
97US-0063540P.
97US-0063541P.
97US-0063544P.
97US-0063564P.
97US-0063734P.
97US-0063870P.
97US-0064103P.
97US-0065311P.
97US-0066120P.
97US-0066466P.
97US-0066772P.
97US-0069335P.
97US-0069425P.
97US-0069870P.
97US-0068017P.
97US-0077450P.
97US-0077632P.
97US-0077649P.
97US-0078886P.
97US-0078939P.
97US-0079664P.
97US-0079786P.
97US-0080107P.
97US-0080194P.
97US-0080327P.
97US-0080333P.
97US-0081049P.
97US-0081070P.
97US-0081195P.
97US-0081838P.
97US-0082568P.
97US-0082569P.
97US-0082704P.
97US-0082797P.
97US-0083322P.
97US-0083495P.
97US-0083496P.
97US-0083499P.
97US-0083559P.
97US-0084366P.
97US-0084414P.
97US-0084640P.
97US-0084643P.
97US-0085579P.
97US-0085580P.
97US-0085582P.
97US-0085700P.
97US-0086023P.
97US-0086392P.
97US-0086486P.
97US-0087098P.
97US-0087208P.
97US-0087609P.
97US-0087759P.
97US-0087827P.
97US-0088025P.
97US-0088028P.
97US-0088029P.
97US-0088033P.
97US-0088167P.
97US-0088202P.
97US-0088212P.
97US-0088217P.
97US-0088655P.
97US-0088722P.
97US-0088738P.
97US-0088740P.
97US-0088811P.
97US-0088824P.
97US-0088825P.

24-OCT-1997;
28-OCT-1997;
28-OCT-1997;
28-OCT-1997;
28-OCT-1997;
31-OCT-1997;
31-OCT-1997;
13-NOV-1997;
21-NOV-1997;
24-NOV-1997;
24-NOV-1997;
11-DEC-1997;
12-DEC-1997;
17-DEC-1997;
18-DEC-1997;
10-MAR-1998;
11-MAR-1998;
11-MAR-1998;
20-MAR-1998;
27-MAR-1998;
27-MAR-1998;
09-APR-1998;
15-APR-1998;
21-APR-1998;
21-APR-1998;
22-APR-1998;
22-APR-1998;
28-APR-1998;
29-APR-1998;
29-APR-1998;
29-APR-1998;
05-MAY-1998;
06-MAY-1998;
07-MAY-1998;
07-MAY-1998;
15-MAY-1998;
15-MAY-1998;
15-MAY-1998;
18-MAY-1998;
22-MAY-1998;
22-MAY-1998;
28-MAY-1998;
28-MAY-1998;
02-JUN-1998;
02-JUN-1998;
04-JUN-1998;
04-JUN-1998;
04-JUN-1998;
04-JUN-1998;
05-JUN-1998;
05-JUN-1998;
05-JUN-1998;
09-JUN-1998;
10-JUN-1998;
10-JUN-1998;
10-JUN-1998;
10-JUN-1998;
```

PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089598P.
PR 18-JUN-1998; 98US-0089598P.
PR 19-JUN-1998; 98US-0089598P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096889P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTACCACCTCTTTCCTTTATCTATTATAAATAATGTTGCTCCACCACGTG 2180

Db 2653 CCTTTTCTTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACATA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 836

ACC89434

ID ACC89434 standard; cDNA; 2846 BP.

AC ACC89434;

XX 11-AUG-2003 (first entry)

DT 11-AUG-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.

OS US2003027264-A1.

XX 06-FEB-2003.

XX 18-JUN-2002; 2002US-00174579.

XX

PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 28-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 97US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 10-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 09-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.

```
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTACCACTCTTCTTTATCTTATTAATAAATGTGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAATAAATAAGGCTTGCTTCTGAAC 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db |||
2773 AA 2774

RESULT 837
ID ABX90248
XX AC ABX90248;
XX DT 01-MAY-2003 (first entry)
XX DE Human secreted/transmembrane protein cDNA, #94.
XX KW Human; gene; ss; PRO; secreted; transmembrane; signal peptide;
XX KW pharmaceutical; diagnostic; therapeutic; gene therapy.
XX OS Homo sapiens.
XX PN US2002160384-A1.
XX PD 31-OCT-2002.
XX PF 14-NOV-2001; 2001US-009925598.
XX PR 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.
```


PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-00968691P.
PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-00968697P.
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998;	98US-0086319P.	PR	18-AUG-1998;	98US-0096959P.
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0097022P.
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097955P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097971P.
PR	03-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0097974P.
PR	04-JUN-1998;	98US-0088028P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098716P.
PR	04-JUN-1998;	98US-0088033P.	PR	01-SEP-1998;	98US-0098723P.
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098803P.
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088202P.	PR	02-SEP-1998;	98US-0098843P.
PR	05-JUN-1998;	98US-0088212P.	PR	09-SEP-1998;	98US-0098602P.
PR	05-JUN-1998;	98US-0088211P.	PR	10-SEP-1998;	98US-0099741P.
PR	09-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099754P.
PR	10-JUN-1998;	98US-0088722P.	PR	10-SEP-1998;	98US-0099763P.
PR	10-JUN-1998;	98US-0088738P.	PR	15-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088740P.	PR	15-SEP-1998;	98US-0100388P.
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0100682P.
PR	10-JUN-1998;	98US-0088824P.	PR	16-SEP-1998;	98US-0100684P.
PR	10-JUN-1998;	98US-0088825P.	PR	16-SEP-1998;	98US-0101751P.
PR	11-JUN-1998;	98US-0088826P.	PR	17-SEP-1998;	98US-0100683P.
PR	11-JUN-1998;	98US-0088861P.	PR	17-SEP-1998;	98US-0100684P.
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100919P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100930P.
PR	12-JUN-1998;	98US-0089090P.	PR	18-SEP-1998;	98US-0100849P.
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0101014P.
PR	16-JUN-1998;	98US-0089512P.	PR	18-SEP-1998;	98US-0101068P.
PR	16-JUN-1998;	98US-0089514P.	PR	23-SEP-1998;	98US-0101471P.
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101472P.
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101475P.
PR	17-JUN-1998;	98US-0089653P.	PR	23-SEP-1998;	98US-0101477P.
PR	18-JUN-1998;	98US-0089908P.	PR	24-SEP-1998;	98US-0101738P.
PR	19-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101739P.
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101743P.
PR	22-JUN-1998;	98US-0090252P.	PR	24-SEP-1998;	98US-0101922P.
PR	22-JUN-1998;	98US-0090254P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090429P.	PR	25-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090435P.	PR	29-SEP-1998;	98US-0102240P.
PR	24-JUN-1998;	98US-0090444P.	PR	29-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090461P.	PR	29-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090533P.	PR	30-SEP-1998;	98US-0102487P.
PR	25-JUN-1998;	98US-0090676P.	PR	30-SEP-1998;	98US-0102570P.
PR	25-JUN-1998;	98US-0090678P.	PR	30-SEP-1998;	98US-0102571P.
PR	25-JUN-1998;	98US-0090688P.	PR	01-OCT-1998;	98US-0102684P.
PR	25-JUN-1998;	98US-0090690P.	PR	01-OCT-1998;	98US-0102687P.
PR	25-JUN-1998;	98US-0090694P.	PR	02-OCT-1998;	98US-0102965P.
PR	25-JUN-1998;	98US-0090695P.	PR	06-OCT-1998;	98US-0103258P.
PR	25-JUN-1998;	98US-0090696P.	PR	06-OCT-1998;	98US-0103449P.
PR	26-JUN-1998;	98US-0090862P.			
PR	26-JUN-1998;	98US-0090863P.			
PR	26-JUN-1998;	98US-0091010P.			
PR	01-JUL-1998;	98US-0091359P.			
PR	01-JUL-1998;	98US-0091544P.			
PR	02-JUL-1998;	98US-0091478P.			
PR	02-JUL-1998;	98US-0091486P.			
PR	02-JUL-1998;	98US-0091628P.			
PR	02-JUL-1998;	98US-0091628P.			
PR	02-JUL-1998;	98US-0091632P.			
PR	24-JUL-1998;	98US-0094006P.			
PR	04-AUG-1998;	98US-0095282P.			
PR	10-AUG-1998;	98US-0095988P.			
PR	10-AUG-1998;	98US-0096012P.			
PR	17-AUG-1998;	98US-0096757P.			
PR	17-AUG-1998;	98US-0096766P.			
			Query Match		
			Best Local Similarity 71.3%; Score 66.6; DB 10; Length 2846;		
			Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
Qy	2121	CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTGGTCTCCACACTG 2180			
Db	2653	CCTTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAGGGTTGGCTTCTGAACATA 2712			
Qy	2181	NCTCCCAA 2240			
Db	2713	CAA 2772			
Qy	2241	AA 2242			
Db	2773	AA 2774			

RESULT 839
ACA93867
ID ACA93867 standard; cDNA; 2846 BP.
XX
AC ACA93867;
XX
DT 18-JUL-2003 (first entry)
XX
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE
DE Human; ss; gene; secreted protein; transmembrane protein; PRO; tumour;
KW proliferation; differentiation; chondrocyte cell; TNF-alpha;
KW tumour necrosis factor-alpha; gene therapy.
XX
XX Homo sapiens.
XX
XX US2003036149-A1.
XX
XX 20-FEB-2003.
XX
XX 02-JUL-2002; 2002US-00187746.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0064103P.
PR 31-OCT-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069435P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089808P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 02-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095598P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR

```
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100389P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Beet Local Similarity 71.3%; Pred No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTTGCTCTCCACCACTG 2180
Db 2653 CCTTTCTTCCCATCTCTTGTACACATTTTAAATAAAATAAGGCTTGCTTCTGAACCTA 2712

Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774
```

RESULT 840

ACD15260

ID ACD15260 standard; cDNA; 2846 BP.

XX

AC ACD15260;

XX

DT 17-AUG-2003 (first entry)

XX

Human secreted/transmembrane protein (PRO) cDNA #85.

XX

Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha; tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy; tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; cervical tumour; liver tumour.

OS Homo sapiens.

XX

FN US2003044923-A1.

XX

PD 06-MAR-2003.

XX

PF 24-JUN-2002; 2002US-00179522.

XX

PR 18-SEP-1997; 97US-0059263P.

PR

PR 18-SEP-1997; 97US-0059266P.

PR

PR 21-OCT-1997; 97US-0062250P.

PR

PR 21-OCT-1997; 97US-0063486P.

PR

PR 24-OCT-1997; 97US-0063120P.

PR

PR 24-OCT-1997; 97US-0063121P.

PR

PR 28-OCT-1997; 97US-0063540P.

PR

PR 28-OCT-1997; 97US-0063541P.

PR

PR 28-OCT-1997; 97US-0063544P.

PR

PR 29-OCT-1997; 97US-0063734P.

PR

PR 31-OCT-1997; 97US-0063870P.

PR

PR 31-OCT-1997; 97US-0064103P.

PR

PR 13-NOV-1997; 97US-0065311P.

PR

PR 24-NOV-1997; 97US-0066466P.

PR

PR 11-DEC-1997; 97US-0066772P.

PR

PR 12-DEC-1997; 97US-0069335P.

PR

PR 17-DEC-1997; 97US-0069425P.

PR

PR 18-DEC-1997; 97US-0068017P.

PR

PR 10-MAR-1998; 98US-0077450P.

PR

PR 11-MAR-1998; 98US-0077632P.

PR

PR 11-MAR-1998; 98US-0077649P.

PR

PR 20-MAR-1998; 98US-0078886P.

PR

PR 27-MAR-1998; 98US-0078939P.

PR

PR 27-MAR-1998; 98US-0079664P.

PR

PR 31-MAR-1998; 98US-0079786P.

PR

PR 31-MAR-1998; 98US-0080107P.

PR

PR 01-APR-1998; 98US-0080333P.

PR

PR 01-APR-1998; 98US-0080327P.

PR

PR 08-APR-1998; 98US-0081049P.

PR

PR 09-APR-1998; 98US-0081195P.

PR

PR 15-APR-1998; 98US-0081838P.

PR

PR 21-APR-1998; 98US-0082568P.

PR

PR 21-APR-1998; 98US-0082569P.

PR

PR 22-APR-1998; 98US-0082704P.

PR

PR 22-APR-1998; 98US-0082797P.

PR

PR 28-APR-1998; 98US-0083322P.

PR

PR 29-APR-1998; 98US-0083495P.

PR

PR 29-APR-1998; 98US-0083496P.

PR

PR 29-APR-1998; 98US-0083499P.

PR

PR 29-APR-1998; 98US-0083559P.

PR

PR 05-MAY-1998; 98US-0084366P.

PR

PR 06-MAY-1998; 98US-0084414P.

PR

PR 07-MAY-1998; 98US-0084639P.

PR

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087088P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087872P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.

PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 01-SEP-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCCTTTTACACATCTTTCTCTTTTATCTTTATATAAAATGTTGGTCTCCACCATG 2180
DB 2653 CCTTTCCTTTCCCATCTCTTGACACATTTTAATAAATAGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAAA 2240
DB 2713 CAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 841

ACD08847

ID ACD08847 standard; cDNA; 2846 BP.

XX AC ACD08847;

XX DT 09-AUG-2003 (first entry)

XX DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX OS Homo sapiens.

XX PN US2003040062-A1.

XX PD 27-FEB-2003.

XX PF 25-JUN-2002; 2002US-00180545.

XX PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069333P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078939P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081195P.

PR 15-APR-1998; 98US-0081838P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083559P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.

PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTTATAAATAATGTTGCTCCCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAATAAGGCTTGCTTCTGAATA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 843
ACF15488
ID ACF15488 standard; cDNA; 2846 BP.
XX
AC ACF15488;
XX
DT 13-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003044926-A1.
XX
PD 06-MAR-2003.
XX
PF 26-JUN-2002; 2002US-00183015.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 28-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083497P.
PR 29-APR-1998; 98US-0083498P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.

[illegible]

PR 02-DEC-1999; 99WO-US028551.
PR 03-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000WO-US024848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-333028/31.
P-PSDB; ABUS5662.

Three hundred and five nucleic acids encoding PRO polypeptides, useful
for the manufacture of a medicament for diagnosing or treating tumor.

Claim 2; Fig 169; 707pp; English.

The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The invention also relates to a method for stimulating the release of
tumour necrosis factor alpha (TNF-alpha) from human blood by contacting
the blood with a sequence of the invention, a method for stimulating the
proliferation or differentiation of chondrocyte cells by contacting the
cells with a PRO polypeptide and a method for detecting the presence of a
tumour in a mammal. The polypeptides and polynucleotides are useful for
the manufacture of a medicament for diagnosing or treating a tumour in a
mammal. Sequences ACA72771-ACA73075 represent human PRO polynucleotides
of the invention. Note: The sequence data for this patent is also
available in electronic format from USPTO at
seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

* Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTTCCTTTATCTTATTAATAAAATGTTGCTCCACCACGTG 2180
Db 2653 CCTTTTCCTCCCACTCTTGTACACATTTTAAATAAAGGCTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 846
ACD03027
ID ACD03027 standard; cDNA; 2846 BP.
XX
AC ACD03027;
XX
DT 01-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 CDNA.
XX
KW Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW chondrocyte stimulator; tumour; adrenal tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; TNF-alpha release;
KW tumour necrosis factor alpha release; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; pharmaceutical; diagnostic; biosensor;
KW bioreactor; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003013153-A1.
XX
PD 16-JAN-2003.
XX
PF 19-JUN-2002; 2002US-00175737.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090679P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 25-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 17-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.

PR	25-JUN-1998,	98US-0096941P
PR	25-JUN-1998,	98US-0096959P
PR	25-JUN-1998,	98US-0096966P
PR	26-JUN-1998,	98US-01005413
PR	26-JUN-1998,	98US-0098626P
PR	26-JUN-1998,	98US-0098633P
PR	26-JUN-1998,	98US-00991010P
PR	01-JUL-1998,	98US-00991359P
PR	01-JUL-1998,	98US-00991544P
PR	02-JUL-1998,	98US-00991748P
PR	02-JUL-1998,	98US-00991486P
PR	02-JUL-1998,	98US-00991266P
PR	02-JUL-1998,	98US-00991628P
PR	02-JUL-1998,	98US-00991632P
PR	24-JUL-1998,	98US-00940006P
PR	04-AUG-1998,	98US-00952826P
PR	10-AUG-1998,	98US-00953988P
PR	10-AUG-1998,	98US-00960122P
PR	17-AUG-1998,	98US-00967575P
PR	17-AUG-1998,	98US-00967666P
PR	17-AUG-1998,	98US-00968667P
PR	17-AUG-1998,	98US-00968916P
PR	17-AUG-1998,	98US-00987233P
PR	18-AUG-1998,	98US-00989879P
PR	18-AUG-1998,	98US-00989499P
PR	18-AUG-1998,	98US-00963599P
PR	26-AUG-1998,	98US-00970222P
PR	26-AUG-1998,	98US-00979526P
PR	26-AUG-1998,	98US-00979543P
PR	26-AUG-1998,	98US-00979555P
PR	26-AUG-1998,	98US-00979719P
PR	26-AUG-1998,	98US-00979747P
PR	26-AUG-1998,	98US-00980146P
PR	01-SEP-1998,	98US-0098716P
PR	01-SEP-1998,	98US-00987233P
PR	02-SEP-1998,	98US-00988032P
PR	02-SEP-1998,	98US-00988212P
PR	02-SEP-1998,	98US-00988843P
PR	09-SEP-1998,	98US-00996022P
PR	10-SEP-1998,	98US-00997416P
PR	10-SEP-1998,	98US-00997549P
PR	10-SEP-1998,	98US-00997633P
PR	10-SEP-1998,	98US-00998122P
PR	15-SEP-1998,	98US-01003388P
PR	15-SEP-1998,	98US-01005622P
PR	16-SEP-1998,	98US-01006644P
PR	16-SEP-1998,	98US-01017519P
PR	16-SEP-1998,	98WC-US019330
PR	17-SEP-1998,	98US-01006863P
PR	17-SEP-1998,	98US-01006844P
PR	17-SEP-1998,	98US-01009191P
PR	17-SEP-1998,	98US-01009303P
PR	23-SEP-1998,	98US-01014755P
PR	23-SEP-1998,	98US-01014776P
PR	23-SEP-1998,	98US-01017388P
PR	24-SEP-1998,	98US-01017399P
PR	24-SEP-1998,	98US-01017433P
PR	24-SEP-1998,	98US-01014712P
PR	24-SEP-1998,	98US-01014722P
PR	24-SEP-1998,	98US-01017866P
PR	29-SEP-1998,	98US-01022070P
PR	29-SEP-1998,	98US-01022404P
PR	29-SEP-1998,	98US-01023330P
PR	30-SEP-1998,	98US-01023313P
PR	30-SEP-1998,	98US-01024877P
PR	30-SEP-1998,	98US-01025707P
PR	30-SEP-1998,	98US-01025719P
PR	01-OCT-1998,	98US-01026844P
PR	01-OCT-1998,	98US-01026877P
PR	02-OCT-1998,	98US-01029659P


```
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.

Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTCTTATCTATTATAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAAATAAAATAGGGTGTGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 849
ADI05057
ID ADI05057 standard; cDNA; 2846 BP.
XX AC ADI05057;
XX DT
XX 06-MAY-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW antibody; human; secreted; transmembrane; PRO; cytostatic; cancer; ss;
XX KW Gene.
XX OS Homo sapiens.
XX PN US2003180848-A1.
XX PD 25-SEP-2003.
XX PF
XX 08-MAY-2002; 2002US-00063694.
XX PR 30-DEC-1998; 98KR-00062142.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 14-MAY-1999; 99US-00311832.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 25-AUG-1999; 99US-00380138.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 25-AUG-1999; 99US-00380142.
XX PR 15-SEP-1999; 99US-00397342.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 12-NOV-1999; 99US-00423844.
XX PR 30-DEC-1999; 99WO-US031374.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 01-MAR-2000; 2000WO-US005601.
XX PR 02-MAR-2000; 2000WO-US005841.
XX PR 21-MAR-2000; 2000WO-US007532.
XX PR 22-MAY-2000; 2000WO-US014042.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 22-AUG-2000; 2000US-0064848.
XX PR 24-AUG-2000; 2000WO-US023328.
XX PR 18-SEP-2000; 2000US-00864610.
XX PR 18-SEP-2000; 2000US-00665350.
XX PR 08-NOV-2000; 2000US-00709238.
XX PR 10-NOV-2000; 2000WO-US030873.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 20-DEC-2000; 2000US-0074259.
XX PR 28-FEB-2001; 2000WO-US034956.
XX PR 22-MAR-2001; 2001WO-US006520.
XX PR 22-MAR-2001; 2001US-00816744.
XX PR 10-MAY-2001; 2001US-00854208.
XX PR 10-MAY-2001; 2001US-00854280.
```

```
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX (GETH ) GENENTECH INC.
XX Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-802876/75.
DR P-PSDB; ADI05058.
XX Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX Example 4; SEQ ID NO 37; 397pp; English.
XX This invention describes a novel antibody that binds to a human secreted
CC and transmembrane PRO polypeptide which is a monoclonal antibody, a
CC humanised antibody, or antibody fragment and is preferably labelled. The
CC antibody has cytostatic activity and can be used to treat cancer. The
CC anti-PRO antibody can be used in diagnostic assays, for e.g. detecting
CC PRO expression in specific cells, tissues, or serum. The anti-PRO
CC antibodies are also useful for the affinity purification of PRO from
CC recombinant cell culture or natural sources. ADI05021-ADI05188 represent
CC human PRO polynucleotides and polypeptides described in the disclosure of
CC the invention.
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match      3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTCTTATCTATTATAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAAATAAAATAGGGTGTGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 850
ADI03407
ID ADI03407 standard; cDNA; 2846 BP.
XX AC ADI03407;
XX DT
XX 06-MAY-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
XX KW cytostatic; vulnery; hyperglycaemic; hypoglycaemic; bone disorder;
XX KW cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
XX KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
XX KW Gene.
XX OS Homo sapiens.
XX PN US2003181654-A1.
XX PD 25-SEP-2003.
XX PF
```


PF 07-MAY-2002; 2002US-00063652.
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00068657.
XX (GETH) GENENTECH INC.

XX Eäton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WT;
XX WPI; 2003-875167/81.
DR P-PSDB; ADI03408.
XX

XX New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.

XX Example 4; Fig 37; 397pp; English.

XX This invention describes a novel human secreted and transmembrane PRO
CC polypeptide and the polynucleotides encoding it which have antiarthritic,
CC anti-diabetic, cytostatic, vulnerary, hyperglycaemic and hypoglycaemic
CC activity. The PRO polypeptides are useful for treating various bone
CC and/or cartilage disorders, for example, sports injuries and arthritis.
CC They are also useful in the therapeutic treatment of disorders where
CC either the stimulation or inhibition of glucose uptake by skeletal muscle
CC would be beneficial, for example, diabetes or hyper- or hypo-
CC insulinemia. They are also useful for treating pericyte-associated
CC tumours and in wound healing. An anti-PRO antibody is useful for the
CC preparation of a medicament useful in the treatment of cancer. The PRO
CC polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. ADI03371-ADI03538 represent the PRO
CC polynucleotides and polypeptides described in the disclosure of the
CC invention.

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTACCACTCTTCTCTTTATCTATTATAAATAATGTGTCTCCACCACGTG 2180
Db 2653 CCTTTTCCTCCCACTCTTGTACACATTTTATAAATAAAGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 851
ADI04802
ID ADI04802 standard; cDNA; 2846 BP.
XX AC ADI04802;
XX DT 06-MAY-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 CDNA.
XX KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
KW cytosolic; vulnerary; hyperglycaemic; hypoglycaemic; bone disorder;
KW cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
XX Gene.
XX OS Homo sapiens.
XX PN US2003181657-A1.
XX PD 25-SEP-2003.
XX PF 07-MAY-2002; 2002US-00063651.
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00068657.
XX


```
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000US-0080139.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US006520.
PR 10-MAY-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX
PA (GETH ) GENENTECH INC.
XX
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX
DR WPI; 2003-875178/81.
DR P-PSDB; ADH90349.
XX
XX
PT New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
XX
PS Disclosure; SEQ ID NO 37; 397pp; English.
XX
CC The invention relates to a novel PRO (secreted and transmembrane protein)
CC polypeptide, and the polynucleotide sequence encoding it. Also included
CC are a vector comprising the novel nucleic acid and a host cell comprising
CC the vector. The polynucleotide sequence is useful in molecular biology as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
CC may also be used in preparing the PRO polypeptide by recombinant
CC techniques, and in generating either transgenic or knock-out animals
CC which, in turn, are useful in the development and screening of
CC therapeutically useful reagents. The PRO polynucleotide sequence is
CC useful in preparing a medicament for treating a condition responsive to
CC the polypeptide or antibody, such as tumours, and in various diagnostic
CC assays. The specification also discloses other PRO proteins and the
CC polynucleotide sequences encoding them. The present sequence encodes a
CC PRO protein.
XX
XX
SQ Sequence 2846 BP; 768 A; 596 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCCTTGGTTTACCACTCTTTCCTTTATCTATTATATAAAATCTGGTCTCCACCACTG 2180
DB 2653 CCTTTTCCTCCCATCTCTGTACACATTTTATAAAATGAGGTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
```

```
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 855
AD103067
ID AD103067 standard; cDNA; 2846 BP.
AC AD103067;
XX
XX 06-MAY-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
XX PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
XX cytostatic; vulnery; hyperglycaemic; hypoglycaemic; bone disorder;
XX cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
XX pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
XX gene.
XX
XX Homo sapiens.
XX
XX US2003181653-A1.
XX
XX 25-SEP-2003.
XX
XX 07-MAY-2002; 2002US-00063650.
XX
XX 30-DEC-1998; 98KR-00062142.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 15-SEP-1999; 99US-00397342.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 30-DEC-1999; 99WO-US031274.
XX 18-FEB-2000; 2000WO-US004341.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 21-MAR-2000; 2000WO-US007532.
XX 22-MAY-2000; 2000WO-US014042.
XX 02-JUN-2000; 2000WO-US015264.
XX 22-AUG-2000; 2000US-00644848.
XX 24-AUG-2000; 2000WO-US023328.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001US-00816744.
XX 10-MAY-2001; 2001US-00854208.
XX 10-MAY-2001; 2001US-00870574.
XX 01-JUN-2001; 2001WO-US017800.
XX 05-JUN-2001; 2001US-00874503.
XX 29-JUN-2001; 2001US-00869599.
XX 18-JUL-2001; 2001US-00908827.
XX 06-DEC-2001; 2001US-00006867.
XX
XX
PA (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
```

[illegible]

Db 2773 AA 2774

RESULT 857

ADH97899

ID ADH97899 standard; cDNA; 2846 BP.

XX AC ADH97899;

XX 06-MAY-2004 (first entry)

DT Novel human secreted and transmembrane protein PRO1344 cDNA.

DE ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

KW affinity purification; secreted and transmembrane protein.

KW Homo sapiens.

OS US2003181674-A1.

PN 25-SEP-2003.

XX 03-MAY-2002; 2002US-00063602.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 18-OCT-1999; 99US-00403297.

XX 12-NOV-1999; 99US-00423844.

XX 30-DEC-1999; 99WO-US031274.

XX 18-FEB-2000; 2000WO-US004341.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005841.

XX 21-MAR-2000; 2000WO-US007532.

XX 22-MAY-2000; 2000WO-US014042.

XX 02-JUN-2000; 2000WO-US015264.

XX 22-AUG-2000; 2000US-00644848.

XX 24-AUG-2000; 2000WO-US023328.

XX 18-SEP-2000; 2000US-00664610.

XX 18-SEP-2000; 2000US-00665350.

XX 08-NOV-2000; 2000US-00709238.

XX 10-NOV-2000; 2000WO-US030873.

XX 20-DEC-2000; 2000WO-US032678.

XX 20-DEC-2000; 2000US-00747259.

XX 20-DEC-2000; 2000WO-US034956.

XX 28-FEB-2001; 2001WO-US006520.

XX 22-MAR-2001; 2001US-00816744.

XX 10-MAY-2001; 2001US-00854280.

XX 30-MAY-2001; 2001US-00870574.

XX 01-JUN-2001; 2001WO-US017800.

XX 03-JUN-2001; 2001US-00874503.

XX 29-JUN-2001; 2001US-00869599.

XX 18-JUL-2001; 2001US-00908827.

XX 06-DEC-2001; 2001US-00006867.

XX (GETH) GENENTECH INC.

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-852265/79.

XX P-PSDB; ADH97900.

XX Novel antibody that binds to a PRO polypeptide, useful for treating

PT cancer and in diagnostic assays, for e.g. detecting PRO expression in

PT specific cells, tissues, or serum.

XX Disclosure; SEQ ID NO 37; 396pp; English.

XX The invention relates to a PRO (secreted and transmembrane protein)

CC polynucleotide appearing as ADH97943 encoding PRO polypeptide having

CC appearing as ADH97943. Also included are a vector comprising the novel

CC nucleic acid and a host cell comprising the vector. The polynucleotide is

CC useful in molecular biology, including uses as hybridisation probes, in

CC chromosome and gene mapping, in generating antisense RNA and DNA, and in

CC gene therapy. The polynucleotide may also be used in preparing PRO

CC transgenic animals or knock-out animals, and in generating either

CC development and screening of therapeutically useful reagents. The PRO

CC polynucleotide is used in preparing a medicament for treating a condition

CC responsive to the polypeptide or antibody, such as tumours, and in

CC various diagnostic assays. The specification discloses 84 PRO proteins

CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. NO. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180

DB 2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTAATAAAATAGGGTTGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAA AA 2240

DB 2713 CAAAAA AA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 858

AD101284

ID AD101284 standard; cDNA; 2846 BP.

XX AC AD101284;

XX 06-MAY-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1344 cDNA.

XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

XX affinity purification; secreted and transmembrane protein.

XX Homo sapiens.

XX US2003190669-A1.

XX 09-OCT-2003.

XX 01-MAY-2002; 2002US-00063521.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 18-OCT-1999; 99US-00403297.

XX 12-NOV-1999; 99US-00423844.

XX 30-DEC-1999; 99WO-US031274.

XX 18-FEB-2000; 2000WO-US004341.

```

PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
FA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-803322/75.
DR P-PSDB; ADI01285.
XX
PT Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
PS Disclosure; Fig 37; 562pp; English.
XX
CC The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACTCTTCTTTATCTATTATAATAAAATGTTGTCCTCCACCACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTTGACACATTTATATAAATGAGGTGGCTTCGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 859
ADI01979
ID ADI01979 standard; cDNA; 2846 BP.
XX
AC ADI01979;
XX
DT 06-MAY-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW antiarthritic; antidiabetic; cytostatic; vulnery; hyperglycaemic;
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW bone disorder; cartilage disorder; sports injury; arthritis;
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
KW chromosome identification; gene therapy; gene; ss; human.
XX
OS Homo sapiens.
XX
PN US2003181652-A1.
XX
PD 25-SEP-2003.
XX
PF 07-MAY-2002; 2002US-00063649.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
(GETH ) GENENTECH INC.
XX
Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
WPI; 2003-875165/81.
P-PSDB; ADI01980.
New isolated PRO polypeptide, useful for treating various bone and/or
cartilage disorders, for example, sports injuries and arthritis.
Disclosure; SEQ ID NO 37; 397pp; English.
The invention describes an isolated PRO (secreted and transmembrane)

```

PR	02-MAR-2000;	2000WO-US005841.1
PR	21-MAR-2000;	2000WO-US007532.1
PR	22-MAR-2000;	2000WO-US011404.2
PR	23-MAR-2000;	2000WO-US011526.4
PR	22-JUN-2000;	2000US-00644848.8
PR	22-AUG-2000;	2000US-00643328.8
PR	24-SEP-2000;	2000US-00664610.0
PR	18-SEP-2000;	2000US-00653530.0
PR	08-NOV-2000;	2000WO-US030823.8
PR	10-NOV-2000;	2000WO-US030873.3
PR	01-DEC-2000;	2000WO-US032678.8
PR	20-DEC-2000;	2000US-00747259.9
PR	20-DEC-2000;	2000WO-US034956.6
PR	28-FEB-2001;	2001WO-US006520.0
PR	22-MAR-2001;	2001US-0816744.4
PR	10-MAY-2001;	2001US-00854208.8
PR	30-MAY-2001;	2001US-00870574.4
PR	01-JUN-2001;	2001WO-US017800.0
PR	05-JUN-2001;	2001US-00874503.3
PR	23-JUN-2001;	2001US-00869599.9
PR	18-JUL-2001;	2001US-00908827.7
PR	06-DEC-2001;	2001US-00906867.7

(GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGGTTTACCACACTCTTTCCTTTTATCTTTATTAATAAAAGTGTGGTCTCCACCACTG 2150

18-JUN-2001; 2001US-000908827.
06-DEC-2001; 2001US-00006867.
(GETH) GENENTECH INC.
Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
WPI; 2003-875168/81.
P-ESDB; ADI03238.
New isolated PRO polypeptide, useful for treating various bone and/or
cartilage disorders, for example, sports injuries and arthritis.
Example 4; Fig 37; 397pp; English.

RESULT	860	
AD103237		
ID	AD103237	standard; cDNA; 2846 BP.
XX	XX	
XX	AC	AD103237;
XX	XX	
DT	06-MAY-2004	(first entry)
XX		
DE	Novel human secreted and transmembrane protein PRO1344	cDNA.
XX		
KW	PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;	
KW	cytostatic; vulnerable; hyperglycaemic; hypoglycaemic; bone disorder;	
KW	cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;	
KW	pericyte-associated tumour; wound healing; cancer; gene therapy; ss;	
KW	gene.	

AD103237
ID AD103237 standard; cDNA; 2846 BP.
XX
XX
AC AD103237;
XX
XX
DT 06-MAY-2004 (first entry)
XX
XX
DE Novel human secreted and transmembrane protein, PRO1344 cDNA.

AC	ADI03237;	Novel human secreted and transmembrane protein PRO1344 cDNA.
XX		
XX		
DT	06-MAY-2004 (first entry)	
XX		
XX		
DE		PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
XX		cystostatic; vulnerable; hyperglycaemic; hypoglycaemic; bone disorder;
KW		cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
KW		pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
KW		gene.

06-MAY-2004	(first entry)	Novel human secreted and transmembrane protein PRO1344 cDNA.
XX	XX	PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
XX	XX	cystostatic; vulnerable; hyperglycaemic; hypoglycaemic; bone disorder;
XX	XX	cardiologic disorder; sports injury; arthritis; glucose uptake; diabetes;
XX	XX	pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
XX	XX	gene.

Novel human secreted and transmembrane protein PRO1344 cDNA.

CC would be beneficial, for example, diabetes or hyper- or hypo-
CC insulinaemia. They are also useful for treating pericyte-associated
CC tumours and in wound healing. An anti-PRO antibody is useful for the
CC preparation of a medicament useful in the treatment of cancer. The PRO
CC polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. AD103201-AD103368 represent the PRO
CC polynucleotides and polypeptides described in the disclosure of the
CC invention.

za
 OS Homo sapiens.
 XX
 PN US2003181655-A1.

XX
PN
US2003181655-A1.

XX PD 25-SEP-2003.

XX
PF
07-MAY-2002: 2002IIS-00063654XX
PR 30-DEC-1998. 98KP-00062142

PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00317822

PR 14-MAY-1999; 99WO-US010733.
PR 25-MAY-1999; 99WO-US010733.
PR 25-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380142.

PR 18-OCT-1999; 99US-00403297.

PR 30-DEC-1999; 99WO-US031274.

PR 01-MAR-2000; 2000WO-US005601.

RESULT 861
AD111424
ID AD111424 standard; cDNA; 2846 BP.

XX AC AD111424;

XX DT 06-MAY-2004 (first entry)

XX DE Human PRO polynucleotide #19.

XX KW Human; PRO; gene; ss; cancer; affinity purification; cytostatic.

XX OS Homo sapiens.

XX PN US2003181681-A1.

XX PD 25-SEP-2003.

XX PF 07-MAY-2002; 2002US-00063646.

XX PR 30-DEC-1998; 98KR-00062142.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 14-MAY-1999; 99US-00311832.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 25-AUG-1999; 99US-00380138.

XX PR 25-AUG-1999; 99US-00380139.

XX PR 25-AUG-1999; 99US-00380142.

XX PR 15-SEP-1999; 99US-00397342.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 12-NOV-1999; 99US-00423844.

XX PR 30-DEC-1999; 99WO-US031274.

XX PR 18-FEB-2000; 2000WO-US004341.

XX PR 01-MAR-2000; 2000WO-US005601.

XX PR 22-MAY-2000; 2000WO-US005841.

XX PR 21-MAR-2000; 2000WO-US007532.

XX PR 02-JUN-2000; 2000WO-US014042.

XX PR 22-AUG-2000; 2000WO-US015264.

XX PR 22-AUG-2000; 2000WO-US064484.

XX PR 24-AUG-2000; 2000WO-US023328.

XX PR 18-SEP-2000; 2000US-00664610.

XX PR 18-SEP-2000; 2000US-00665350.

XX PR 08-NOV-2000; 2000US-00709238.

XX PR 10-NOV-2000; 2000WO-US030873.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 20-DEC-2000; 2000US-00747259.

XX PR 28-DEC-2000; 2000WO-US034956.

XX PR 28-FEB-2001; 2001WO-US006520.

XX PR 22-MAR-2001; 2001US-00816744.

XX PR 10-MAY-2001; 2001US-00854208.

XX PR 30-MAY-2001; 2001US-00870574.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 05-JUN-2001; 2001US-00874503.

XX PR 29-JUN-2001; 2001US-00869599.

XX PR 18-JUL-2001; 2001US-00908827.

XX PR 06-DEC-2001; 2001US-00006867.

XX FA (GETH) GENENTECH INC.

XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX PI WPI; 2003-898871/82.

XX PI P-PSDB; AD111425.

XX PT Novel antibody that binds to a PRO polypeptide, useful for treating

XX PT cancer and in diagnostic assays, for e.g. detecting PRO expression in

XX PT specific cells, tissues, or serum.

XX PS Disclosure; SEQ ID NO 37; 396pp; English.

XX The invention relates to an antibody that binds to a human PRO
CC polypeptide. The invention also relates to human PRO polynucleotides
CC encoding the PRO polypeptides of the invention. The antibody is
CC preferably a monoclonal or humanised antibody, or an antibody fragment,
CC and is used to treat cancer. The anti-PRO antibody can be used in
CC diagnostic assays, e.g. for detecting PRO expression in specific cells,
CC tissues or serum. The anti-PRO antibodies are also useful for the
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence represents a human PRO polynucleotide of the
XX invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTCTTTTATCTTATTAATAAAATGTTGCTCCCACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAGGCTTCTGCACTA 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 862
AD102326
ID AD102326 standard; cDNA; 2846 BP.
XX AC AD102326;
XX DT 06-MAY-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW antiathritic; antidiabetic; cytostatic; vulnary; hyperglycaemic;
KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
KW bone disorder; cartilage disorder; sports injury; arthritis;
KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
XX chromosome identification; gene therapy; gene; ss; human.
OS Homo sapiens.
XX US2003181650-A1.
XX PD 25-SEP-2003.
XX PF 07-MAY-2002; 2002US-00063642.
XX PR 30-DEC-1998; 98KR-00062142.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 14-MAY-1999; 99US-00311832.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 25-AUG-1999; 99US-00380138.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 25-AUG-1999; 99US-00380142.
XX PR 15-SEP-1999; 99US-00397342.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 12-NOV-1999; 99US-00423844.
XX PR 30-DEC-1999; 99WO-US031274.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 01-MAR-2000; 2000WO-US005601.
XX PR 02-MAR-2000; 2000WO-US005841.
XX PR 21-MAR-2000; 2000WO-US007532.
XX PR 22-MAY-2000; 2000WO-US014042.

CC and is used to treat cancer. The anti-PRO antibody can be used in
 CC diagnostic assays, e.g. for detecting PRO expression in specific cells,
 CC tissues or serum. The anti-PRO antibodies are also useful for the
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. This sequence represents a human PRO polynucleotide of the
 CC invention.

XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTTTATTAATAAATGTTGCTCCACCACTG 2180
 Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAGGCTTGGCTTCGAACATA 2712

Qy 2181 NCTCCCAA 2240
 Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242
 Db 2773 AA 2774

RESULT 864
 ADI05401
 ID ADI05401 standard; cDNA; 2846 BP.
 XX
 AC ADI05401;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX
 KW PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
 KW cystostatic; vulnary; hyperglycaemic; hypoglycaemic; bone disorder;
 KW cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
 KW pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
 KW gene.

XX
 OS Homo sapiens.
 OS
 FN US2003190716-A1.
 XX
 PD 09-OCT-2003.
 XX
 PF 03-MAY-2002; 2002US-00063617.
 XX
 PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000WO-US0644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-0064610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 PA (GETH) GENENTECH INC.
 XX
 FI Eaton DL, Filvaroff E, Gerritsen MB, Goddard A, Godowski PJ;
 FI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX
 DR WPI; 2003-831627/77.
 DR P-PSDB; ADI05402.
 XX
 PT New isolated PRO polypeptide, useful for treating various bone and/or
 PT cartilage disorders, for example, sports injuries and arthritis.
 XX
 PS Example 4; SEQ ID NO 37; 395pp; English.
 XX
 CC This invention describes a novel human secreted and transmembrane PRO
 CC polypeptide and the polynucleotides encoding it which have antiarthritic,
 CC antidiabetic, cytostatic, vulnary, hyperglycaemic and hypoglycaemic
 CC activity. The PRO polypeptides are useful for treating various bone
 CC and/or cartilage disorders, for example, sports injuries and arthritis.
 CC They are also useful in the therapeutic treatment of disorders where
 CC either the stimulation or inhibition of glucose uptake by skeletal muscle
 CC would be beneficial, for example, diabetes or hyper- or hypo-
 CC insulinemia. They are also useful for treating pericyte-associated
 CC tumours and in wound healing. An anti-PRO antibody is useful for the
 CC preparation of a medicament useful in the treatment of cancer. The PRO
 CC polypeptides are also useful as molecular weight markers, or for
 CC chromosome identification. The PRO genes are useful as hybridisation
 CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 CC The PRO genes may also be used in gene therapy, particularly for
 CC replacing a defective gene. ADI05365-ADI05532 represent the PRO
 CC polynucleotides and polypeptides described in the disclosure of the
 CC invention.

XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTTTTATTAATAAATGTTGCTCCACCACTG 2180
 Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAGGCTTGGCTTCGAACATA 2712

Qy 2181 NCTCCCAA 2240
 Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242
 Db 2773 AA 2774

RESULT 865
 ADH79473
 ID ADH79473 standard; cDNA; 2846 BP.
 XX
 AC ADH79473;
 XX
 DT 06-MAY-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE ss; gene, human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
KW Homo sapiens.
OS US2003191290-A1.
PN 09-OCT-2003.
PD 07-MAY-2002; 2002US-00063668.
PF 30-DEC-1998; 98KR-00062142.
PF 08-MAR-1999; 99WO-US005028.
PF 14-MAY-1999; 99US-00311832.
PF 14-MAY-1999; 99WO-US010733.
PF 25-AUG-1999; 99US-00380137.
PF 25-AUG-1999; 99US-00380138.
PF 25-AUG-1999; 99US-00380139.
PF 25-AUG-1999; 99US-00380142.
PF 18-SEP-1999; 99US-00397342.
PF 18-OCT-1999; 99US-00403297.
PF 12-NOV-1999; 99US-00423844.
PF 30-DEC-1999; 99WO-US031274.
PF 18-FEB-2000; 2000WO-US004341.
PF 01-MAR-2000; 2000WO-US005601.
PF 02-MAR-2000; 2000WO-US005841.
PF 22-MAR-2000; 2000WO-US007532.
PF 02-JUN-2000; 2000WO-US014042.
PF 24-AUG-2000; 2000US-00644848.
PF 24-AUG-2000; 2000WO-US023328.
PF 18-SEP-2000; 2000US-00664610.
PF 18-SEP-2000; 2000US-00665350.
PF 08-NOV-2000; 2000US-00709238.
PF 10-NOV-2000; 2000WO-US030873.
PF 01-DEC-2000; 2000WO-US032678.
PF 20-DEC-2000; 2000US-00747259.
PF 20-DEC-2000; 2000WO-US034956.
PF 28-FEB-2001; 2001WO-US006520.
(GETH) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-803332/75.
DR P-PSDB; ADH79474.
XX Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX Disclosure; SEQ ID NO 37; 394pp; English.
XX The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or

CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACCTCTTTCTTTCTTTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCITTTCTTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 866
AD119430
ID AD119430 standard; cDNA; 2846 BP.
XX AC AD119430;
XX 06-MAY-2004 (first entry)
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
KW ss; gene, human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX Homo sapiens.
XX US2003181675-A1.
XX 25-SEP-2003.
XX 03-MAY-2002; 2002US-00063606.
XX 30-DEC-1998; 98KR-00062142.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 30-DEC-1999; 99WO-US031274.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 22-MAR-2000; 2000WO-US007532.
XX 02-JUN-2000; 2000WO-US014042.
XX 24-AUG-2000; 2000US-00644848.
XX 24-AUG-2000; 2000WO-US023328.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.

```
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-852266/79.
XX P-PSDB; ADI19431.
XX
XX Novel antibody that binds to a PRO polypeptide, useful for treating
XX cancer and in diagnostic assays, for e.g. detecting PRO expression in
XX specific cells, tissues, or serum.
XX
XX Disclosure; SEQ ID NO 37; 396pp; English.
XX
XX The invention relates to a PRO (secreted and transmembrane protein)
XX polynucleotide appearing as ADI19474 encoding PRO polypeptide having
XX appearing as ADI19474. Also included are a vector comprising the novel
XX nucleic acid and a host cell comprising the vector. The polynucleotide is
XX useful in molecular biology, including uses as hybridisation probes, in
XX chromosome and gene mapping, in generating antisense RNA and DNA, and in
XX gene therapy. The polynucleotide may also be used in preparing PRO
XX transgenic animals or knock-out animals which, in turn, are useful in the
XX development and screening of therapeutically useful reagents. The PRO
XX polynucleotide is used in preparing a medicament for treating a condition
XX responsive to the polypeptide or antibody, such as tumours, and in
XX various diagnostic assays. The specification discloses 84 PRO proteins
XX and 84 PRO polynucleotides. The present sequence encodes a PRO protein.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 10; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Oy 2121 CCTTTGCTTTACCACTCTTCCTTTTATCTATTATTAATAAATGTTGCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCACTCTCTGTACACATTTTATAAATAAGGTTGCTTCTGAACATA 2712
Oy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Oy 2241 AA 2242
Db ||
2773 AA 2774
XX
XX RESULT 867
XX ADI05231
XX ID ADI05231 standard; cDNA; 2846 BP.
XX
XX AC ADI05231;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX PRO; human; secreted; transmembrane; antiarthritic; antidiabetic;
XX cytostatic; vulnery; hyperglycaemic; hypoglycaemic; bone disorder;
XX cartilage disorder; sports injury; arthritis; glucose uptake; diabetes;
XX pericyte-associated tumour; wound healing; cancer; gene therapy; ss;
XX gene.
```

```
XX
XX Homo sapiens.
XX US2003181677-A1.
XX
XX 25-SEP-2003.
XX
XX 03-MAY-2002; 2002US-00063611.
XX
XX 30-DEC-1998; 98KR-00062142.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 15-SEP-1999; 99US-00397342.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 30-DEC-1999; 99WO-US031274.
XX 18-FEB-2000; 2000WO-US004341.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 21-MAR-2000; 2000WO-US007532.
XX 22-MAY-2000; 2000WO-US014042.
XX 02-JUN-2000; 2000WO-US015264.
XX 22-AUG-2000; 2000US-00644848.
XX 24-AUG-2000; 2000WO-US023328.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001US-00816744.
XX 10-MAY-2001; 2001US-00854208.
XX 30-MAY-2001; 2001US-00870574.
XX 01-JUN-2001; 2001WO-US017800.
XX 05-JUN-2001; 2001US-00874503.
XX 29-JUN-2001; 2001US-00869599.
XX 18-JUL-2001; 2001US-00908827.
XX 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-875172/81.
XX P-PSDB; ADI05232.
XX
XX New isolated PRO polypeptide, useful for treating various bone and/or
XX cartilage disorders, for example, sports injuries and arthritis.
XX
XX Example 4; SEQ ID NO 37; 397pp; English.
```

```
XX
XX This invention describes a novel human secreted and transmembrane PRO
XX polypeptide and the polynucleotides encoding it which have antiarthritic,
XX antidiabetic, cytostatic, vulnery, hyperglycaemic and hypoglycaemic
XX activity. The PRO polypeptides are useful for treating various bone
XX and/or cartilage disorders, for example, sports injuries and arthritis.
XX They are also useful in the therapeutic treatment of disorders where
XX either the stimulation or inhibition of glucose uptake by skeletal muscle
XX would be beneficial, for example, diabetes or hyper- or hypo-
XX insulinemia. They are also useful for treating pericyte-associated
XX tumours and in wound healing. An anti-PRO antibody is useful for the
XX preparation of a medicament useful in the treatment of cancer. The PRO
XX polypeptides are also useful as molecular weight markers, or for
XX chromosome identification. The PRO genes are useful as hybridisation
```



```

PA (GETH ) GENENTECH INC.
XX
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-852268/79.
DR P-PSDB; ADI01640.
XX
XX Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
XX Disclosure; Fig 37; 396pp; English.
XX
XX The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTTCTTCCCTCCCACTCTTGTACACATTTTAATAAAATGTTGGTCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 871
ADI01809
XX ADI01809 standard; cDNA; 2846 BP.
XX
XX AC ADI01809;
XX
XX 06-MAY-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX ss; Gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
XX affinity purification; secreted and transmembrane protein.
XX
XX Homo sapiens.
XX
XX US2003181680-A1.
XX
XX 25-SEP-2003.
XX
XX 07-MAY-2002; 2002US-00063643.
XX
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR

```

```

PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 24-AUG-2000; 2000US-00644848.
PR 18-SEP-2000; 2000US-00664610.
PR 08-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-875173/81.
DR P-PSDB; ADI01810.
XX
XX Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX
XX Disclosure; Fig 37; 396pp; English.
XX
XX The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTTCTTCCCTCCCACTCTTGTACACATTTTAATAAAATGTTGGTCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

```


Db 2773 AA 2774

RESULT 872

ADH79813

ID ADH79813 standard; cDNA; 2846 BP.

XX AC ADH79813;

XX DT 06-MAY-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

XX KW affinity purification; secreted and transmembrane protein.

XX OS Homo sapiens.

XX US2003191289-A1.

XX 09-OCT-2003.

XX 07-MAY-2002; 2002US-00063657.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 18-OCT-1999; 99US-00403297.

XX 12-NOV-1999; 99US-00423844.

XX 30-DEC-1999; 99WO-US031274.

XX 18-FEB-2000; 2000WO-US004341.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005841.

XX 21-MAR-2000; 2000WO-US007532.

XX 22-MAY-2000; 2000WO-US014042.

XX 02-JUN-2000; 2000WO-US015264.

XX 22-AUG-2000; 2000US-00644848.

XX 24-AUG-2000; 2000WO-US023328.

XX 18-SEP-2000; 2000US-00664610.

XX 18-SEP-2000; 2000US-00665350.

XX 08-NOV-2000; 2000US-00709238.

XX 10-NOV-2000; 2000WO-US030873.

XX 01-DEC-2000; 2000WO-US032678.

XX 20-DEC-2000; 2000US-00747259.

XX 20-DEC-2000; 2000WO-US034956.

XX 28-FEB-2001; 2001WO-US006520.

XX 22-MAR-2001; 2001US-00816744.

XX 10-MAY-2001; 2001US-00854208.

XX 10-MAY-2001; 2001US-00854280.

XX 30-MAY-2001; 2001US-00870574.

XX 01-JUN-2001; 2001WO-US017800.

XX 05-JUN-2001; 2001US-00874503.

XX 29-JUN-2001; 2001US-00869599.

XX 18-JUL-2001; 2001US-00908827.

XX 06-DEC-2001; 2001US-00006867.

(GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;

Pi Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-803331/75.

DR P-PSDB; ADH79814.

XX Novel antibody that binds to a PRO polypeptide, useful for treating

PT cancer and in diagnostic assays, for e.g. detecting PRO expression in

PT specific cells, tissues, or serum.

XX Disclosure; SEQ ID NO 37; 394pp; English.

XX The invention describes an antibody that specifically binds to a PRO

CC polypeptide having a fully defined amino acid sequence given in the

CC specification. The antibody is useful in identifying PRO polypeptides

CC useful for various industrial applications, including pharmaceuticals,

CC diagnostics, biosensors and bioreactors. The antibody is also used for

CC affinity purification of PRO polypeptides from recombinant cell culture

CC or natural sources. The antibody, PRO polypeptide, or its agonists or

CC antagonists, may be used for preparing a medicament for diagnosing or

CC treating a condition responsive to the antibody, PRO polypeptide, or its

CC agonists or antagonists. This sequence encodes a novel human secreted and

CC transmembrane PRO polypeptide.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTTGCTCCCACTG 2180

Db 2653 CCTTTCTTCCCATCTCTTGACACATTTTATAAAATAGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 873

AD104631

ID AD104631 standard; cDNA; 2846 BP.

XX AC AD104631;

XX 06-MAY-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1344 cDNA.

XX antibody; human; secreted; transmembrane; PRO; cytostatic; cancer; ss;

XX gene.

XX Homo sapiens.

XX US2003171550-A1.

XX 11-SEP-2003.

XX 02-MAY-2002; 2002US-00063526.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99US-00311832.

XX 14-MAY-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 18-OCT-1999; 99US-00403297.

XX 12-NOV-1999; 99US-00423844.

XX 30-DEC-1999; 99WO-US031274.

XX 18-FEB-2000; 2000WO-US004341.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005841.

XX 21-MAR-2000; 2000WO-US007532.

XX 22-MAY-2000; 2000WO-US014042.

XX 02-JUN-2000; 2000WO-US015264.

CC would be beneficial, for example, diabetes or hyper- or hypo-
 CC insulinaemia. They are also useful for treating pericyte-associated
 CC tumours and in wound healing. The anti-PRO antibody is useful for the
 CC preparation of a medicament useful in the treatment of cancer. The PRO
 CC polypeptides are also useful as molecular weight markers, or for
 CC chromosome identification. The PRO genes are useful as hybridisation
 CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 CC The PRO genes may also be used in gene therapy, particularly for
 CC replacing a defective gene. This sequence encodes a secreted and
 CC transmembrane PRO protein.

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTCTTATTAATAAATGTTGCTCCCACTG 2180
 DB 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAATAAATGTTGCTTCTGAAC 2712
 QY 2181 NCTCCAAAAA 2240
 DB 2713 CAAAAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774

RESULT 875
 ADH78086
 ID ADH78086 standard; cDNA; 2846 BP.
 AC ADH78086;
 DT 06-MAY-2004 (first entry)
 DE Human PRO polynucleotide #19.
 KW Human; PRO; gene; ss; cancer; affinity purification; cytostatic.
 OS Homo sapiens.
 XX US2003181667-A1.
 XX 25-SEP-2003.
 XX 02-MAY-2002; 2002US-00063540.
 XX 30-DEC-1998; 98KR-00062142.
 XX 08-MAR-1999; 99WO-US005028.
 XX 14-MAY-1999; 99US-00311832.
 XX 14-MAY-1999; 99WO-US010733.
 XX 25-AUG-1999; 99US-00380137.
 XX 25-AUG-1999; 99US-00380138.
 XX 25-AUG-1999; 99US-00380139.
 XX 25-AUG-1999; 99US-00380142.
 XX 15-SEP-1999; 99US-00397342.
 XX 18-OCT-1999; 99US-00403297.
 XX 12-NOV-1999; 99US-00423844.
 XX 30-DEC-1999; 99WO-US031274.
 XX 18-FEB-2000; 2000WO-US004341.
 XX 01-MAR-2000; 2000WO-US005601.
 XX 02-MAR-2000; 2000WO-US005841.
 XX 21-MAR-2000; 2000WO-US007532.
 XX 22-MAY-2000; 2000WO-US014042.
 XX 02-JUN-2000; 2000WO-US015264.
 XX 22-AUG-2000; 2000US-00644848.
 XX 24-AUG-2000; 2000WO-US023328.
 XX 18-SEP-2000; 2000US-00664610.
 XX 18-SEP-2000; 2000US-00665350.
 XX 08-NOV-2000; 2000US-00709238.

PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 PA (GETH) GENENTECH INC.
 XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX WPI; 2003-811659/76.
 DR P-PSDB; ADH78087.
 XX Novel antibody that binds to a PRO polypeptide, useful for treating
 PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
 PT specific cells, tissues, or serum.
 XX Disclosure; SEQ ID NO 37; 396pp; English.
 XX The invention relates to an antibody that binds to a human PRO
 CC polypeptide. The invention also relates to human PRO polynucleotides
 CC encoding the PRO polypeptides of the invention. The antibody is
 CC preferably a monoclonal or humanised antibody, or an antibody fragment,
 CC and is used to treat cancer. The anti-PRO antibody can be used in
 CC diagnostic assays, e.g. for detecting PRO expression in specific cells,
 CC tissues or serum. The anti-PRO antibodies are also useful for the
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. This sequence represents a human PRO polynucleotide of the
 CC invention.

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTCTTATTAATAAATGTTGCTCCCACTG 2180
 DB 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAATAAATGTTGCTTCTGAAC 2712
 QY 2181 NCTCCAAAAA 2240
 DB 2713 CAAAAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774

RESULT 876
 ADI25725
 ID ADI25725 standard; cDNA; 2846 BP.
 XX ADI25725;
 AC ADI25725;
 XX 06-MAY-2004 (first entry)
 DT Novel human secreted and transmembrane protein PRO1344 cDNA.
 DE ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.
 XX Homo sapiens.


```

PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX PA (GETH ) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-852262/79.
DR P-PSDB; ADI25896.
XX Novel antibody that binds to a PRO polypeptide, useful for treating
PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
PT specific cells, tissues, or serum.
XX Disclosure; SEQ ID NO 37; 396pp; English.
XX The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAATGTTGCTCTCCACCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 878
ADK65407
ID ADK65407 standard; cDNA; 2846 BP.
AC ADK65407;
XX 06-MAY-2004 (first entry)
DT Novel human secreted and transmembrane protein PRO1344 cDNA.
DE sg; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX Homo sapiens.
XX US2003073821-A1.
XX 17-APR-2003.
XX 02-MAY-2002; 2002US-00063566.
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.

```

```

PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 15-SEP-1999; 99US-00380142.
PR 18-OCT-1999; 99US-00397342.
PR 12-NOV-1999; 99US-00403297.
PR 30-DEC-1999; 99US-00423844.
PR 01-MAR-2000; 2000WO-US004341.
PR 02-MAR-2000; 2000WO-US005601.
PR 21-MAR-2000; 2000WO-US005841.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 24-AUG-2000; 2000WO-US064848.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 20-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX (GETH ) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-730025/69.
DR P-PSDB; ADK65408.
XX New antibody that binds to a secreted protein (designated a PRO
PT polypeptide) PRO1106, potentially useful as a diagnostic or therapeutic
PT agent.
XX Disclosure; SEQ ID NO 37; 235pp; English.
XX The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX SQ Sequence 2846 BP; 768 A; 697 C; 744 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 10; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAATGTTGCTCTCCACCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

```


PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00854280.
 PR 01-JUN-2001; 2001US-00870574.
 PR 05-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001US-00874503.
 PR 18-JUL-2001; 2001US-00869599.
 PR 06-DEC-2001; 2001US-00908827.
 XX 06-DEC-2001; 2001US-00006867.
 PA (GETH) GENENTECH INC.
 PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX WPI; 2003-8033329/75.
 DR P-PSDB; ADH79991.
 XX Novel antibody that binds to a PRO polypeptide, useful for treating
 PT cancer and in diagnostic assays, for e.g. detecting PRO expression in
 PT specific cells, tissues, or serum.
 XX Disclosure; SEQ ID NO 37; 394pp; English.
 PS The invention describes an antibody that specifically binds to a PRO
 XX polypeptide having a fully defined amino acid sequence given in the
 CC specification. The antibody is useful in identifying PRO polypeptides
 CC useful for various industrial applications, including pharmaceuticals,
 CC diagnostics, biosensors and bioreactors. The antibody is also used for
 CC affinity purification of PRO polypeptides from recombinant cell culture
 CC or natural sources. The antibody, PRO polypeptide, or its agonists or
 CC antagonists, may be used for preparing a medicament for diagnosing or
 CC treating a condition responsive to the antibody, PRO polypeptide, or its
 CC agonists or antagonists. This sequence encodes a novel human secreted and
 CC transmembrane PRO polypeptide.
 XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 SQ Query Match 3.0%; Score 66.6; DB 10; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTATAAATAATGTTGGTCTCCACCACTG 2180
 Db 2653 CTTTTTCTTTCCCATCTCTTGTACACATTTTATAAATAAAGGGTTGGCTTCTGAAC 2712
 Qy 2181 NCTCCCAAA 2240
 Db 2713 CAAAAAATAAA 2772
 Qy 2241 AA 2242
 Db 2773 AA 2774
 RESULT 881
 ADL32775

ID ADL32775 standard; cDNA; 2846 BP.
 AC ADL32775;
 XX 20-MAY-2004 (first entry)
 DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
 KW secreted and transmembrane protein; PRO; chromosome mapping;
 KW gene mapping; tumour.
 XX Homo sapiens.
 OS US2003207396-A1.
 PN 06-NOV-2003.
 PD 11-JUL-2002; 2002US-00194486.
 PF 05-JUN-2000; 2000US-0209832P.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-864789/80.
 DR P-PSDB; ADL32776.
 XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
 PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
 PT particularly for treating e.g. lung or breast tumors, or arthritis in a
 PT mammal.
 XX Claim 2; SEQ ID NO 169; 707pp; English.
 PS The invention describes 305 nucleic acids encoding PRO polypeptides
 CC (secreted and transmembrane). The polynucleotide is useful in molecular
 CC biology, including uses as hybridisation probes, in chromosome and gene
 CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
 CC polynucleotide may also be used in preparing PRO polypeptides by
 CC recombinant techniques, and in generating either transgenic animals or
 CC knock-out animals which, in turn, are useful in the development and
 CC screening of therapeutically useful reagents. The PRO polypeptide or the
 CC antibody is used in preparing a medicament for treating a condition
 CC responsive to the polypeptide or antibody, such as tumours, and in
 CC various diagnostic assays. This sequence encodes a novel human secreted
 CC and transmembrane PRO polypeptide.
 XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 SQ Query Match 3.0%; Score 66.6; DB 11; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTATAAATAATGTTGGTCTCCACCACTG 2180
 Db 2653 CTTTTTCTTTCCCATCTCTTGTACACATTTTATAAATAAAGGGTTGGCTTCTGAAC 2712
 Qy 2181 NCTCCCAAA 2240
 Db 2713 CAAAAAATAAA 2772
 Qy 2241 AA 2242
 Db 2773 AA 2774
 RESULT 882
 ADM30309

ID ADM30309 standard; cDNA; 2846 BP.
 XX AC ADM30309;
 XX DT 20-MAY-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX KW Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
 XX KW secreted and transmembrane protein; PRO; chromosome mapping;
 XX KW gene mapping; tumour.
 XX OS Homo sapiens.
 XX US2003073813-A1.
 XX PD 17-APR-2003.
 XX PF 25-JUL-2002; 2002US-00205904.
 XX PR 26-JUN-1998; 98US-00105413.
 PR 16-SEP-1998; 98WO-US019330.
 PR 07-OCT-1998; 98US-00168978.
 PR 07-OCT-1998; 98WO-US021141.
 PR 06-NOV-1998; 98US-00187368.
 PR 01-DEC-1998; 98WO-US025108.
 PR 07-DEC-1998; 98US-00202054.
 PR 03-MAR-1999; 99US-00254311.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US021090.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028551.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-006564610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00866028.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 20-JUN-2001; 2001WO-US019692.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 30-JUL-2001; 2001US-00918585.
 06-AUG-2001; 2001US-00924419.
 13-AUG-2001; 2001US-00929404.
 16-AUG-2001; 2001US-00931836.
 28-AUG-2001; 2001US-00941992.
 29-AUG-2001; 2001WO-US027039.
 04-SEP-2001; 2001US-00946374.
 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-585312/55.
 DR P-PSDB; ADM30310.
 XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 XX hybridization probes in chromosome and gene mapping.
 PS Claim 2; SEQ ID NO 169; 701pp; English.
 XX The invention describes 305 nucleic acids encoding PRO polypeptides
 CC (secreted and transmembrane). The polynucleotide is useful in molecular
 CC biology, including uses as hybridisation probes, in chromosome and gene
 CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
 CC polynucleotide may also be used in preparing PRO polypeptides by
 CC recombinant techniques, and in generating either transgenic animals or
 CC knock-out animals which, in turn, are useful in the development and
 CC screening of therapeutically useful reagents. The PRO polypeptide or the
 CC antibody is used in preparing a medicament for treating a condition
 CC responsive to the polypeptide or antibody, such as tumours, and in
 CC various diagnostic assays. This sequence encodes a novel human secreted
 CC and transmembrane PRO polypeptide.
 XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 SQ
 Query Match 3.0%; Score 66.6; DB 11; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTTCCTTACCACCTCTTCTTCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
 DB 2653 CCTTTCCTTCCCCTCTCTTGACACATTTTAATAAATAGGGTGGCTTCTGACTA 2712
 QY 2181 NCTCCCAA 2240
 DB 2713 CAAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774
 RESULT 883
 ADL93721
 ID ADL93721 standard; cDNA; 2846 BP.
 XX AC ADL93721;
 XX DT 20-MAY-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.
 XX OS Homo sapiens.


```
XX US2003040013-A1.
XX PD 27-FEB-2003.
XX
XX 02-MAY-2002; 2002US-00063554.
XX
XX 30-DEC-1998; 98KR-00062142.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 15-SEP-1999; 99US-00397342.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 30-DEC-1999; 99WO-US031274.
XX 18-FEB-2000; 2000WO-US004341.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 21-MAR-2000; 2000WO-US007532.
XX 22-MAY-2000; 2000WO-US014042.
XX 02-JUN-2000; 2000WO-US015264.
XX 24-AUG-2000; 2000US-00644848.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 01-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001US-00816744.
XX 10-MAY-2001; 2001US-00854208.
XX 30-MAY-2001; 2001US-00854280.
XX 01-JUN-2001; 2001WO-US017800.
XX 05-JUN-2001; 2001US-00874503.
XX 29-JUN-2001; 2001US-00869599.
XX 18-JUL-2001; 2001US-00908827.
XX 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ,
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI,
XX
XX WPI; 2003-456484/43.
XX P-PSDB; ADL93722.
XX
XX Novel monoclonal antibody that binds to secreted and transmembrane
XX polypeptide, useful for detecting and purifying the polypeptide and also
XX for treating conditions responsive to the antibody.
XX
XX Disclosure; SEQ ID NO 37; 235pp; English.
XX
XX The invention describes an antibody that specifically binds to a PRO
XX polypeptide having a fully defined amino acid sequence given in the
XX specification. The antibody is useful in identifying PRO polypeptides
XX useful for various industrial applications, including pharmaceuticals,
XX diagnostics, biosensors and bioreactors. The antibody is also used for
XX affinity purification of PRO polypeptides from recombinant cell culture
XX or natural sources. The antibody, PRO polypeptide, or its agonists or
XX antagonists, may be used for preparing a medicament for diagnosing or
XX treating a condition responsive to the antibody, PRO polypeptide, or its
XX agonists or antagonists. This sequence encodes a novel human secreted and
XX transmembrane PRO polypeptide.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
```

Query Match 3.0%; Score 66.6; DB 11; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCITTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAAAATGTTGCTCTCCACCACGTG 2180
DB 2653 CCITTTGCTTTCTCCCATCTCTTTGTACACATTTTAAATAAAGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 884
ADC52175
ID ADC52175 standard; cDNA; 2846 BP.
AC ADC52175;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW ss: gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
XX affinity purification; secreted and transmembrane protein.
XX
OS Homo sapiens.
XX
PN US2003130483-A1.
XX
PD 10-JUL-2003.
XX
PF 03-MAY-2002; 2002US-00063588.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 24-AUG-2000; 2000US-00644848.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 01-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
PR

```

PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00008867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski RJ;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2004-020352/02.
XX P-PSDB; ADC52176.
XX
XX New isolated PRO polypeptide, for use in diagnosing and treating cancer
XX and tumor conditions, in particular stomach, lung, esophageal or kidney
XX tumors, and melanoma.
XX
XX Disclosure; SEQ ID NO 37; 409pp; English.
XX
XX The invention describes an antibody that specifically binds to a PRO
XX polypeptide having a fully defined amino acid sequence given in the
XX specification. The antibody is useful in identifying PRO polypeptides
XX useful for various industrial applications, including pharmaceuticals,
XX diagnostics, biosensors and bioreactors. The antibody is also used for
XX affinity purification of PRO polypeptides from recombinant cell culture
XX or natural sources. The antibody, PRO polypeptide, or its agonists or
XX antagonists, may be used for preparing a medicament for diagnosing or
XX treating a condition responsive to the antibody, PRO polypeptide, or its
XX agonists or antagonists. This sequence encodes a novel human secreted and
XX transmembrane PRO polypeptide.
XX
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.08; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.34; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTCTTTATCTATTATAAAAAATGTTGGTCTCCACCACGTG 2180
Dy 2653 CCYTTCTTCCCATCTCTTGACACATTTTATAAATAAGGTTGGCTTCTGAACATA 2712

Qy 2181 NCTCCCAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Dy 2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Dy 2773 AA 2774

RESULT 885
ADE74306
ID ADE74306 standard; cDNA; 2846 BP.
XX
XX AC ADE74306;
XX
XX 29-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.
XX
XX Homo sapiens.
XX
XX US2003211572-A1.
XX
XX 13-NOV-2003.
XX
XX 18-JUN-2002; 2002US-00174570.
XX
XX 18-SEP-1997; 97US-0059263P.
XX
XX 18-SEP-1997; 97US-0059266P.

```

```

PR 17-OCT-1997;
PR 21-OCT-1997;
PR 24-OCT-1997;
PR 28-OCT-1997;
PR 28-OCT-1997;
PR 28-OCT-1997;
PR 28-OCT-1997;
PR 29-OCT-1997;
PR 31-OCT-1997;
PR 31-OCT-1997;
PR 13-NOV-1997;
PR 21-NOV-1997;
PR 24-NOV-1997;
PR 11-DEC-1997;
PR 12-DEC-1997;
PR 17-DEC-1997;
PR 18-DEC-1997;
PR 10-MAR-1998;
PR 11-MAR-1998;
PR 11-MAR-1998;
PR 20-MAR-1998;
PR 20-MAR-1998;
PR 27-MAR-1998;
PR 27-MAR-1998;
PR 31-MAR-1998;
PR 31-MAR-1998;
PR 01-APR-1998;
PR 01-APR-1998;
PR 08-APR-1998;
PR 08-APR-1998;
PR 09-APR-1998;
PR 15-APR-1998;
PR 21-APR-1998;
PR 21-APR-1998;
PR 22-APR-1998;
PR 22-APR-1998;
PR 23-APR-1998;
PR 23-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 05-MAY-1998;
PR 06-MAY-1998;
PR 07-MAY-1998;
PR 07-MAY-1998;
PR 07-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 18-MAY-1998;
PR 22-MAY-1998;
PR 22-MAY-1998;
PR 28-MAY-1998;
PR 28-MAY-1998;
PR 02-JUN-1998;
PR 02-JUN-1998;
PR 03-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 03-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 09-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;

```

```

97US-0062250P.
97US-0063486P.
97US-0063120P.
97US-0063121P.
97US-0063540P.
97US-0063541P.
97US-0063544P.
97US-0063564P.
97US-0063734P.
97US-0063870P.
97US-0064103P.
97US-0065311P.
97US-0066120P.
97US-0066466P.
97US-0066772P.
97US-0069335P.
97US-0069425P.
97US-0069870P.
97US-0068017P.
97US-0077450P.
97US-0077632P.
97US-0077649P.
97US-0078886P.
97US-0078939P.
97US-0079664P.
97US-0079786P.
97US-0080107P.
97US-0080194P.
97US-0080327P.
97US-0080333P.
97US-0081049P.
97US-0081070P.
97US-0081195P.
97US-0081838P.
97US-0082568P.
97US-0082569P.
97US-0082704P.
97US-0082797P.
97US-0083322P.
97US-0083495P.
97US-0083496P.
97US-0083499P.
97US-0083559P.
97US-0084366P.
97US-0084414P.
97US-0084639P.
97US-0084640P.
97US-0084643P.
97US-0085579P.
97US-0085580P.
97US-0085582P.
97US-0085700P.
97US-0086023P.
97US-0086392P.
97US-0086486P.
97US-0087098P.
97US-0087208P.
97US-0087609P.
97US-0087759P.
97US-0087827P.
97US-0088025P.
97US-0088028P.
97US-0088029P.
97US-0088033P.
97US-0088326P.
97US-0088367P.
97US-0088202P.
97US-0088212P.
97US-0088217P.
97US-0088655P.
97US-0088722P.
97US-0088738P.
97US-0088740P.

```

```
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088867P.
PR 11-JUN-1998; 98US-0088870P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 12-JUN-1998; 98US-0089511P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089658P.
PR 19-JUN-1998; 98US-0089908P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTCTTTTATCTTTATTAATAAAATGTTGTCTCCACCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATTAAGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 886
ADE74918
ID ADE74918 standard; cDNA; 2846 BP.
XX ADE74918;
XX 29-JAN-2004 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast
XX prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.
XX Homo sapiens.
XX US2003211574-A1.
XX 13-NOV-2003.
XX 26-JUN-2002; 2002US-00183005.
XX 18-SEP-1997; 97US-0059263P.
```

PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 28-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087088P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087877P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 12-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 03-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.

PR	05-NOV-1997	97WO-US0200669
PR	12-NOV-1997	97US-006518669
PR	13-NOV-1997	97US-00653111P
PR	24-NOV-1997	97US-00667770P
PR	25-FEB-1998	97US-00759450P
PR	20-MAR-1998	98US-00789100P
PR	28-APR-1998	98US-0083322P
PR	07-MAY-1998	98US-00846000P
PR	28-MAY-1998	98US-00871066P
PR	02-JUN-1998	98US-00876070P
PR	02-JUN-1998	98US-0087609P
PR	02-JUN-1998	98US-00877599P
PR	03-JUN-1998	98US-0087827P
PR	04-JUN-1998	98US-00880211P
PR	04-JUN-1998	98US-0088025P
PR	04-JUN-1998	98US-0088026P
PR	04-JUN-1998	98US-0088028P
PR	04-JUN-1998	98US-0088029P
PR	04-JUN-1998	98US-00880300P
PR	04-JUN-1998	98US-0088033P
PR	05-JUN-1998	98US-0088326P
PR	05-JUN-1998	98US-0088167P
PR	05-JUN-1998	98US-0088202P
PR	05-JUN-1998	98US-0088212P
PR	05-JUN-1998	98US-0088217P
PR	09-JUN-1998	98US-0088655P
PR	10-JUN-1998	98US-0088734P
PR	10-JUN-1998	98US-0088738P
PR	10-JUN-1998	98US-0088742P
PR	10-JUN-1998	98US-0088810P
PR	10-JUN-1998	98US-0088824P
PR	10-JUN-1998	98US-0088826P
PR	11-JUN-1998	98US-0088858P
PR	11-JUN-1998	98US-0088861P
PR	11-JUN-1998	98US-0088876P
PR	12-JUN-1998	98US-0088910P
PR	15-JUN-1998	98US-0089105P
PR	16-JUN-1998	98US-0089440P
PR	16-JUN-1998	98US-0089512P
PR	16-JUN-1998	98US-0089514P
PR	17-JUN-1998	98US-0089532P
PR	17-JUN-1998	98US-0089538P
PR	17-JUN-1998	98US-0089598P
PR	17-JUN-1998	98US-0089599P
PR	17-JUN-1998	98US-0089600P
PR	17-JUN-1998	98US-0089653P
PR	18-JUN-1998	98US-0089801P
PR	18-JUN-1998	98US-0089907P
PR	18-JUN-1998	98US-0089908P
PR	19-JUN-1998	98US-0089947P
PR	19-JUN-1998	98US-0089948P
PR	19-JUN-1998	98US-0089952P
PR	22-JUN-1998	98US-0090246P
PR	22-JUN-1998	98US-0090252P
PR	22-JUN-1998	98US-0090254P
PR	23-JUN-1998	98US-0090349P
PR	23-JUN-1998	98US-0090355P
PR	24-JUN-1998	98US-0090429P
PR	24-JUN-1998	98US-0090431P
PR	24-JUN-1998	98US-0090435P
PR	24-JUN-1998	98US-0090444P
PR	24-JUN-1998	98US-0090445P
PR	24-JUN-1998	98US-0090472P
PR	24-JUN-1998	98US-0090535P
PR	24-JUN-1998	98US-0090540P
PR	24-JUN-1998	98US-0090542P
PR	24-JUN-1998	98US-0090557P
PR	25-JUN-1998	98US-0090676P
PR	25-JUN-1998	98US-0090678P
PR	25-JUN-1998	98US-0090690P
PR	25-JUN-1998	98US-0090694P
PR	25-JUN-1998	98US-0090695P
PR	25-JUN-1998	98US-0090696P
PR	25-JUN-1998	98US-0090862P

```
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-009339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 10-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 17-SEP-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.

PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGCCTTACCACTCTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
Db |||
QY 2773 AA 2774

RESULT 888
ADG11606
ID ADG11606 standard; cDNA; 2846 BP.
XX AC
XX ADG11606;
XX AC
XX ADG11606;
DT 26-FEB-2004 (first entry)
XX cDNA encoding human PRO1344 polypeptide.
DE Human; PRO polypeptide; secreted protein; transmembrane protein;
XX transgenic; tumour; cytostatic; gene therapy; gene; ss.
XX Homo sapiens.
OS US2003228655-A1.
XX PN
XX US2003228655-A1.
XX PD
XX 11-DEC-2003.
XX PF
XX 20-NOV-2001; 2001US-00989733.
XX PR
XX 10-AUG-1998; 98US-0095916P.
```

```

PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH ) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen MB, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NP;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PW, Wood WI;
PI Zhang Z;
XX
XX WPI; 2004-081070/08.
DR P-PSDB; ADG11607.
XX
XX New PRO polypeptide useful in diagnosing or treating cardiac
PT insufficiency disorders, retinal disorders, kidney disorders, obesity,
PT diabetes, cancer, thalassemia, or arthritis.
XX
XX Claim 2; SEQ ID NO 230; 648pp; English.
XX
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for
CC identifying agonists or antagonists. The PRO polypeptide or the antibody
CC may be used in preparing a medicament for treating a condition responsive
CC to the polypeptide or antibody, such as tumours, and in various
CC diagnostic assays. The polynucleotide sequences encoding PRO polypeptides
CC are useful as hybridisation probes, in chromosome and gene mapping, in
CC the generation of antisense RNA and DNA, in the preparation of PRO
CC polypeptides, for generating transgenic animals or knockout animals, and
CC in gene therapy. The present sequence encodes a human PRO polypeptide of
CC the invention. Note: The sequence data for this patent was obtained in
CC electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/paipdIdentry.html.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGTCTTACCACTCTTTCTTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
Dy 2653 CCTTTCTCTCCCATCTCTTGTACACATTTTAATAAATAAGGCTTGCTTCTGAAC 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Dy 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Dy 2773 AA 2774
RESULT 889
ADF96131
ID ADF96131 standard; cDNA; 2846 BP.
XX
XX ADF96131;
XX
XX 26-FEB-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
KW secreted and transmembrane protein; PRO; chromosome mapping;
KW gene mapping; tumour.

```

```

XX OS Homo sapiens.
XX
XX US2003215909-A1.
XX
XX 20-NOV-2003.
XX
XX 24-JUN-2002; 2002US-00179523.
XX
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 11-DEC-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081195P.
XX 15-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 28-APR-1998; 98US-0082797P.
XX 29-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 15-MAY-1998; 98US-0085579P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
XX 22-MAY-1998; 98US-0086486P.
XX 28-MAY-1998; 98US-0087098P.
XX 28-MAY-1998; 98US-0087208P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088028P.

```


PD 25-SEP-2003.
XX 08-MAY-2002; 2002US-00063714.
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US0005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US011274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-0074259.
PR 28-FEB-2001; 2001WO-US004956.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX (GETH) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WT;
XX WPI; 2004-020826/02.
DR P-PSDB; ADH25090.
XX New nucleic acids encoding PRO polypeptides, useful in diagnosing and
XX treating disorders that affect glucose or free fatty acid in skeletal
XX muscle, such as diabetes, hypoinsulinemia or hyperinsulinemia.
XX Disclosure; SEQ ID NO 37; 398pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide comprising the 642 amino acid sequence (S1) defined in the
XX specification. The PRO polypeptides are useful for treating various bone
XX and/or cartilage disorders, for example, sports injuries and arthritis.
XX They are also useful in the therapeutic treatment of disorders where
XX either the stimulation or inhibition of glucose uptake by skeletal muscle
XX would be beneficial, for example, diabetes or hyper- or hypo-
XX insulinaemia. They are also useful for treating pericyte-associated
XX tumours and in wound healing. The anti-PRO antibody is useful for the
XX preparation of a medicament useful in the treatment of cancer. The PRO
XX polypeptides are also useful as molecular weight markers, or for
XX chromosome identification. The PRO genes are useful as hybridisation
XX probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
XX The PRO genes may also be used in gene therapy, particularly for
XX replacing a defective gene. This sequence encodes a secreted and
XX transmembrane PRO protein.

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTATTATAAATGTTGCTCCACACTG 2180
Db 2653 CCTTTTCCTCCCATCTCTTGACACATTTTAAATAAAATAGGCTTGGCTTCTGAATA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 897
ADH33721
ID ADH33721 standard; cDNA; 2846 BP.
XX AC ADH33721;
XX DT 11-MAR-2004 (first entry)
XX DE Human PRO polynucleotide #19.
XX KW Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;
XX KW chondrocyte cell; tumour; cancer.
XX OS Homo sapiens.
XX PN US2003181645-A1.
XX PD 25-SEP-2003.
XX 03-MAY-2002; 2002US-00063604.
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US0005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00397342.
PR 15-SEP-1999; 99US-00403297.
PR 18-OCT-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 01-FEB-2000; 2000WO-US004341.
PR 02-MAR-2000; 2000WO-US005601.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-0074259.
PR 28-FEB-2001; 2001WO-US004956.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX (GETH) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WT;
XX WPI; 2004-020826/02.
DR P-PSDB; ADH25090.
XX New nucleic acids encoding PRO polypeptides, useful in diagnosing and
XX treating disorders that affect glucose or free fatty acid in skeletal
XX muscle, such as diabetes, hypoinsulinemia or hyperinsulinemia.
XX Disclosure; SEQ ID NO 37; 398pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide comprising the 642 amino acid sequence (S1) defined in the
XX specification. The PRO polypeptides are useful for treating various bone
XX and/or cartilage disorders, for example, sports injuries and arthritis.
XX They are also useful in the therapeutic treatment of disorders where
XX either the stimulation or inhibition of glucose uptake by skeletal muscle
XX would be beneficial, for example, diabetes or hyper- or hypo-
XX insulinaemia. They are also useful for treating pericyte-associated
XX tumours and in wound healing. The anti-PRO antibody is useful for the
XX preparation of a medicament useful in the treatment of cancer. The PRO
XX polypeptides are also useful as molecular weight markers, or for
XX chromosome identification. The PRO genes are useful as hybridisation
XX probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
XX The PRO genes may also be used in gene therapy, particularly for
XX replacing a defective gene. This sequence encodes a secreted and
XX transmembrane PRO protein.

PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 08-DEC-2001; 2001US-00008867.
XX
PA (GETH) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2004-059335/06.
DR P-PSDB; ADH33722.
XX
XX New isolated PRO polypeptide, useful for treating various bone and/or
PT cartilage disorders, for example, sports injuries and arthritis.
XX
XX Disclosure; SEQ ID NO 37; 397pp; English.
XX
XX The invention relates to human PRO polypeptides and the PRO
CC polynucleotides encoding them. The invention also relates to an antibody
CC that specifically binds to the polypeptide, a method for stimulating the
CC release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a
CC method for stimulating proliferation or differentiation of chondrocyte
CC cells and a method for detecting the presence of a tumour in a mammal
CC comprising comparing the level of expression of any PRO polypeptide,
CC given in the specification, in a test sample of cells taken from the
CC mammal with a control sample of normal cells of the same cell type, where
CC a higher level of expression of the PRO polypeptide in the test sample as
CC compared to the control sample indicates the presence of a tumour in the
CC mammal. The polynucleotides are useful as hybridisation probes in
CC chromosome and gene mapping or in generating antisense RNA and DNA, for
CC preparing PRO polypeptides, in assays to identify other proteins or
CC molecules involved in binding reactions, to generate transgenic animals
CC or knockout animals, which in turn are useful in the development and
CC screening of therapeutically useful reagents, for chromosome
CC identification and in tissue typing. The PRO polypeptides and
CC polynucleotides are also useful in gene therapy and as molecular weight
CC markers for protein electrophoresis. The anti-PRO antibodies may be used
CC in diagnostic assays for PRO or for the affinity purification of PRO from
CC recombinant cell culture or natural sources. This sequence represents a
CC human PRO polynucleotide of the invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAGGGTGTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 898
ADG82818
ID ADG82818 standard; cDNA; 2846 BP.
XX
AC ADG82818;
XX
XX 11-MAR-2004 (first entry)
DT
XX Human PRO polynucleotide #85.
DE
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW cancer; tumour; adrenal; lung; colon; breast; prostate; rectum; cervix;
KW

KW liver; tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell.
XX Homo sapiens.
XX US2003215910-A1.
PD 20-NOV-2003.
XX
XX 18-JUL-2002; 2002US-00199463.
XX
XX 09-JUN-1998; 98US-0086555P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-021842/02.
DR P-PSDB; ADG82819.
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
XX Claim 2; SEQ ID NO 169; 695pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. adrenal tumour, lung tumour, colon tumour, breast
CC tumour, prostate tumour, rectal tumour, cervical tumour, or liver tumour)
CC in a mammal, for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood or for stimulating the proliferation or
CC differentiation of chondrocyte cells. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, and in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies. The PRO polypeptides are useful as molecular markers for
CC protein electrophoresis, and in tissue typing. This sequence represents a
CC human PRO polynucleotide of the invention. Note: The sequence data for
CC this patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAGGGTGTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 899
ADH02364

Db	2773 AA 2774	
	RESULT 901	
	ADG69368	
ID	ADG69368 standard; cDNA; 2846 BP.	
XX	AC	ADG69368;
XX	AC	
DT	11-MAR-2004	(first entry)
XX	DE	Novel human secreted and transmembrane protein PRO1344 cDNA.
XX	ss;	gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW	KW	affinity purification; secreted and transmembrane protein.
XX	XX	
XX	XX	Homo sapiens.
XX	XX	US2003180846-A1.
PN	XX	
PD	XX	.25-SEP-2003.
XX	XX	
PF	XX	08-MAY-2002; 2002US-00063692.
XX	XX	
XX	XX	30-DEC-1998; 98KR-00062142.
XX	XX	08-MAR-1999; 99WO-US0005028.
PR	PR	14-MAY-1999; 99US-00311832.
PR	PR	14-MAY-1999; 99WO-US010733.
PR	PR	25-AUG-1999; 99US-00380137.
PR	PR	25-AUG-1999; 99US-00380138.
PR	PR	25-AUG-1999; 99US-00380139.
PR	PR	25-AUG-1999; 99US-00380142.
PR	PR	15-SEP-1999; 99US-00397342.
PR	PR	18-OCT-1999; 99US-00403297.
PR	PR	12-NOV-1999; 99US-00423844.
PR	PR	30-DEC-1999; 99WO-US001274.
PR	PR	18-FEB-2000; 2000WO-US004341.
PR	PR	01-MAR-2000; 2000WO-US005601.
PR	PR	02-MAR-2000; 2000WO-US005841.
PR	PR	21-MAR-2000; 2000WO-US007532.
PR	PR	22-MAY-2000; 2000WO-US014042.
PR	PR	02-JUN-2000; 2000WO-US015264.
PR	PR	22-AUG-2000; 2000US-00644848.
PR	PR	24-AUG-2000; 2000WO-US023328.
PR	PR	18-SEP-2000; 2000US-0064610.
PR	PR	18-SEP-2000; 2000US-0065350.
PR	PR	08-NOV-2000; 2000US-00709238.
PR	PR	10-NOV-2000; 2000WO-US030873.
PR	PR	01-DEC-2000; 2000WO-US032678.
PR	PR	20-DEC-2000; 2000US-00747259.
PR	PR	20-DEC-2000; 2000WO-US034956.
PR	PR	28-FEB-2001; 2001WO-US006520.
PR	PR	22-MAR-2001; 2001US-00816744.
PR	PR	10-MAY-2001; 2001US-00854208.
PR	PR	10-MAY-2001; 2001US-00854280.
PR	PR	30-MAY-2001; 2001US-00870574.
PR	PR	01-JUN-2001; 2001WO-US017800.
PR	PR	05-JUN-2001; 2001US-00874503.
PR	PR	29-JUN-2001; 2001US-00869599.
PR	PR	18-JUL-2001; 2001US-00908827.
PR	PR	06-DEC-2001; 2001US-00006867.
XX	XX	(GETH) GENENTECH INC.
XX	XX	
PI	PI	Eaton DJ, Pilvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI	PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX	XX	
XX	XX	WPI; 2004-020803/02.
XX	XX	P-PSDB; ADG69369.
XX	XX	
XX	XX	New secreted and transmembrane PRO nucleic acid, for use in molecular
PT	PT	biology, chromosome and gene mapping, in generating antisense RNA and
PT	PT	DNA, in various diagnostic assays and in gene therapy.

XX Claim 1; SEQ ID NO 37; 398pp; English.

XX The invention relates to a PRO (secreted and transmembrane protein)

CC polynucleotide appearing as ADG69412 encoding PRO polypeptide having

CC appearing as ADG69412. Also included are a vector comprising the novel

CC nucleic acid and a host cell comprising the vector. The polynucleotide is

CC useful in molecular biology, including uses as hybridisation probes, in

CC chromosome and gene mapping, in generating antisense RNA and DNA, and in

CC gene therapy. The polynucleotide may also be used in preparing PRO

CC polypeptides by recombinant techniques, and in generating either

CC transgenic animals or knock-out animals which, in turn, are useful in the

CC development and screening of therapeutically useful reagents. The PRO

CC polynucleotide is used in preparing a medicament for treating a condition

CC responsive to the polypeptide or antibody, such as tumours, and in

CC various diagnostic assays. The specification discloses 84 PRO proteins

CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2241 AA 2242

Db ||

QY 2773 AA 2774

Db ||

RESULT 902

ADH39189

ID ADH39189 standard; cDNA; 2846 BP.

XX

AC ADH39189;

XX

DT 11-MAR-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

KW affinity purification; secreted and transmembrane protein.

XX

OS Homo sapiens.

XX

PN US2003180917-A1.

XX

PD 25-SEP-2003.

XX

XX 08-MAY-2002; 2002US-00063720.

PP

PP 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.

PR 08-NOV-2000; 2000US-00709238.

PR 10-DEC-2000; 2000WO-US030873.

PR 01-NOV-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001US-00816744.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 30-MAY-2001; 2001US-00870574.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 29-JUN-2001; 2001US-00869599.

PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006967.

XX (GETH) GENENTECH INC.

PA

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

PI

XX WPI, 2004-020829/02.

DR P-FSDB; ADH39190.

XX

PT New PRO nucleic acid, useful for preparing a medicament for treating a

PT condition associated with a PRO nucleic acid e.g., cancer, by gene

PT therapy.

XX

PS Disclosure; SEQ ID NO 37; 396pp; English.

XX

CC The invention relates to a novel PRO (secreted and transmembrane protein)

CC polypeptide, and the polynucleotide sequence encoding it. Also included

CC are a vector comprising the novel nucleic acid and a host cell comprising

CC the vector. The polynucleotide sequence is useful in molecular biology as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence

CC may also be used in preparing the PRO polypeptide by recombinant

CC techniques, and in generating either transgenic or knock-out animals

CC which, in turn, are useful in the development and screening of

CC therapeutically useful reagents. The PRO polynucleotide sequence is

CC useful in preparing a medicament for treating a condition responsive to

CC the polypeptide or antibody, such as tumours, and in various diagnostic

CC assays. The specification also discloses other PRO proteins and the

CC polynucleotide sequences encoding them. The present sequence encodes a

CC PRO protein.

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2241 AA 2242

Db ||

QY 2773 AA 2774

Db ||

RESULT 903

that specifically binds to the polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal comprising comparing the level of expression of any PRO polypeptide, given in the specification, in a test sample of cells taken from the mammal with a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptide in the test sample as compared to the control sample indicates the presence of a tumour in the mammal. The polynucleotides are useful as hybridisation probes in chromosome and gene mapping or in generating antisense RNA and DNA, for preparing PRO polypeptides, in assays to identify other proteins or molecules involved in binding reactions, to generate transgenic animals or knockout animals, which in turn are useful in the development and screening of therapeutically useful reagents, for chromosome identification and in tissue typing. The PRO polypeptides and polynucleotides are also useful in gene therapy and as molecular weight markers for protein electrophoresis. The anti-PRO antibodies may be used in diagnostic assays for PRO or for the affinity purification of PRO from recombinant cell culture or natural sources. This sequence represents a human PRO polynucleotide of the invention.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CTTTGGCTTACCACTCTTCTTTATCTATTATTAATAATGTGCTCCACCACTG 2180
Db 2653 CTTTTCCTTCCCACTCTTGTACACATTTTAAATAAGGTGGCTTCTGAACCTA 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 905

ID ADH19476 standard; cDNA; 2846 BP.

AC ADH19476;

DT 11-MAR-2004 (first entry)

XX Human cDNA encoding secreted/transmembrane protein PRO1344.

XX PRO; secreted protein; transmembrane protein;
XX hypertrophy of neonatal heart; angiogenesis;
XX vascular endothelial growth factor; VEGF-stimulated proliferation;
XX endothelial cell; T-lymphocyte proliferation; retinal neuron;
XX c-fos induction; adipocyte cell; chondrocyte differentiation;
XX pancreatic beta-cell precursor differentiation; gene therapy; tumour;
XX cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;
XX rod photoreceptor cell.

XX Homo sapiens.

XX US2003228656-A1.

XX 11-DEC-2003.

XX 14-NOV-2001; 2001US-00992643.

XX 10-JUN-1998; 98US-0088742P.

XX 22-DEC-1998; 98US-0113296P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 16-DEC-1999; 99WO-US030095.

PR 30-MAR-2000; 2000WO-US008439.
PR 28-AUG-2001; 2001US-00941992.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Garber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI ROY MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WT;
XX Zhang Z;

XX WPI; 2004-052022/05.
DR P-PSDB; ADH19477.

XX New secreted and transmembrane nucleic acids and polypeptides, designated as PRO, useful for treating inflammation, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, or cancer.

PS Claim 2; SEQ ID NO 230; 648pp; English.

XX The invention relates to an isolated nucleic acid molecule comprising the full-length coding sequence of the DNA ATCC Accession Numbers given in the specification, or comprising a sequence with at least 80% identity to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an extracellular domain of the polypeptide; or (b) any of 147 nucleotide sequences fully defined in the specification. Also included are the PRO proteins (or their extracellular domains) with or without their associated extracellular domains), expression vectors, host cells, PRO chimeric proteins, anti-PRO antibodies, methods of detecting polypeptide in a sample, methods of linking a bioactive molecule to a cell expressing a polypeptide and methods of modulating at least one biological activity of a cell expressing the polypeptide. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, promoting angiogenesis, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or PFA uptake by adipocyte cells, inducing proliferation and/or re-differentiation of chondrocytes, or inducing pancreatic beta-cell precursor differentiation. In particular, these are useful for detecting or treating tumours and certain cancers (colon, lung or breast cancers) in mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The present sequence is a cDNA encoding a PRO protein.

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CTTTGGCTTACCACTCTTCTTTATCTATTATTAATAATGTGCTCCACCACTG 2180
Db 2653 CTTTTCCTTCCCACTCTTGTACACATTTTAAATAAGGTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCCAA 2240
Db 2713 CAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 906

ADG85473

ID ADG85473 standard; cDNA; 2846 BP.

XX ADG85473;

AC ADG85473;

XX

DT 11-MAR-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX Homo sapiens.
XX US2003166848-A1.
XX 04-SEP-2003.
XX 02-MAY-2002; 2002US-00063560.
XX 30-DEC-1998; 98KR-00062142.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 15-SEP-1999; 99US-00397342.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 30-DEC-1999; 99WO-US031274.
XX 01-MAR-2000; 2000WO-US004341.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 21-MAR-2000; 2000WO-US007532.
XX 22-MAY-2000; 2000WO-US014042.
XX 02-JUN-2000; 2000WO-US015264.
XX 22-AUG-2000; 2000US-00644848.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX (GENTECH) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2004-020613/02.
XX P-PSDB; ADG85474.
XX New secreted and transmembrane PRO polypeptides and polynucleotides,
PT useful for treating e.g. pericyte-associated tumors, sports-related joint
PT problems, articular cartilage defects, osteoarthritis, or rheumatoid
PT arthritis.
XX Disclosure; SEQ ID NO 37; 397pp; English.
XX The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for

CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTACCACCTCTTCCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
DB 2653 CCTTTCCTTCCCACTCTCTGTACACATTTAATAAAATAGGTGTTGGTCTTGACTA 2712
QY 2181 NCTCCCAAAAAA AA 2240
DB 2713 CAAAAA AA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 907
ADH06267
ID ADH06267 standard; cDNA; 2846 BP.
XX
AC ADH06267;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX Homo sapiens.
XX US2003180854-A1.
XX 25-SEP-2003.
XX 08-MAY-2002; 2002US-00063709.
XX 30-DEC-1998; 98KR-00062142.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 15-SEP-1999; 99US-00397342.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 30-DEC-1999; 99WO-US031274.
XX 01-MAR-2000; 2000WO-US004341.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 21-MAR-2000; 2000WO-US007532.
XX 22-MAY-2000; 2000WO-US014042.
XX 02-JUN-2000; 2000WO-US015264.
XX 22-AUG-2000; 2000US-00644848.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001US-00816744.
XX 10-MAY-2001; 2001US-00854208.
XX 10-MAY-2001; 2001US-00854280.
XX 30-MAY-2001; 2001US-00870574.
XX 01-JUN-2001; 2001WO-US017800.
XX 05-JUN-2001; 2001US-00874503.
XX 29-JUN-2001; 2001US-00869599.
XX 18-JUL-2001; 2001US-00908827.
XX 06-DEC-2001; 2001US-00006867.
XX (GENTECH) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2004-020613/02.
XX P-PSDB; ADG85474.
XX New secreted and transmembrane PRO polypeptides and polynucleotides,
PT useful for treating e.g. pericyte-associated tumors, sports-related joint
PT problems, articular cartilage defects, osteoarthritis, or rheumatoid
PT arthritis.
XX Disclosure; SEQ ID NO 37; 397pp; English.
XX The invention describes an antibody that specifically binds to a PRO
CC polypeptide having a fully defined amino acid sequence given in the
CC specification. The antibody is useful in identifying PRO polypeptides
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for

PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX
 DR WPI: 2004-020809/02.
 DR P-PSDB; ADH06268.
 XX
 PT New PRO polypeptide and nucleic acid encoding the polypeptide, for use in
 PT gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 PS Disclosure; SEQ ID NO 37; 398pp; English.
 XX
 CC The invention relates to a novel PRO (secreted and transmembrane protein)
 CC polypeptide, and the polynucleotide sequence encoding it. Also included
 CC are a vector comprising the novel nucleic acid and a host cell comprising
 CC the vector. The polynucleotide sequence is useful in molecular biology as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
 CC may also be used in preparing the PRO polypeptide by recombinant
 CC techniques, and in generating either transgenic or knock-out animals
 CC which, in turn, are useful in the development and screening of
 CC therapeutically useful reagents. The PRO polynucleotide sequence is
 CC useful in preparing a medicament for treating a condition responsive to
 CC the polypeptide or antibody, such as tumours, and in various diagnostic
 CC assays. The specification also discloses other PRO proteins and the
 CC polynucleotide sequences encoding them. The present sequence encodes a
 CC PRO protein.
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAAATGTTGCTCCACCACTG 2180
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAAATAAAATAAGGTTGGCTTCTGAACCTA 2712
 QY 2181 NCTCCCAAA 2240
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2713 CAAAAAATAA 2772
 QY 2241 AA 2242
 Db || 2773 AA 2774
 RESULT 908
 ADH30097
 ID ADH30097 standard; cDNA; 2846 BP.
 AC ADH30097;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.

XX OS Homo sapiens.
 XX US2003180856-A1.
 XX
 PD 25-SEP-2003.
 XX
 PF 08-MAY-2002; 2002US-00063724.
 XX
 PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99WO-US011832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00869599.
 PR 29-JUN-2001; 2001US-00874503.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX
 DR WPI: 2004-020811/02.
 DR P-PSDB; ADH30098.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in molecular biology, chromosome and gene mapping, in generating
 PT antisense RNA and DNA, in various diagnostic assays and in gene therapy.
 XX
 PS Disclosure; SEQ ID NO 37; 398pp; English.
 XX
 CC The invention describes an antibody that specifically binds to a PRO
 CC polypeptide having a fully defined amino acid sequence given in the
 CC specification. The antibody is useful in identifying PRO polypeptides
 CC useful for various industrial applications, including pharmaceuticals,
 CC diagnostics, biosensors and bioreactors. The antibody is also used for
 CC affinity purification of PRO polypeptides from recombinant cell culture
 CC or natural sources. The antibody, PRO polypeptide, or its agonists or
 CC antagonists, may be used for preparing a medicament for diagnosing or
 CC treating a condition responsive to the antibody, PRO polypeptide, or its
 CC agonists or antagonists. This sequence encodes a novel human secreted and
 CC transmembrane PRO polypeptide.

```
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGTTTACCACCTCTTTCCCTTTTATCTCTTATTAATAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAATAAGGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774
RESULT 909
ADH24409
ID ADH24409 standard; cDNA; 2846 BP.
AC ADH24409;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW cystostatic; antidiabetic; antiarthritic; osteopathic; antirheumatic;
KW human; secreted and transmembrane; PRO; PRO180; PRO218; PRO263; PRO295;
KW PRO874; PRO300; PRO1864; PRO1282; PRO1063; PRO1773; cancer; diabetes;
KW osteoarthritis; rheumatoid arthritis; chromosome mapping; gene mapping;
KW chromosome identification; tissue typing; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003180910-A1.
XX
PD 25-SEP-2003.
XX
PF 08-MAY-2002; 2002US-00063710.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-NAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-NAR-2000; 2000WO-US005601.
PR 02-NAR-2000; 2000WO-US005841.
PR 21-NAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000US-0023328.
PR 18-SEP-2000; 2000US-00684610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WJ;
XX
DR WPI; 2004-020823/02.
DR P-PSDB; ADH24410.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acid
PT molecules, useful in gene therapy or preparing a medicament for treating
PT a condition that is responsive to the PRO polypeptide or anti-PRO
PT antibody, e.g. diabetes.
XX
PS Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC The invention describes a novel isolated nucleic acid encoding a human
CC secreted and transmembrane PRO protein. Specifically claimed are secreted
CC and transmembrane polypeptides, e.g. PRO180, PRO218, PRO263, PRO295,
CC PRO874, PRO300, PRO1864, PRO1282, PRO1063, or PRO1773 polypeptide. The
CC PRO polypeptides or anti-PRO antibodies are useful in preparing a
CC medicament for treating a condition that is responsive to the PRO
CC polypeptide or anti-PRO antibody, e.g. cancer, diabetes, osteoarthritis
CC or rheumatoid arthritis. The PRO nucleotide sequences may be used as
CC hybridization probes in chromosome and gene mapping, or in generating
CC antisense RNA and DNA. The PRO nucleic acids are also useful in preparing
CC PRO polypeptides, in assays to identify other proteins or molecules
CC involved in binding reaction, in generating transgenic animals or
CC knockout animals, which in turn are useful in the development and
CC screening of therapeutically useful reagents, for chromosome
CC identification, and tissue typing. The PRO polypeptides and nucleic acid
CC molecules are also useful in gene therapy, and as molecular weight
CC markers for protein electrophoresis purposes. The anti-PRO antibodies may
CC be used in diagnostic assays for PRO, or for the affinity purification of
CC PRO from recombinant cell culture or natural sources. This sequence
CC encodes a novel human secreted and transmembrane PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGTTTACCACCTCTTTCCCTTTTATCTCTTATTAATAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAATAAGGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774
RESULT 910
ADH33068
ID ADH33068 standard; cDNA; 2846 BP.
XX
AC ADH33068;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PRO polynucleotide #85.
XX
```


The invention relates to a PRO (secreted and transmembrane protein) polynucleotide appearing as ADG69582 encoding PRO polypeptide having appearing as ADG69582. Also included are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide is useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide may also be used in preparing PRO polypeptides by recombinant techniques, and in generating either transgenic animals or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide is used in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification discloses 84 PRO proteins and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

Sequence 2846 BP: 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other

	Query Match	3.0%; Score 66.6; DB 12; Length 2846;
	Best Local Similarity 71.3%; Pred. No. 0.00023;	
	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
Qy	2121 CCTTTGGTTTACCACTCTTTCCCTTTTATCTATTATAATAAAATGTTGGTCTCCACCACTG 2180	
Db	2653 CCTTTTCCTTCCCATCTCTTTGACACATTTTATAATAAATAGGGTTGGCTTCTGAACTA 2712	
Qy	2181 NCTCCCAAA 2240	
Db	2713 CAAAAAATAAA 2772	
Qy	2241 AA 2242	
Db	2773 AA 2774	

RESULT 912
ADH07801
ID ADH07801 standard; cDNA; 2846 BP.
XX
XX ADH07801;
XX
XX
DT 11-MAR-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE
DE
XX
XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
KW

PR	22-AUG-2000;	2000US-00644848.
PR	24-AUG-2000;	2000WO-US023328.
PR	18-SEP-2000;	2000WO-US0664610.
PR	18-SEP-2000;	2000US-00665350.
PR	08-NOV-2000;	2000US-00709238.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAR-2001;	2001US-00816744.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	30-MAY-2001;	2001US-00870574.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	29-JUN-2001;	2001US-00869599.
PR	18-JUL-2001;	2001US-00908827.
PR	06-DEC-2001;	2001US-00006867.
XX	(GETH) GENENTECH INC.	
XX	Eaton DL, Filvaroff E, Gerritsen ME,	Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Watanabe CK,	Wood WI,
PI	WPI; 2004-031859/03.	
XX	P-PSDB: ADHQ7802.	
DR		

One hundred and seventy nucleic acids encoding PRO polypeptides, useful for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation, particularly for treating e.g. lung or breast tumors, or arthritis in a mammal.

XX PS Disclosure: SEQ ID NO 37; 398pp; English.

The invention relates to a novel PRO (secreted and transmembrane protein) polypeptide, and the polynucleotide sequence encoding it. Also included are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide sequence is useful in molecular biology as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide sequence may also be used in preparing the PRO polypeptide by recombinant techniques, and in generating either transgenic or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide sequence is useful in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification also discloses other PRO proteins and the polynucleotide sequences encoding them. The present sequence encodes a PRO protein.

XX
Sequence
2846 BP:
768 A:
696 C:
745 G:
637 T:
0 U:
0 Other:

Query Match	3.0%	Score 66.6;	DB 12;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches 87;	Conservative	0;	Mismatches 35;	Indels 0;
				Gaps 0;

RESULT 913
ADG85813
ID ADG85813 standard; cDNA; 2846 BP.


```
XX ADG85813;
XX
XX 11-MAR-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
XX affinity purification; secreted and transmembrane protein.
XX
XX Homo sapiens.
XX
XX US2003180861-A1.
XX
XX 25-SEP-2003.
XX
XX 09-MAY-2002; 2002US-00063742.
XX
XX 30-DEC-1998; 98KR-00062142.
XX
XX 08-MAR-1999; 99WO-US005028.
XX
XX 14-MAY-1999; 99US-00311832.
XX
XX 14-MAY-1999; 99WO-US010733.
XX
XX 25-AUG-1999; 99US-00380137.
XX
XX 25-AUG-1999; 99US-00380138.
XX
XX 25-AUG-1999; 99US-00380139.
XX
XX 25-AUG-1999; 99US-00380142.
XX
XX 15-SEP-1999; 99US-00397342.
XX
XX 18-OCT-1999; 99US-00403297.
XX
XX 12-NOV-1999; 99US-00423844.
XX
XX 30-DEC-1999; 99WO-US031274.
XX
XX 18-DEC-2000; 2000WO-US004341.
XX
XX 01-MAR-2000; 2000WO-US005601.
XX
XX 02-MAR-2000; 2000WO-US005841.
XX
XX 21-MAR-2000; 2000WO-US007532.
XX
XX 22-MAY-2000; 2000WO-US014042.
XX
XX 02-JUN-2000; 2000WO-US015264.
XX
XX 22-AUG-2000; 2000US-00644848.
XX
XX 24-AUG-2000; 2000WO-US023328.
XX
XX 18-SEP-2000; 2000US-00664610.
XX
XX 18-SEP-2000; 2000US-00665350.
XX
XX 08-NOV-2000; 2000US-00709238.
XX
XX 10-NOV-2000; 2000WO-US030873.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 20-DEC-2000; 2000US-00747259.
XX
XX 28-FEB-2001; 2000WO-US034956.
XX
XX 28-FEB-2001; 2001WO-US006520.
XX
XX 22-MAR-2001; 2001US-00816744.
XX
XX 10-MAY-2001; 2001US-00854208.
XX
XX 10-MAY-2001; 2001US-00854280.
XX
XX 30-MAY-2001; 2001US-00870574.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 05-JUN-2001; 2001US-00874503.
XX
XX 29-JUN-2001; 2001US-00869599.
XX
XX 18-JUL-2001; 2001US-00908827.
XX
XX 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski RJ;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2004-020813/02.
XX
XX P-PSDB; ADG85814.
XX
XX New PRO polypeptide and nucleic acid encoding the polypeptide, for use in
XX gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Disclosure; SEQ ID NO 37; 398pp; English.
XX
XX The invention describes an antibody that specifically binds to a PRO
XX polypeptide having a fully defined amino acid sequence given in the
XX specification. The antibody is useful in identifying PRO polypeptides
```

```
CC useful for various industrial applications, including pharmaceuticals,
CC diagnostics, biosensors and bioreactors. The antibody is also used for
CC affinity purification of PRO polypeptides from recombinant cell culture
CC or natural sources. The antibody, PRO polypeptide, or its agonists or
CC antagonists, may be used for preparing a medicament for diagnosing or
CC treating a condition responsive to the antibody, PRO polypeptide, or its
CC agonists or antagonists. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 12; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX QY 2121 CCTTTGCTTTACCACTCTTCTCTTTATCTTATTAATAAAATGTTGCTCCACCCTG 2180
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAAATAGGTTGGCTTCTGACTA 2712
XX
XX QY 2181 NCTCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
XX
XX QY 2241 AA 2242
XX ||
XX Db 2773 AA 2774
XX
XX RESULT 914
XX ADH39359
XX ID ADH39359 standard; cDNA; 2846 BP.
XX
XX AC ADH39359;
XX
XX DT 11-MAR-2004 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
XX affinity purification; secreted and transmembrane protein.
XX
XX OS Homo sapiens.
XX
XX XX US2003180916-A1.
XX
XX PD 25-SEP-2003.
XX
XX PF 08-MAY-2002; 2002US-00063717.
XX
XX PR 30-DEC-1998; 98KR-00062142.
XX
XX PR 08-MAR-1999; 99WO-US005028.
XX
XX PR 14-MAY-1999; 99US-00311832.
XX
XX PR 14-MAY-1999; 99WO-US010733.
XX
XX PR 25-AUG-1999; 99US-00380137.
XX
XX PR 25-AUG-1999; 99US-00380138.
XX
XX PR 25-AUG-1999; 99US-00380139.
XX
XX PR 25-AUG-1999; 99US-00380142.
XX
XX PR 15-SEP-1999; 99US-00397342.
XX
XX PR 18-OCT-1999; 99US-00403297.
XX
XX PR 12-NOV-1999; 99US-00423844.
XX
XX PR 30-DEC-1999; 99WO-US031274.
XX
XX PR 01-MAR-2000; 2000WO-US005601.
XX
XX PR 02-MAR-2000; 2000WO-US005841.
XX
XX PR 21-MAR-2000; 2000WO-US007532.
XX
XX PR 22-MAY-2000; 2000WO-US014042.
XX
XX PR 02-JUN-2000; 2000WO-US015264.
XX
XX PR 22-AUG-2000; 2000US-00644848.
XX
XX PR 24-AUG-2000; 2000WO-US023328.
XX
XX PR 18-SEP-2000; 2000US-00664610.
XX
XX PR 18-SEP-2000; 2000US-00665350.
XX
XX PR 08-NOV-2000; 2000US-00709238.
XX
XX PR 10-NOV-2000; 2000WO-US030873.
```

Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; tumour; cancer.

Homo sapiens.

US2003181637-A1.

25-SEP-2003.

02-MAY-2002; 2002US-00063527.

30-DEC-1998; 98KR-00062142.

08-MAR-1999; 99WO-US005028.

14-MAY-1999; 99US-00311832.

14-MAY-1999; 99WO-US010733.

25-AUG-1999; 99US-00380137.

25-AUG-1999; 99US-00380138.

25-AUG-1999; 99US-00380139.

25-AUG-1999; 99US-00380142.

15-SEP-1999; 99US-00397342.

18-OCT-1999; 99US-00403297.

12-NOV-1999; 99US-00423844.

30-DEC-1999; 99WO-US031274.

18-FEB-2000; 2000WO-US004341.

01-MAR-2000; 2000WO-US005601.

02-MAR-2000; 2000WO-US005841.

21-MAR-2000; 2000WO-US007532.

22-MAY-2000; 2000WO-US014042.

02-JUN-2000; 2000WO-US015264.

22-AUG-2000; 2000US-00644848.

24-AUG-2000; 2000WO-US023328.

18-SEP-2000; 2000US-00664610.

18-SEP-2000; 2000US-00665350.

08-NOV-2000; 2000US-00709238.

01-NOV-2000; 2000WO-US030873.

01-DEC-2000; 2000WO-US032678.

20-DEC-2000; 2000US-00747259.

20-DEC-2000; 2000WO-US034956.

28-FEB-2001; 2001WO-US006520.

22-MAR-2001; 2001US-00816744.

10-MAY-2001; 2001US-00854208.

10-MAY-2001; 2001US-00854280.

30-MAY-2001; 2001US-00870574.

01-JUN-2001; 2001WO-US017800.

05-JUN-2001; 2001US-00874503.

23-JUN-2001; 2001US-00869599.

18-JUL-2001; 2001US-00908827.

06-DEC-2001; 2001US-00008867.

(GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ; Grimaldi JC, Gurney AL, Watanabe CK, Wood WI; P-PSDB; ADH33552.

WPI; 2004-059332/06.

P-PSDB; ADH33552.

New isolated PRO polypeptide, useful for treating various bone and/or cartilage disorders, for example, sports injuries and arthritis.

Disclosure; SEQ ID NO 37; 335pp; English.

The invention relates to human PRO polypeptides and the PRO polynucleotides encoding them. The invention also relates to an antibody that specifically binds to the polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal comprising comparing the level of expression of any PRO polypeptide, given in the specification, in a test sample of cells taken from the mammal with a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptide in the test sample as compared to the control sample indicates the presence of a tumour in the

KW 20-DEC-2000; 2000WO-US032678.

KW 20-DEC-2000; 2000US-00747259.

XX 28-FEB-2001; 2000WO-US034956.

OS 22-MAR-2001; 2001WO-US006520.

PN 10-MAY-2001; 2001US-00816744.

XX 10-MAY-2001; 2001US-00854208.

PD 30-MAY-2001; 2001US-00870574.

XX 01-JUN-2001; 2001WO-US017800.

XX 05-JUN-2001; 2001US-00874503.

XX 29-JUN-2001; 2001US-00869599.

XX 18-JUL-2001; 2001US-00908827.

XX 06-DEC-2001; 2001US-00008867.

PA (GETH) GENENTECH INC.

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ; PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI; XX XX P-PSDB; ADH33552.

DR WPI; 2004-020828/02.

DR P-PSDB; ADH33552.

XX New nucleic acids encoding PRO polypeptides, useful in diagnosing and treating disorders that affect glucose or free fatty acid in skeletal muscle, such as diabetes, hypoinsulinemia or hyperinsulinemia.

PT Disclosure; SEQ ID NO 37; 398pp; English.

XX The invention relates to a novel PRO (secreted and transmembrane protein) polypeptide, and the polynucleotide sequence encoding it. Also included are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide sequence is useful in molecular biology as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide sequence may also be used in preparing the PRO polypeptide by recombinant techniques, and in generating either transgenic or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide sequence is useful in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification also discloses other PRO proteins and the polynucleotide sequences encoding them. The present sequence encodes a PRO protein.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTTTATCTTATTAATAAAATGTTGCTCCACCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATGAGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 915

ADH33551

ID ADH33551 standard; cDNA; 2846 BP.

XX AC ADH33551;

XX 11-MAR-2004 (first entry)

DT Human PRO polynucleotide #19.

DE

XX

CC mammal. The polynucleotides are useful as hybridisation probes in
 CC chromosome and gene mapping or in generating antisense RNA and DNA, for
 CC preparing PRO polypeptides, in assays to identify other proteins or
 CC molecules involved in binding reactions, to generate transgenic animals
 CC or knockout animals, which in turn are useful in the development and
 CC screening of therapeutically useful reagents, for chromosome
 CC identification and in tissue typing. The PRO polypeptides and
 CC polynucleotides are also useful in gene therapy and as molecular weight
 CC markers for protein electrophoresis. The anti-PRO antibodies may be used
 CC in diagnostic assays for PRO or for the affinity purification of PRO from
 CC recombinant cell culture or natural sources. This sequence represents a
 CC human PRO polynucleotide of the invention.

XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTCTTTATCTTATTAATAAATGTTGTCCTCCACCACTG 2180
 Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAATAAGGCTTGGCTTCTGAACCTA 2712
 QY 2181 NCTCCCAAA 2240
 Db 2713 CAAAAAATAAA 2772
 QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 916

ADH33891
 ID ADH33891 standard; cDNA; 2846 BP.

XX AC ADH33891;

XX DT 11-MAR-2004 (first entry)

XX DE Human PRO polynucleotide #19.

XX KW Human; PRO; gene; 88; tumour necrosis factor-alpha; TNF-alpha; blood;
 KW chondrocyte cell; tumour; cancer.

XX OS Homo sapiens.

XX PN US2003181644-A1.

XX PD 25-SEP-2003.

XX PF 03-MAY-2002; 2002US-00063600.

XX PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US0005028.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99WO-US010733.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.

PR 15-SEP-1999; 99US-00397342.

PR 18-OCT-1999; 99US-00403297.

PR 12-NOV-1999; 99US-00423844.

PR 30-DEC-1999; 99WO-US031274.

PR 18-FEB-2000; 2000WO-US004341.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005841.

PR 21-MAR-2000; 2000WO-US007532.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 01-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 10-MAY-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX (GETH) GENENTECH INC.

PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX WPI; 2004-059334/06.

DR P-PSDB; ADH33892.

XX New isolated PRO polypeptide, useful for treating various bone and/or
 XX cartilage disorders, for example, sports injuries and arthritis.

XX Disclosure; SEQ ID NO 37; 397pp; English.

XX The invention relates to human PRO polypeptides and the PRO
 CC polynucleotides encoding them. The invention also relates to an antibody
 CC that specifically binds to the polypeptide, a method for stimulating the
 CC release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a
 CC method for stimulating proliferation or differentiation of chondrocyte
 CC cells and a method for detecting the presence of any PRO polypeptide,
 CC comprising comparing the level of expression of any PRO polypeptide,
 CC given in the specification, in a test sample of cells taken from the
 CC mammal with a control sample of normal cells of the same cell type, where
 CC a higher level of expression of the PRO polypeptide in the test sample as
 CC compared to the control sample indicates the presence of a tumour in the
 CC mammal. The polynucleotides are useful as hybridisation probes in
 CC chromosome and gene mapping or in generating antisense RNA and DNA, for
 CC preparing PRO polypeptides, in assays to identify other proteins or
 CC molecules involved in binding reactions, to generate transgenic animals
 CC or knockout animals, which in turn are useful in the development and
 CC screening of therapeutically useful reagents, for chromosome
 CC identification and in tissue typing. The PRO polypeptides and
 CC polynucleotides are also useful in gene therapy and as molecular weight
 CC markers for protein electrophoresis. The anti-PRO antibodies may be used
 CC in diagnostic assays for PRO or for the affinity purification of PRO from
 CC recombinant cell culture or natural sources. This sequence represents a
 CC human PRO polynucleotide of the invention.

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTCTTTATCTTATTAATAAATGTTGTCCTCCACCACTG 2180
 Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAATAAGGCTTGGCTTCTGAACCTA 2712
 QY 2181 NCTCCCAAA 2240
 Db 2713 CAAAAAATAAA 2772
 QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 917
ADH01101
ID ADH01101 standard; cDNA; 2846 BP.
XX
AC ADH01101;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PRO polynucleotide #19.
XX
DE Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;
KW chondrocyte cell; tumour; cancer.
XX
OS Homo sapiens.
XX
PN US2003180838-A1.
XX
PD 25-SEP-2003.
XX
PF 07-MAY-2002; 2002US-00063669.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 10-MAY-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2004-020795/02.
XX P-PSDB; ADH01102.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Disclosure; SEQ ID NO 37; 398pp; English.

XX The invention relates to human PRO polypeptides and the PRO
CC polynucleotides encoding them. The invention also relates to an antibody
CC that specifically binds to the polypeptide, a method for stimulating the
CC release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a
CC method for stimulating proliferation or differentiation of chondrocyte
CC cells and a method for detecting the presence of a tumour in a mammal
CC comprising comparing the level of expression of any PRO polypeptide,
CC given in the specification, in a test sample of cells taken from the
CC mammal with a control sample of normal cells of the same cell type, where
CC a higher level of expression of the PRO polypeptide in the test sample as
CC compared to the control sample indicates the presence of a tumour in the
CC mammal. The polynucleotides are useful as hybridisation probes in
CC chromosome and gene mapping or in generating antisense RNA and DNA, for
CC preparing PRO polypeptides, in assays to identify other proteins or
CC molecules involved in binding reactions, to generate transgenic animals
CC or knockout animals, which in turn are useful in the development and
CC screening of therapeutically useful reagents, for chromosome
CC identification and in tissue typing. The PRO polypeptides and
CC polynucleotides are also useful in gene therapy and as molecular weight
CC markers for protein electrophoresis. The anti-PRO antibodies may be used
CC in diagnostic assays for PRO or for the affinity purification of PRO from
CC recombinant cell culture or natural sources. This sequence represents a
CC human PRO polynucleotide of the invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTTACCACTCTTTCTCTTTATCTATTATAAAATGTTGGTCTCCACCACGTG 2180
DB 2653 CCTTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAA AA 2240
DB 2713 CAAAAA AA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 918
ADG69708
ID ADG69708 standard; cDNA; 2846 BP.
XX
AC ADG69708;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX
OS Homo sapiens.
XX
PN US2003180843-A1.
XX
PD 25-SEP-2003.
XX
PF 07-MAY-2002; 2002US-00063676.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
XX

PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 01-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.

(GETH) GENENTECH INC.

PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WT;
 PI

XX MPI; 2004-020800/02.
 XX P-PSDB; ADG69709.

XX New PRO polypeptide and nucleic acid encoding the polypeptide, for use in
 PT gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.

XX Disclosure; SEQ ID NO 37; 398pp; English.

XX The invention relates to a PRO (secreted and transmembrane protein)-
 CC polynucleotide appearing as ADG69752 encoding PRO polypeptide having
 CC appearing as ADG69752. Also included are a vector comprising the novel
 CC nucleic acid and a host cell comprising the vector. The polynucleotide is
 CC useful in molecular biology, including uses as hybridisation probes, in
 CC chromosome and gene mapping, in generating antisense RNA and DNA, and in
 CC gene therapy. The polynucleotide may also be used in preparing PRO
 CC polypeptides by recombinant techniques, and in generating either
 CC transgenic animals or knock-out animals which, in turn, are useful in the
 CC development and screening of therapeutically useful reagents. The PRO
 CC polynucleotide is used in preparing a medicament for treating a condition
 CC responsive to the polypeptide or antibody, such as tumours, and in
 CC various diagnostic assays. The specification discloses 84 PRO proteins
 CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTTTATCTATTATTAATAAATGTGTCTCCACCACTG 2180
 |||||

Db 2653 CTTTTCCTCCCATCTTGTACACATTTTAATAAATAGGGTTTGGCTTCTGAACTA 2712
 |||||

Qy 2181 NCTCCCAA 2240
 |||||

Db 2713 CAAA 2772
 |||||

Oy 2241 AA 2242
 Db 2773 AA 2774
 RESULT 919
 ADH20969
 ID ADH20969 standard; cDNA; 2846 BP.
 XX
 AC ADH20969;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human cDNA encoding secreted/transmembrane protein PRO1344.
 XX
 KW PRO; secreted protein; transmembrane protein;
 KW hypertrophy of neonatal heart; angiogenesis;
 KW vascular endothelial growth factor; VEGF-stimulated proliferation;
 KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
 KW c-fos induction; adipocyte cell; chondrocyte differentiation;
 KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
 KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;
 KW rod photoreceptor cell.
 XX
 OS Homo sapiens.
 XX
 PN US2003224358-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 15-NOV-2001; 2001US-00997641.
 XX
 PR 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97WO-US020069.
 PR 12-NOV-1997; 97US-0065186P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 16-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.

Query Match	3.0%;	Score	66.6;	DB 12;	Length	2846;
Best Local Similarity	71.3%;	Prod. No.	0.0003;			
Matches	87;	Conservative	0;	Mismatches	35;	Indels
						Gaps
						0;
2121	CCTTTGGCTTTACCACTCTTTCCTTTTAACTATTATAAAAAATGTTGGTCTCCACACACTG	2180				
2653	CCTTTTCCTCCCATCTCTTTGACACATTTTATAAAATTAAGGGTTGGCTTCTGAACATA	2712				
2181	NCTCCAAA	2240				
2713	CAAAAAAATAAA	2772				

QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 920
 ADH02194
 ID ADH02194 standard; cDNA; 2846 BP.
 XX AC ADH02194;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human PRO polynucleotide #19.
 XX KW Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;
 KW chondrocyte cell; tumour; cancer.
 XX OS Homo sapiens.
 XX PN US2003180841-A1.
 XX PD 25-SEP-2003.
 XX PF 07-MAY-2002; 2002US-00063674.
 XX PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 25-AUG-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403237.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000WO-US0644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX (GETH) GENENTECH INC.
 XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX WPI; 2004-020798/02.
 DR P-ESDB; ADH02195.
 XX

PT New PRO polypeptide and nucleic acid encoding the polypeptide, for use in
 PT gene therapy, chromosome identification, tissue typing, or as
 XX hybridization probes in chromosome and gene mapping.
 PS Disclosure; SEQ ID NO 37; 398pp; English.
 XX
 CC The invention relates to human PRO polypeptides and the PRO
 CC polynucleotides encoding them. The invention also relates to an antibody
 CC that specifically binds to the polypeptide, a method for stimulating the
 CC release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a
 CC method for stimulating proliferation or differentiation of chondrocyte
 CC cells and a method for detecting the presence of a tumour in a mammal
 CC comprising comparing the level of expression of any PRO polypeptide,
 CC given in the specification, in a test sample of cells from the
 CC mammal with a control sample of normal cells of the same cell type, where
 CC a higher level of expression of the PRO polypeptide in the test sample as
 CC compared to the control sample indicates the presence of a tumour in the
 CC mammal. The polynucleotides are useful as hybridisation probes in
 CC chromosome and gene mapping or in generating antisense RNA and DNA, for
 CC preparing PRO polypeptides, in assays to identify other proteins or
 CC molecules involved in binding reactions, to generate transgenic animals
 CC or knockout animals, which in turn are useful in the development and
 CC screening of therapeutically useful reagents, for chromosome
 CC identification and in tissue typing. The PRO polypeptides and
 CC polynucleotides are also useful in gene therapy and as molecular weight
 CC markers for protein electrophoresis. The anti-PRO antibodies may be used
 CC in diagnostic assays for PRO or for the affinity purification of PRO from
 CC recombinant cell culture or natural sources. This sequence represents a
 CC human PRO polynucleotide of the invention.
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGTCTTACCACTCTTCTTTATCTTATTAATAAAATGTTGCTCCACACTG 2180
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAAATAGGGTTCGCTTCTGAACATA 2712
 QY 2181 NCTCCCAA 2240
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2713 CAAAAAIAA 2772
 QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 921
 ADG69198
 ID ADG69198 standard; cDNA; 2846 BP.
 XX AC ADG69198;
 XX DT 11-MAR-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.
 XX OS Homo sapiens.
 XX PN US2003180847-A1.
 XX PD 25-SEP-2003.
 XX PF 08-MAY-2002; 2002US-00063693.
 XX PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.

[illegible]

PR 30-MAR-2000; 2000WO-US008439.
 PR 28-AUG-2001; 2001US-00941992.
 XX (GETH) GENENTECH INC.
 XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;
 XX WPI: 2004-021947/02.
 DR P-PSDB; ADH20010.
 XX New genes and secreted and transmembrane polypeptides, useful for
 PT treating or diagnosing e.g. cancers or tumors in mammals, or as
 PT diagnostics, biosensors or bioreactors.
 XX Claim 2; SEQ ID NO 230; 648pp; English.
 XX The invention relates to an isolated nucleic acid molecule comprising the
 CC full-length coding sequence of the DNA ATCC Accession Numbers given in
 CC the specification, or comprising a sequence with at least 80% identity
 CC to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an
 CC extracellular domain of the polypeptide; or (b) any of 147 nucleotide
 CC sequences fully defined in the specification. Also included are the PRO
 CC proteins (or their extracellular domains) with or without their associated
 CC extracellular domains), expression vectors, host cells, PRO chimeric
 CC proteins, anti-PRO antibodies, methods of detecting polypeptide in a
 CC sample, methods of linking a bioactive molecule to a cell expressing a
 CC polypeptide and methods of modulating at least one biological activity of
 CC a cell expressing the polypeptide. The PRO polypeptides or
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal
 CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
 CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
 CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
 CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
 CC fos in endothelial cells, modulating glucose or FFA uptake by adipocyte
 CC cells, inducing proliferation and/or re-differentiation of chondrocytes,
 CC or inducing pancreatic beta-cell precursor differentiation. In
 CC particular, these are useful for detecting or treating tumours and
 CC certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,
 CC dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes
 CC may also be used in gene therapy, particularly for replacing a defective
 CC gene. The present sequence is a cDNA encoding a PRO protein.
 XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred No. 0.00023;
 Matches 87; Conservative 0; Mismatches 33; Indels 0; Gaps 0;
 QY 2121 CTTTGGCTTTACCACTCTTTCTTTATCTTTATTAATAAAATGTTGCTCCACCACTG 2180
 Db CTTTCTCTCTCCCTCTCTGTACACATTTTATAATAAAGGTTGCTTCTGACTA 2712
 QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
 Db CTTTCTCTCTCTCCCTCTCTGTACACATTTTATAATAAAGGTTGCTTCTGACTA 2712
 QY 2241 AA 2242
 Db 2773 AA 2774
 RESULT 926
 ADH02534
 ID ADH02534 standard; cDNA; 2846 BP.
 XX AC ADH02534;
 XX 11-MAR-2004 (first entry)
 DT

XX Human PRO polynucleotide #19.
 DE Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;
 KW chondrocyte cell; tumour; cancer.
 XX Homo sapiens.
 OS US2003180840-A1.
 PN 25-SEP-2003.
 PD 07-MAY-2002; 2002US-00063671.
 XX 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00864610.
 PR 18-SEP-2000; 2000US-0065350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 12-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00869599.
 PR 29-JUN-2001; 2001US-00874503.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX (GETH) GENENTECH INC.
 PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX WPI: 2004-020797/02.
 DR P-PSDB; ADH02535.
 XX New PRO polypeptide and nucleic acid encoding the polypeptide, for use in
 PT gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX Disclosure; SEQ ID NO 37; 398pp; English.
 XX The invention relates to human PRO polypeptides and the PRO
 CC polynucleotides encoding them. The invention also relates to an antibody
 CC that specifically binds to the polypeptide, a method for stimulating the
 CC release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a
 CC method for stimulating proliferation or differentiation of chondrocyte
 CC cells and a method for detecting the presence of a tumour in a mammal
 CC comprising comparing the level of expression of any PRO polypeptide,

XX AC ADH07631;
 XX DT 11-MAR-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX DE ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.
 XX OS Homo sapiens.
 XX PN US2003180850-A1.
 XX PD 25-SEP-2003.
 XX PF 08-MAY-2002; 2002US-00063699.
 XX PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 01-MAR-2000; 2000WO-US004341.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000US-00644848.
 PR 18-SEP-2000; 2000US-00654610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 30-MAY-2001; 2001US-00854280.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX (GETH) GENENTECH INC.
 XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX WPI; 2004-020806/02.
 DR P-PSDB; ADH07632.
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in molecular biology, chromosome and gene mapping, in generating
 PT antisense RNA and DNA, in various diagnostic assays and in gene therapy.
 XX Disclosure; SEQ ID NO 37; 398pp; English.
 XX The invention relates to a novel PRO (secreted and transmembrane protein)
 CC polypeptide, and the polynucleotide sequence encoding it. Also included
 CC are a vector comprising the novel nucleic acid and a host cell comprising

the vector. The polynucleotide sequence is useful in molecular biology as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA, and in gene therapy. The polynucleotide sequence
 CC may also be used in preparing the PRO polypeptide by recombinant
 CC techniques, and in generating either transgenic or knock-out animals
 CC which, in turn, are useful in the development and screening of
 CC therapeutically useful reagents. The PRO polynucleotide sequence is
 CC useful in preparing a medicament for treating a condition responsive to
 CC the polypeptide or antibody, such as tumours, and in various diagnostic
 CC assays. The specification also discloses other PRO proteins and the
 CC polynucleotide sequences encoding them. The present sequence encodes a
 CC PRO protein.
 XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGGCTTTACCACTCTTCTTTTATCTTATTAATAAAATGTGTCTCCACACTG 2180
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAATAGGCTTGGCTTCTCACTA 2712
 QY 2181 NCTCCCAA 2240
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2713 CAAA 2772
 QY 2241 AA 2242
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2773 AA 2774

RESULT 929
 ADG86153
 ID ADG86153 standard; cDNA; 2846 BP.
 XX AC ADG86153;
 XX DT 11-MAR-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 KW ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
 KW affinity purification; secreted and transmembrane protein.
 XX OS Homo sapiens.
 XX PN US2003180863-A1.
 XX PD 25-SEP-2003.
 XX PF 08-MAY-2002; 2002US-00063744.
 XX PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 01-MAR-2000; 2000WO-US004341.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000US-00644848.

CC would be beneficial, for example, diabetes or hyper- or hypo-
 CC insulinaemia. They are also useful for treating pericyte-associated
 CC tumours and in wound healing. The anti-PRO antibody is useful for the
 CC preparation of a medicament useful in the treatment of cancer. The PRO
 CC polypeptides are also useful as molecular weight markers, or for
 CC chromosome identification. The PRO genes are useful as hybridisation
 CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 CC The PRO genes may also be used in gene therapy, particularly for
 CC replacing a defective gene. This sequence encodes a secreted and
 CC transmembrane PRO protein.

XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTAATAAAATGTTGCTCCCACTG 2180
 Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
 Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
 Db 2773 AA 2774

RESULT 931
 ADH25797
 ID ADH25797 standard; cDNA; 2846 BP.

XX
 AC ADH25797;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX
 KW antiarthritic; antidiabetic; cytostatic; vulnary; hyperglycaemic;
 KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
 KW bone disorder; cartilage disorder; sports injury; arthritis;
 KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
 KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
 KW chromosome identification; gene therapy; gene; ss; human.

XX
 OS Homo sapiens.

XX
 FN US2003180911-A1.
 XX
 PD 25-SEP-2003.

XX
 PF 08-MAY-2002; 2002US-00063711.

XX
 PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.

PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.

PA (GETH) GENENTECH INC.

XX
 XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX
 DR WPI; 2004-020824/02.
 DR P-PSDB; ADH25798.

XX
 PT New secreted and transmembrane PRO nucleic acid molecule, useful in gene
 PT therapy or preparing a medicament for treating a condition that is
 PT responsive to a PRO polypeptide or anti-PRO antibody, e.g. diabetes.

XX
 PS Disclosure; SEQ ID NO 37; 398pp; English.

XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
 CC specification. The PRO polypeptides are useful for treating various bone
 CC and/or cartilage disorders, for example, sports injuries and arthritis.
 CC They are also useful in the therapeutic treatment of disorders where
 CC either the stimulation or inhibition of glucose uptake by skeletal muscle
 CC would be beneficial, for example, diabetes or hyper- or hypo-
 CC insulinaemia. They are also useful for treating pericyte-associated
 CC tumours and in wound healing. The anti-PRO antibody is useful for the
 CC preparation of a medicament useful in the treatment of cancer. The PRO
 CC polypeptides are also useful as molecular weight markers, or for
 CC chromosome identification. The PRO genes are useful as hybridisation
 CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 CC The PRO genes may also be used in gene therapy, particularly for
 CC replacing a defective gene. This sequence encodes a secreted and
 CC transmembrane PRO protein.

XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTAATAAAATGTTGCTCCCACTG 2180
 Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
 Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
 Db 2773 AA 2774

RESULT 932
 ADH38363
 ID ADH38363 standard; cDNA; 2846 BP.

XX AC ADH38363;
XX DT 11-MAR-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW human; PRO; membrane bound protein; membrane bound receptor;
XX KW cell proliferation; cell migration; cell differentiation;
XX KW mitogenic factor; survival factor; cytotoxic factor;
XX KW differentiation factor; neurotrophic factor; hormone; cell receptor;
XX KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.
XX OS Homo sapiens.
XX PN US2003180922-A1.
XX PD 25-SEP-2003.
XX PF 08-MAY-2002; 2002US-00063732.
XX PR 30-DEC-1998; 98KR-00062142.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 14-MAY-1999; 99US-00311832.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 25-AUG-1999; 99US-00380138.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 25-AUG-1999; 99US-00380142.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 12-NOV-1999; 99US-00423844.
XX PR 30-DEC-1999; 99WO-US031274.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 01-MAR-2000; 2000WO-US005601.
XX PR 02-MAR-2000; 2000WO-US005841.
XX PR 21-MAR-2000; 2000WO-US007532.
XX PR 22-MAY-2000; 2000WO-US014042.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 22-AUG-2000; 2000US-00644848.
XX PR 24-AUG-2000; 2000WO-US023328.
XX PR 18-SEP-2000; 2000US-00664510.
XX PR 18-SEP-2000; 2000US-00665350.
XX PR 08-NOV-2000; 2000US-00709238.
XX PR 10-NOV-2000; 2000WO-US030873.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 20-DEC-2000; 2000US-00747259.
XX PR 28-DEC-2000; 2000WO-US034956.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 22-MAR-2001; 2001US-00816744.
XX PR 10-MAY-2001; 2001US-00854208.
XX PR 10-MAY-2001; 2001US-00854280.
XX PR 30-MAY-2001; 2001US-00870574.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 05-JUN-2001; 2001US-00874503.
XX PR 29-JUN-2001; 2001US-00869599.
XX PR 18-JUL-2001; 2001US-00908827.
XX PR 06-DEC-2001; 2001US-00006867.
XX PA (GETH) GENENTECH INC.
XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
XX PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX P-PSDB; ADH38364.
XX WPI; 2004-020831/02.
XX DR P-PSDB; ADH38364.
XX PT New PRO nucleic acid, useful for preparing a medicament for treating a
XX PT condition associated with PRO nucleic acid e.g., cancer.
XX PS Disclosure; SEQ ID NO 37; 398pp; English.
XX XX This invention relates to novel nucleic acids encoding human PRO secreted

CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neurotrophic factors and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTCTGCTTACCACCTCTTCTCTTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTTCTCTCCCACTCTCTGTACACATTTTAAATAAATAAGGGTCTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
DB 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 933
ADH57202
ID ADH57202 standard; cDNA; 2846 BP.
XX AC ADH57202;
XX DT 25-MAR-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW human; PRO; membrane bound protein; membrane bound receptor;
XX KW cell proliferation; cell migration; cell differentiation;
XX KW mitogenic factor; survival factor; cytotoxic factor;
XX KW differentiation factor; neurotrophic factor; hormone; cell receptor;
XX KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.
XX OS Homo sapiens.
XX PN US2003181642-A1.
XX PD 25-SEP-2003.
XX PF 03-MAY-2002; 2002US-00063593.
XX PR 30-DEC-1998; 98KR-00062142.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 14-MAY-1999; 99US-00311832.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 25-AUG-1999; 99US-00380138.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 25-AUG-1999; 99US-00380142.
XX PR 15-SEP-1999; 99US-00397342.

XX Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2004-020830/02.
DR P-PSDB; ADH52191.
XX
DR New PRO nucleic acid, useful for preparing a medicament for treating a
PT condition associated with PRO nucleic acid e.g., cancer.
XX
PS Disclosure; SEQ ID NO 37; 398pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neurotrophins and hormones), which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTTTTATCTATTATTAATAAAGTTGGTCTCCACACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAATAAAGTTGGTCTTGAAC 2712

Qy 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 935
ADH49556
ID ADH49556 standard; cDNA; 2846 BP.
XX
AC ADH49556;
XX
DT 25-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophin; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gens.
XX
OS Homo sapiens.
XX
PN US2003180857-A1.
XX

PD 25-SEP-2003.
XX
PF 08-MAY-2002; 2002US-00063727.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-0064610.
PR 18-SEP-2000; 2000US-0065350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001WO-US034956.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2004-020812/02.
DR P-PSDB; ADH49557.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in molecular biology, chromosome and gene mapping, in generating
PT antisense RNA and DNA, in various diagnostic assays and in gene therapy.
XX
XX Disclosure; Fig 37; 398pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neurotrophins and hormones), which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a

PN US2003181683-A1.
XX 25-SEP-2003.
XX 07-MAY-2002; 2002US-00063653.
XX 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US0005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US007532.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 22-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 14-SEP-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 28-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
(GETH) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX P-PSDB; ADI11255.
XX WPI; 2004-119210/12.
XX Novel antibody that binds to a PRO polypeptide, useful for treating in
XX cancer and in diagnostic assays, for e.g. detecting PRO expression in
XX specific cells, tissues, or serum.
XX Disclosure; SEQ ID NO 37; 396pp; English.
XX The invention relates to an antibody that binds to a human PRO
XX polypeptide. The invention also relates to human PRO polynucleotides
XX encoding the PRO polypeptides of the invention. The antibody is
XX preferably a monoclonal or humanised antibody, or an antibody fragment,
XX and is used to treat cancer. The anti-PRO antibody can be used in
XX diagnostic assays, e.g. for detecting PRO expression in specific cells,
XX tissues or serum. The anti-PRO antibodies are also useful for the
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. This sequence represents a human PRO polynucleotide of the
XX invention.
XX Sequence 2846 BP; 768 A; 596 C; 745 G; 637 T; 0 U; 0 Other;
SQ Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CTTTGTTCACCACTCTTTCCTTTTATCTATTAATAAAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CTTTGTTCCTCCCATCTCTTGACATTTTAAATAAAGGTTGGTCTTCTGACTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
DB 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 938
ADH98919
ID ADH98919 standard; cDNA; 2846 BP.
XX AC ADH98919;
XX DT 15-APR-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW antihypertensive; antidiabetic; cytostatic; vulnery; hyperglycaemic;
XX KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
XX KW bone disorder; cartilage disorder; sports injury; arthritis;
XX KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
XX KW hyper-insulinaemia; pericyte-associated tumour; wound healing; cancer;
XX KW chromosome identification; gene therapy; gene; ss; human.
XX OS Homo sapiens.
XX PN US2003190698-A1.
XX PD 09-OCT-2003.
XX PF 08-MAY-2002; 2002US-00063718.
XX PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US0005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 22-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX (GETH) GENENTECH INC.
 PA
 PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX
 XX WPI; 2004-020979/02.
 DR P-PSDB; ADH98920.
 XX
 PT New PRO nucleic acid, useful for preparing a medicament for treating a
 PT condition associated with the PRO nucleic acid e.g., cancer, by gene
 PT therapy.
 XX
 XX Disclosure; SEQ ID NO 37; 398pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
 CC specification. The PRO polypeptides are useful for treating various bone
 CC and/or cartilage disorders, for example, sports injuries and arthritis.
 CC They are also useful in the therapeutic treatment of disorders where
 CC either the stimulation or inhibition of glucose uptake by skeletal muscle
 CC would be beneficial, for example, diabetes or hyper- or hypo-
 CC insulinaemia. They are also useful for treating pericyte-associated
 CC tumours and in wound healing. The anti-PRO antibody is useful for the
 CC preparation of a medicament useful in the treatment of cancer. The PRO
 CC polypeptides are also useful as molecular weight markers, or for
 CC chromosome identification. The PRO genes are useful as hybridisation
 CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 CC The PRO genes may also be used in gene therapy, particularly for
 CC replacing a defective gene. This sequence encodes a secreted and
 CC transmembrane PRO protein.
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CCTTGGCTTACCACTCTTCTTATCTATTAATAAATGTTGCTCCACCACTG 2180
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAGGCTTGCCTCTCACTA 2712
 Qy 2181 NCTCCCAA 2240
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2713 CAAAAAIAA 2772
 Qy 2241 AA 2242
 ||
 Db 2773 AA 2774
 RESULT 939
 ID ADI02149
 ID ADI02149 standard; cDNA; 2846 BP.
 XX AC ADI02149;
 XX
 XX 22-APR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX
 KW antiarthritic; antidiabetic; cytostatic; vulnery; hyperglycaemic;
 KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
 KW bone disorder; cartilage disorder; sports injury; arthritis;
 KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
 KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
 KW chromosome identification; gene therapy; gene; ss; human.
 XX
 OS Homo sapiens.

XX US2003190699-A1.
 XX 09-OCT-2003.
 XX
 XX 09-MAY-2002; 2002US-00063741.
 XX
 PR 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 18-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014842.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000WO-US023328.
 PR 24-AUG-2000; 2000WO-US024848.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX (GETH) GENENTECH INC.
 PA
 XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 FI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 PI
 XX
 XX WPI; 2004-020980/02.
 XX P-PSDB; ADI02150.
 XX
 PT New PRO nucleic acid, useful for preparing a medicament for treating a
 PT condition associated with PRO nucleic acid e.g., cancer.
 XX
 XX Disclosure; SEQ ID NO 37; 398pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
 CC specification. The PRO polypeptides are useful for treating various bone
 CC and/or cartilage disorders, for example, sports injuries and arthritis.
 CC They are also useful in the therapeutic treatment of disorders where
 CC either the stimulation or inhibition of glucose uptake by skeletal muscle
 CC would be beneficial, for example, diabetes or hyper- or hypo-
 CC insulinaemia. They are also useful for treating pericyte-associated
 CC tumours and in wound healing. The anti-PRO antibody is useful for the
 CC preparation of a medicament useful in the treatment of cancer. The PRO
 CC polypeptides are also useful as molecular weight markers, or for
 CC chromosome identification. The PRO genes are useful as hybridisation
 CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 CC The PRO genes may also be used in gene therapy, particularly for
 CC replacing a defective gene. This sequence encodes a secreted and


```

XX PD 05-FEB-2004.
XX PF 17-JUL-2002; 2002US-00197709.
XX PR 18-DEC-1997; 97US-0068017P.
XX PR 01-DEC-1998; 98WO-US025108.
XX PR 03-MAR-1999; 99US-00254311.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 15-JAN-2002; 2002US-00052586.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PU, Gurney AL;
XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2004-224694/21.
XX DR P-PSDB; ADJ54808.
XX FT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX FT in gene therapy, as diagnostic markers for the presence of cancerous
XX FT tumors, and as therapeutic targets for treating the tumors.
XX PS Claim 2; SEQ ID NO 169; 700pp; English.
XX CC The invention relates to human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX CC diagnostics, biosensors or bioreactors. They are particularly useful for
XX CC detecting tumours (e.g. adrenal tumour, lung tumour, colon tumour, breast
XX CC tumour, prostate tumour, rectal tumour, cervical tumour, or liver tumour)
XX CC in a mammal, for stimulating the release of tumour necrosis factor (TNF) -
XX CC alpha from human blood or for stimulating the proliferation of
XX CC differentiation of chondrocyte cells. The PRO nucleic acids are useful as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX CC technology, in generating transgenic animals or knock-out animals which
XX CC may be used in the development and screening of therapeutically useful
XX CC reagents, in gene therapy, in chromosome identification, as chromosome
XX CC markers and in generating probes. The PRO polypeptides, or anti-PRO
XX CC antibodies, are useful for preparing a medicament for treating a
XX CC condition which is responsive to the PRO polypeptides or anti-PRO
XX CC antibodies, such as bone or cartilage disorders (e.g. arthritis) and
XX CC cancer. The PRO polypeptides are useful as molecular markers for protein
XX CC electrophoresis, and in tissue typing. This sequence represents a human
XX CC PRO polynucleotide of the invention. Note: The sequence data for this
XX CC patent is also available in electronic format from USPTO at
XX CC seqdata.uspto.gov/sequence.html.
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
    Query Match 3.0%; Score 66.6; DB 12; Length 2846;
    Best Local Similarity 71.3%; Pred. No. 0.00023;
    Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTTGGCTTTACCACTCTTTCTTTATCTATTATAAATAATGTTGCTTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAATAAGGTTGGCTTCTGAACTA 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 942
ADJ98563
ID ADJ98563 standard; cDNA; 2846 BP.
XX AC ADJ98563;

```

```

XX DT 06-MAY-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW antiarthritic; antidiabetic; cytostatic; vulnerary; hyperglycaemic;
XX KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
XX KW bone disorder; cartilage disorder; sports injury; arthritis;
XX KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
XX KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
XX KW chromosome identification; gene therapy; gene; ss; human.
XX OS Homo sapiens.
XX PN US2003187197-A1.
XX PD 02-OCT-2003.
XX PF 07-MAY-2002; 2002US-00063647.
XX PR 30-DEC-1998; 98KR-00062142.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 14-MAY-1999; 99US-00311832.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 25-AUG-1999; 99US-00380138.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 25-AUG-1999; 99US-00380142.
XX PR 15-SEP-1999; 99US-00397342.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 30-DEC-1999; 99WO-US031274.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 01-MAR-2000; 2000WO-US005601.
XX PR 02-MAR-2000; 2000WO-US005841.
XX PR 21-MAR-2000; 2000WO-US007532.
XX PR 22-MAY-2000; 2000WO-US014042.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 22-AUG-2000; 2000US-00644848.
XX PR 24-AUG-2000; 2000WO-US023328.
XX PR 18-SEP-2000; 2000US-00664610.
XX PR 18-SEP-2000; 2000US-00665350.
XX PR 08-NOV-2000; 2000US-00709238.
XX PR 10-NOV-2000; 2000WO-US030873.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 20-DEC-2000; 2000US-00747259.
XX PR 20-DEC-2000; 2000WO-US034956.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 22-MAR-2001; 2001US-00816744.
XX PR 10-MAY-2001; 2001US-00854208.
XX PR 30-MAY-2001; 2001US-00870574.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 05-JUN-2001; 2001US-00874503.
XX PR 29-JUN-2001; 2001US-00895999.
XX PR 18-JUL-2001; 2001US-00908827.
XX PR 06-DEC-2001; 2001US-00006867.
XX PA (GETH ) GENENTECH INC.
XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;
XX PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX DR WPI; 2004-009972/01.
XX DR P-PSDB; ADJ98564.
XX FT New isolated PRO polypeptide, useful for treating various bone and/or
XX FT cartilage disorders, for example, sports injuries and arthritis.
XX PS Disclosure; SEQ ID NO 37; 397pp; English.
XX CC The invention describes an isolated PRO (secreted and transmembrane)
XX CC polypeptide comprising the 642 amino acid sequence (S1) defined in the

```


RESULT 944
ADH78892
ID ADH78892 standard; cDNA; 2846 BP.
XX
AC ADH78892;
XX
DT 06-MAY-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
XX ss; gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;
KW affinity purification; secreted and transmembrane protein.
XX
XX Homo sapiens.
OS
XX US2003181703-A1.
PN
XX
PD 25-SEP-2003.
XX
PF 08-MAY-2002; 2002US-00063723.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US0031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 28-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2004-088894/09.
DR P-PSDB; ADH78893.
XX
XX New PRO nucleic acid, useful for preparing a medicament for treating a
PT condition associated with the PRO nucleic acid e.g., cancer, by gene
PT therapy.
XX
XX Disclosure; SEQ ID NO 37; 398bp; English.
PS

The invention relates to a PRO (secreted and transmembrane protein)
 polynucleotide appearing as ADH78958 encoding PRO polypeptide having
 appearing as ADH78959. Also included are a vector comprising the novel
 nucleic acid and a host cell comprising the vector. The polynucleotide is
 useful in molecular biology, including uses as hybridisation probes, in
 chromosome and gene mapping, in generating antisense RNA and DNA, and in
 gene therapy. The polynucleotide may also be used in preparing PRO
 polypeptides by recombinant techniques, and in generating either
 transgenic animals or knock-out animals which, in turn, are useful in the
 development and screening of therapeutically useful reagents. The PRO
 polynucleotide is used in preparing a medicament for treating a condition
 responsive to the polypeptide or antibody, such as tumours, and in
 various diagnostic assays. The specification discloses 84 PRO proteins
 and 84 PRO polynucleotides. The present sequence encodes a PRO protein.
 Sequence 2846 BP: 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other
 SQ

Query Match	3.0%	Score	66.6	DB	12	Length	2846
Best Local Similarity	71.3%	Pred. No.	0.00023				
Matches	87	Conservative	0	Mismatches	35	Indels	0
							Gaps
Qy	2121	CCITTTGCTTTTACCACTCTTTCCCTTTTATCTATTATAAAAAATGTTGGTCTCCACCACTG	2180				
Db	2653	CCITTTTCCTTCCCACTCTCTGTGACATTTTATAAAATPAGGGTGTCTCTGAACCTA	2712				
Qy	2181	NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2240				
Db	2713	CAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA	2772				
Qy	2241	AA	2242				
Db	2773	AA	2774				

RESULT	945	
ADJ99126		
ID	ADJ99126	standard; cDNA; 2846 BP.
XX		
AC	ADJ99126;	
XX		
DT	06-MAY-2004	(first entry)
XX		
DE	Novel human secreted and transmembrane protein PRO1344	cdNA.
XX		
KW	antiarthritic; anidiabetic; cytostatic; vulnery; hyperglycaemic;	
KW	hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;	
KW	bone disorder; cartilage disorder; sports injury; arthritis;	
KW	glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;	
KW	hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;	
KW	chromosome identification; gene therapy; gene; ss; human.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003186408-A1.	
XX		
PD	02-OCT-2003.	
XX		
PF	08-MAY-2002; 2002US-00063688.	
XX		
PR	30-DEC-1998; 98XR-00062142.	
PR	08-MAR-1999; 99WO-US005028.	
PR	14-MAY-1999; 99US-00311832.	
PR	14-MAY-1999; 99WO-US010733.	
PR	25-AUG-1999; 99US-00380137.	
PR	25-AUG-1999; 99US-00380138.	
PR	25-AUG-1999; 99US-00380139.	
PR	25-AUG-1999; 99US-00380142.	
PR	15-SEP-1999; 99US-00397342.	
PR	18-OCT-1999; 99US-00403297.	
PR	12-NOV-1999; 99US-00423844.	
PR	30-DEC-1999; 99WO-US031274.	
PR	18-FEB-2000; 2000WO-US004341.	

PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 22-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX XX

(GETH) GENENTECH INC.

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2004-032011/03.
 DR P-PSDB; ADJ99127.

XX Isolated nucleic acid useful in molecular biology, has nucleic acid
 PT sequence identity to: e.g. nucleic acid sequence encoding polypeptide
 PT having specified amino acid sequence, and specified nucleic acid
 PT sequence.

XX Disclosure; SEQ ID NO 37; 398pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
 CC specification. The PRO polypeptides are useful for treating various bone
 CC and/or cartilage disorders, for example, sports injuries and arthritis.
 CC They are also useful in the therapeutic treatment of disorders where
 CC either the stimulation or inhibition of glucose uptake by skeletal muscle
 CC would be beneficial, for example, diabetes or hyper- or hypo-
 CC insulinaemia. They are also useful for treating pericyte-associated
 CC tumours and in wound healing. The anti-PRO antibody is useful for the
 CC preparation of a medicament useful in the treatment of cancer. The PRO
 CC polypeptides are also useful as molecular weight markers, or for
 CC chromosome identification. The PRO genes are useful as hybridisation
 CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
 CC The PRO genes may also be used in gene therapy, particularly for
 CC replacing a defective gene. This sequence encodes a secreted and
 CC transmembrane PRO protein.

XX Sequence 2846 BP; 768 A; 596 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCCTTGGTTTACCACTCTTCCCTTTATCTATATATAAAATGTTGGTCTCCACCACTG 2180
 Db 2653 CTTTTTCCCCCATCTCTGTACACATTTTATAAAATAGGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242
 ||

Db 2773 AA 2774
 RESULT 946
 ADJ99296
 ID ADJ99296 standard; cDNA; 2846 BP.
 XX AC ADJ99296;
 XX DT 06-MAY-2004 (first entry)
 XX Novel human secreted and transmembrane protein PRO1344 cDNA.
 DE antiarthritis; antidiabetic; cytostatic; vulnerary; hyperglycaemic;
 KW hypoglycaemic; antibody therapy; PRO; secreted and transmembrane;
 KW bone disorder; cartilage disorder; sports injury; arthritis;
 KW glucose uptake; skeletal muscle; diabetes; hyper-insulinaemia;
 KW hypo-insulinaemia; pericyte-associated tumour; wound healing; cancer;
 KW chromosome identification; gene therapy; gene; ss; human.
 OS Homo sapiens.
 XX US2003187196-A1.
 XX 02-OCT-2003.
 XX 01-MAY-2002; 2002US-00063520.
 XX 30-DEC-1998; 98KR-00062142.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99WO-US010733.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 15-SEP-1999; 99US-00397342.
 PR 12-OCT-1999; 99US-00403297.
 PR 12-NOV-1999; 99US-00423844.
 PR 30-DEC-1999; 99WO-US031274.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00665350.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-FEB-2001; 2001WO-US034956.
 PR 22-MAR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR -29-JUN-2001; 2001US-00869599.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-DEC-2001; 2001US-00006867.
 XX (GETH) GENENTECH INC.
 PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
 XX WPI; 2004-009971/01.
 DR P-PSDB; ADJ99297.

XX New isolated PRO polypeptide, useful for treating various bone and/or
FT cartilage disorders, for example, sports injuries and arthritis.
XX
XX Disclosure; SEQ ID NO 37; 396pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide comprising the 642 amino acid sequence (S1) defined in the
CC specification. The PRO polypeptides are useful for treating various bone
CC and/or cartilage disorders, for example, sports injuries and arthritis.
CC They are also useful in the therapeutic treatment of disorders where
CC either the stimulation or inhibition of glucose uptake by skeletal muscle
CC would be beneficial, for example, diabetes or hyper- or hypo-
CC insulinemia. They are also useful for treating pericyte-associated
CC tumours and in wound healing. The anti-PRO antibody is useful for the
CC preparation of a medicament useful in the treatment of cancer. The PRO
CC polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. This sequence encodes a secreted and
CC transmembrane PRO protein.

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0;

Qy	2121	CCTTTGGTTTACCACTCTTTTCCTTTTATCTATTATAAAATGTGGTCTCCACCACTG	2180
Db	2653	CTTTTCTTTCCCATCTCTTGTAACACATTTTATAAAATAAGGTTGGCTTCTGAACTA	2712
Qy	2181	NTCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2240
Db	2713	CAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2772
Qy	2241	AA 2242	
Db	2773	AA 2774	

RESULT 947

ADJ98914
ID ADJ98914 standard; cDNA: 2846 BP.

AC ADJ98914;

XX	06-MAY-2004 (first entry)
DT	

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

ss: gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor; affinity purification; secreted and transmembrane protein.

OS Homo sapiens.

XX
PN
US2003187242-A1.

02-OCT-2003.

07-MAY-2002; 2002US-00063677.

XX
PR 30-DEC-1998; 98KR-00062142.

PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.

PR I4-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.

PR 25-AUG-1999; 99US-00380142.
DP 15-SEP-1999. 99US-00397343

PR 18-OCT-1999; 99US-00403297.

PR	12-NOV-1999;	99US-00423844.
PR	30-DEC-1999;	99NO-US031274.
PR	18-FEB-2000;	2000MO-US034341.
PR	01-MAR-2000;	2000MO-US005601.
PR	02-MAR-2000;	2000MO-US005841.
PR	21-MAR-2000;	2000MO-US007532.
PR	23-MAY-2000;	2000MO-US014044.
PR	22-JUN-2000;	2000MO-US015264.
PR	22-AUG-2000;	2000US-00644848.
PR	24-AUG-2000;	2000MO-US023328.
PR	18-SEP-2000;	2000US-00664610.
PR	18-SEP-2000;	2000US-00653550.
PR	08-NOV-2000;	2000US-00709238.
PR	10-NOV-2000;	2000MO-US030873.
PR	01-DEC-2000;	2000MO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000MO-US034956.
PR	28-FEB-2001;	2001MO-US006520.
PR	22-MAR-2001;	2001US-00816744.
PR	13-MAY-2001;	2001US-00854208.
PR	30-MAY-2001;	2001US-00854280.
PR	30-MAY-2001;	2001US-00870574.
PR	01-JUN-2001;	2001MO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	29-JUN-2001;	2001US-00865959.
PR	18-JUL-2001;	2001US-00908827.
PR	06-DEC-2001;	2001US-00908687.

(GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

WPI; 2004-032056/03.

P-PSDB; ADJ98915.

New isolated nucleic acid molecule for use in preparing a medicament useful in the treatment of condition that is responsive to the PRO polypeptide, agonist or antagonists or anti-PRO antibody.

Disclosure; SEQ ID NO 37; 398pp; English.

The invention relates to a PRO (secreted and transmembrane protein) polynucleotide appearing as ADJ9900 encoding PRO polypeptide having appearing as ADJ9901. Also included are a vector comprising the novel nucleic acid and a host cell comprising the vector. The polynucleotide is useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide may also be used in preparing PRO polypeptides by recombinant techniques, and in generating either transgenic animals or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polynucleotide is used in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The specification discloses 84 PRO proteins, and 84 PRO polynucleotides. The present sequence encodes 84 PRO proteins.

Sequence 2846 BP: 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;

Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87: Conservative 0: Mismatches 35: Indels 0: Gaps 0:

2121 CCCTTGGCTTTACCACTCTCTTTCCTTTTATCTTATTAATAAAATGTGGTCTCCACCACTG 2180

2653 CATTTCCTTCCCATCTCTTGTACACATTTTATAAAATAAGGGTTGGCTTCTGAACCTA 2712

2181 NCTCCCAAAAAAAAAAAAAAAAAA 2240

[illegible]

C
C
C
C
C
C
C

Db 2773 AA 2774

RESULT 948

ADH79062

ID ADH79062 standard; cDNA; 2846 BP.

XX AC ADH79062;

XX DT 06-MAY-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX KW ss: gene; human; PRO; pharmaceutical; diagnostic; biosensor; bioreactor;

XX KW affinity purification, secreted and transmembrane protein.

XX OS Homo sapiens.

XX PN US2003181702-A1.

XX PD 25-SEP-2003.

XX PF 08-MAY-2002; 2002US-00063721.

XX PR 30-DEC-1998; 98KR-00062142.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 14-MAY-1999; 99US-00311832.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 25-AUG-1999; 99US-00380138.

XX PR 25-AUG-1999; 99US-00380139.

XX PR 25-AUG-1999; 99US-00380142.

XX PR 15-SEP-1999; 99US-00397342.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 12-NOV-1999; 99US-00423844.

XX PR 30-DEC-1999; 99WO-US031274.

XX PR 30-DEC-1999; 99WO-US031274.

XX PR 01-MAR-2000; 2000WO-US004341.

XX PR 02-MAR-2000; 2000WO-US005601.

XX PR 21-MAR-2000; 2000WO-US007532.

XX PR 22-MAY-2000; 2000WO-US014042.

XX PR 02-JUN-2000; 2000WO-US015264.

XX PR 24-AUG-2000; 2000US-00644848.

XX PR 24-AUG-2000; 2000WO-US023328.

XX PR 18-SEP-2000; 2000US-00664610.

XX PR 18-SEP-2000; 2000US-00665350.

XX PR 08-NOV-2000; 2000US-00709238.

XX PR 01-NOV-2000; 2000WO-US030873.

XX PR 20-DEC-2000; 2000US-00747259.

XX PR 20-DEC-2000; 2000WO-US034956.

XX PR 28-FEB-2001; 2001WO-US006520.

XX PR 22-MAR-2001; 2001US-00816744.

XX PR 10-MAY-2001; 2001US-00854208.

XX PR 10-MAY-2001; 2001US-00854280.

XX PR 30-MAY-2001; 2001US-00870574.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 25-JUN-2001; 2001US-00874503.

XX PR 29-JUN-2001; 2001US-00869599.

XX PR 18-JUL-2001; 2001US-00908827.

XX PR 06-DEC-2001; 2001US-00006867.

XX PA (GETH) GENENTECH INC.

XX PI Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX P-PSDB; ADH79063.

XX WPI: 2004-080359/08.

XX DR New PRO nucleic acid, useful for preparing a medicament for treating a

XX PT condition associated with the PRO nucleic acid e.g., cancer, by gene

XX PT therapy.

XX PS Disclosure; SEQ ID NO 37; 398pp; English.

XX CC The invention relates to a PRO (secreted and transmembrane protein)

CC polynucleotide appearing as ADH79123 encoding PRO polypeptide having

CC appearing as ADH79124. Also included are a vector comprising the novel

CC nucleic acid and a host cell comprising the vector. The polynucleotide is

CC useful in molecular biology, including uses as hybridisation probes, in

CC chromosome and gene mapping, in generating antisense RNA and DNA, and in

CC gene therapy. The polynucleotide may also be used in preparing PRO

CC polypeptides by recombinant techniques, and in generating either

CC transgenic animals or knock-out animals which, in turn, are useful in the

CC development and screening of therapeutically useful reagents. The PRO

CC polynucleotide is used in preparing a medicament for treating a condition

CC responsive to the polypeptide or antibody, such as tumours, and in

CC various diagnostic assays. The specification discloses 84 PRO proteins

CC and 84 PRO polynucleotides. The present sequence encodes a PRO protein.

XX

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 12; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180

DB 2653 CCTTTCTTCCCATCTCTGTGACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAA 2240

DB 2713 CAAAAAATAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 949

ADK00922

ID ADK00922 standard; cDNA; 2846 BP.

XX AC ADK00922;

XX DT 06-MAY-2004 (first entry)

XX DE Human PRO polynucleotide #19.

XX KW Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;

XX KW chondrocyte cell; tumour; cancer.

XX OS Homo sapiens.

XX PN US2003186407-A1.

XX PD 02-OCT-2003.

XX PR 08-MAY-2002; 2002US-00063684.

XX PR 30-DEC-1998; 98KR-00062142.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 14-MAY-1999; 99US-00311832.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 25-AUG-1999; 99US-00380138.

XX PR 25-AUG-1999; 99US-00380139.

XX PR 25-AUG-1999; 99US-00380142.

XX PR 15-SEP-1999; 99US-00397342.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 12-NOV-1999; 99US-00423844.

XX PR 30-DEC-1999; 99WO-US031274.

XX PR 18-FEB-2000; 2000WO-US004341.

XX PR 01-MAR-2000; 2000WO-US005601.

XX PR 02-MAR-2000; 2000WO-US005841.

Db	2713 CAAA
Qy	2241 AA 2242
Db	2773 AA 2774
 RESULT 950 ADK14443	
ID	ADK14443 standard; cDNA; 2846 BP.
XX	AC ADK14443;
XX	XX
DT	06-MAY-2004 (first entry)
DE	Novel human secreted and transmembrane protein PRO1344 cDNA.
XX	PRO; human; secreted; transmembrane; cancer; antibody; ss; gene.
KW	Homo sapiens.
OS	US2003187229-A1.
XX	XX
PB	02-OCT-2003.
XX	XX
PF	03-MAY-2002; 2002US-00063578.
XX	XX
PR	30-DEC-1998; 98KR-00062142.
PR	08-MAR-1999; 99WO-US005028.
PR	14-MAY-1999; 99US-00311832.
PR	14-MAY-1999; 99WO-US010733.
PR	25-AUG-1999; 99US-00380137.
PR	25-AUG-1999; 99US-00380138.
PR	25-AUG-1999; 99US-00380139.
PR	25-AUG-1999; 99US-00380142.
PR	15-SEP-1999; 99US-00397342.
PR	18-OCT-1999; 99US-00403297.
PR	12-NOV-1999; 99US-00423844.
PR	30-DEC-1999; 99WO-US031274.
PR	18-FEB-2000; 2000WO-US004341.
PR	01-MAR-2000; 2000WO-US005601.
PR	02-MAR-2000; 2000WO-US005841.
PR	21-MAR-2000; 2000WO-US007532.
PR	22-MAY-2000; 2000WO-US014042.
PR	02-JUN-2000; 2000WO-US015264.
PR	22-AUG-2000; 2000US-0064848.
PR	24-AUG-2000; 2000WO-US023328.
PR	18-SEP-2000; 2000US-0064610.
PR	18-SEP-2000; 2000US-0065350.
PR	08-NOV-2000; 2000US-00709238.
PR	10-NOV-2000; 2000WO-US030873.
PR	01-DEC-2000; 2000WO-US032678.
PR	20-DEC-2000; 2000US-00747259.
PR	20-DEC-2000; 2000WO-US034956.
PR	28-FEB-2001; 2001WO-US006520.
PR	22-MAR-2001; 2001US-00816744.
PR	10-MAY-2001; 2001US-00854208.
PR	10-MAY-2001; 2001US-00854280.
PR	30-MAY-2001; 2001US-00870574.
PR	01-JUN-2001; 2001WO-US017800.
PR	05-JUN-2001; 2001US-00874503.
PR	29-JUN-2001; 2001US-00869599.
PR	18-JUL-2001; 2001US-00908827.
PR	06-DEC-2001; 2001US-00006867.
XX	XX
PA	(GETH) GENENTECH INC.
XX	XX
PI	Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI,
XX	XX
DR	WPI; 2004-009981/01.
DR	P-PSDB; ADK14444.


```

PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-238495/22.
DR P-PSDB; ADM31475.
XX
XX New isolated nucleic acids encoding secreted and transmembrane PRO
PT polypeptides, useful for stimulating the release of tumor necrosis factor
PT alpha from human blood and detecting the presence of a tumor in a mammal.
XX
XX Claim 2; SEQ ID NO 169; 706pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO polypeptides
CC (secreted and transmembrane). The polynucleotide is useful in molecular
CC biology, including uses as hybridisation probes, in chromosome and gene
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
CC polynucleotide may also be used in preparing PRO polypeptides by
CC recombinant techniques, and in generating either transgenic animals or
CC knock-out animals which, in turn, are useful in the development and
CC screening of therapeutically useful reagents. The PRO polypeptide or the
CC antibody is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. This sequence encodes a novel human secreted
CC and transmembrane PRO polypeptide. Note: This sequence is also available
CC in electronic format from the US patent office at
CC ftp.seqdata.uspto.gov/sequence.html?DocID=20040048334.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Oy 2121 CCTTGGCTTTACCACTCTTCTTTATCTTATTATAATAAATGTGTCTCCACCACTG 2180
Db CTTTCTCTTCCCATCTCTGTACACATTTTATAATAAATAGGTTGGCTTCTGAACATA 2712
Oy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db CTTTCTCTTCCCATCTCTGTACACATTTTATAATAAATAGGTTGGCTTCTGAACATA 2712
Oy 2241 AA 2242
Db 2773 AA 2774
RESULT 953
ADM36521
ID ADM36521 standard; cDNA; 2846 BP.
XX
XX ADM36521;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE
XX Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
KW secreted and transmembrane protein; PRO; chromosome mapping;
KW gene mapping; tumour.
XX
XX Homo sapiens.
OS
XX US2004053358-A1.
XX
XX 18-MAR-2004.
PD
XX
XX 23-JUL-2002; 2002US-00201853.
XX
XX
XX

```

```

PR 18-NOV-1998; 98US-0108851P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-247725/23.
DR P-PSDB; ADM36522.
XX
XX New secreted and transmembrane PRO polypeptide and nucleic acid, for use
PT in gene therapy, as diagnostic markers for the presence of cancerous
PT tumors, and as therapeutic targets for treating the tumors.
XX
XX Claim 2; SEQ ID NO 169; 700pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO polypeptides
CC (secreted and transmembrane). The polynucleotide is useful in molecular
CC biology, including uses as hybridisation probes, in chromosome and gene
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
CC polynucleotide may also be used in preparing PRO polypeptides by
CC recombinant techniques, and in generating either transgenic animals or
CC knock-out animals which, in turn, are useful in the development and
CC screening of therapeutically useful reagents. The PRO polypeptide or the
CC antibody is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. This sequence encodes a novel human secreted
CC and transmembrane PRO polypeptide. Note: This sequence is also available
CC in electronic format from the US patent office at
CC ftp.seqdata.uspto.gov/sequence.html?DocID=20040053358.
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Oy 2121 CCTTGGCTTTACCACTCTTCTTTATCTTATTATAATAAATGTGTCTCCACCACTG 2180
Db CTTTCTCTTCCCATCTCTGTACACATTTTATAATAAATAGGTTGGCTTCTGAACATA 2712
Oy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db CTTTCTCTTCCCATCTCTGTACACATTTTATAATAAATAGGTTGGCTTCTGAACATA 2712
Oy 2241 AA 2242
Db 2773 AA 2774
RESULT 954
ADM40326
ID ADM40326 standard; cDNA; 2846 BP.
XX
XX ADM40326;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE
XX Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
KW secreted and transmembrane protein; PRO; chromosome mapping;
KW gene mapping; tumour.
XX
XX Homo sapiens.
OS
XX US2004048335-A1.
XX
XX 11-MAR-2004.
PD
XX
XX
XX

```



```
Db      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy      2241 AA 2242
        ||
Db      2773 AA 2774

RESULT 956
ADN37934
ID      ADN37934 standard; cDNA; 2846 BP.
XX
AC      ADN37934;
XX
DT      29-JUL-2004 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW      Human; ss; gene; cytostatic; gene therapy; chondrocyte stimulator;
KW      secreted and transmembrane protein; PRO; chromosome mapping;
KW      gene mapping; tumour.
XX
OS      Homo sapiens.
XX
PN      US2004091959-A1.
XX
PD      13-MAY-2004.
XX
PF      26-JUL-2002; 2002US-00206916.
XX
PR      05-JUN-2000; 2000US-0209832P.
PR      28-FEB-2001; 2001WO-US006520.
PR      15-JAN-2002; 2002US-00052586.
XX
PA      (GETH ) GENENTECH INC.
XX
PI      Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PU, Gurney AL;
PI      Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2004-374950/35.
P-PSDB; ADN37935.
XX
New isolated, secreted and transmembrane PRO polypeptides and nucleic
acids, useful for diagnosing, preventing and/or treating tumors, such as
adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX
Claim 2; SEQ ID NO 169; 706pp; English.
XX
The invention describes 305 nucleic acids encoding PRO polypeptides
(secreted and transmembrane). The polynucleotide is useful in molecular
biology, including uses as hybridisation probes, in chromosome and gene
mapping, in generating antisense RNA and DNA, and in gene therapy. The
polynucleotide may also be used in preparing PRO polypeptides by
recombinant techniques, and in generating either transgenic animals or
knock-out animals which, in turn, are useful in the development and
screening of therapeutically useful reagents. The PRO polypeptide or the
antibody is used in preparing a medicament for treating a condition
responsive to the polypeptide or antibody, such as tumors, and in
various diagnostic assays. This sequence encodes a novel human secreted
and transmembrane PRO polypeptide.
XX
SQ      Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 12; Length 2846;
Best Local Similarity 71.3%; Pred. NO. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy      2121 CCTTGGCTTTACCACTCTTCTCTTTATCTATTATAAATGTGCTCTCCACCACTG 2180
        |||||
Db      2653 CCTTTCTCTCCCACTCTCTGTACACATTTTATAAATAAGGTTGGCTCTGAACTA 2712
        |||||
Qy      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
        |||||
```

```
Db      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy      2241 AA 2242
        ||
Db      2773 AA 2774

RESULT 957
ACA67289
ID      ACA67289 standard; cDNA; 2848 BP.
XX
AC      ACA67289;
XX
DT      23-JUN-2003 (first entry)
XX
DE      cDNA encoding human secreted polypeptide PRO1344.
XX
KW      Human; gene; ss; affinity purification.
XX
OS      Homo sapiens.
XX
PN      US2003027212-A1.
XX
PD      06-FEB-2003.
XX
PF      02-MAY-2002; 2002US-00063544.
XX
PR      30-DEC-1998; 98KR-00062142.
PR      08-MAR-1999; 99WO-US005028.
PR      14-MAY-1999; 99US-00311832.
PR      14-MAY-1999; 99WO-US010733.
PR      25-AUG-1999; 99US-00380137.
PR      25-AUG-1999; 99US-00380138.
PR      25-AUG-1999; 99US-00380139.
PR      25-AUG-1999; 99US-00380142.
PR      15-SEP-1999; 99US-00397342.
PR      18-OCT-1999; 99US-00403297.
PR      12-NOV-1999; 99US-00423844.
PR      30-DEC-1999; 99WO-US031274.
PR      18-FEB-2000; 2000WO-US004341.
PR      01-MAR-2000; 2000WO-US005601.
PR      02-MAR-2000; 2000WO-US005841.
PR      21-MAR-2000; 2000WO-US007532.
PR      22-MAY-2000; 2000WO-US014042.
PR      02-JUN-2000; 2000WO-US015264.
PR      22-AUG-2000; 2000US-00644848.
PR      24-AUG-2000; 2000WO-US023328.
PR      18-SEP-2000; 2000US-00664610.
PR      18-SEP-2000; 2000US-00665350.
PR      08-NOV-2000; 2000US-00709238.
PR      10-NOV-2000; 2000WO-US030873.
PR      01-DEC-2000; 2000WO-US032678.
PR      20-DEC-2000; 2000US-00747259.
PR      20-DEC-2000; 2000WO-US034956.
PR      28-FEB-2001; 2001WO-US006520.
PR      22-MAR-2001; 2001US-00816744.
PR      10-MAY-2001; 2001US-00854208.
PR      30-MAY-2001; 2001US-00854280.
PR      01-JUN-2001; 2001US-00870574.
PR      05-JUN-2001; 2001WO-US017800.
PR      29-JUN-2001; 2001US-00874503.
PR      18-JUL-2001; 2001US-00908927.
PR      06-DEC-2001; 2001US-00006867.
XX
PA      (GETH ) GENENTECH INC.
XX
PI      Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;
PI      Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
WPI; 2003-341840/32.
P-PSDB; ABU81164.
XX
```

PT New monoclonal antibody that binds to a secreted and transmembrane
PT polypeptide, useful for detecting and purifying the polypeptide and also
for treating conditions responsive to the antibody.

XX Example 4; Fig 37; 235pp; English.

CC The invention relates to an antibody that binds to a secreted and
CC transmembrane polypeptide, PRO1136. The antibody is useful for preparing
CC a medicament useful in the treatment of a condition responsive to anti-
CC PRO antibody. The antibody is also useful in diagnostic assays for PRO,
CC by detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. The present sequence represents a cDNA encoding a PRO
CC polypeptide of the invention

SQ Sequence 2848 BP; 769 A; 696 C; 746 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 8; Length 2848;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
QY 2121 CCTTTCCTTTACCACTCTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 2655 CCTTTTCCTTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACTA 2714
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 2715 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAA 2774
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
      ||
DB 2775 AA 2776
```

RESULT 958
ADL43698/c
ID ADL43698 standard; DNA; 228 BP.

XX ADL43698;

XX 20-MAY-2004 (first entry)

XX Human ovarian cancer DNA marker #17588.

XX Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.

XX Homo sapiens.

XX WO200170979-A2.

XX 27-SEP-2001.

XX 21-MAR-2001; 2001WO-US009126.

XX 21-MAR-2000; 2000US-0191031P.

XX 25-MAY-2000; 2000US-0207124P.

XX 15-JUN-2000; 2000US-0211940P.

XX 07-JUL-2000; 2000US-0216820P.

XX 25-JUL-2000; 2000US-0220661P.

XX 21-DEC-2000; 2000US-0257672P.

XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

XX Lee J, Lillie J;

XX WPI; 2001-611502/70.

XX Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
PT cancer cells as compared to their normal non-cancerous ovarian cells are
PT used to characterize stage, grade, histological type of ovarian cancer.

XX Disclosure; SEQ ID NO 17588; 106pp; English.

XX

CC The invention relates to nucleic acid markers which are overexpressed in
CC ovarian cancer cells as compared to their expression in normal (i.e. non-
CC cancerous) ovarian cells. The invention also relates to polypeptides
CC encoded by the markers, antibodies that selectively bind to the
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk
CC of developing ovarian cancer involving inhibiting expression of a gene
CC corresponding to a marker of the invention and a method of treating a
CC patient afflicted with ovarian cancer comprising providing to cells of
CC the patient an antisense oligonucleotide complementary to a marker of the
CC invention. The markers are useful for assessing if a patient is afflicted
CC with ovarian cancer, which involves comparing the level of expression of
CC a marker in a patient sample and a normal level of expression of the
CC expression levels indicates ovarian cancer. A difference between the
CC marker corresponds to a secreted protein or to a transcribed
CC polynucleotide or its portion. The level of expression of the marker is
CC assessed by detecting the presence in the sample, a protein or protein
CC fragment corresponding to the marker. The presence of protein or protein
CC fragment is detected using an antibody that specifically binds with the
CC protein or protein fragment. Alternatively, the level of expression of
CC the marker is assessed by detecting the presence of a transcribed
CC polynucleotide which anneals with the marker or anneals with a portion of
CC the polynucleotide comprising the marker, under stringent conditions. The
CC marker is also used for monitoring the progression of ovarian cancer in a
CC patient which involves detecting expression of the marker in a patient
CC sample at a first point in time, repeating the method at a subsequent
CC time and comparing the level of expression. The method is carried out
CC using an ovarian tissue sample. A composition comprising a marker,
CC polypeptide or antibody of the invention is used to treat ovarian cancer.
CC This sequence represents a human ovarian cancer DNA marker of the
CC invention.

SQ Sequence 228 BP; 55 A; 25 C; 31 G; 117 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.4; DB 5; Length 228;
Best Local Similarity 70.4%; Pred. No. 0.00012;
Matches 88; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

```
QY 2118 TCGCCTTTCCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCA 2177
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 228 TGGTGTTTTTTTATCTCTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 169
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2178 CTGNCCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA 2237
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 168 TAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 169
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2238 AAAAA 2242
      |||||
DB 108 AAAAA 104
```

RESULT 959
AAH82206/c

ID AAH82206 standard; DNA; 255 BP.

XX AAH82206;

XX 21-SEP-2001 (first entry)

XX Rat differential transcription-associated cDNA SEQ ID 715.

XX Differential transcription; human; rat; tumour cell; cytostatic;

XX Ras modulator; Class II tumour suppressor gene; gene therapy; ss.

XX Rattus sp.

XX WO200157058-A2.

XX 09-AUG-2001.

XX 31-JAN-2001; 2001WO-EP001003.

XX 31-JAN-2000; 2000DE-01004102.

XX


```

PR 18-JUL-2000; 2000US-0219007P.
PR 13-DEC-2000; 2000US-0255281P.
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX Schlegel R, Endege WO, Monahan JE;
XX WPI; 2001-662795/76.
XX Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer.
XX
PS Claim 1; Page 750; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for: (a) assessing whether
CC a patient is afflicted with prostate cancer; (b) monitoring the
CC progression of prostate cancer in a patient; (c) assessing the efficacy
CC of a test compound to inhibit prostate cancer in a patient; (d) assessing
CC the efficacy of a therapy for inhibiting prostate cancer in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)
CC determining whether prostate cancer has metastasized in a patient; (h)
CC assessing the aggressiveness or indolence of prostate cancer in a patient
CC ; (I) is also useful as a pharmacodynamic or pharmacogenomic marker
XX
SQ Sequence 300 BP; 125 A; 22 C; 19 G; 101 T; 0 U; 33 Other;
Query Match 3.0%; Score 66.4; DB 5; Length 300;
Best Local Similarity 67.7%; Pred. No. 0.00013;
Matches 88; Conservative 0; Mismatches 42; Indels 0; Gaps 0;
QY 2113 AATGATCGCTTGTCTTACACATCTTCTTTTATCTTATTAATAAAGTGTGCTC 2172
DB 145 AATTTTNTTTTNTTTTTCCTTTTAAATTTTNTTNTTTTAAATNAAATTTT 86
QY 2173 CACCACGTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2232
DB 85 TTTTTCNCNCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 26
QY 2233 AAAAAAATA 2242
DB 25 AAAAAAATA 16
RESULT 962
ACN49736/C
ID ACN49736 standard; cDNA; 489 BP.
XX ACN49736;
AC ACN49736;
XX 02-DEC-2004 (first entry)
DT 02-DEC-2004 (first entry)
XX Cotton primed seed EST Clone ID: LIB3825-026-Q6-N6-B11, SEQ:4517.
DE
XX Cotton; plant; EST; expressed sequence tag; transgenic plant; seed;
KW variety DP50B; library LIB3825; molecular tag; molecular marker;
KW genetic mapping; molecular mapping; seed germination; plant growth;
KW plant quality; plant yield; plant breeding; tissue printing; ss.
XX
XX Gossypium hirsutum.
XX
XX US2004123340-A1.
XX 24-JUN-2004.
XX 12-DEC-2001; 2001US-00021323.
XX 14-DEC-2000; 2000US-0255619P.
XX (DEIK/) DEIKMAN J.
PA

```

```

PA (FENG/) FENG P C C.
PA (FINC/) FINCHER K L.
PA (ZIEG/) ZIEGLER T E.
XX
XX Deikman J, Feng PCC, Fincher KL, Ziegler TE;
XX WPI; 2004-479808/45.
XX
XX New isolated nucleic acid molecule that encodes a plant protein or its
PT fragment, useful for isolating a variety of agronomically significant
PT genes associated with plant growth, quality or yield, and as molecular
PT tags to map genes.
XX
PS Claim 1; SEQ ID NO 4517; 34pp; English.
XX
CC The invention relates to 17880 cotton expressed sequence tags (ESTs;
CC ACN45220-ACN63099). The ESTs were isolated from cDNA libraries generated
CC from primed or non-primed seeds from variety DP50B, mature seeds from
CC variety Coker 312 Boswell 96 Field, and androecium tissue, gynoecium
CC tissue, developing fibres, carpel walls and septa from variety
CC Nucton33B. The invention also relates to substantially purified
CC proteins or their fragments encoded by nucleic acid molecules of the
CC invention, and to transformed plants having a nucleic acid construct
CC comprising a nucleic acid of the invention. The cotton ESTs are useful as
CC molecular tags to isolate genetic regions, to isolate genes, to map
CC genes, to determine gene function and to determining whether genes are
CC members of a particular gene family. The nucleic acid molecules may be
CC used for isolating a variety of agronomically significant genes
CC associated with plant growth, quality, yield, and could also serve as
CC links in metabolic and catabolic pathways. The nucleic acid molecules are
CC also useful for identifying genes important in initiating and maintaining
CC seed germination or that may be used to mitigate stresses encountered
CC during seed germination. The ESTs additionally enable the acquisition of
CC promoters and cis-regulatory elements which will be useful to express
CC agronomically significant genes in these tissues and/or other tissues,
CC and also permits the acquisition of molecular markers useful in breeding
CC schemes, genetic and molecular mapping, and in cloning of agronomically
CC significant genes. The nucleic acid molecules are further useful for
CC detecting the expression level or pattern of a protein or mRNA and for
CC detecting the presence or quantity of a protein by tissue printing. The
CC cotton variety DP50B primed seed cDNA library (LIB3825). The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format directly from the US patent office at
CC seqdata.uspto.gov/sequence.html?DocID=US20040123340
XX
SQ Sequence 489 BP; 234 A; 8 C; 81 G; 165 T; 0 U; 1 Other;
Query Match 3.0%; Score 66.4; DB 13; Length 489;
Best Local Similarity 61.3%; Pred. No. 0.00015;
Matches 106; Conservative 0; Mismatches 67; Indels 0; Gaps 0;
QY 2070 TTTCTAGTCCCAAGTGTCTGTGACATATATTCATTCATCATGATGCGCTTGTCTT 2129
DB 259 TTTCTTCCCACTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 200
QY 2130 TACCACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 2189
DB 199 TTATTTATTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 140
QY 2190 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
DB 139 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 87
RESULT 963
ABV39211/C
ID ABV39211 standard; cDNA; 522 BP.
XX ABV39211;
AC ABV39211;
XX 16-SEP-2002 (first entry)
DT
XX

```

DE Human prostate expression marker cDNA 39202.
XX Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW pharmacogenomic marker; gene; ss.
XX Homo sapiens.
OS
XX WO200160860-A2.
PN
XX 23-AUG-2001.
PD
XX 20-FEB-2001; 2001WO-US005171.
PF
XX 17-FEB-2000; 2000US-0183319P.
PR
XX 16-MAR-2000; 2000US-0189862P.
PR
XX 25-MAY-2000; 2000US-0207454P.
PR
XX 09-JUN-2000; 2000US-0211314P.
PR
XX 18-JUL-2000; 2000US-0219007P.
PR
XX 13-DEC-2000; 2000US-0255281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX Schlegel R, Endege WO, Monahan JE;
PI
XX WPI; 2001-662795/76.
DR
XX Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer.
PT
XX Claim 1; Page 7960; 11750pp; English.
PS
XX The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for: (a) assessing whether
CC a patient is afflicted with prostate cancer; (b) monitoring the
CC progression of prostate cancer in a patient; (c) assessing the efficacy
CC of a test compound to inhibit prostate cancer in a patient; (d) assessing
CC the efficacy of a therapy for inhibiting prostate cancer in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)
CC determining whether prostate cancer has metastasized in a patient; (h)
CC assessing the aggressiveness or indolence of prostate cancer in a patient
CC ; (i) is also useful as a pharmacodynamic or pharmacogenomic marker
XX
SQ Sequence 522 BP; 138 A; 92 C; 94 G; 198 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.4; DB 5; Length 522;
Best Local Similarity 61.3%; Pred. No. 0.00015;
Matches 106; Conservative 0; Mismatches 67; Indels 0; Gaps 0;
QY 2070 TTCTAGTCTCCTCAAGTCTGCTGACACATATATCATTCATCCATGATCGCTTTGCTT 2129
Db 305 TTTTAACTTTTAAAGGGTTTGTCTCGAGTAAATTTAAATAAAGGGCCCTTTT 246
QY 2130 TACCACCTTTCTCTTTTATTTATTAATAAATAATGTTGCTCTCCACCACTGCTCCCAA 2189
Db 245 AGCCCTTTTGGTTTCTCTGCGCAATAAATAATTTTCAAAAGGTTCTTCGGGAAAA 186
QY 2190 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2242
Db 185 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 133
RESULT 964
ACN47393
ID ACN47393 standard; cDNA; 550 BP.
XX
XX ACN47393;
XX
XX 02-DEC-2004 (first entry)
XX Cotton primed seed EST Clone ID: LIB3825-011-Q1-K6-A12, SEQ:2174.

XX Cotton; plant; EST; expressed sequence tag; transgenic plant; seed;
KW variety DP50B; library LIB3825; molecular tag; molecular marker;
KW genetic mapping; molecular mapping; seed germination; plant growth;
XX plant quality; plant yield; plant breeding; tissue printing; ss.
XX Gossypium hirsutum.
OS
XX US2004123340-A1.
PN
XX 24-JUN-2004.
PD
XX 12-DEC-2001; 2001US-00021323.
PF
XX 14-DEC-2000; 2000US-0255619P.
PR
XX (DEIK/) DEIKMAN J.
PA (FENG/) FENG P C C.
PA (FINC/) FINCHER K L.
PA (ZIEG/) ZIEGLER T E.
XX
XX Deikman J, Feng PCC, Fincher KL, Ziegler TE;
PI
XX WPI; 2004-479808/45.
DR
XX New isolated nucleic acid molecule that encodes a plant protein or its
PT fragment, useful for isolating a variety of agronomically significant
PT genes associated with plant growth, quality or yield, and as molecular
PT tags to map genes.
PT
XX Claim 1; SEQ ID NO 2174; 34pp; English.
PS
XX The invention relates to 17880 cotton expressed sequence tags (ESTs;
CC ACN45220-ACN63099). The ESTs were isolated from cDNA libraries generated
CC from primed or non-primed seeds from variety DP50B, mature seeds from
CC variety Coker 312 Boswell 96 Field, and androecium tissue, gynoeceum
CC tissue, developing fibres, carpel walls and septa from variety
CC Nucleon31B. The invention also relates to substantially purified
CC proteins or their fragments encoded by nucleic acid molecules of the
CC invention, and to transformed plants having a nucleic acid construct
CC comprising a nucleic acid of the invention. The cotton ESTs are useful as
CC molecular tags to isolate genetic regions, to isolate genes, to map
CC genes, to determine gene function and to determine whether genes are
CC members of a particular gene family. The nucleic acid molecules may be
CC used for isolating a variety of agronomically significant genes
CC associated with plant growth, quality, yield, and could also serve as
CC links in metabolic and catabolic pathways. The nucleic acid molecules are
CC also useful for identifying genes important in initiating and maintaining
CC seed germination or that may be used to mitigate stresses encountered
CC during seed germination. The ESTs additionally enable the acquisition of
CC promoters and cis-regulatory elements which will be useful to express
CC agronomically significant genes in these tissues and/or other tissues,
CC and also permits the acquisition of molecular markers useful in breeding
CC schemes, genetic and molecular mapping, and in cloning of agronomically
CC significant genes. The nucleic acid molecules are further useful for
CC detecting the expression level or pattern of a protein or mRNA and for
CC detecting the presence or quantity of a protein by tissue printing. The
CC present sequence represents a specifically claimed EST isolated from a
CC cotton variety DP50B primed seed cDNA library (LIB3825). The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format directly from the US patent office at
CC seqdata.uspto.gov/sequence.html?docID=US20040123340
XX
SQ Sequence 550 BP; 281 A; 88 C; 118 G; 63 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.4; DB 13; Length 550;
Best Local Similarity 62.4%; Pred. No. 0.00015;
Matches 103; Conservative 0; Mismatches 62; Indels 0; Gaps 0;
QY 2078 TCCTCAAGTCTGCTGACACATATATCATTCATCCATGATCGCTTTTACCCTC 2137
Db 4 TCTTCATATCTTAGTGTATAAATGATGCTGTGTAGTCATAGTTTGTGCAATAA 63

```
Qy 2138 TTTCCTTTTATCTATTATAAAAAATGTTGGTCTCCACCACTGCTCCAAAAA 2197
Db 64 AAAATCCTTCTCGAAAAA 123
Qy 2198 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 124 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 168

RESULT 965
AAL02457
ID AAL02457 standard; cDNA; 823 BP.
XX
AC AAL02457;
XX
DT 21-NOV-2001 (first entry)
XX
Human reproductive system related antigen cDNA SEQ ID NO: 2458.
XX
Human; reproductive system related antigen; reproductive system disorder;
cancer; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN W0200155320-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US0001339.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225477P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 14-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244517P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
```

PR	17-NOV-2000; 2000US-0249244P.	
PR	17-NOV-2000; 2000US-0249245P.	
PR	17-NOV-2000; 2000US-0249264P.	
PR	17-NOV-2000; 2000US-0249265P.	
PR	17-NOV-2000; 2000US-0249297P.	
PR	17-NOV-2000; 2000US-0249299P.	
PR	17-NOV-2000; 2000US-0249300P.	
PR	01-DEC-2000; 2000US-0250160P.	
PR	01-DEC-2000; 2000US-0250391P.	
PR	05-DEC-2000; 2000US-0251030P.	
PR	05-DEC-2000; 2000US-0251988P.	
PR	05-DEC-2000; 2000US-0256719P.	
PR	06-DEC-2000; 2000US-0251479P.	
PR	08-DEC-2000; 2000US-0251856P.	
PR	08-DEC-2000; 2000US-0251868P.	
PR	08-DEC-2000; 2000US-0251869P.	
PR	08-DEC-2000; 2000US-0251989P.	
PR	08-DEC-2000; 2000US-0251990P.	
PR	11-DEC-2000; 2000US-0254097P.	
PR	05-JAN-2001; 2001US-0255967P.	
XX		
XX	(HUMA-) HUMAN GENOME SCI INC.	
XX		
XX	Rosen CA, Barash SC, Ruben SM;	
PI		
XX	WPI; 2001-465570/50.	
DR	P-PSDB; AAM96487.	
XX		
PT	Isolated nucleic acid molecule encoding a reproductive system antigen is	
PT	used in preventing, treating or ameliorating a medical condition.	
XX		
PS	Claim 1; SEQ ID NO 2458; 1297pp + Sequence Listing; English.	
XX		
CC	The present invention provides the protein and coding sequences of a	
CC	number of human reproductive system related antigens. These can be used	
CC	in the prevention and treatment of reproductive system disorders,	
CC	including cancer. The present sequence is a coding sequence of the	
CC	c invention	
XX		
XX	Sequence 823 BP; 327 A; 147 C; 154 G; 195 T; 0 U; 0 Other;	
XX		
XX	Query Match 3.0%; Score 66.4; DB 4; Length 823;	
XX	Best Local Similarity 75.2%; Pred. NO. 0.00017;	
XX	Matches 82; Conservative 0; Mismatches 27; Indels 0; Gaps 0;	
QY	2134 ACTCTTCCCTTTATCTATTATTAATAAAATGTTGTGCTCCACCTGCTCCCAAAAAA 2193	
DB	689 ACTATACGTATATATTTTCTGAATAAAATATTTTCTTAAAAAATAAAAAA 748	
QY	2194 AA 2242	
DB	749 AA 797	
XX		
XX	RESULT 966	
XX	ABA07664	
ID	ABA07664 standard; cDNA; 823 BP.	
XX		
AC	ABA07664;	
XX		
XX	11-JAN-2002 (first entry)	
XX		
DE	Human ovarian and breast cancer associated polynucleotide SEQ ID NO 221.	
XX		
KW	Cytostatic; immunosuppressive; nontropic; neuroprotective; antiviral;	
KW	antiallergic; hepatotropic; antidiabetic; antinflammatory; antifungal;	
KW	vulnerable; anticonvulsant; antibacterial; antifungal; antiparasitic;	
KW	cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;	
KW	neurological disease; infection; human; secreted protein; ss.	
XX		
XX	Homo sapiens.	
XX		
PN	WO200155325-A2.	

PA (DFRA/) DI FRANCESCO V.
XX Beasley EM, Ketchum KA, Di Francesco V;
XX WPI; 2003-165811/16.
XX P-PSDB; ABG73827.
XX Novel human enzyme protein related to transferase enzyme subfamily and
PT nucleic acid molecule encoding the protein for diagnosing, treating
PT disease or condition mediated by enzyme protein and for identifying
PT modulators.
XX Claim 4; Fig 1; 132pp; English.
XX The invention relates to an isolated human enzyme peptide belonging to
CC the transferase enzyme subfamily. The polypeptide is useful for
CC identifying a modulator of the expression of the peptide, identifying an
CC agent that binds to the peptide, to identify the peptides binding
CC partner/ligand, in competition binding assays. The enzyme-modulating
CC agents are useful in an animal or other model to determine the efficacy,
CC toxicity, mechanism of action or side effects of treatment with such an
CC agent. The enzyme proteins also provide a target for diagnosing a disease
CC or predisposition to a disease mediated by the peptide, in
CC pharmacogenomic analysis and for treating disorders characterised by an
CC absence or inappropriate, or unwanted expression of the protein. A
CC pharmacological composition containing an agent identified from the peptide
CC is useful for treating a disease or condition mediated by a human enzyme
CC protein. The peptide and its corresponding nucleic acid are useful as
CC models for the development of human therapeutic targets, aid in the
CC identification of therapeutic proteins and serve as targets for the
CC development of human therapeutic agents that modulate enzyme activity in
CC cells and tissues that express the enzyme, as a query sequence to perform
CC a search against sequence databases to identify other family members or
CC related sequences. The nucleic acid is useful designing ribozymes,
CC constructing transgenic animals, for monitoring the effectiveness of
CC modulating compounds on the expression or activity of the enzyme gene in
CC clinical trials or in a treatment regimen, in diagnostic assays for
CC qualitative change in enzyme nucleic acid expression and for testing an
CC individual for a genotype. A host cell expressing the peptide is useful
CC for producing a enzyme protein or peptide, conducting cell-based assays
CC involving the enzyme protein, identifying enzyme protein mutants and to
CC produce non-human transgenic animals which are useful for studying the
CC function of a enzyme protein and identifying and evaluating modulators of
CC enzyme protein activity. The present sequence represents cDNA encoding a
CC human transferase which may be an alternative splice form of human
CC tyrosylprotein sulphotransferase 1
XX
XX Sequence 1781 BP; 571 A; 366 C; 408 G; 436 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.4; DB 8; Length 1781;
Best Local Similarity 81.7%; Pred. No. 0.00022;
Matches 76; Conservative 0; Mismatches 17; Indels 0; Gaps 0;
QY 2150 TTATTAATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2209
Db 1661 TTTGAATAAAATGTTGAGGACCTCTCTGTTCTTAA 1720
QY 2210 AAAAAA 2242
Db 1721 AAAAAA 1753
RESULT 968
AAD47901
ID AAD47901 standard; cDNA; 1781 BP.
XX
XX AAD47901;
XX
XX 12-FEB-2004 (first entry)
XX Human transferase-related enzyme encoding cDNA.
XX Human; gene; transferase; tyrosylprotein sulphotransferase; chromosome 7;

KW therapeutic; drug target; inflammatory disorder; haemological disorder;
KW single nucleotide polymorphism; SNP; ss.
OS Homo sapiens.
FH Key Location/Qualifiers
FT 5'UTR 1..240
FT CDS /tag= a
FT 241..1371
FT /tag= b
FT /product= "Transferase-related enzyme"
FT 1372..1781
FT /tag= c
XX
XX US2003138837-A1.
XX 24-JUL-2003.
XX 30-JAN-2003; 2003US-00354065.
XX 28-MAR-2001; 2001US-00818512.
XX (APPL-) APPLERA CORP.
XX Beasley EM, Ketchum KA, Di Francesco V;
XX WPI; 2003-851726/79.
XX P-PSDB; ABW01917.
XX New isolated human enzyme proteins, useful for developing therapeutic or
PT diagnostic compositions, particularly for developing modulators of
PT transferase enzyme activity in cells or tissues.
XX Claim 4; SEQ ID NO 1; 135pp; English.
XX The present invention relates to human enzyme and gene related to
CC transferases in general, specifically sulforanase and tyrosylprotein
CC sulforanase in particular. The transferase-related gene of the
CC invention is located on human chromosome 7. The enzyme and nucleic acid
CC molecules of the invention are useful in the development of human
CC therapeutics and diagnostic compositions. These molecules serve as
CC potential targets for the development of therapeutics to treat disorders
CC associated with transferases (e.g. inflammatory or haemological
CC disorders). The single nucleotide polymorphisms (SNPs) identified in the
CC gene are valuable markers for the diagnosis, prognosis, prevention and/or
CC treatment of the disorders. The enzyme is also useful for raising
CC antibodies or eliciting an immune response; as a reagent in assays
CC designed to quantitatively determine levels of the protein (or its
CC binding partner or ligand) in biological fluids; and as markers for
CC tissues in which the corresponding protein is preferentially expressed.
XX The present sequence is human transferase-related enzyme encoding cDNA
XX Sequence 1781 BP; 571 A; 366 C; 408 G; 436 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.4; DB 10; Length 1781;
Best Local Similarity 81.7%; Pred. No. 0.00022;
Matches 76; Conservative 0; Mismatches 17; Indels 0; Gaps 0;
QY 2150 TTATTAATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2209
Db 1661 TTTGAATAAAATGTTGAGGACCTCTCTGTTCTTAA 1720
QY 2210 AAAAAA 2242
Db 1721 AAAAAA 1753
RESULT 969
ADI62940
ID ADI62940 standard; cDNA; 1874 BP.
XX
XX ADI62940;
XX

DT 29-JAN-2004 (first entry)
 XX Human structural and cytoskeleton-associated protein (SCAP) gene #10.
 XX human; structural and cytoskeleton-associated protein; SCAP;
 KW arteriosclerosis; atherosclerosis; cirrhosis; hepatitis; myelofibrosis;
 KW psoriasis; cancer; pneumonia; chronic bronchitis; yellow fever;
 KW influenza; measles; mumps; HIV; human T lymphotropic virus; rabies;
 KW gastroenteritis; encephalitis; rubella; epilepsy;
 KW ischaemic cerebrovascular disease; stroke; cerebral neoplasms;
 KW Alzheimer's disease; Pick's disease; Huntington's disease; dementia;
 KW Parkinson's disease; amyotrophic lateral sclerosis; atrophy;
 KW hereditary ataxia; multiple sclerosis; meningitis; brain abscess;
 KW prion disease; Creutzfeldt-Jakob disease; insomnia; neurofibromatosis;
 KW cerebral palsy; myasthenia gravis; anxiety; gene; ds.
 .XX
 OS Homo sapiens.
 XX
 XX WO2003062391-A2.
 XX
 XX 31-JUL-2003.
 XX
 XX 16-JAN-2003; 2003WO-US001772.
 XX
 XX 18-JAN-2002; 2002US-0350702P.
 XX 25-JAN-2002; 2002US-0351715P.
 XX 15-FEB-2002; 2002US-0357402P.
 XX 10-MAY-2002; 2002US-0379880P.
 XX 17-MAY-2002; 2002US-0381599P.
 XX 07-JUN-2002; 2002US-0387270P.
 XX 19-JUL-2002; 2002US-0397125P.
 XX (INCY-) INCYTE GENOMICS INC.
 XX
 XX Yue H, Griffin JA, Richardson TW, Tang YT, Thangavelu K;
 PI Forsythe IJ, Becha SD, Chawla NK, Hafalia AJA, Swarnakar A;
 PI Marquiza JP, Gorvad AE, Baughn MR, Lu DAM, Arvizu CS, Kable AE;
 PI Lee SY, Ramkumar J, Jiang X, Jackson AA, Khare R, Elliott VS;
 PI Bulloch SA, Xu Y, Lee S, Lehr-Mason PM;
 XX
 XX WPI; 2003-671468/63.
 DR P-PSDB; ADE15631.
 XX
 XX New isolated polypeptides useful for treating e.g. cell proliferative
 PT disorders, viral infections and neurological disorders.
 PT
 XX
 XX Claim 5; SEQ ID NO 41; 357pp; English.
 PS
 XX The invention comprises the amino acid and coding sequences of human
 CC structural and cytoskeleton-associated proteins (SCAP). The SCAP DNA and
 CC protein sequences of the invention are useful for the diagnosis and
 CC treatment of: arteriosclerosis, atherosclerosis, cirrhosis, hepatitis,
 CC myelofibrosis, psoriasis, primary cancer, pneumonia, chronic bronchitis,
 CC yellow fever, influenza, measles, mumps, HIV, human T lymphotropic virus,
 CC rabies, gastroenteritis, encephalitis, rubella, epilepsy, ischaemic
 CC cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease,
 CC Pick's disease, Huntington's disease, dementia, Parkinson's disease,
 CC amyotrophic lateral sclerosis, atrophy, hereditary ataxias, multiple
 CC sclerosis, meningitis, brain abscess, prion disease, Creutzfeldt-Jakob
 CC disease, insomnia, neurofibromatosis, cerebral palsy, myasthenia gravis,
 CC anxiety. The present DNA sequence encodes a human SCAP of the invention.
 XX
 SQ Sequence 4816 BP; 1464 A; 1040 C; 1188 G; 1124 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.4; DB 10; Length 4816;
 Best Local Similarity 66.7%; Pred. NO. 0.0003;
 Matches 94; Conservative 0; Mismatches 47; Indels 0; Gaps 0;
 QY 2102 TCATTCCATCAATGATCGCTTTGCTTTTACCACTCTTTCTTTTATCTTATTAATAAA 2161
 Db 4396 TCCTCCAGGCAAGTTGGCAAACTGTGGCCCCCACTGTCTCATATTTGTTTAAATAAA 4455
 QY 2162 ATGTTGGTCTCCCACTGNCCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAA 2221

Db 4456 TTTTATTGGACACAAAAAATAAAAAAAAAAAAAAAAAAAAAA 4515
 QY 2222 AAAAAAATAAAAAAAAAAAAAA 2242
 Db 4516 AAAAAAATAAAAAAAAAAAAAA 4536
 RESULT 972
 AAL20476/C
 ID AAL20476 standard; cDNA; 379 BP.
 AC AAL20476;
 XX 07-DEC-2001 (first entry)
 XX Human breast cancer expressed polynucleotide 12933.
 XX Human; breast cancer; cell marker; cytostatic; ss.
 XX Homo sapiens.
 XX WO200151628-A2.
 XX 19-JUL-2001.
 XX 10-JAN-2001; 2001WO-US000798.
 XX 14-JAN-2000; 2000US-0176077P.
 XX 14-MAR-2000; 2000US-0189167P.
 XX 24-MAR-2000; 2000US-0192099P.
 XX 29-MAR-2000; 2000US-0193480P.
 XX 15-MAY-2000; 2000US-0205230P.
 XX 09-JUN-2000; 2000US-0211315P.
 XX 25-JUL-2000; 2000US-0220534P.
 XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
 XX Lillie J, Xu Y, Wang Y, Steinmann K;
 XX WPI; 2001-451856/48.
 XX New peptide useful as a marker for the diagnosis of breast cancer.
 PT
 XX Claim 1; Page 2290; 3695pp; English.
 PS
 XX The invention relates to human breast cancer expressed polynucleotides
 CC (AAL07544-AAL26789) and methods of assessing whether a patient is
 CC afflicted with breast cancer by examining the correlation between the
 CC expression of certain markers and the cancerous state of breast cells.
 CC The polynucleotides and encoded polypeptides are potential markers for
 CC detecting, diagnosing, monitoring, characterising treating and
 CC potentially preventing breast cancer. The polynucleotides and encoded
 CC polypeptides are also useful for isolating compounds with cytostatic
 CC activity
 XX
 SQ Sequence 379 BP; 82 A; 107 C; 39 G; 151 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.2; DB 4; Length 379;
 Best Local Similarity 71.7%; Pred. NO. 0.00015;
 Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
 QY 2123 TTTCGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTGNC 2182
 Db 212 TTTTCTTTTAACTCCCTTTCTTTTATTAATAAAATATATATAATAA 153
 QY 2183 TCCCAAAAAAATAAAAAAAAAAAAAAATAAAAAAAAAAAAAA 2242
 Db 152 AAAAAAATAAAAAAAAAAAAAAATAAAAAAAAAAAAAA 93
 RESULT 973
 AAI89390

CC sample at a first point in time, repeating the method at a subsequent
CC time and comparing the level of expression. The method is carried out
CC using an ovarian tissue sample. A composition comprising a marker,
CC polypeptide or antibody of the invention is used to treat ovarian cancer.
CC This sequence represents a human ovarian cancer DNA marker of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 476 BP; 146 A; 13 C; 38 G; 184 T; 0 U; 95 Other;

Query Match 3.0%; Score 66.2; DB 5; Length 476;
Best Local Similarity 50.4%; Pred. No. 0.00016;
Matches 114; Conservative 0; Mismatches 112; Indels 0; Gaps 0;
QY 2017 TTTTGGATATCTCCACCTTGCAATTTGATGGCATAATCACTCCGGTTGCTTTCTAG 2076
DB 302 TTTTATTAANAACCCANNNTTATNTTTTTTTTTTATNCANTTAATTTTATAAA 243
QY 2077 GTCTCAAGTGCTCGTGACACATAATCATCTCCATCCCAATGATCGCTTTCCTTACCCT 2136
DB 242 AAATNTTGNNTGNNCCCNCTTTTTTTTTTTTNNCNTAAANNNTTTTTTTTTT 183
QY 2137 CTTTCCTTTTATCTTATTAATAAAATGTTGGTCCACCCTGCTCCCAAAAAAAA 2196
DB 182 TAATNNANTTTTNTAATTTNNAANTTTTTTTTTTTTNNAAANTTNNAANAANA 123
QY 2197 AAAAAA 2242
DB 122 AAAAAA 77

RESULT 977
ADI17958/c
ID ADI17958 standard; DNA; 476 BP.
XX
AC ADI17958;
DT 20-MAY-2004 (first entry)
XX
DE Human ovarian cancer DNA marker #4700.
XX
KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.
XX
OS Homo sapiens.
XX
PN WO200170979-A2.
XX
PD 27-SEP-2001.
XX
PF 21-MAR-2001; 2001WO-US009126.
XX
PR 21-MAR-2000; 2000US-0191031P.
PR 25-MAY-2000; 2000US-0207124P.
PR 15-JUN-2000; 2000US-0211940P.
PR 07-JUL-2000; 2000US-0216820P.
PR 26-JUL-2000; 2000US-0220661P.
PR 21-DEC-2000; 2000US-0257672P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Lee J, Lillie J;
XX
WIPI; 2001-611502/70.
XX
PT Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
PT cancer cells as compared to their normal non-cancerous ovarian cells are
PT used to characterize stage, grade, histological type of ovarian cancer.
XX
PS Disclosure; SEQ ID NO 4700; 106pp; English.
XX
CC The invention relates to nucleic acid markers which are overexpressed in
CC ovarian cancer cells as compared to their expression in normal (i.e. non-

CC cancerous) ovarian cells. The invention also relates to polypeptides
CC encoded by the markers, antibodies that selectively bind to the
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk
CC of developing ovarian cancer involving inhibiting expression of a gene
CC corresponding to a marker of the invention and a method of treating a
CC patient afflicted with ovarian cancer comprising providing to cells of
CC the patient an antisense oligonucleotide complementary to a marker of the
CC invention. The markers are useful for assessing if a patient is afflicted
CC with ovarian cancer, which involves comparing the level of expression of
CC a marker in a patient sample and a normal level of expression of the
CC marker in a control non-ovarian cancer sample. A difference between the
CC expression levels indicates ovarian cancer. The level of expression of a
CC marker corresponds to a secreted protein or to a transcribed
CC polynucleotide or its portion. The level of expression of the marker is
CC assessed by detecting the presence in the sample, a protein or protein
CC fragment corresponding to the marker. The presence of protein or protein
CC fragment is detected using an antibody that specifically binds with the
CC protein or protein fragment. Alternatively, the level of expression of
CC the marker is assessed by detecting the presence of a transcribed
CC polynucleotide which anneals with the marker or anneals with a portion of
CC the polynucleotide comprising the marker, under stringent conditions. The
CC marker is also used for monitoring the progression of ovarian cancer in a
CC patient which involves detecting expression of the marker in a patient
CC sample at a first point in time, repeating the method at a subsequent
CC time and comparing the level of expression. The method is carried out
CC using an ovarian tissue sample. A composition comprising a marker,
CC polypeptide or antibody of the invention is used to treat ovarian cancer.
CC This sequence represents a human ovarian cancer DNA marker of the
CC invention.
XX
SQ Sequence 476 BP; 146 A; 13 C; 38 G; 184 T; 0 U; 95 Other;

Query Match 3.0%; Score 66.2; DB 5; Length 476;
Best Local Similarity 50.4%; Pred. No. 0.00016;
Matches 114; Conservative 0; Mismatches 112; Indels 0; Gaps 0;
QY 2017 TTTTGGATATCTCCACCTTGCAATTTGATGGCATAATCACTCCGGTTGCTTTCTAG 2076
DB 302 TTTTATTAANAACCCANNNTTATNTTTTTTTTTTATNCANTTAATTTTATAAA 243
QY 2077 GTCTCAAGTGCTCGTGACACATAATCATCTCCATCCCAATGATCGCTTTCCTTACCCT 2136
DB 242 AAATNTTGNNTGNNCCCNCTTTTTTTTTTTTNNCNTAAANNNTTTTTTTTTT 183
QY 2137 CTTTCCTTTTATCTTATTAATAAAATGTTGGTCCACCCTGCTCCCAAAAAAAA 2196
DB 182 TAATNNANTTTTNTAATTTNNAANTTTTTTTTTTTTNNAAANTTNNAANAANA 123
QY 2197 AAAAAA 2242
DB 122 AAAAAA 77

RESULT 978
ACN46735/c
ID ACN46735 standard; cDNA; 486 BP.
XX
AC ACN46735;
XX
DT 02-DEC-2004 (first entry)
XX
DE Cotton primed seed EST Clone ID: LIB3825-003-Q1-N6-E5, SEQ:1516.
XX
KW Cotton; plant; EST; expressed sequence tag; transgenic plant; seed;
KW variety DP50B; library LIB3825; molecular tag; molecular marker;
KW genetic mapping; molecular mapping; seed germination; plant growth;
KW plant quality; plant yield; plant breeding; tissue printing; ss.
OS Gossypium hirsutum.
XX
PN US2004123340-A1.
XX
PD 24-JUN-2004.


```

PD 27-SEP-2001.
XX
XX
XX PF 21-MAR-2001; 2001WO-US009126.
XX
XX
XX PR 21-MAR-2000; 2000US-0191031P.
XX
XX PR 25-MAY-2000; 2000US-0207124P.
XX
XX PR 15-JUN-2000; 2000US-0211940P.
XX
XX PR 07-JUL-2000; 2000US-0216820P.
XX
XX PR 25-JUL-2000; 2000US-0220661P.
XX
XX PR 21-DEC-2000; 2000US-0257672P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX PA Lee J, Lillie J;
XX
XX DR WPI; 2001-611502/70.
XX
XX
XX PT Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
XX PT cancer cells as compared to their normal non-cancerous ovarian cells are
XX PT used to characterize stage, grade, histological type of ovarian cancer.
XX
XX PS Disclosure; SEQ ID NO 11024; 106pp; English.
XX
XX
XX CC The invention relates to nucleic acid markers which are overexpressed in
XX CC ovarian cancer cells as compared to their expression in normal (i.e. non-
XX CC cancerous) ovarian cells. The invention also relates to polypeptides
XX CC encoded by the markers, antibodies that selectively bind to the
XX CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk
XX CC of developing ovarian cancer involving inhibiting expression of a gene
XX CC corresponding to a marker of the invention and a method of treating a
XX CC patient afflicted with ovarian cancer comprising providing to cells of
XX CC the patient an antisense oligonucleotide complementary to a marker of the
XX CC invention. The markers are useful for assessing if a patient is afflicted
XX CC with ovarian cancer, which involves comparing the level of expression of
XX CC a marker in a patient sample and a normal level of expression of the
XX CC marker in a control non-ovarian cancer sample. A difference between the
XX CC expression levels indicates ovarian cancer. The level of expression of a
XX CC marker corresponds to a secreted protein or to a transcribed
XX CC polynucleotide or its portion. The level of expression of the marker is
XX CC assessed by detecting the presence in the sample, a protein or protein
XX CC fragment corresponding to the marker. The presence of protein or protein
XX CC fragment is detected using an antibody that specifically binds with the
XX CC protein or protein fragment. Alternatively, the level of expression of
XX CC the marker is assessed by detecting the presence of a transcribed
XX CC polynucleotide which anneals with the marker or anneals with a portion of
XX CC the polynucleotide comprising the marker, under stringent conditions. The
XX CC marker is also used for monitoring the progression of ovarian cancer in a
XX CC patient which involves detecting expression of the marker in a patient
XX CC sample at a first point in time, repeating the method at a subsequent
XX CC time and comparing the level of expression. The method is carried out
XX CC using an ovarian tissue sample. A composition comprising a marker,
XX CC polypeptide or antibody of the invention is used to treat ovarian cancer.
XX CC This sequence represents a human ovarian cancer DNA marker of the
XX CC invention.
XX
XX SQ Sequence 723 BP; 229 A; 56 C; 74 G; 251 T; 0 U; 113 Other;
XX
XX
XX Query Match 3.0%; Score 66.2; DB 5; Length 723;
XX Best Local Similarity 69.2%; Pred. No. 0.00018;
XX Matches 83; Conservative 0; Mismatches 37; Indels 0; Gaps 0;
XX
XX Qy 2123 TTGGCTTTACCACTCTTTCCCTTTATCTATTATAAAATGTTGGTCTCCACCACCTGNC 2182
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 181 TTTTITTTCCNCNGTNTTNTTAAATTTTNNAAAAAATNTTTTTTTTTTTAA 122
XX
XX Qy 2183 TCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 121 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 62
XX
XX
XX RESULT 986
XX ADL38237/c
XX ID ADL38237 standard; DNA; 810 BP.

```

Query Match 3.0%; Score 66.2; DB 5; Length 810;

CC	the polynucleotide comprising the marker, under stringent conditions. The	
CC	marker is also used for monitoring the progression of ovarian cancer in a	
CC	patient which involves detecting expression of the marker in a patient	
CC	sample at a first point in time, repeating the method at a subsequent	
CC	time and comparing the level of expression. The method is carried out	
CC	using an ovarian tissue sample. A composition comprising a marker,	
CC	polypeptide or antibody of the invention is used to treat ovarian cancer.	
CC	This sequence represents a human ovarian cancer DNA marker of the	
CC	invention.	
XX		
SQ	Sequence 810 BP; 225 A; 35 C; 137 G; 283 T; 0 U; 130 Other;	
	Query Match 3.0%; Score 66.2; DB 5; Length 810;	
	Best Local Similarity 77.0%; Pred. No. 0.00019;	
	Matches 77; Conservative 0; Mismatches 23; Indels 0; Gaps 0;	
QY	2143 TTTTATCTTATTATATAAATGTGTGCTCCACCACTGCTCCAAAAA 2202	
DB	184 TTTTATCTTATTATATAAATGTGTGCTCCACCACTGCTCCAAAAA 125	
QY	2203 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242	
DB	124 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 85	
RESULT 988		
ACN84830/C	ACN84830 standard; DNA; 874 BP.	
XX	ACN84830;	
XX	02-DEC-2004 (first entry)	
XX	Breast cancer related marker, seq id 5980.	
DE	Cancer; breast; tumour; cytostatic; marker; detection; therapy; ds.	
KW	Homo sapiens.	
OS	US2003099974-A1.	
XX	29-MAY-2003.	
XX	18-JUL-2002; 2002US-00198846.	
PF	18-JUL-2001; 2001US-0306220P.	
PR	(MILL-) MILLENNIUM PHARM INC.	
XX	Lillie J, Xu Y, Wang Y, Steinmann K;	
XX	WPI; 2003-787014/74.	
XX	Novel isolated polypeptide associated with breast cancer, useful for	
PT	detecting presence of polypeptide in sample, as a marker for breast	
PT	cancer.	
PT	Disclosure; SEQ ID NO 5980; 36pp; English.	
XX	The invention relates to an isolated polypeptide (I) associated with a	
XX	breast cancer which is encoded by a nucleic acid molecule comprising a	
CC	nucleotide sequence (S). Further disclosed is an antibody that binds to	
CC	the polypeptide of the invention. The activity of the polypeptide of the	
CC	invention may be described as cytostatic. The antibody is useful for	
CC	detecting the presence of (I) in a sample. Nucleic acid molecules of the	
CC	invention are useful in the detection of breast tumours. (I) is useful as	
CC	a marker for breast cancer and in breast cancer therapy. Sequences given	
CC	in records ACN78851-ACN92934 represent nucleic acid markers associated	
CC	with breast cancer. Note: The sequence listing does not form part of the	
CC	specification but may be obtained in electronic format from the USPTO web	
CC	site at seqdata.uspto.gov/sequence.html?DocID=20030099974	
XX	Sequence 874 BP; 205 A; 153 C; 103 G; 257 T; 0 U; 156 Other;	

CC thyroiditis), reproductive system disorders (e.g. premenstrual syndrome, CC polycystic ovary syndrome), infectious diseases caused by bacteria, CC fungal, viral, parasitic, protozoal, and/or blood-related disorders and CC infections, leukopaenia, leukaemias, arthritis, asthma, autoimmune CC diseases, rheumatoid arthritis, immune deficiency, psoriasis, CC haemophilia, diabetes mellitus, allergies, and bone cancers, Paget's CC disease, gout, osteoporosis, arrhythmia, angina, prostate cancer, renal CC disorders, urolithiasis, Alzheimer's disease, Parkinson's disease, CC schizophrenia, attention deficit disorder, obsessive compulsive CC pneumonia, obesity, goiter, ulcerative colitis, hepatitis. They are also CC useful for stimulating epithelial cell proliferation and basal CC keratinocytes for wound healing, and to stimulate hair follicle CC production and healing of dermal wounds

XX SQ	Sequence 878 BP; 262 A; 213 C; 132 G; 271 T; 0 U; 0 Other;
	Query Match 3.0%; Score 66.2; DB 8; Length 878; Best Local Similarity 76.9%; Pred. No. 0.0002; Matches 80; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY	2139 TTCCCTTTTATCTATTATAAAAAAATGTGCTTCACCACTGCNCTCCAAAAAAAAAAAAAA 2198
Db	· 772 TGCCCTTTTCCTTTTTTCAGAAAATGGTTTTCCTCGTTTGTAATAAAAAAAAAAAAAAA 831

[illegible]

KW	human; PRO; immune related disease; inflammatory immune response;
KW	immune response stimulation; anti allergic; anti anaemic; anti arthritic;
KW	anti diarrhetic; anti diabetic; anti inflammatory; anti psoriatic;
KW	anti rheumatic; antithyroid; CNS; dermatological; gastrointestinal;
KW	haemostatic; hepatotropic; immunostimulant; immunosuppressive; muscular;
KW	nephrotropic; neuroprotective; osteopathic; respiratory; vasotropic;
KW	virucide; Gene therapy; Gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO2004039956-A2.
XX	
PD	13-MAY-2004.

28-OCT-2003; 2003WO-US034381.
29-OCT-2002; 2002US-0422472P.
(GETH) GENENTECH INC

XX Aggarwal S, Clark H, Gurney AL, Schoenfeld J, Williams PM;
PI Wood WI, Wu TD;
XX WPI; 2004-376182/35.
DR P-PSDB: ADP55851.

XX New PRO polynucleotides and polypeptides, useful in diagnosing
XX and treating an immune related disease, e.g. systemic lupus
XX erythematosus, rheumatoid arthritis, diabetes mellitus or asthma and in
XX stimulating an immune response.
XX
XX Claim 2; SEQ ID NO 1826; 3009pp; English.
XX
XX The present invention describes an isolated PRO nucleic acid (I). Also
XX
XX

described: (1) a vector comprising (1); (2) a host cell comprising the vector of (1); (3) a process for producing a PRO polypeptides; (4) an isolated PRO polypeptide; (5) a chimeric molecule comprising the polypeptide of (4) fused to a heterologous amino acid sequence; (6) an antibody which specifically binds to a polypeptide of (4); (7) a composition of matter comprising a polypeptide of (4), an agonist or antagonist of the polypeptide or an antibody that binds to the polypeptide in combination with a carrier; (8) an article of manufacture comprising a container, a label on the container and a composition of matter of (7); (9) a method of treating an immune related disease in a mammal; (10) a method for determining the presence of a PRO polypeptide in a sample suspected of having the polypeptide; (11) a method of diagnosing an immune related disease or an inflammatory immune response in a mammal; (12) a method of identifying a compound that inhibits or mimics the activity of or expression of a gene encoding a PRO polypeptide; and (13) a method of stimulating the immune response in a mammal. The PRO sequences have anti-allergic, anti-nausea, anti-arthritis, anti-rheumatic, antidiabetic, anti-inflammatory, antipsoriatic, antihemostatic, antithyroid, CNS, dermatological, gastrointestinal, haemostatic, hepatotropic, immunostimulant, immunosuppressive, muscular, nephrotropic, neuroprotective, osteopathic, respiratory, vasotropic and virucide activities, and can be used in gene therapy. The nucleic acid (1) and the encoded polypeptides, compositions, kits and methods are useful in diagnosing and treating an immune related disease and in stimulating an immune response. The present sequence represents a human PRO nucleotide sequence from the present invention.

Sequence 1153 BP; 374 A; 218 C; 239 G; 322 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 13; Length 1153;
Best Local Similarity 71.7%; Pred. No. 0.00021;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 2123 TTGCTTTACACCTCTTCCTTTATCTTATTAATAAAATGTGGTCTCCACCACTGNC 2182
DB 1033 TTTGTTTGGCTATGATTCATTTTTTTTACTTAAAAATAAAACCTATACCAACAGTAGT 1092
QY 2183 TCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
DB 1093 GTGCCAAGTAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1152

RESULT 991

AAF81788

ID AAF81788 standard; cDNA; 1315 BP.

XX AAF81788;

12-JUN-2001 (first entry)

Human secreted protein gene 2 SEQ ID NO:12.

Human; secreted protein; diagnosis; immunomodulatory; antisclerotic; dermatological; immunosuppressive; anti-inflammatory; anti-HIV; immunostimulant; cytoskeletal; cardiant; vascular; anti-angiogenic; ophthalmological; neuroprotectant; neurotropic; anticonvulsant; vaccine; antialzheimer; antiparkinsonian; antimicrobial; vulnery; gene therapy; immune disorder; hyperproliferative disorder; cardiovascular disease; cancer; angiogenic disorder; neurological disorder; infectious disease; wound healing; regeneration; chemotaxis; ss.

Homo sapiens.

WO200112775-A2.

22-FEB-2001.

16-AUG-2000; 2000WO-US023325.

17-AUG-1999; 99US-0149182P.

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Ni J, Florence KA, Fiscella M, Wei P, Baker KP;
Birze CE, Young PE, Komatsoulis GA, Moore PA, Soppat DR;
WPI; 2001-147550/15.
P-PSDB; AAB74734.

Nucleic acids encoding 25 human secreted polypeptides, useful for preventing, diagnosing and/or treating e.g. cancers, Parkinson's disease and diabetic retinopathy.

Claim 1; Page 441-442; 485pp; English.

AAF81787 to AAF81817 encode the human secreted proteins given in AAB74733 to AAB74772. Human secreted proteins can have activities based on the tissues and cells they are expressed in. Example of activities include: immunomodulatory; antisclerotic; dermatological; immunosuppressive; anti-inflammatory; anti-HIV; immunostimulant; cytoskeletal; cardiant; anti-angiogenic; ophthalmological; neuroprotectant; neurotropic; anticonvulsant; antialzheimer; antiparkinsonian; antimicrobial; and vulnery. Human secreted proteins can be used in gene therapy and vaccine. Human secreted protein nucleotide sequences (NAMI) and proteins (PEPI) may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate polypeptide expression. For example, NAMI and PEPI may be used to treat disorders associated with decreased expression by rectifying mutations or deletions in a patients genome that affect the activity of proteins by expressing inactive proteins or to supplement the patients own production of polypeptides. Disorders that may be prevented, diagnosed and/or treated include immune disorders, hyperproliferative disorders (e.g. cancers), cardiovascular diseases, angiogenic disorders, neurological disorders, infectious diseases and/or for promoting wound healing, regeneration and /or chemotaxis. AAF81778 to AAF81786 and AAB74732 represent sequences used in the exemplification of the present invention

Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 4; Length 1315;
Best Local Similarity 84.1%; Pred. No. 0.00022;
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 2155 AATAAAATGTGGTCTCCACCACTGNCCTCCAAAAAATAAAAAAATAAAAAA 2214
DB 1200 AATAAAATGAAAGTAGTCTCTCAAAAAAATAAAAAAATAAAAAAATAAAAAA 1259
QY 2215 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
DB 1260 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1287

RESULT 992

ADA40552

ID ADA40552 standard; cDNA; 1315 BP.

XX ADA40552;

20-NOV-2003 (first entry)

Human secreted protein encoding cDNA.

Human; secreted protein; cancer; hyperproliferative disorder; rheumatoid arthritis; autoimmune disorder; haematopoietic disorder; anaemia; allergic reaction; asthma; cardiovascular disorder; wound healing; cytoskeletal; immunosuppressive; neurotropic; neuroprotective; antiallergic; hepatotropic; antidiabetic; anti-inflammatory; vulnery; cardiant; gene therapy; ss.

Homo sapiens.

WO2002102993-A2.

27-DEC-2002.

19-MAR-2002; 2002WO-US008123.

XX 21-MAR-2001; 2001US-0277340P.
 PR 19-JUL-2001; 2001US-0306171P.
 PR 13-NOV-2001; 2001US-0331287P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Rosen CA, Ruben SM;
 XX WPI; 2003-175238/17.
 DR New human secreted proteins and nucleic acid molecules, useful for
 XX preparing a diagnostic or pharmaceutical composition for diagnosing,
 PT preventing or treating cancer or other hyperproliferative disorder,
 PT asthma, allergies or AIDS.
 XX Claim 9; SEQ ID NO 934; 3205pp; English.
 PS The invention relates to novel genes ADA39629-ADA40565 and proteins
 XX ADA40566-ADA41501 for human secreted proteins, useful for preventing,
 CC treating or ameliorating medical conditions e.g. by protein or gene
 CC therapy. The polypeptides, nucleic acid molecules, antibodies or their
 CC fragments, and agonists or antagonists that bind to the polypeptide are
 CC useful for preparing a diagnostic or pharmaceutical composition for
 CC diagnosing or treating cancer or other hyperproliferative disorder. The
 CC polypeptides and nucleic acid molecules are also useful for detecting,
 CC preventing, diagnosing, prognosticating, treating or ameliorating cancer
 CC or other hyperproliferative disorders including neoplasms, autoimmune
 CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus
 CC erythematosus, multiple sclerosis, autoimmune thyroiditis or haemolytic
 CC anaemia), haematopoietic or haematological disorders (e.g. anaemia,
 CC thrombocytopenia), allergic reactions including asthma or eczema,
 CC inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory
 CC bowel disease or Crohn's disease), neurodegenerative disorders (e.g.
 CC Alzheimer's disease or Parkinson's disease), cardiovascular disorders
 CC (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial,
 CC fungal or viral infections including HIV/AIDS), or wound healing and
 CC disorders of epithelial cell proliferation. The nucleic acids are also
 CC useful for chromosome identification, radiation hybrid mapping or long-
 CC range restriction mapping, as molecular weight markers, or as
 CC hybridization or diagnostic probes. The polypeptides and antibodies are
 CC useful for providing immunological probes for differential identification
 CC of the tissues immunohistochemistry assays. Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;
 SQ Query Match 3.0%; Score 66.2; DB 8; Length 1315;
 Best Local Similarity 84.1%; Pred. No. 0.00022;
 Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
 Qy 2155 AATAAAATGTGGTCTCCACACTGCTCCCAAAAAAAAAAAAAAAAAAAAAA 2214
 Db 1200 AATAAAATGAAAGTATCTCTCTCAAAAAAAAAAAAAAAAAAAAAA 1259
 Qy 2215 AAAAAAAAAAAAAAAAAAAAAA 2242
 Db 1260 AAAAAAAAAAAAAAAAAAAAAA 1287
 RESULT 993
 ACC50854
 ID ACC50854 standard; cDNA; 1315 BP.
 XX ACC50854;
 XX 12-JUN-2003 (first entry)
 DT Human secreted protein coding sequence, SEQ ID 521.
 DE Cardiant; antiarrhythmic; antiarteriosclerotic; vasotrophic; cytostatic;
 KW

KW vulnery; antiinflammatory; nootropic; neuroprotective;
 KW antiparkinsonian; gene therapy; human; cardiovascular disorder; gene; ss.
 XX Homo sapiens.
 OS WO200295010-A2.
 FN 28-NOV-2002.
 XX 19-MAR-2002; 2002WO-US009785.
 PF 21-MAR-2001; 2001US-0277340P.
 PR 19-JUL-2001; 2001US-0306171P.
 PR 13-NOV-2001; 2001US-0331287P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Rosen CA, Ruben SM;
 XX WPI; 2003-129429/12.
 DR Novel human secreted proteins, useful for detecting, preventing,
 PT diagnosing, prognosticating, treating and/or ameliorating cardiovascular
 PT disorders such as arrhythmia.
 XX Claim 21; SEQ ID NO 521; 1881pp; English.
 PS The present invention relates to novel human secreted proteins (ABR47633-
 CC ABR48145) and their coding sequences (ACC50344-ACC50856). The proteins
 CC or their coding sequences are useful for the preparation of a diagnostic
 CC or pharmaceutical composition for diagnosing or treating a cardiovascular
 CC disorder (e.g., arrhythmia, tachycardia, cardiac arrest, coronary
 CC arteriosclerosis and myocardial ischaemia), neural disorders, immune
 CC system disorders, muscular disorders, reproductive disorders,
 CC gastrointestinal disorders, pulmonary disorders, renal disorders,
 CC proliferative disorders and/or cancerous diseases and conditions, for
 CC wound healing and epithelial cell proliferation, to treat inflammation or
 CC infection, for treating thrombosis and arteriosclerosis, for treating or
 CC preventing neural damage which occurs in neuronal disorders or
 CC neurodegenerative conditions such as Alzheimer's disease and Parkinson's
 CC disease, to enhance bone and periodontal regeneration and aid in tissue
 CC transplants or bone grafts, to prevent skin aging or hair loss, to
 CC stimulate growth and differentiation of haematopoietic cells and bone
 CC marrow cells when used in combination with other cytokines, to maintain
 CC organs before transplantation or for supporting cell culture of primary
 CC tissues, to increase or decrease differentiation or proliferation of
 CC embryonic stem cells, or to modulate mammalian characteristics or
 CC metabolism. Note: The sequence data for this patent was published in
 CC electronic format and is available from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;
 SQ Query Match 3.0%; Score 66.2; DB 8; Length 1315;
 Best Local Similarity 84.1%; Pred. No. 0.00022;
 Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
 Qy 2155 AATAAAATGTGGTCTCCACACTGCTCCCAAAAAAAAAAAAAAAAAAAAAA 2214
 Db 1200 AATAAAATGAAAGTATCTCTCTCAAAAAAAAAAAAAAAAAAAAAA 1259
 Qy 2215 AAAAAAAAAAAAAAAAAAAAAA 2242
 Db 1260 AAAAAAAAAAAAAAAAAAAAAA 1287
 RESULT 994
 ADCT3986
 ID ADCT3986 standard; DNA; 1315 BP.
 XX ADCT3986;
 XX 01-JAN-2004 (first entry)
 DT

```

XX DE Human secreted protein-related DNA - SEQ ID 619.
XX DE
XX DE antianaemic; antirheumatic; antiarthritic; antiinflammatory; antithyroid;
XX DE antidiabetic; immunosuppressive; dermatological; nephrotropic;
XX DE antiparkinsonian; neuroprotective; nootropic; antibacterial; virucide;
XX DE fungicide; antiparasitic; antiarteriosclerotic; vulnerary; cytostatic;
XX DE haemopoietic; haematologic; anaemia; autoimmune disorder;
XX DE rheumatoid arthritis; inflammation; Grave's disease; diabetes;
XX DE systemic lupus erythematosus; glomerulonephritis; neurodegenerative;
XX DE Parkinson's; Alzheimer's; wound; hyperproliferative; atherosclerosis;
XX DE cancer; bacterial; viral; fungal; parasitic infection; gene therapy;
XX DE human; gene; ds.
XX OS Homo sapiens.
XX PN WO2003038063-A2.
XX PD 08-MAY-2003.
XX PF 19-MAR-2002; 2002WO-US008277.
XX PR 21-MAR-2001; 2001US-0277340P.
XX PR 19-JUL-2001; 2001US-0306171P.
XX PR 13-NOV-2001; 2001US-0331287P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Rosen CA, Ruben SM;
XX PI WPI; 2003-430516/40.
XX DR P-PSDB; ADC74601.
XX PT New human secreted polypeptide for diagnosing, preventing or treating
XX PT hemopoietic or hematologic disorders (e.g. anemia), autoimmune
XX PT disorders (e.g. diabetes) or hyperproliferative disorders (e.g. cancer or
XX PT atherosclerosis).
XX PS Claim 27; SEQ ID NO 619; 2272pp; English.
XX CC The invention relates to a novel human secreted polypeptide comprising a
XX CC defined sequence given in the specification. The polypeptide, nucleic
XX CC acid molecule, antibody, agonist or antagonist of the invention may be
XX CC useful for preparing a composition for diagnosing or treating a
XX CC hemopoietic or haematologic disorder such as anaemia, autoimmune
XX CC disorders such as rheumatoid arthritis, inflammation, Grave's disease,
XX CC diabetes, systemic lupus erythematosus or glomerulonephritis,
XX CC neurodegenerative disorders including Parkinson's disease and Alzheimer's
XX CC disease, wounds and hyperproliferative disorders including
XX CC atherosclerosis or cancer, as well as bacterial, viral, fungal or
XX CC parasitic infections. The polypeptide may also be used during gene
XX CC therapy procedures and for identifying a binding partner by contacting
XX CC the polypeptide with a binding partner and determining whether the
XX CC binding partner increases or decreases the activity of the polypeptide.
XX CC The current sequence is that of the human secreted protein-related DNA of
XX CC the invention.
XX SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.2; DB 10; Length 1315;
Best Local Similarity 84.1%; Pred. No. 0.00022;
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
QY 2155 AATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAA 2214
DB 1200 AATAAAATGAAGTATCTCTCAAAAAAAAAAAAAAAAAAAAAA 1259
QY 2215 AAAAAAAAAAAAAAAAAAAAAA 2242
DB 1260 AAAAAAAAAAAAAAAAAAAAAA 1287
RESULT 995

```

```

ADD37810
ID ADD37810 standard; cDNA; 1315 BP.
XX AC ADD37810;
XX DT 15-JAN-2004 (first entry)
XX DE Human secreted protein encoding sequence #292.
XX KW human secreted protein; Antiallergic; Antiinflammatory; Antibacterial;
XX KW Anti-HIV; Cytostatic; Immunosuppressive; Hemostatic; ss.
XX OS Homo sapiens.
XX PN WO200290526-A2.
XX PD 14-NOV-2002.
XX PF 19-MAR-2002; 2002WO-US008279.
XX PR 21-MAR-2001; 2001US-0277340P.
XX PR 19-JUL-2001; 2001US-0306171P.
XX PR 13-NOV-2001; 2001US-0331287P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Rosen CA, Ruben SM;
XX PI WPI; 2003-140218/13.
XX PT New human secreted proteins and nucleic acid molecules, useful for
XX PT preparing a diagnostic or pharmaceutical composition for diagnosing or
XX PT treating allergic or asthmatic disorders, or related immediate
XX PT hypersensitivity disorders.
XX PS Claim 7; SEQ ID NO 292; 1323pp; English.
XX CC The present invention relates to an isolated polypeptide or human
XX CC secreted protein. The polypeptides, nucleic acid molecules, antibodies or
XX CC their fragments, and agonists or antagonists that bind are useful for
XX CC preparing a diagnostic or pharmaceutical composition for diagnosing or
XX CC treating allergic or asthmatic disorders. The polypeptide is also useful
XX CC for identifying a binding partner by contacting the polypeptide with a
XX CC binding partner, and determining whether the binding partner increases or
XX CC decreases the activity of the polypeptide. The polypeptides and nucleic
XX CC acid molecules are also useful for detecting, preventing, diagnosing,
XX CC prognosticating, treating or ameliorating inflammatory disorders
XX CC neoplastic diseases, wound healing and disorders of epithelial cell
XX CC proliferation, immune disorders, cardiovascular disorders, blood-related
XX CC disorders, infectious diseases, endocrine disorders, or gastrointestinal
XX CC disorders. The nucleic acids are also useful for chromosome
XX CC identification, radiation hybrid mapping or long-range restriction
XX CC mapping, as molecular weight markers, or as hybridization or diagnostic
XX CC probes. The polypeptides and antibodies are useful for providing
XX CC immunological probes for differential identification of the tissues
XX CC immunohistochemistry assays. The present sequence represents a human
XX CC secreted protein encoding sequence.
XX SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.2; DB 10; Length 1315;
Best Local Similarity 84.1%; Pred. No. 0.00022;
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
QY 2155 AATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAA 2214
DB 1200 AATAAAATGAAGTATCTCTCAAAAAAAAAAAAAAAAAAAAAA 1259
QY 2215 AAAAAAAAAAAAAAAAAAAAAA 2242
DB 1260 AAAAAAAAAAAAAAAAAAAAAA 1287

```


RESULT 996
ADA56701
ID ADA56701 standard; DNA; 1315 BP.
XX
AC ADA56701;
XX
DT 20-NOV-2003 (first entry)
XX
DE Gene encoding human secreted protein #574.
XX
KW immunosuppressive; antiinflammatory; antiasthmatic; antiallergic;
KW cytosatic; cerebroprotective; neuroprotective; nootropic;
KW cardiovascular; antiarteriosclerotic; gene therapy;
KW human secreted protein; immune disorder; inflammation;
KW respiratory disease; cancer; CNS disorder; neurodegenerative disorders;
KW inflammatory bowel disease; nephritis; Crohn's disease; asthma; allergy;
KW multiple sclerosis; ischaemic brain injury; Parkinson's disease;
KW Alzheimer's disease; atherosclerosis; myocarditis; chromosome mapping;
KW triple helix formation; antisense gene therapy; forensic biology; ds;
KW gene.
XX
OS Homo sapiens.
XX
PN WO2002102994-A2.
XX
PD 27-DEC-2002.
XX
PF 19-MAR-2002; 2002WO-US008278.
XX
PR 21-MAR-2001; 2001US-0277340P.
PR 19-JUL-2001; 2001US-0306171P.
PR 13-NOV-2001; 2001US-0331287P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
WPI; 2003-167512/16.
DR P-PSDB; ADA57594.
XX
PT New human secreted polypeptides and polynucleotides, useful for
PT diagnosing, treating or preventing e.g. immune disorders, inflammatory
PT conditions, respiratory disorders, cancers, CNS disorders, or
PT neurodegenerative disorders.
XX
PS Claim 21; SEQ ID NO 890; 1754pp; English.
XX
CC The invention relates to 592 new human secreted polypeptides useful for
CC diagnosing, treating or preventing e.g. immune disorders, inflammatory
CC conditions, respiratory disorders, cancers, CNS disorders, or
CC neurodegenerative disorders, or polypeptides comprising an amino acid
CC sequence at least 95% identical to the new sequences. The polypeptides,
CC antibodies or antibody fragments that bind to the polypeptides, nucleic
CC acids encoding the polypeptides, agonists or antagonists that binds to
CC the polypeptide, are useful in preparing diagnostic or pharmaceutical
CC compositions for diagnosing, treating or preventing an e.g. immune
CC disorders, inflammatory conditions (e.g. inflammatory bowel disease,
CC nephritis or Crohn's disease), respiratory disorders (e.g. asthma and
CC allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders
CC (e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative
CC disorders (e.g. Parkinson's disease or Alzheimer's disease), and
CC cardiovascular disorders (e.g. atherosclerosis or myocarditis). The
CC polynucleotides are useful for chromosome identification, chromosome
CC mapping, for controlling gene expression through triple helix formation
CC from minusc biological samples, in forensic biology, and as hybridization
CC probes. The polypeptides are useful for as molecular weight markers on
CC sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
CC gels, to raise antibodies, for testing biological activities, and for
CC treating or preventing neural disorders, immune system disorders,
CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
CC renal, proliferative and/or cancerous diseases. This sequence corresponds
CC to a gene encoding one of the polypeptide of the invention. Note: The

CC sequence data for this patent did form part of the printed specification,
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 U; 0 Other;
XX
Query Match 3.0%; Score 66.2; DB 10; Length 1315;
Best Local Similarity 84.1%; Pred. NO. 0.00022;
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
XX
QY 2155 AATAAATGTTGCTCTCCACCACTGNTCCCAAAAAAAAAAAAAAAAAAAAAA 2214
Db 1200 AATAAATGTTGCTCTCTCCACCACTGNTCCCAAAAAAAAAAAAAAAAAAAAAA 1259
QY 2215 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 1260 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1287
XX
RESULT 997
ADA40234
ID ADA40234 standard; cDNA; 1317 BP.
XX
AC ADA40234;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted protein encoding cDNA.
XX
KW Human; secreted protein; cancer; hyperproliferative disorder;
KW rheumatoid arthritis; autoimmune disorder; haematopoietic disorder;
KW anaemia; allergic reaction; asthma; cardiovascular disorder;
KW wound healing; cytostatic; immunosuppressive; nootropic; neuroprotective;
KW antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory;
KW vulnery; cardiant; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN WO2002102993-A2.
XX
PD 27-DEC-2002.
XX
PF 19-MAR-2002; 2002WO-US008123.
XX
PR 21-MAR-2001; 2001US-0277340P.
PR 19-JUL-2001; 2001US-0306171P.
PR 13-NOV-2001; 2001US-0331287P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
WPI; 2003-175238/17.
XX
PT New human secreted proteins and nucleic acid molecules, useful for
PT preparing a diagnostic or pharmaceutical composition for diagnosing,
PT preventing or treating cancer or other hyperproliferative disorder,
PT asthma, allergies or AIDS.
XX
PS Claim 9; SEQ ID NO 616; 3205pp; English.
XX
CC The invention relates to novel genes ADA39629-ADA40565 and proteins
CC ADA40566-ADA41501 for human secreted proteins, useful for preventing,
CC treating or ameliorating medical conditions e.g. by protein or gene
CC therapy. The polypeptides, nucleic acid molecules, antibodies or their
CC fragments, and agonists or antagonists that bind to the polypeptide are
CC useful for preparing a diagnostic or pharmaceutical composition for
CC diagnosing or treating cancer or other hyperproliferative disorder. The
CC polypeptides and nucleic acid molecules are also useful for detecting,
CC preventing, diagnosing, prognosticating, treating or ameliorating cancer
CC or other hyperproliferative disorders including neoplasms, autoimmune
CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus
CC erythematosus, multiple sclerosis, autoimmune thyroiditis or haemolytic

anaemia), haematopoietic or haematological disorders (e.g. anaemia, thrombocytopenia), allergic reactions including asthma or eczema, inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory bowel disease or Crohn's disease), neurodegenerative disorders (e.g. Alzheimer's disease or Parkinson's disease), cardiovascular disorders (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial, fungal or viral infections including HIV/AIDS), or wound healing and disorders of epithelial cell proliferation. The nucleic acids are also useful for chromosome identification, radiation hybrid mapping or long-range restriction mapping, as molecular weight markers, or as hybridization or diagnostic probes. The polypeptides and antibodies are useful for providing immunological probes for differential identification of the tissues immunohistochemistry assays. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.

Sequence 1317 BP; 419 A; 331 C; 290 G; 277 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 8; Length 1317;
Best Local Similarity 84.1%; Pred. No. 0.00022;
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 2155 AATAAAATGTTGCTCTCCACCACTGCTCCAAAAA 2214
Db 1202 AATAAAATGAAGTATCTCTCAAAAAA 1261

QY 2215 AAAAAA 2242
Db 1262 AAAAAA 1289

RESULT 998
ACC50674
ID ACC50674 standard; cDNA; 1317 BP.
AC ACC50674;
XX
XX 12-JUN-2003 (first entry)
XX Human secreted protein coding sequence, SEQ ID 341.
XX
XX Cardiant; antiarrhythmic; antiarteriosclerotic; vasotropic; cytostatic;
XX vulary; antiinflammatory; nootropic; neuroprotective;
XX antiparkinsonian; gene therapy; human; cardiovascular disorder; gene; ss.
XX
XX Homo sapiens.
XX WO200295010-A2.
XX
XX 28-NOV-2002.
XX
XX 19-MAR-2002; 2002WO-US009785.
XX
XX 21-MAR-2001; 2001US-0277340P.
XX PR 19-JUL-2001; 2001US-0306171P.
XX PR 13-NOV-2001; 2001US-0331287P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Ruben SM;
XX
XX WPI; 2003-129429/12.
XX
XX Novel human secreted proteins, useful for detecting, preventing,
XX PT diagnosing, prognosticating, treating and/or ameliorating cardiovascular
XX PT disorders such as arrhythmia.
XX
XX Claim 21; SEQ ID NO 341; 1881bp; English.
XX
XX The present invention relates to novel human secreted proteins (ABR47633-
XX ABR48145) and their coding sequences (ACC50344-ACC50956). The proteins
XX and their coding sequences are useful for the preparation of a diagnostic

or pharmaceutical composition for diagnosing or treating a cardiovascular disorder (e.g., arrhythmia, tachycardia, cardiac arrest, coronary arteriosclerosis and myocardial ischaemia), neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, renal disorders, for proliferative disorders and/or cancerous diseases and conditions, for wound healing and epithelial cell proliferation, to treat inflammation or infection, for treating thrombosis and arteriosclerosis, for treating or preventing neural damage which occurs in neuronal disorders or neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease, to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts, to prevent skin aging or hair loss, to stimulate growth and differentiation of haematopoietic cells and bone marrow cells when used in combination with other cytokines, to maintain organs before transplantation or for supporting cell culture of primary tissues, to increase or decrease differentiation or proliferation of embryonic stem cells, or to modulate mammalian characteristics or metabolism. Note: The sequence data for this patent was published in electronic format and is available from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 1317 BP; 419 A; 331 C; 290 G; 277 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.2; DB 8; Length 1317;
Best Local Similarity 84.1%; Pred. No. 0.00022;
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 2155 AATAAAATGTTGCTCTCCACCACTGCTCCAAAAA 2214
Db 1202 AATAAAATGAAGTATCTCTCAAAAAA 1261

QY 2215 AAAAAA 2242
Db 1262 AAAAAA 1289

RESULT 999
ADC73758
ID ADC73758 standard; DNA; 1317 BP.
XX
XX ADC73758;
XX
XX 01-JAN-2004 (first entry)
XX Human secreted protein-related DNA - SEQ ID 391.
XX
XX antianaemic; antirheumatic; antiarthritic; antiinflammatory; antithyroid;
XX antidiabetic; immunosuppressive; dermatologic; nephrotropic;
XX antiparkinsonian; neuroprotective; nootropic; antibacterial; virucide;
XX fungicide; antiparasitic; antiarteriosclerotic; vulnerary; cytostatic;
XX haemopoietic; haematologic; anaemia; autoimmune disorder;
XX rheumatoid arthritis; inflammation; Grave's disease; diabetes;
XX systemic lupus erythematosus; glomerulonephritis; neurodegenerative;
XX Parkinson's; Alzheimer's; wound; hyperproliferative; atherosclerosis;
XX cancer; bacterial; viral; fungal; parasitic infection; gene therapy;
XX human; gene; ds.
XX
XX Homo sapiens.
XX WO2003038063-A2.
XX
XX 08-MAY-2003.
XX
XX 19-MAR-2002; 2002WO-US008277.
XX
XX 21-MAR-2001; 2001US-0277340P.
XX PR 19-JUL-2001; 2001US-0306171P.
XX PR 13-NOV-2001; 2001US-0331287P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Ruben SM;
XX
XX

DR WPI: 2003-430516/40.
 XX P-PSDB; ADC74373.
 XX
 PT New human secreted polypeptide for diagnosing, preventing or treating
 PT hematopoietic or hematologic disorders (e.g. anemia), autoimmune
 PT disorders (e.g. diabetes) or hyperproliferative disorders (e.g. cancer or
 PT atherosclerosis).
 XX
 XX Claim 27; SEQ ID NO 391; 2272pp; English.
 XX
 CC The invention relates to a novel human secreted polypeptide comprising a
 CC defined sequence given in the specification. The polypeptide, nucleic
 CC acid molecule, antibody, agonist or antagonist of the invention may be
 CC useful for preparing a composition for diagnosing or treating a
 CC haemopoietic or haematologic disorder such as anaemia, autoimmune
 CC disorders such as rheumatoid arthritis, inflammation, Grave's disease,
 CC diabetes, systemic lupus erythematosus or glomerulonephritis,
 CC neurodegenerative disorders including Parkinson's disease and Alzheimer's
 CC disease, wounds and hyperproliferative disorders including
 CC atherosclerosis or cancer, as well as bacterial, viral, fungal or
 CC parasitic infections. The polypeptide may also be used during gene
 CC therapy procedures and for identifying a binding partner by contacting
 CC the polypeptide with a binding partner and determining whether the
 CC binding partner increases or decreases the activity of the polypeptide.
 CC The current sequence is that of the human secreted protein-related DNA of
 CC the invention.
 XX
 SQ Sequence 1317 BP; 419 A; 331 C; 290 G; 277 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.2; DB 10; Length 1317;
 Best Local Similarity 84.1%; Pred. No. 0.00022;
 Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
 QY 2155 AATAAAATGTTGGTCTCCACCTGCTCCCAAAAAA 2242
 DB 1202 AATAAAATGAAGTATCTCTCAAAAAA 1261
 QY 2215 AAAAAA 2242
 DB 1262 AAAAAA 1289
 RESULT 1000
 ADD37713
 ID ADD37713 standard; cDNA; 1317 BP.
 XX
 AC ADD37713;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human secreted protein encoding sequence #195.
 XX
 KW human secreted protein; Antiallergic; Antiinflammatory; Antibacterial;
 KW Anti-HIV; Cytostatic; Immunosuppressive; Hemostatic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200290526-A2.
 XX
 PD 14-NOV-2002.
 XX
 PF 19-MAR-2002; 2002WO-US008279.
 XX
 PR 21-MAR-2001; 2001US-0277340P.
 PR 19-JUL-2001; 2001US-030617P.
 PR 13-NOV-2001; 2001US-0331287P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Ruben SM;
 XX
 DR WPI: 2003-140218/13.
 XX

PT New human secreted proteins and nucleic acid molecules, useful for
 PT preparing a diagnostic or pharmaceutical composition for diagnosing or
 PT treating allergic or asthmatic disorders, or related immediate
 XX hypersensitivity disorders.
 PS Claim 7; SEQ ID NO 195; 1323pp; English.
 XX
 CC The present invention relates to an isolated polypeptide or human
 CC secreted protein. The polypeptides, nucleic acid molecules, antibodies or
 CC their fragments, and agonists or antagonists that bind are useful for
 CC preparing a diagnostic or pharmaceutical composition for diagnosing or
 CC treating allergic or asthmatic disorders. The polypeptide is also useful
 CC for identifying a binding partner by contacting the polypeptide with a
 CC binding partner, and determining whether the binding partner increases or
 CC decreases the activity of the polypeptide. The polypeptides and nucleic
 CC acid molecules are also useful for detecting, preventing, diagnosing,
 CC prognosticating, treating or ameliorating inflammatory disorders
 CC neoplastic diseases, wound healing and disorders of epithelial cell
 CC proliferation, immune disorders, cardiovascular disorders, blood-related
 CC disorders, infectious diseases, endocrine disorders, or gastrointestinal
 CC disorders. The nucleic acids are also useful for chromosome
 CC identification, radiation hybrid mapping or long-range restriction
 CC mapping, as molecular weight markers, or as hybridization or diagnostic
 CC probes. The polypeptides and antibodies are useful for providing
 CC immunological probes for differential identification of the tissues
 CC immunohistochemistry assays. The present sequence represents a human
 CC secreted protein encoding sequence.
 XX
 SQ Sequence 1317 BP; 419 A; 331 C; 290 G; 277 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.2; DB 10; Length 1317;
 Best Local Similarity 84.1%; Pred. No. 0.00022;
 Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
 QY 2155 AATAAAATGTTGGTCTCCACCTGCTCCCAAAAAA 2214
 DB 1202 AATAAAATGAAGTATCTCTCAAAAAA 1261
 QY 2215 AAAAAA 2242
 DB 1262 AAAAAA 1289
 RESULT 1001
 ADA56395
 ID ADA56395 standard; DNA; 1317 BP.
 XX
 AC ADA56395;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Gene encoding human secreted protein #574.
 XX
 KW immunosuppressive; antiinflammatory; antiasthmatic; antiallergic;
 KW cytostatic; cerebrotective; neuroprotective; nootropic;
 KW cardiovascular; antiarteriosclerotic; gene therapy;
 KW human secreted protein; immune disorder; inflammation;
 KW respiratory disorder; cancer; CNS disorder; neurodegenerative disorders;
 KW inflammatory bowel disease; nephritis; Crohn's disease; asthma; allergy;
 KW multiple sclerosis; ischaemic brain injury; Parkinson's disease;
 KW Alzheimer's disease; atherosclerosis; myocarditis; chromosome mapping;
 KW triple helix formation; antisense gene therapy; forensic biology; ds;
 KW gene.
 XX
 OS Homo sapiens.
 XX
 PN WO2002102994-A2.
 XX
 PD 27-DEC-2002.
 XX
 PR 19-MAR-2002; 2002WO-US008278.
 PR 21-MAR-2001; 2001US-0277340P.
 XX

```
PR 19-JUL-2001; 2001US-0306171P.
PR 13-NOV-2001; 2001US-0331287P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Ruben SM;
XX WPI; 2003-167512/16.
XX P-PSDB; ADA57291.
XX New human secreted polypeptides and polynucleotides, useful for
PT diagnosing, treating or preventing e.g. immune disorders, inflammatory
PT conditions, respiratory disorders, cancers, CNS disorders, or
PT neurodegenerative disorders.
XX Claim 21; SEQ ID NO 584; 1754pp; English.
XX The invention relates to 592 new human secreted polypeptides useful for
CC diagnosing, treating or preventing e.g. immune disorders, inflammatory
CC conditions, respiratory disorders, cancers, CNS disorders, or
CC neurodegenerative disorders, or polypeptides comprising an amino acid
CC sequence at least 95% identical to the new sequences. The polypeptides,
CC antibodies or antibody fragments that bind to the polypeptides, nucleic
CC acids encoding the polypeptides, agonists or antagonists that binds to
CC the polypeptide, are useful in preparing diagnostic or pharmaceutical
CC compositions for diagnosing, treating or preventing an e.g. immune
CC disorders, inflammatory conditions (e.g. inflammatory bowel disease,
CC nephritis or Crohn's disease), respiratory disorders (e.g. asthma and
CC allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders
CC (e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative
CC disorders (e.g. Parkinson's disease or Alzheimer's disease), and
CC cardiovascular disorders (e.g. atherosclerosis or myocarditis). The
CC polynucleotides are useful for chromosome identification, chromosome
CC mapping, for controlling gene expression through triple helix formation
CC or antisense DNA or RNA, in gene therapy, for identifying individuals
CC from minute biological samples, in forensic biology, and as hybridization
CC probes. The polypeptides are useful for as molecular weight markers on
CC sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
CC gels, to raise antibodies, for testing biological activities, and for
CC treating or preventing neural disorders, immune system disorders,
CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
CC renal, proliferative and/or cancerous diseases. This sequence corresponds
CC to a gene encoding one of the polypeptide of the invention. Note: The
CC sequence data for this patent did form part of the printed specification,
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 1317 BP; 419 A; 331 C; 290 G; 277 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.2; DB 10; Length 1317;
Best Local Similarity 84.1%; Pred. No. 0.00022;
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
QY 2155 AATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAA 2214
Db 1202 AATAAAATGAAGTAGTCTCTCTCAAAAAAAAAAAAAAAAAAAAAA 1261
QY 2215 AAAAAAAAAAAAAAAAAAAAAA 2242
Db 1262 AAAAAAAAAAAAAAAAAAAAAA 1289
RESULT 1002
AAC98225
ID AAC98225 standard; cDNA; 1321 BP.
XX AAC98225;
XX 09-MAR-2001 (first entry)
XX Human colon cancer antigen nucleotide sequence SEQ ID NO:235.
XX Human; colon cancer; colon cancer antigen; diagnosis; detection;
```

```
KW identification; cytostatic; cardioactive; neuroprotective; vulnery;
KW immunomodulatory; muscular; gynaecological; gastrointestinal;
KW nephrotropic; anti-infective; antibacterial; gene therapy; wound;
KW neural disorder; immune system disorder; muscular disorder;
KW reproductive disorder; gastrointestinal disorder; renal disorder;
KW infectious disease; cardiovascular disorder; ss.
XX Homo sapiens.
XX WO200055351-A1.
XX 21-SEP-2000.
XX 08-MAR-2000; 2000WO-US005883.
XX 12-MAR-1999; 99US-0124270P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Ruben SM;
XX WPI; 2000-587534/55.
XX P-PSDB; AAB53468.
XX Colon cancer associated gene sequences, referred to as colon cancer
PT antigens, useful for the treatment, prevention, and diagnosis of colon
PT disorders such as colon cancer.
XX Claim 1; Page 656-657; 2104pp; English.
XX AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC vulnery, nephrotropic, anti-infective and antibacterial activities, and
CC can be used in gene therapy. The colon cancer antigen polynucleotides,
CC proteins and antibodies to the proteins are useful for the prevention,
CC treatment and diagnosis of colon disorders, such as colon cancer. The
CC polynucleotides may be used in diagnostics and research, such as for
CC chromosome identification, and as hybridisation probes. The proteins may
CC also be used to prevent diseases such as neural disorders, immune system
CC disorders, muscular disorders, reproductive disorders, gastrointestinal
CC disorders, wounds, renal disorders, infectious diseases, and
CC cardiovascular disorders. AAC98764 to AAC98772 and AAB54007 represent
CC sequences used in the exemplification of the present invention
XX SQ Sequence 1321 BP; 420 A; 326 C; 296 G; 276 T; 0 U; 3 Other;
Query Match 3.0%; Score 66.2; DB 3; Length 1321;
Best Local Similarity 84.1%; Pred. No. 0.00022;
Matches 74; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
QY 2155 AATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAA 2214
Db 1195 AATAAAATGAAGTAGTCTCTCTCAAAAAAAAAAAAAAAAAAAAAA 1254
QY 2215 AAAAAAAAAAAAAAAAAAAAAA 2242
Db 1255 AAAAAAAAAAAAAAAAAAAAAA 1282
RESULT 1003
ADI42582
ID ADI42582 standard; DNA; 1337 BP.
XX ADI42582;
XX 22-APR-2004 (first entry)
XX Plant transcription factor polynucleotide #671.
XX transgenic; plant; enhanced tolerance to abiotic stress;
KW glyophosphate tolerance; hormone sensitivity; disease resistance;
```

KW sugar sensing; flowering; flower structure; stem bifurcation;
 KW branching pattern; apical dominance; trichome; stem morphology;
 KW root growth; root hair; seed development; cell proliferation;
 KW cell differentiation; premature senescence; necrosis; plant size;
 KW leaf morphology; seed morphology; seed biochemistry; root anthocyanin;
 KW plant anthocyanin; light response; shade avoidance; bioinformatic;
 KW transcription factor; gene; ds.
 XX
 OS Glycine max.
 XX
 PN US2004019927-A1.
 XX
 PD 29-JAN-2004.
 XX
 XX 25-FEB-2003; 2003US-00374780.
 PF
 XX 18-APR-2001; 2001US-00837944.
 PR
 XX (SHER/) SHERMAN B K.
 PA (RIEC/) RIECHMANN J L.
 PA (JIAN/) JIANG C.
 PA (HEAR/) HEARD J E.
 PA (HAKE/) HAAKE V.
 PA (CREE/) CREELMAN R A.
 PA (RATC/) RATCLIFFE O.
 PA (ADAM/) ADAM L J.
 PA (REUB/) REUBER T L.
 PA (KEDD/) KEDDIE J.
 PA (BROU/) BROUN P E.
 PA (PILG/) PILGRIM M L.
 PA (DUBE/) DUBELL A N.
 PA (PINE/) PINEDA O.
 PA (YUGG/) YU G.
 XX
 PI Sherman BK, Riechmann JL, Jiang C, Heard JE, Haake V;
 PI Creelman RA, Ratcliffe O, Adam LJ, Reuber TL, Keddie J, Broun PE;
 PI Pilgrim ML, Dubell AN, Pineda O, Yu G;
 XX
 DR WPI; 2004-132245/13.
 XX
 XX New transgenic plant comprising a recombinant polynucleotide of any one
 PT of more than 500 nucleotide sequences, useful in bioinformatic search
 PT methods.
 XX
 PS Claim 1; SEQ ID NO 1045; 435pp; English.
 XX
 CC The invention describes a transgenic plant comprising a recombinant
 CC polynucleotide of any one of more than 500 nucleotide sequences fully
 CC defined in the specification or its complement. The method of the
 CC invention can be used to produced a plant having altered traits such as:
 CC enhanced tolerance to abiotic stress; glyphosphate tolerance; hormone
 CC sensitivity; disease resistance; sugar sensing; early or late flowering;
 CC altered flower structure, change in stem bifurcations, altered branching
 CC pattern, reduced apical dominance, reduced trichome density; lack of
 CC trichomes; reduced ectopic trichome development; altered trichome
 CC development; increase in trichome number; altered stem morphology;
 CC increased root growth; increased root hairs; altered seed development;
 CC altered cell proliferation or cell differentiation; rapid development;
 CC premature senescence; increased necrosis; increase in seedling or plant
 CC size; decreased plant size; leaf morphology; seed morphology; seed
 CC biochemistry; increase in root anthocyanins; increase in plant
 CC anthocyanins; or alteration in light response or shade avoidance. The
 CC transgenic plant, polynucleotides and polypeptides are useful in
 CC bioinformatic search methods. This sequence represents a plant
 CC transcription factor, and an orthologue of Arabidopsis thaliana
 CC creation of a transgenic plant with altered traits.
 XX
 SQ Sequence 1337 BP; 437 A; 296 C; 239 G; 365 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.2; DB 12; Length 1337;
 Best Local Similarity 58.0%; Pred. NO. 0.00022;
 Matches 116; Conservative 0; Mismatches 84; Indels 0; Gaps 0;

2043 TTGATTGGCAATATCACTCCGGTTTGTCTTCTAGGTCTCTCAAGTCTCGTGACACATAAT 2102

 1122 TTATTGTGTAATAATAATAGTCGCTGATGATGCAATAATATAGTACCGGTACAGTTGAAC 1181

 2103 CATTCCATCCAAATGATCGCTTTGCTTTTACCACTCTTCTTCTTATCTTATTAATAAAAA 2162

 1182 ATTTTGGCCAAATTTCCCTTTTGTGTACTCTTCTTCTTCGCGCAATTGA 1241

 2163 TGTGTGCTCCACCACCTGCTCCCAAAAAA 2242

 1242 TGGTAGTCATTAAGAAAAA 1321

 2223 AAAAAA 2242

 1302 AAAAAA 1321

RESULT 1004
 ADO02883
 ID ADO02883 standard; cDNA; 1337 BP.
 XX
 AC ADO02883;
 XX
 DT 01-JUL-2004 (first entry)
 DE
 DE
 KW Soybean orthologue of Thalecress transcription factor, cDNA #152.
 KW Soybean; transcription factor; ss; gene; plant; transgenic;
 KW abiotic stress; cold tolerance; heat tolerance; drought; osmotic stress;
 KW phosphate limitation; potassium limitation; nitrogen limitation;
 KW hormone sensitivity; disease resistance; sugar sensing; seed germination;
 KW flowering; inflorescence architectural change;
 KW meristem cell differentiation; phyllotaxy; apical dominance;
 KW trichome development; seed development; premature senescence;
 KW delayed senescence; lethality; necrosis; plant size; leaf morphology;
 KW seed morphology; secondary metabolism; light response; shade avoidance.
 XX
 OS Glycine max.
 XX
 PN US2004045049-A1.
 XX
 PD 04-MAR-2004.
 XX
 PF 10-APR-2003; 2003US-00412699.
 XX
 PR 13-SEP-1999; 39US-00394519.
 PR 21-JAN-2000; 2000US-00489376.
 PR 17-FEB-2000; 2000US-00506720.
 PR 22-MAR-2000; 2000US-00532591.
 PR 22-MAR-2000; 2000US-00533029.
 PR 22-MAR-2000; 2000US-00533030.
 PR 22-MAR-2000; 2000US-00533392.
 PR 22-MAR-2000; 2000US-00533648.
 PR 06-APR-2000; 2000WO-US009448.
 PR 16-NOV-2000; 2000US-00713994.
 PR 17-MAR-2001; 2001US-00819142.
 PR 17-APR-2001; 2001US-00837444.
 PR 30-JAN-2002; 2002US-00958131.
 PR 14-JUN-2002; 2002US-00171468.
 PR 09-AUG-2002; 2002US-00225066.
 PR 09-AUG-2002; 2002US-00225067.
 PR 17-DEC-2002; 2002US-0434166P.
 PR 25-FEB-2003; 2003US-00374780.
 XX
 (ZHAN/) ZHANG J.
 PA (FROM/) FROMM M E.
 PA (HEAR/) HEARD J E.
 PA (RIEC/) RIECHMANN J L.
 PA (ADAM/) ADAM L J.
 PA (BROU/) BROUN P E.
 PA (PINE/) PINEDA O.

PA (REUB/) REUBER T L.
PA (KEDD/) KEDDIE J S.
PA (YUGG/) YU G.
PA (JIANG/) JIANG C.
PA (SAMA/) SAMAH R S.
PA (PILG/) PILGRIM M L.
PA (CREE/) CREELMAN R A.
PA (DUBE/) DUBELL A N.
PA (RATC/) RATCLIFFE O.
PA (KIMI/) KUMIMOTO R.
PA (SHER/) SHERMAN B K.
XX
PI Zhang J, Fromm ME, Heard JE, Riechmann JL, Adam LJ, Broun PE;
PI Pineda O, Reuber TL, Keddle JS, Yu G, Jiang C, Samaha RS;
PI Pilgrim ML, Creelman RA, Dubell AN, Ratcliffe O, Kumimoto R;
PI Sherman BK;
XX
DR WPI; 2004-225755/21.
XX
PT New transgenic plant, useful in developing phenotypes with altered or
PT improved characteristics or traits.
XX
PS Claim 1; SEQ ID NO 1297; 213pp; English.
XX
CC The invention relates to a transgenic plant comprises a recombinant
CC polynucleotide having a polynucleotide sequence or its complementary
CC sequence comprising a sequence encoding a polypeptide, that initiates
CC transcription (i.e. a transcription factor) from Arabidopsis, Soybean,
CC Rice, Rape or Corn, comprising any of the sequences appearing as ADO01588
CC -ADO03527 or ADO03530-ADO03559. Also included are using a transgenic
CC plant to grow a progeny plant, an expression cassette (comprising a
CC constitutive, inducible or tissue-specific promoter and a recombinant
CC polynucleotide described above), a host cell comprising the expression
CC cassette, producing a modified plant having a modified trait, identifying
CC a factor that is modulated by or interacts with a polypeptide encoded by
CC the polynucleotide sequence and identifying at least one downstream
CC polynucleotide sequence that is subject to a regulatory effect of any of
CC the polypeptides encoded by the polynucleotide described above. The
CC transgenic plant is useful for producing a plant that has an altered
CC trait e.g. an enhanced tolerance to abiotic stress (increased tolerance
CC to chilling, germination in cold conditions, freezing tolerance, tolerance
CC to heat, tolerance to drought, tolerance to osmotic stress, tolerance to
CC salt, tolerance to phosphate limitation, tolerance to potassium
CC limitation, decreased sensitivity to nitrogen limitation), altered
CC hormone sensitivity, reduced sensitivity to abscisic acid, an altered
CC response to ethylene, disease resistance, altered susceptibility to
CC Botrytis, altered susceptibility to Fusarium, altered susceptibility to
CC Erysiphe, altered susceptibility to Pseudomonas syringae, altered
CC susceptibility to Sclerotinia, altered sugar sensing, improved seed
CC germination and seedling vigor, early flowering, late flowering, extended
CC period of flowering, an inflorescence architectural change, a change in
CC stem bifurcations, a lack of a shoot meristem, reduced meristem cell
CC differentiation, altered phyllotaxy, altered branching pattern, reduced
CC apical dominance, reduced trichome density, ectopic trichome development,
CC altered trichome development, altered stem morphology, increased root
CC growth, increased root hairs, altered seed development, altered cell
CC proliferation/cell differentiation, premature senescence, delayed
CC senescence, lethality, increased necrosis, an increase in seedling or
CC plant size, decreased plant size, a change in leaf morphology, increased
CC altered leaf development, increased leaf size and mass, glossy leaves,
CC leaf cell expansion, change in seed morphology, altered seed coloration,
CC increased seed size, decreased seed size, altered seed shape, change in
CC leaf biochemistry, increased leaf wax, an alteration in leaf prenyl lipid
CC content, increased leaf insoluble sugars, decreased leaf insoluble
CC sugars, increased leaf anthocyanins, an alteration of leaf fatty acid
CC content, an alteration of leaf glucosinolate content, change in seed
CC biochemistry, an increase in seed oil content, decrease in seed oil
CC content, increase in seed fatty acid content, decrease in seed fatty acid
CC content, increase in seed protein content, decrease in seed protein
CC content, alteration in seed prenyl lipid content, increase in seed
CC sterols, upregulation of genes involved in secondary metabolism, increase
CC in root anthocyanins, increase in plant anthocyanins, and alteration in
CC light response or shade avoidance. The present sequence encodes an

CC orthologue of a thalecress transcription factor isolated from Soybean.
XX
SQ Sequence 1337 BP; 437 A; 296 C; 239 G; 365 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.2; DB 12; Length 1337;
Best Local Similarity 58.0%; Pred. No. 0.00022;
Matches 116; Conservative 0; Mismatches 84; Indels 0; Gaps 0;
QY 2043 TTGATTGGCATATCACTCCGGTTTCTTCTAGGTCCTCAAGTCTCGTGACACATAAT 2102
DB 1122 TTATTTGTATATAATAATTAGTCGCTGATATGATATATATATAGTACCGTGACATGAAC 1181
QY 2103 CATTCATCCAAATGATCGCTTTTGCTTTTACCACTCTTTCTTTATCTTATTAATAAAA 2162
DB 1182 ATTTTGGCCCAATTTTCCCTTTTGTGTTGTTACTCTTCACTTTCTTTTCCGCAATTGA 1241
QY 2163 TGTGTGCTCCCACTGCTCCCAAAAAA 2242
DB 1242 TGGTAGTCTATAAGAAAAA 2242
QY 2223 AAAAAA 1321
DB 1302 AAAAAA 1321
RESULT 1005
AAV59706
ID AAV59706 standard; DNA; 1378 BP.
XX
AC AAV59706;
DT 19-JAN-1999 (first entry)
XX
DE Human secreted protein gene 14 clone HPMPD84.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Homo sapiens.
XX
PN MO9839448-A2.
XX
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98WO-US004493.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.

```
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 08-JUL-1997; 97US-0049610P.
PR 16-AUG-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056633P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.

PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;
XX Bednarik DP, Endress CA, Yu G, Ni J, Feng P, Young PE, Greene JM;
XX Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
XX Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
XX WPI; 1998-506364/43.
XX P-PSDB; AAW74923.
XX
XX New isolated human genes and the secreted polypeptide(s) they encode -
XX useful for diagnosis and treatment of e.g. cancers, neurological
XX disorders, immune diseases, inflammation or blood disorders.
XX
XX Claim 1; Page 434-435; 721pp; English.
XX
XX This sequence represents a nucleic acid molecule designated Gene 14 from
XX the human cDNA clone HPMFD84 (deposited as clone ATCC 97897 and ATCC
XX 209043) which encodes a secreted human protein. The gene can be used to
XX generate fusion proteins by linking to the gene to a human immunoglobulin
XX Fc portion (e.g. AAV59502) for increasing the stability of the fused to
XX protein as compared to the human protein only. The invention relates to
XX 186 novel genes and their fragments (nucleic acid sequences: AAV59511-
XX V59812; amino acid sequences AAW74731-W75026) which are useful for
XX preventing, treating or ameliorating medical conditions e.g. by protein
XX or gene therapy. Also, pathological conditions can be diagnosed by
XX determining the amount of the new polypeptides in a sample or by
XX determining the presence of mutations in the new polynucleotides.
XX Specific uses are described for each of the 186 polynucleotides, based on
XX which tissues they are most highly expressed in (see AAV59511 for
XX described uses)
XX
XX Sequence 1378 BP; 494 A; 254 C; 248 G; 377 T; 0 U; 5 Other;

Query Match 3.0%; Score 66.2; DB 2; Length 1378;
Best Local Similarity 71.7%; Pred. No. 0.00023;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

Qy 2123 TTTCCTTTACACCTCTTCCTTTTCTTTTATATATAAAAGTTGGCTCCACCACTGNC 2182
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1245 TTCTATGTACAACCTGATGCTTGTCTTTATTTAATAATTTATCAGAGTGAAAAAAA 1304
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 2183 TCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1305 AAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1364
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 1006
ABS73695
ID ABS73695 standard; cDNA; 1378 BP.
XX
AC ABS73695;
XX
XX 15-JAN-2003 (first entry)
XX
XX Human cDNA #2 for novel secreted protein gene 14.
XX
XX Human; ss; gene; secreted protein; autoimmune disease; chemotaxis;
XX rheumatoid arthritis; hyperproliferative disorder; breast neoplasm;
XX liver neoplasm cardiovascular disorder; cardiac arrest; skin aging;
XX cerebrovascular disorder; cerebral ischemia; angiogenesis; sunburn;
XX nervous system disorders; Alzheimer's disease; infection;
XX ocular disorder; corneal infection; wound healing; tissue regeneration;
XX epithelial cell proliferation; organ transplantation; food additive;
XX preservative; nutritional.
XX
```

OS Homo sapiens.
XX PN US6420526-B1.
XX PD 16-JUL-2002.
XX PF 08-SEP-1998; 98US-00149476.
XX PR 07-MAR-1997; 97US-0038621P.
XX PR 07-MAR-1997; 97US-0040161P.
XX PR 07-MAR-1997; 97US-0040162P.
XX PR 07-MAR-1997; 97US-0040163P.
XX PR 07-MAR-1997; 97US-0040333P.
XX PR 07-MAR-1997; 97US-0040334P.
XX PR 07-MAR-1997; 97US-0040336P.
XX PR 07-MAR-1997; 97US-0040626P.
XX PR 11-APR-1997; 97US-0043311P.
XX PR 11-APR-1997; 97US-0043312P.
XX PR 11-APR-1997; 97US-0043313P.
XX PR 11-APR-1997; 97US-0043314P.
XX PR 11-APR-1997; 97US-0043315P.
XX PR 11-APR-1997; 97US-0043568P.
XX PR 11-APR-1997; 97US-0043569P.
XX PR 11-APR-1997; 97US-0043576P.
XX PR 11-APR-1997; 97US-0043578P.
XX PR 11-APR-1997; 97US-0043580P.
XX PR 11-APR-1997; 97US-0043659P.
XX PR 11-APR-1997; 97US-0043670P.
XX PR 11-APR-1997; 97US-0043671P.
XX PR 11-APR-1997; 97US-0043672P.
XX PR 11-APR-1997; 97US-0043674P.
XX PR 23-MAY-1997; 97US-0047422P.
XX PR 23-MAY-1997; 97US-0047500P.
XX PR 23-MAY-1997; 97US-0047501P.
XX PR 23-MAY-1997; 97US-0047502P.
XX PR 23-MAY-1997; 97US-0047503P.
XX PR 23-MAY-1997; 97US-0047581P.
XX PR 23-MAY-1997; 97US-0047582P.
XX PR 23-MAY-1997; 97US-0047583P.
XX PR 23-MAY-1997; 97US-0047584P.
XX PR 23-MAY-1997; 97US-0047585P.
XX PR 23-MAY-1997; 97US-0047586P.
XX PR 23-MAY-1997; 97US-0047587P.
XX PR 23-MAY-1997; 97US-0047588P.
XX PR 23-MAY-1997; 97US-0047589P.
XX PR 23-MAY-1997; 97US-0047590P.
XX PR 23-MAY-1997; 97US-0047592P.
XX PR 23-MAY-1997; 97US-0047593P.
XX PR 23-MAY-1997; 97US-0047594P.
XX PR 23-MAY-1997; 97US-0047595P.
XX PR 23-MAY-1997; 97US-0047596P.
XX PR 23-MAY-1997; 97US-0047597P.
XX PR 23-MAY-1997; 97US-0047598P.
XX PR 23-MAY-1997; 97US-0047599P.
XX PR 23-MAY-1997; 97US-0047600P.
XX PR 23-MAY-1997; 97US-0047601P.
XX PR 23-MAY-1997; 97US-0047612P.
XX PR 23-MAY-1997; 97US-0047613P.
XX PR 23-MAY-1997; 97US-0047614P.
XX PR 23-MAY-1997; 97US-0047615P.
XX PR 23-MAY-1997; 97US-0047617P.
XX PR 23-MAY-1997; 97US-0047618P.
XX PR 23-MAY-1997; 97US-0047632P.
XX PR 23-MAY-1997; 97US-0047633P.
XX PR 06-JUN-1997; 97US-0048964P.
XX PR 06-JUN-1997; 97US-0048974P.
XX PR 13-JUN-1997; 97US-0049610P.
XX PR 08-JUL-1997; 97US-0051926P.
XX PR 16-JUL-1997; 97US-0052874P.
XX PR 18-AUG-1997; 97US-0055724P.
XX PR 22-AUG-1997; 97US-0056630P.
XX PR 22-AUG-1997; 97US-0056631P.
XX PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
PR 06-MAR-1998; 98WO-US004493.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Ruben SM, Rosen CA, Fischer CL, Soppet DP, Carter KC;
PI Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX WPI: 2002-634796/68.
XX P-PSDB; ABG95377.
PT New isolated human secreted protein for diagnosing, preventing, treating
PT or ameliorating medical conditions and used as a food additive or
PT preservative.
XX Example 1; SEQ ID NO 208; 129pp; English.
XX The invention relates to an isolated protein that is one of 186 human
XX secreted proteins, given in the specification, encoded by one of 309 cDNA
XX sequences also given in the specification. The protein is used in a
XX pharmaceutical composition used to prevent, treat or ameliorate a medical
XX condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs,
XX chickens or sheep. Disorders which are diagnosed or treated include
XX autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
XX disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
XX e.g. cardiac arrest, cerebrovascular disorders e.g. Alzheimer's disease,
XX angiodysplasia, nervous system disorders e.g. Alzheimer's disease,
XX infections caused by bacteria, viruses and fungi and ocular disorders
XX e.g. corneal infection. The polypeptides can also be used to aid wound
XX healing and epithelial cell proliferation, to prevent skin aging due to
XX sunburn, to maintain organs before transplantation, for supporting cell
XX culture of primary tissues, to regenerate tissues and in chemotaxis. The
XX polypeptides can also be used as a food additive or preservative to
XX increase or decrease storage capabilities, fat content, lipid, protein,
XX carbohydrate, vitamins, minerals, cofactors and other nutritional
XX components. The present sequence represents a cDNA derived from a gene
XX encoding one of the novel human secreted proteins of the invention. Note:

CC This sequence did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=6420526B1

[illegible]

RESULT 1007	
ACD82838	
ID	ACD82838 standard; cDNA; 1378 BP.
XX	
XX	ACD82838;
XX	
XX	22-SEP-2003 (first entry)
XX	
XX	cDNA sequence #198 containing coding region of a human secreted protein.
XX	
KW	Human; secreted protein; hyperproliferative disorder; leukaemia;
KW	breast cancer; wound; reproductive disorder; blood-related disorder;
KW	haemophilia; thrombocytopaenia; immunodeficiency; thymic hypoplasia;
KW	Wiskott-Aldrich syndrome; autoimmune disorder; multiple sclerosis;
KW	graft-versus-host disease; Hashimoto's thyroiditis; allergy; asthma;
KW	viral infection; bacterial infection; fungal infection; AIDS; sepsis;
KW	renal disorder; kidney failure; cardiovascular disorder; cytostatic;
KW	angina pectoris; cerebral ischaemia; congenital heart defect;
KW	respiratory disorder; neurological disorder; Alzheimer's disease;
KW	Parkinson's disease; inflammation; Crohn's disease; vulvurary;
KW	immunosuppressive; antibacterial; haemostatic; thrombolytic;
KW	anticoagulant; neuroprotective; thyromimetic; anti allergic;
KW	antisthmatic; virucide; fungicide; anti-HIV; nephrotropic; antiangiinal;
KW	cerebroprotective; cardiact; nootropic; antiparkinsonian;
KW	antiinflammatory; gene; ss.
KW	

[illegible]

Claim 4: SEO ID NO 208: 260pp: English.

XX Sequence 1378 BP; 494 A; 254 C; 248 G; 377 T; 0 U; 5 Other;
SQ Query Match 3.0%; Score 66.2; DB 12; Length 1378;
Best Local Similarity 71.7%; Pred. No. 0.00023;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
QY 2123 TTTCCTTTACCACTCTTCCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTGNC 2182
Db 1245 TTCTATGTACACTGATGCTTCTTCTTATTTTAAATAATTTATCAGAGTGAAAAA 1304
QY 2183 TCCCAA 2242
Db 1305 AA 1364
RESULT 1010
ACC69466
ID ACC69466 standard; cDNA; 1856 BP.
XX ACC69466;
AC AC
AT 16-JUL-2003 (first entry)
XX Human malignant neoplasm related protein encoding cDNA SEQ ID NO:3.
DE Human; malignant neoplasm; cytostatic; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX
FH Key Location/Qualifiers
FT CDS 81..1580
FT /tag= a
FT /product= "malignant neoplasm related protein"
XX
XX WO2003025135-A2.
XX 27-MAR-2003.
XX
XX 16-SEP-2002; 2002WO-US029371.
XX
XX 14-SEP-2001; 2001US-0318891P.
XX 14-SEP-2001; 2001US-0318905P.
XX 17-SEP-2001; 2001US-0322468P.
XX 18-SEP-2001; 2001US-0322732P.
XX 18-SEP-2001; 2001US-0322733P.
XX 18-SEP-2001; 2001US-0322790P.
XX 19-SEP-2001; 2001US-0323078P.
XX 24-SEP-2001; 2001US-0324050P.
XX 24-SEP-2001; 2001US-0324246P.
XX 26-SEP-2001; 2001US-0324621P.
XX 27-SEP-2001; 2001US-0324910P.
XX 19-APR-2002; 2002US-0373595P.
XX
XX (GENE-) GENE LOGIC INC.
XX
XX Nation M, Diggins JC, Porter M, Lu S, Orr M;
XX WPI; 2003-342663/32.
XX P-PSDB; ABR43427.
XX
XX New nucleic acid molecule, useful for preparing a composition for
XX treating malignant neoplasm of the cervix, uterus, breast, colon, rectum,
XX intestine, kidney, liver, lung, stomach, ovary, pancreas, thyroid gland,
XX or lymph node.
XX
XX Claim 1; Page 50-52; 127pp; English.
XX
XX ACC69465 to ACC69488 (I) encode the human malignant neoplasm related
XX proteins given in ABR43426 to ABR43449 (II). (II) are differentially
XX expressed in malignant neoplasms. (I) and (II) have cytostatic activity
XX and can be used in gene therapy. The (I) nucleic acids can be used for
XX preparing a composition for treating malignant neoplasm of the cervix,
XX

CC endometrium, uterus, breast, colon, rectum, intestine, kidney, liver,
CC lung, stomach, ovary, pancreas, thyroid gland, lymph node, skin,
CC oesophagus, larynx, adrenal gland, prostate, vulva, connective tissue or
CC soft tissue
XX
SQ Sequence 1856 BP; 395 A; 556 C; 472 G; 433 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.2; DB 8; Length 1856;
Best Local Similarity 71.7%; Pred. No. 0.00025;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
QY 2123 TTTCCTTTACCACTCTTCCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTGNC 2182
Db 1718 TTTCCTTTGATTTTTCGTAATAAATAATTTTATATATAATAATCTATATCTATATC 1777
QY 2183 TCCCAA 2242
Db 1778 TATTAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 1837
RESULT 1011
ACA92442
ID ACA92442 standard; DNA; 1867 BP.
XX ACA92442;
AC AC
AT 15-JUL-2003 (first entry)
XX DNA encoding human PMM-27.
XX
XX Human; protein modification and maintenance molecule; PMM; cancer;
XX cell proliferation disorder; atherosclerosis; neurological disorder;
XX epilepsy; Huntington's disease; stroke; immune disorder; allergy;
XX inflammatory disorder; AIDS; developmental disorder; hypothyroidism;
XX Cushing's syndrome; gastrointestinal disorder; epithelial disorder;
XX infection; cytostatic; antiarteriosclerotic; anticonvulsant; nootropic;
XX neuroprotective; cerebroprotective; anti-HIV; antiallergic; vulnerary;
XX antiinflammatory; thyromimetic; gene; ds.
XX
XX Homo sapiens.
XX
XX WO2003031939-A2.
XX
XX 17-APR-2003.
XX
XX 11-OCT-2002; 2002WO-US032850.
XX
XX 12-OCT-2001; 2001US-0329689P.
XX 25-OCT-2001; 2001US-0335703P.
XX 09-NOV-2001; 2001US-0348887P.
XX 28-NOV-2001; 2001US-0334145P.
XX 06-DEC-2001; 2001US-0337451P.
XX 14-DEC-2001; 2001US-0340584P.
XX
XX (INCY-) INCYTE GENOMICS INC.
XX
XX Ramkumar J, Gorvad AE, Baughn MR, Emerling BM, Yang J, Lee SY;
XX Tran UK, Becha SD, Duggan BM, Lee EA, Griffin JA, Li JX;
XX Sprague WW, Hafalia AJA, Chawla NK, Lehr-Mason PM, Kable AE, Yue H;
XX Marquis JP, Yao MG, Richardson TW, Tang TY, Jin P, Chien D;
XX Bhatia U, Burrill JD, Lee S, Blake JJ, Ho A, Zheng W;
XX WPI; 2003-430274/40.
XX P-PSDB; ABU92047.
XX
XX New human protein modification and maintenance molecules (PMM), useful
XX for diagnosing, treating and preventing diseases or conditions associated
XX with the aberrant PMM expression e.g. cancer, atherosclerosis, or
XX infections.
XX
XX Claim 5; Page 301-302; 311pp; English.
XX
XX The present invention relates to the isolation of human protein
XX

PR	11-APR-1997;	97US-0043568P
PR	11-APR-1997;	97US-0043569P
PR	11-APR-1997;	97US-0043576P
PR	11-APR-1997;	97US-0043578P
PR	11-APR-1997;	97US-0043580P
PR	11-APR-1997;	97US-0043670P
PR	11-APR-1997;	97US-0043670P
PR	11-APR-1997;	97US-0043671P
PR	11-APR-1997;	97US-0043672P
PR	11-APR-1997;	97US-0043674P
PR	23-MAY-1997;	97US-0047492P
PR	23-MAY-1997;	97US-0047502P
PR	23-MAY-1997;	97US-0047501P
PR	23-MAY-1997;	97US-0047503P
PR	23-MAY-1997;	97US-0047503P
PR	23-MAY-1997;	97US-0047582P
PR	23-MAY-1997;	97US-0047583P
PR	23-MAY-1997;	97US-0047584P
PR	23-MAY-1997;	97US-0047585P
PR	23-MAY-1997;	97US-0047586P
PR	23-MAY-1997;	97US-0047587P
PR	23-MAY-1997;	97US-0047588P
PR	23-MAY-1997;	97US-0047589P
PR	23-MAY-1997;	97US-0047590P
PR	23-MAY-1997;	97US-0047592P
PR	23-MAY-1997;	97US-0047593P
PR	23-MAY-1997;	97US-0047594P
PR	23-MAY-1997;	97US-0047595P
PR	23-MAY-1997;	97US-0047596P
PR	23-MAY-1997;	97US-0047597P
PR	23-MAY-1997;	97US-0047614P
PR	23-MAY-1997;	97US-0047615P
PR	23-MAY-1997;	97US-0047617P
PR	23-MAY-1997;	97US-0047618P
PR	23-MAY-1997;	97US-0047632P
PR	23-MAY-1997;	97US-0047633P
PR	06-JUN-1997;	97US-0048664P
PR	06-JUN-1997;	97US-0048974P
PR	13-JUN-1997;	97US-0049610P
PR	18-JUL-1997;	97US-0052872P
PR	18-AUG-1997;	97US-0052724P
PR	22-AUG-1997;	97US-0056630P
PR	22-AUG-1997;	97US-0056631P
PR	22-AUG-1997;	97US-0056632P
PR	22-AUG-1997;	97US-0056633P
PR	22-AUG-1997;	97US-0056637P
PR	22-AUG-1997;	97US-0056675P
PR	22-AUG-1997;	97US-0056876P
PR	22-AUG-1997;	97US-0056877P
PR	22-AUG-1997;	97US-0056878P
PR	22-AUG-1997;	97US-0056879P
PR	22-AUG-1997;	97US-0056880P
PR	22-AUG-1997;	97US-0056881P
PR	22-AUG-1997;	97US-0056882P
PR	22-AUG-1997;	97US-0056883P
PR	22-AUG-1997;	97US-0056884P
PR	22-AUG-1997;	97US-0056885P
PR	22-AUG-1997;	97US-0056886P
PR	22-AUG-1997;	97US-0056887P
PR	22-AUG-1997;	97US-0056888P

PR 11-APR-1997; 97US-0043568P.
 PR 11-APR-1997; 97US-0043569P.
 PR 11-APR-1997; 97US-0043576P.
 PR 11-APR-1997; 97US-0043578P.
 PR 11-APR-1997; 97US-0043580P.
 PR 11-APR-1997; 97US-0043669P.
 PR 11-APR-1997; 97US-0043670P.
 PR 11-APR-1997; 97US-0043671P.
 PR 11-APR-1997; 97US-0043672P.
 PR 11-APR-1997; 97US-0043674P.
 PR 23-MAY-1997; 97US-0047492P.
 PR 23-MAY-1997; 97US-0047500P.
 PR 23-MAY-1997; 97US-0047501P.
 PR 23-MAY-1997; 97US-0047502P.
 PR 23-MAY-1997; 97US-0047503P.
 PR 23-MAY-1997; 97US-0047581P.
 PR 23-MAY-1997; 97US-0047582P.
 PR 23-MAY-1997; 97US-0047583P.
 PR 23-MAY-1997; 97US-0047584P.
 PR 23-MAY-1997; 97US-0047585P.
 PR 23-MAY-1997; 97US-0047586P.
 PR 23-MAY-1997; 97US-0047587P.
 PR 23-MAY-1997; 97US-0047588P.
 PR 23-MAY-1997; 97US-0047589P.
 PR 23-MAY-1997; 97US-0047590P.
 PR 23-MAY-1997; 97US-0047592P.
 PR 23-MAY-1997; 97US-0047593P.
 PR 23-MAY-1997; 97US-0047594P.
 PR 23-MAY-1997; 97US-0047595P.
 PR 23-MAY-1997; 97US-0047596P.
 PR 23-MAY-1997; 97US-0047597P.
 PR 23-MAY-1997; 97US-0047598P.
 PR 23-MAY-1997; 97US-0047599P.
 PR 23-MAY-1997; 97US-0047600P.
 PR 23-MAY-1997; 97US-0047601P.
 PR 23-MAY-1997; 97US-0047612P.
 PR 23-MAY-1997; 97US-0047613P.
 PR 23-MAY-1997; 97US-0047614P.
 PR 23-MAY-1997; 97US-0047615P.
 PR 23-MAY-1997; 97US-0047617P.
 PR 23-MAY-1997; 97US-0047618P.
 PR 23-MAY-1997; 97US-0047632P.
 PR 23-MAY-1997; 97US-0047633P.
 PR 06-JUN-1997; 97US-0048964P.
 PR 06-JUN-1997; 97US-0048974P.
 PR 13-JUN-1997; 97US-0049610P.
 PR 08-JUL-1997; 97US-0051926P.
 PR 16-JUL-1997; 97US-0052874P.
 PR 18-AUG-1997; 97US-0055724P.
 PR 22-AUG-1997; 97US-0056630P.
 PR 22-AUG-1997; 97US-0056631P.
 PR 22-AUG-1997; 97US-0056632P.
 PR 22-AUG-1997; 97US-0056633P.
 PR 22-AUG-1997; 97US-0056636P.
 PR 22-AUG-1997; 97US-0056637P.
 PR 22-AUG-1997; 97US-0056662P.
 PR 22-AUG-1997; 97US-0056664P.
 PR 22-AUG-1997; 97US-0056845P.
 PR 22-AUG-1997; 97US-0056862P.
 PR 22-AUG-1997; 97US-0056864P.
 PR 22-AUG-1997; 97US-0056872P.
 PR 22-AUG-1997; 97US-0056874P.
 PR 22-AUG-1997; 97US-0056875P.
 PR 22-AUG-1997; 97US-0056876P.
 PR 22-AUG-1997; 97US-0056877P.
 PR 22-AUG-1997; 97US-0056878P.
 PR 22-AUG-1997; 97US-0056879P.
 PR 22-AUG-1997; 97US-0056880P.
 PR 22-AUG-1997; 97US-0056881P.
 PR 22-AUG-1997; 97US-0056882P.
 PR 22-AUG-1997; 97US-0056884P.
 PR 22-AUG-1997; 97US-0056886P.
 PR 22-AUG-1997; 97US-0056887P.
 PR 22-AUG-1997; 97US-0056889P.

PR 22-AUG-1997; 97US-0056889P.
 PR 22-AUG-1997; 97US-0056892P.
 PR 22-AUG-1997; 97US-0056893P.
 PR 22-AUG-1997; 97US-0056894P.
 PR 22-AUG-1997; 97US-0056903P.
 PR 22-AUG-1997; 97US-0056908P.
 PR 22-AUG-1997; 97US-0056909P.
 PR 22-AUG-1997; 97US-0056910P.
 PR 22-AUG-1997; 97US-0056911P.
 PR 05-SEP-1997; 97US-0057650P.
 PR 05-SEP-1997; 97US-0057669P.
 PR 05-SEP-1997; 97US-0057761P.
 PR 12-SEP-1997; 97US-0058785P.
 PR 09-OCT-1997; 97US-0061660P.
 PR 06-MAR-1998; 98WO-US004493.
 PR 08-SEP-1998; 98US-00149476.
 PR 17-MAR-2000; 2000US-0190068P.
 XX
 PA (RUBE/) RUBEN S M.
 PA (ROSE/) ROSEN C A.
 PA (SOPP/) SOPPET D R.
 PA (CART/) CARTER K C.
 PA (BEDN/) BEDNARIK D P.
 PA (ENDR/) ENDRESS G A.
 PA (YUGG/) YU G.
 PA (NIJJ/) NI J.
 PA (FENG/) FENG P.
 PA (YOUN/) YOUNG P B.
 PA (GREE/) GREENE J M.
 PA (FERR/) FERRIE A M.
 PA (DUAN/) DUAN D R.
 PA (HUJJ/) HU J.
 PA (FLOR/) FLORENCE K A.
 PA (OLSE/) OLSEN H S.
 PA (FISC/) FISCHER C L.
 PA (EBEN/) EBNER R.
 PA (BREW/) BREWER L A.
 PA (MOOR/) MOORE P A.
 PA (SHIY/) SHI Y.
 PA (LAFL/) LAFLEUR D W.
 PA (LIYY/) LI Y.
 PA (ZENG/) ZENG Z.
 PA (KYAW/) KYAW H.
 XX
 PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
 PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
 PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
 PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
 XX WPI; 2003-521800/49.
 DR P-PSDB; ABO34387.
 DR
 XX
 PT New genes and its encoded prostate cancer antigen proteins, useful for
 PT preventing, treating, ameliorating or diagnosing e.g. prostate cancers,
 PT thymic hypoplasia, multiple sclerosis, AIDS, angina pectoris or cerebral
 PT ischemia.
 XX
 PS Claim 4; SEQ ID NO 24; 260pp; English.
 CC
 CC The present invention relates to the isolation of novel human secreted
 CC proteins and the polynucleotide sequences encoding them. The invention
 CC also discloses vectors, host cells, antibodies, and recombinant methods
 CC for producing human secreted proteins. The polypeptide and polynucleotide
 CC sequences for the secreted proteins are useful for preventing, treating,
 CC ameliorating or diagnosing medical conditions such as hyperproliferative
 CC disorders (e.g. leukaemia or breast cancers), wounds, reproductive
 CC disorders, blood-related disorders (e.g. haemophilia or
 CC thrombocytopaenia), immunodeficiencies (e.g. Wiskott-Aldrich syndrome or
 CC thymic hypoplasia), autoimmune disorders (e.g. graft-versus-host disease,
 CC multiple sclerosis or Hashimoto's thyroiditis), allergies (e.g. asthma),
 CC viral or bacterial or fungal infections (e.g. AIDS or sepsis), renal
 CC disorders (e.g. kidney failure), cardiovascular disorders (e.g. angina
 CC pectoris, cerebral ischaemia or congenital heart defects), respiratory

PR	23-MAY-1997	97US-00475844
PR	23-MAY-1997	97US-00475853
PR	23-MAY-1997	97US-00475866
PR	23-MAY-1997	97US-00475877
PR	23-MAY-1997	97US-00475888
PR	23-MAY-1997	97US-00475899
PR	23-MAY-1997	97US-00475900
PR	23-MAY-1997	97US-00475922
PR	23-MAY-1997	97US-00475933
PR	23-MAY-1997	97US-00475944
PR	23-MAY-1997	97US-00475955
PR	23-MAY-1997	97US-00475966
PR	23-MAY-1997	97US-00475977
PR	23-MAY-1997	97US-00475988
PR	23-MAY-1997	97US-00475999
PR	23-MAY-1997	97US-00476000
PR	23-MAY-1997	97US-00476010
PR	23-MAY-1997	97US-00476122
PR	23-MAY-1997	97US-00476133
PR	23-MAY-1997	97US-00476144
PR	23-MAY-1997	97US-00476155
PR	23-MAY-1997	97US-00476170
PR	23-MAY-1997	97US-00476188
PR	23-MAY-1997	97US-00476322
PR	23-MAY-1997	97US-00476332
PR	23-MAY-1997	97US-00476344
PR	06-JUN-1997	97US-00489644
PR	06-JUN-1997	97US-00489744
PR	13-JUN-1997	97US-00496100
PR	18-JUL-1997	97US-00518262
PR	16-JUL-1997	97US-00528744
PR	18-AUG-1997	97US-00557244
PR	22-AUG-1997	97US-00566300
PR	22-AUG-1997	97US-00566312
PR	22-AUG-1997	97US-00566322
PR	22-AUG-1997	97US-00566336
PR	22-AUG-1997	97US-00566372
PR	22-AUG-1997	97US-00566632
PR	22-AUG-1997	97US-00566644
PR	22-AUG-1997	97US-00568454
PR	22-AUG-1997	97US-00568622
PR	22-AUG-1997	97US-00568644
PR	22-AUG-1997	97US-00568722
PR	22-AUG-1997	97US-00568744
PR	22-AUG-1997	97US-00568755
PR	22-AUG-1997	97US-00568776
PR	22-AUG-1997	97US-00568778
PR	22-AUG-1997	97US-00568799
PR	22-AUG-1997	97US-00568800
PR	22-AUG-1997	97US-00568812
PR	22-AUG-1997	97US-00568822
PR	22-AUG-1997	97US-00568844
PR	22-AUG-1997	97US-00568866
PR	22-AUG-1997	97US-00568872
PR	22-AUG-1997	97US-00568894
PR	22-AUG-1997	97US-00569033
PR	22-AUG-1997	97US-00569088
PR	22-AUG-1997	97US-00569093
PR	22-AUG-1997	97US-00569222
PR	22-AUG-1997	97US-00569833
PR	22-AUG-1997	97US-00569844
PR	22-AUG-1997	97US-00569877
PR	22-AUG-1997	97US-00569886
PR	05-SEP-1997	97US-00576500
PR	05-SEP-1997	97US-00576699
PR	15-SEP-1997	97US-00577612
PR	15-SEP-1997	97US-00578755
PR	09-OCT-1997	97US-00616600
PR	06-MAR-1998	98WO-US004493
PR	08-SEP-1998	98US-00149476
PR	16-MAR-2000	2000US-01900688
PR	17-MAR-2001	2001US-00893391

PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 03-SEP-1997; 97US-0057650P.
PR 03-SEP-1997; 97US-0057669P.
PR 03-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
PR 06-MAR-1998; 98WC-US004493.
PR 08-SEP-1998; 98US-00149476.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
PI Endreas CA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
PI Duan R, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX WPI; 2004-131264/13.
XX P-PSDB; ADH74050.
XX
XX Isolated nucleic acid molecules encoding human secreted proteins, useful
PT for preventing, diagnosing and treating disorders associated with
PT aberrant expression and activity.
XX
XX Claim 3; SEQ ID NO 24; 142pp; English.
XX
XX The invention relates to isolated nucleic acid molecules and the human
CC secreted proteins (SPs) they encode. The proteins and nucleic acids may
CC be used in the prevention, diagnosis and treatment of diseases associated
CC with inappropriate SP expression e.g. cancer, haematopoietic disorders,
CC endocrine disorders, diseases of the immune system, inflammatory
CC disorders and many others. Full details of disorders that may be
CC prevented, diagnosed and/or treated by the above methods are given in the
CC specification. The nucleic acid molecules may be used to produce their
CC proteins. The nucleic acid and it's complementary sequences may also be
CC used as DNA probes in diagnostic assays to detect and quantitate the
CC presence of similar nucleic acids in samples, and therefore which

CC patients may be in need of restorative therapy. The SPs may also be used
CC as antigens in the production of antibodies against the proteins and in
CC assays to identify modulators of SP expression and activity. The anti-SP
CC antibodies and antagonists may also be used to down regulate expression
CC and activity. The anti-SP antibodies may also be used as diagnostic
CC agents for detecting the presence of the proteins in samples (e.g. by
CC enzyme linked immunosorbant assay (ELISA)). The present sequence
CC represents a human secreted protein cDNA.
XX
XX Sequence 2323 BP; 760 A; 467 C; 438 G; 658 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.2; DB 12; Length 2323;
Best Local Similarity 71.7%; Pred. No. 0.00027;
Matches 86; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
QY 2123 TTGCTTTACCACTCTTCTTTATTAATAAATGTTGCTCCACCACATGNC 2182
DB 2183 TTCTATGTACACTGATGCTTCTTATTTTAAATAATTTATCAGAGTGAATAAAAAA 2242
QY 2183 TCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
DB 2243 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2302
RESULT 1017
ABV44911/c
ID ABV44911 standard; cDNA; 375 BP.
XX
XX AC ABV44911;
XX
XX 16-SEP-2002 (first entry)
XX Human prostate expression marker cDNA 44902.
XX
XX Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW pharmacogenomic marker; gene; ss.
XX
XX Homo sapiens.
XX
XX WO200160860-A2.
XX
XX 23-AUG-2001.
XX
XX 20-FEB-2001; 2001WO-US005171.
XX
XX 17-FEB-2000; 2000US-0183319P.
PR 16-MAR-2000; 2000US-0189862P.
PR 25-MAY-2000; 2000US-0207454P.
PR 09-JUN-2000; 2000US-0211314P.
PR 18-JUL-2000; 2000US-0219007P.
PR 13-DEC-2000; 2000US-0255281P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX Schlegel R, Endege WO, Monahan JE;
XX
XX WPI; 2001-662795/76.
XX
XX Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer.
XX
XX Claim 1; Page 8902; 11750pp; English.
XX
XX The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for: (a) assessing whether
CC a patient is afflicted with prostate cancer; (b) monitoring the
CC progression of prostate cancer in a patient; (c) assessing the efficacy
CC of a test compound to inhibit prostate cancer in a patient; (d) assessing
CC the efficacy of a therapy for inhibiting prostate cancer in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)

CC determining whether prostate cancer has metastasized in a patient; (h)
CC assessing the aggressiveness or indolence of prostate cancer in a patient
CC ; (i) is also useful as a pharmacodynamic or pharmacogenomic marker
XX
SQ Sequence 375 BP; 100 A; 43 C; 40 G; 191 T; 0 U; 1 Other;

Query Match 2.9%; Score 66; DB 5; Length 375;
Best Local Similarity 75.7%; Pred. No. 0.00017;
Matches 81; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 2136 TCTTCCCTTTATCTTATTAATAAAGTTGGTCTCCACCACTGCTCCCAAAAAA 2195
Db 273 TTTTTTTTTTTTTTAAATAAATAAATTTTTTTTTTAAAAA 214
QY 2196 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 213 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 167

RESULT 1018
ADI69792/c
ID ADI69792 standard; DNA; 384 BP.
XX
AC ADI69792;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human ovarian cancer DNA marker #2534.
XX
KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.
XX
OS Homo sapiens.
XX
PN WO200170979-A2.
XX
PD 27-SEP-2001.
XX
PF
XX
PR 21-MAR-2001; 2001WO-US009126.
XX
PR 21-MAR-2000; 2000US-0191031P.
XX
PR 25-MAY-2000; 2000US-0207124P.
XX
PR 15-JUN-2000; 2000US-0211940P.
XX
PR 07-JUL-2000; 2000US-0216820P.
XX
PR 25-JUL-2000; 2000US-0220661P.
XX
PR 21-DEC-2000; 2000US-0257672P.
XX

(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

Lee J, Lillie J;

WPI; 2001-611502/70.

Novel isolated nucleic acid molecules (markers) overexpressed in ovarian cancer cells as compared to their normal non-cancerous ovarian cells are used to characterize stage, grade, histological type of ovarian cancer.

Disclosure; SEQ ID NO 2534; 106pp; English.

The invention relates to nucleic acid markers which are overexpressed in ovarian cancer cells as compared to their expression in normal (i.e. non-cancerous) ovarian cells. The invention also relates to polypeptides encoded by the markers, antibodies that selectively bind to the polypeptides, a method of inhibiting ovarian cancer in a patient at risk of developing ovarian cancer involving inhibiting expression of a gene corresponding to a marker of the invention and a method of treating a patient afflicted with ovarian cancer comprising providing to cells of the patient an antisense oligonucleotide complementary to a marker of the invention. The markers are useful for assessing if a patient is afflicted with ovarian cancer, which involves comparing the level of expression of a marker in a patient sample and a normal level of expression of the marker in a control non-ovarian cancer sample. A difference between the expression levels indicates ovarian cancer. The level of expression of a marker corresponds to a secreted protein or to a transcribed

CC polynucleotide or its portion. The level of expression of the marker is assessed by detecting the presence in the sample, a protein or protein fragment corresponding to the marker. The presence of protein or protein fragment is detected using an antibody that specifically binds with the protein or protein fragment. Alternatively, the level of expression of the marker is assessed by detecting the presence of a transcribed polynucleotide which anneals with the marker or anneals with a portion of the polynucleotide comprising the marker, under stringent conditions. The marker is also used for monitoring the progression of ovarian cancer in a patient which involves detecting expression of the marker in a patient sample at a first point in time, repeating the method at a subsequent time and comparing the level of expression. The method is carried out using an ovarian tissue sample. A composition comprising a marker, polypeptide or antibody of the invention is used to treat ovarian cancer. This sequence represents a human ovarian cancer DNA marker of the invention.

SQ Sequence 384 BP; 93 A; 41 C; 47 G; 150 T; 0 U; 53 Other;

Query Match 2.9%; Score 66; DB 5; Length 384;
Best Local Similarity 70.4%; Pred. No. 0.00017;
Matches 81; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
QY 2128 TTTACCACTCTTCTCTTTTATCTTATTAATAAAGTTGGTCTCCACCACTGCTCCA 2187
Db 215 TTTTTTANTTTTTTTTTTTTTTTTTTTTNGAANNAANGTTTNTAATTTCCCCCNAA 156
QY 2188 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 155 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 101

RESULT 1019

ADI76128/c
ID ADI76128 standard; DNA; 384 BP.

XX
AC ADI76128;

XX
DT 20-MAY-2004 (first entry)

XX
DE Human ovarian cancer DNA marker #8970.

XX
KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.

XX
OS Homo sapiens.

XX
PN WO200170979-A2.

XX
PD 27-SEP-2001.

XX
PF 21-MAR-2001; 2001WO-US009126.

XX
PR 21-MAR-2000; 2000US-0191031P.

XX
PR 25-MAY-2000; 2000US-0207124P.

XX
PR 15-JUN-2000; 2000US-0211940P.

XX
PR 07-JUL-2000; 2000US-0216820P.

XX
PR 25-JUL-2000; 2000US-0220661P.

XX
PR 21-DEC-2000; 2000US-0257672P.

XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

XX
PI Lee J, Lillie J;

XX
DR WPI; 2001-611502/70.

Novel isolated nucleic acid molecules (markers) overexpressed in ovarian cancer cells as compared to their normal non-cancerous ovarian cells are used to characterize stage, grade, histological type of ovarian cancer.
XX
Disclosure; SEQ ID NO 8870; 106pp; English.
XX
The invention relates to nucleic acid markers which are overexpressed in ovarian cancer cells as compared to their expression in normal (i.e. non-

PR 22-AUG-1997; 97US-0056874P.
 PR 22-AUG-1997; 97US-0056875P.
 PR 22-AUG-1997; 97US-0056876P.
 PR 22-AUG-1997; 97US-0056877P.
 PR 22-AUG-1997; 97US-0056878P.
 PR 22-AUG-1997; 97US-0056879P.
 PR 22-AUG-1997; 97US-0056880P.
 PR 22-AUG-1997; 97US-0056881P.
 PR 22-AUG-1997; 97US-0056882P.
 PR 22-AUG-1997; 97US-0056884P.
 PR 22-AUG-1997; 97US-0056886P.
 PR 22-AUG-1997; 97US-0056887P.
 PR 22-AUG-1997; 97US-0056888P.
 PR 22-AUG-1997; 97US-0056889P.
 PR 22-AUG-1997; 97US-0056892P.
 PR 22-AUG-1997; 97US-0056893P.
 PR 22-AUG-1997; 97US-0056903P.
 PR 22-AUG-1997; 97US-0056908P.
 PR 22-AUG-1997; 97US-0056909P.
 PR 22-AUG-1997; 97US-0056910P.
 PR 22-AUG-1997; 97US-0056911P.
 PR 05-SEP-1997; 97US-0057650P.
 PR 05-SEP-1997; 97US-0057669P.
 PR 05-SEP-1997; 97US-0057761P.
 PR 12-SEP-1997; 97US-0058785P.
 PR 02-OCT-1997; 97US-0061060P.
 PR 06-MAR-1998; 98WO-US004493.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Ruben SM, Rosen CA, Fischer CL, Soppet DP, Carter KC;
 PI Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
 PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
 PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
 XX
 DR WPI; 2002-634796/68.
 DR P-PSDB; ABG95479.
 XX
 PT New isolated human secreted protein for diagnosing, preventing, treating
 PT or ameliorating medical conditions and used as a food additive or
 PT preservative.
 PT
 PS Example 1; SEQ ID NO 310; 129pp; English.
 XX
 CC The invention relates to an isolated protein that is one of 186 human
 CC secreted proteins, given in the specification, encoded by one of 309 cDNA
 CC sequences also given in the specification. The protein is used in a
 CC pharmaceutical composition used to prevent, treat or ameliorate a medical
 CC condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs,
 CC chickens or sheep. Disorders which are diagnosed or treated include
 CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
 CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
 CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
 CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,
 CC infections caused by bacteria, viruses and fungi and ocular disorders
 CC e.g. corneal infection. The polypeptides can also be used to aid wound
 CC healing and epithelial cell proliferation, to prevent skin aging due to
 CC sunburn, to maintain organs before transplantation, for supporting cell
 CC culture of primary tissues, to regenerate tissues and in chemotaxis. The
 CC polypeptides can also be used as a food additive or preservative to
 CC increase or decrease storage capabilities, fat content, lipid, protein,
 CC carbohydrate, vitamins, minerals, cofactors and other nutritional
 CC components. The present sequence represents a cDNA derived from a gene
 CC encoding one of the novel human secreted proteins of the invention. Note:
 CC This sequence did not form part of the printed specification, but was
 CC obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html?DocID=642052691
 XX
 SQ Sequence 1181 BP; 357 A; 228 C; 295 G; 298 T; 0 U; 3 Other;
 Query Match 2.9%; Score 66; DB 6; Length 1181;
 Best Local Similarity 70.7%; Pred. No. 0.00024;

Matches 87; Conservative 0; Mismatches 36; Indels 0; Gaps 0;
 Oy 2120 GCCTTGTCTTACCACTCTTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACT 2179
 Db 1055 GCATTGTCTTTAAACCACTTCTTTGTTTAAATAAATAAAGTAAATAAGCTAGTT 1114
 Oy 2180 GNCCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2239
 Db 1115 CTATTGAATGCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1174
 Oy 2240 AAA 2242
 Db 1175 AAA 1177
 RESULT 1027
 ACD82940
 ID ACD82940 standard; cDNA; 1181 BP.
 XX
 AC ACD82940;
 XX
 DT 22-SEP-2003 (first entry)
 XX
 DE cDNA sequence #300 containing coding region of a human secreted protein.
 XX
 KW Human; secreted protein; hyperproliferative disorder; leukaemia;
 KW breast cancer; wound; reproductive disorder; blood-related disorder;
 KW haemophilia; thrombocytopenia; immunodeficiency; thymic hypoplasia;
 KW Wiskott-Aldrich syndrome; autoimmune disorder; multiple sclerosis;
 KW - graft-versus-host disease; Hashimoto's thyroiditis; allergy; asthma;
 KW viral infection; bacterial infection; fungal infection; AIDS; sepsis;
 KW renal disorder; kidney failure; cardiovascular disorder; cytostatic;
 KW angina pectoris; cerebral ischaemia; congenital heart defect;
 KW respiratory disorder; neurological disorder; Alzheimer's disease;
 KW Parkinson's disease; inflammation; Crohn's disease; vulvarity;
 KW immunosuppressive; antibacterial; haemostatic; thrombolytic;
 KW anticoagulant; neuroprotective; thyromimetic; antiallergic;
 KW antiasthmatic; virucide; fungicide; anti-HIV; nephrotropic; antianginal;
 KW cerebroprotective; cardiant; nootropic; antiparkinsonian;
 KW antiinflammatory; gene; ss.
 XX
 OS Homo sapiens.
 XX
 FN US2003049618-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 16-MAR-2001; 2001US-00809391.
 XX
 PR 07-MAR-1997; 97US-0038621P.
 PR 07-MAR-1997; 97US-0040162P.
 PR 07-MAR-1997; 97US-0040163P.
 PR 07-MAR-1997; 97US-0040333P.
 PR 07-MAR-1997; 97US-0040334P.
 PR 07-MAR-1997; 97US-0040336P.
 PR 07-MAR-1997; 97US-0040626P.
 PR 11-APR-1997; 97US-0043311P.
 PR 11-APR-1997; 97US-0043312P.
 PR 11-APR-1997; 97US-0043313P.
 PR 11-APR-1997; 97US-0043314P.
 PR 11-APR-1997; 97US-0043315P.
 PR 11-APR-1997; 97US-0043568P.
 PR 11-APR-1997; 97US-0043569P.
 PR 11-APR-1997; 97US-0043576P.
 PR 11-APR-1997; 97US-0043578P.
 PR 11-APR-1997; 97US-0043580P.
 PR 11-APR-1997; 97US-0043669P.
 PR 11-APR-1997; 97US-0043670P.
 PR 11-APR-1997; 97US-0043671P.
 PR 11-APR-1997; 97US-0043672P.
 PR 11-APR-1997; 97US-0043674P.
 PR 23-MAY-1997; 97US-0047492P.
 PR 23-MAY-1997; 97US-0047500P.

PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 13-JUN-1997; 97US-0048974P.
PR 08-JUL-1997; 97US-0049610P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 09-OCT-1997; 97US-0061660P.
PR 06-MAR-1998; 98WO-US004493.
PR 08-SEP-1998; 98US-00149476.
PR 17-MAR-2000; 2000US-0190068P.
XX
PA (RUBE/) RUBEN S M.
PA (ROSE/) ROSEN C A.
PA (SOPE/) SOPPET D R.
PA (CART/) CARTER K C.
PA (BEDN/) BEDNARIK D P.
PA (ENDR/) ENDRESS G A.
PA (YUGG/) YU G.
PA (NIJU/) NI J.
PA (FENG/) FENG P.
PA (YOUN/) YOUNG P E.
PA (GREE/) GREENE J M.
PA (FERE/) FERRIE A M.
PA (DUAN/) DUAN D R.
PA (HUJU/) HU J.
PA (FLOS/) FLORENCE K A.
PA (OLSE/) OLSEN H S.
PA (FISC/) FISCHER C L.
PA (EBNE/) EBNER R.
PA (BREW/) BREWER L A.
PA (MOOR/) MOORE P A.
PA (SHIY/) SHI Y.
PA (LAFLE/) LAFLEUR D W.
PA (LIYY/) LI Y.
PA (ZENG/) ZENG Z.
PA (KYAW/) KYAW H.
XX
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik JP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM, Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R, Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
PI WPI: 2003-521800/49.
DR P-PSDB; ABO34673.
XX
PT New genes and its encoded prostate cancer antigen proteins, useful for preventing, treating, ameliorating or diagnosing e.g. prostate cancers, thymic hypoplasia, multiple sclerosis, AIDS, angina pectoris or cerebral ischemia.
PT
XX
PS Claim 4; SEQ ID NO 310; 260pp; English.
XX
CC The present invention relates to the isolation of novel human secreted proteins and the polynucleotide sequences encoding them. The invention also discloses vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The polypeptide and polynucleotide sequences for the secreted proteins are useful for preventing, treating, ameliorating or diagnosing medical conditions such as hyperproliferative disorders (e.g. leukemia or breast cancers), wounds, reproductive disorders, blood-related disorders (e.g. haemophilia or thrombocytopaenia), immunodeficiencies (e.g. Wiskott-Aldrich syndrome or thymic hypoplasia), autoimmune disorders (e.g. AIDS or sepsis), renal viral or bacterial or fungal infections (e.g. AIDS or sepsis), renal multiple sclerosis or Hashimoto's thyroiditis, allergies (e.g. asthma), disorders (e.g. kidney failure), cardiovascular disorders (e.g. angina pectoris, cerebral ischaemia or congenital heart defects), respiratory disorders, neurological disorders (e.g. Alzheimer's disease or Parkinson's disease), and inflammations (e.g. Crohn's disease). The polynucleotide or polypeptide may also be used as vaccine adjuvants.
CC ACD82641-ACD82950 encode human secreted proteins or their fragments.
CC Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from the USPTO web site at seqdata.uspto.gov/psipdIDEntry.html
XX
SQ Sequence 1181 BP; 357 A; 228 C; 295 G; 298 T; 0 U; 3 Other;
Query Match 2.9%; Score 66; DB 9; Length 1181;
Best Local Similarity 70.7%; Pred. NO. 0.00024;

Matches 87; Conservative 0; Mismatches 36; Indels 0; Gaps 0;			
Oy	2120 GCCTTGTGTTACCACTCTTTCCTTTTACTTATTAATAAATGTTGGTCTCCACCACT	2179'	
Db	1055 GCATTGCTTTTAAACCACTTCTTTTGTAAATAAATAAAGTAAGCTAGTT	1114	
Oy	2180 GNCCTCCCAA	2239	
Db	1115 CTATTGAATGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	1174	
Oy	2240 AAA 2242		
Db	1175 AAA 1177		
RESULT 1028			
AD123025			
ID	AD123025 standard; cDNA; 1181 BP.		
XX			
AC	AD123025;		
XX			
DT	22-APR-2004 (first entry)		
XX			
DE	cDNA encoding novel human secreted protein seq id 310.		
XX			
KW	cytostatic; gene therapy; cancer; human; secreted protein; gene; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003175858-A1.		
XX			
PD	18-SEP-2003.		
XX			
PF	18-JUN-2001; 2001US-00882171.		
XX			
PR	07-MAR-1997; 97US-0038621P.		
PR	07-MAR-1997; 97US-0040162P.		
PR	07-MAR-1997; 97US-0040163P.		
PR	07-MAR-1997; 97US-0040333P.		
PR	07-MAR-1997; 97US-0040334P.		
PR	07-MAR-1997; 97US-0040336P.		
PR	07-MAR-1997; 97US-0040626P.		
PR	11-APR-1997; 97US-0043311P.		
PR	11-APR-1997; 97US-0043312P.		
PR	11-APR-1997; 97US-0043313P.		
PR	11-APR-1997; 97US-0043314P.		
PR	11-APR-1997; 97US-0043315P.		
PR	11-APR-1997; 97US-0043568P.		
PR	11-APR-1997; 97US-0043569P.		
PR	11-APR-1997; 97US-0043576P.		
PR	11-APR-1997; 97US-0043578P.		
PR	11-APR-1997; 97US-0043580P.		
PR	11-APR-1997; 97US-0043659P.		
PR	11-APR-1997; 97US-0043670P.		
PR	11-APR-1997; 97US-0043671P.		
PR	11-APR-1997; 97US-0043672P.		
PR	11-APR-1997; 97US-0043674P.		
PR	23-MAY-1997; 97US-0047492P.		
PR	23-MAY-1997; 97US-0047500P.		
PR	23-MAY-1997; 97US-0047501P.		
PR	23-MAY-1997; 97US-0047502P.		
PR	23-MAY-1997; 97US-0047503P.		
PR	23-MAY-1997; 97US-0047581P.		
PR	23-MAY-1997; 97US-0047582P.		
PR	23-MAY-1997; 97US-0047583P.		
PR	23-MAY-1997; 97US-0047584P.		
PR	23-MAY-1997; 97US-0047585P.		
PR	23-MAY-1997; 97US-0047586P.		
PR	23-MAY-1997; 97US-0047587P.		
PR	23-MAY-1997; 97US-0047588P.		
PR	23-MAY-1997; 97US-0047589P.		
PR	23-MAY-1997; 97US-0047590P.		
PR	23-MAY-1997; 97US-0047592P.		
PR	23-MAY-1997; 97US-0047593P.		
PR	23-MAY-1997; 97US-0047595P.		
PR	23-MAY-1997; 97US-0047596P.		
PR	23-MAY-1997; 97US-0047597P.		
PR	23-MAY-1997; 97US-0047598P.		
PR	23-MAY-1997; 97US-0047599P.		
PR	23-MAY-1997; 97US-0047600P.		
PR	23-MAY-1997; 97US-0047601P.		
PR	23-MAY-1997; 97US-0047612P.		
PR	23-MAY-1997; 97US-0047613P.		
PR	23-MAY-1997; 97US-0047614P.		
PR	23-MAY-1997; 97US-0047615P.		
PR	23-MAY-1997; 97US-0047617P.		
PR	23-MAY-1997; 97US-0047618P.		
PR	23-MAY-1997; 97US-0047632P.		
PR	06-JUN-1997; 97US-0048964P.		
PR	06-JUN-1997; 97US-0048974P.		
PR	13-JUN-1997; 97US-0049610P.		
PR	08-JUL-1997; 97US-0051926P.		
PR	16-JUL-1997; 97US-0052874P.		
PR	18-AUG-1997; 97US-0055724P.		
PR	22-AUG-1997; 97US-0056630P.		
PR	22-AUG-1997; 97US-0056631P.		
PR	22-AUG-1997; 97US-0056632P.		
PR	22-AUG-1997; 97US-0056636P.		
PR	22-AUG-1997; 97US-0056637P.		
PR	22-AUG-1997; 97US-0056662P.		
PR	22-AUG-1997; 97US-0056664P.		
PR	22-AUG-1997; 97US-0056845P.		
PR	22-AUG-1997; 97US-0056862P.		
PR	22-AUG-1997; 97US-0056864P.		
PR	22-AUG-1997; 97US-0056872P.		
PR	22-AUG-1997; 97US-0056874P.		
PR	22-AUG-1997; 97US-0056875P.		
PR	22-AUG-1997; 97US-0056876P.		
PR	22-AUG-1997; 97US-0056877P.		
PR	22-AUG-1997; 97US-0056878P.		
PR	22-AUG-1997; 97US-0056879P.		
PR	22-AUG-1997; 97US-0056880P.		
PR	22-AUG-1997; 97US-0056881P.		
PR	22-AUG-1997; 97US-0056882P.		
PR	22-AUG-1997; 97US-0056884P.		
PR	22-AUG-1997; 97US-0056886P.		
PR	22-AUG-1997; 97US-0056887P.		
PR	22-AUG-1997; 97US-0056888P.		
PR	22-AUG-1997; 97US-0056889P.		
PR	22-AUG-1997; 97US-0056892P.		
PR	22-AUG-1997; 97US-0056893P.		
PR	22-AUG-1997; 97US-0056894P.		
PR	22-AUG-1997; 97US-0056903P.		
PR	22-AUG-1997; 97US-0056908P.		
PR	22-AUG-1997; 97US-0056909P.		
PR	22-AUG-1997; 97US-0056910P.		
PR	22-AUG-1997; 97US-0056911P.		
PR	05-SEP-1997; 97US-0057650P.		
PR	05-SEP-1997; 97US-0057659P.		
PR	05-SEP-1997; 97US-0057761P.		
PR	12-SEP-1997; 97US-0058785P.		
PR	09-OCT-1997; 97US-0061660P.		
PR	06-MAR-1998; 98WO-US004493.		
PR	08-SEP-1998; 98US-00149476.		
PR	17-MAR-2000; 2000US-0190068P.		
PR	16-MAR-2001; 2001US-00809391.		
XX	(RUBE//) RUBEN S M.		
PA	(ROSE//) ROSEN C A.		
PA	(SOPP//) SOPPET D R.		
PA	(CART//) CARTER K C.		
PA	(BEDN//) BEDNARIK D P.		
PA	(ENDR//) ENDRESS G A.		
PA	(YUGG//) YU G.		


```
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048944P.
PR 06-JUN-1997; 97US-0048945P.
PR 08-JUN-1997; 97US-0049610P.
PR 08-JUN-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056633P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
PR 06-MAR-1998; 98WO-US004493.
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Rosen CA, Fischer CL, Soppet DP, Carter KC;
PI Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
XX Moore PA, Shi Y, Latleir DW, Li Y, Zeng Z, Kyaw H;
XX
XX WPI; 2002-634796/68.
XX P-PSDB; ABG95355.
XX
XX New isolated human secreted protein for diagnosing, preventing, treating
PT or ameliorating medical conditions and used as a food additive or
```

```
PT preservative.
XX
XX Example 1; SEQ ID NO 186; 129pp; English.
XX
XX The invention relates to an isolated protein that is one of 186 human
CC secreted proteins, given in the specification, encoded by one of 309 cDNA
CC sequences also given in the specification. The protein is used in a
CC pharmaceutical composition used to prevent, treat or ameliorate a medical
CC condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs,
CC chickens or sheep. Disorders which are diagnosed or treated include
CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC angioneurosis, nervous system disorders e.g. Alzheimer's disease,
CC infections caused by bacteria, viruses and fungi and ocular disorders
CC e.g. corneal infection. The polypeptides can also be used to aid wound
CC healing and epithelial cell proliferation, to prevent skin aging due to
CC sunburn, to maintain organs before transplantation, for supporting cell
CC culture of primary tissues, to regenerate tissues and in chemotaxis. The
CC polypeptides can also be used as a food additive or preservative to
CC increase or decrease storage capabilities, fat content, lipid, protein,
CC carbohydrate, vitamins, minerals, cofactors and other nutritional
CC components. The present sequence represents a cDNA derived from a gene
CC encoding one of the novel human secreted proteins of the invention. Note:
CC This sequence did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=642052681
XX
XX Sequence 1212 BP; 363 A; 241 C; 307 G; 300 T; 0 U; 1 Other;
XX
XX Query Match 2.9%; Score 66; DB 6; Length 1212;
XX Best Local Similarity 70.7%; Pred. No. 0.00024;
XX Matches 87; Conservative 0; Mismatches 36; Indels 0; Gaps 0;
XX
QY 2120 GCCTTTGCTTTACCACTCTTCTCTTTTATCTATTAATAAATGTGTCTCCACCACCT 2179
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1086 GCATTTCGTTTAAACCACTTCTCTTTTAAATAATAATAAAGTAAATAGCTAGTT 1145
QY 2180 GNTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2239
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1146 CTATTGAATGCATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA 1205
QY 2240 AAA 2242
Db |||
1206 AAA 1208
XX
XX RESULT 1033
XX ACD82816
XX ID ACD82816 standard; cDNA; 1212 BP.
XX
XX AC ACD82816;
XX
XX XX
XX 22-SEP-2003 (first entry)
XX
XX cDNA sequence #176 containing coding region of a human secreted protein.
XX
XX Human; secreted protein; hyperproliferative disorder; leukaemia;
XX breast cancer; wound; reproductive disorder; blood-related disorder;
XX haemophilia; thrombocytopaenia; immunodeficiency; thymic hypoplasia;
XX Wiskott-Aldrich syndrome; autoimmune disorder; multiple sclerosis;
XX graft-versus-host disease; Hashimoto's thyroiditis; allergy; asthma;
XX viral infection; bacterial infection; fungal infection; AIDS; sepsis;
XX renal disorder; kidney failure; cardiovascular disorder; cytostatic;
XX angina pectoris; cerebral ischaemia; congenital heart defect;
XX respiratory disorder; neurological disorder; Alzheimer's disease;
XX Parkinson's disease; inflammation; Crohn's disease; vulvectomy;
XX immunosuppressive; antibacterial; haemostatic; thrombolytic;
XX anticoagulant; neuroprotective; thyromimetic; antiallergic;
XX antiasthmatic; virucide; fungicide; anti-HIV; nephrotropic;
XX cerebroprotective; cardiant; nootropic; antiparkinsonian;
XX antiinflammatory; gene; ss.
XX
```

OS Homo sapiens.
 XX US2003049618-A1.
 XX 13-MAR-2003.
 XX PF 16-MAR-2001; 2001US-00809391.
 XX
 PR 07-MAR-1997; 97US-0038621P.
 PR 07-MAR-1997; 97US-0040162P.
 PR 07-MAR-1997; 97US-0040163P.
 PR 07-MAR-1997; 97US-0040333P.
 PR 07-MAR-1997; 97US-0040334P.
 PR 07-MAR-1997; 97US-0040336P.
 PR 07-MAR-1997; 97US-0040337P.
 PR 11-APR-1997; 97US-0043311P.
 PR 11-APR-1997; 97US-0043312P.
 PR 11-APR-1997; 97US-0043313P.
 PR 11-APR-1997; 97US-0043314P.
 PR 11-APR-1997; 97US-0043315P.
 PR 11-APR-1997; 97US-0043569P.
 PR 11-APR-1997; 97US-0043576P.
 PR 11-APR-1997; 97US-0043578P.
 PR 11-APR-1997; 97US-0043580P.
 PR 11-APR-1997; 97US-0043582P.
 PR 11-APR-1997; 97US-0043670P.
 PR 11-APR-1997; 97US-0043671P.
 PR 11-APR-1997; 97US-0043672P.
 PR 11-APR-1997; 97US-0043674P.
 PR 23-MAY-1997; 97US-0047492P.
 PR 23-MAY-1997; 97US-0047500P.
 PR 23-MAY-1997; 97US-0047501P.
 PR 23-MAY-1997; 97US-0047502P.
 PR 23-MAY-1997; 97US-0047503P.
 PR 23-MAY-1997; 97US-0047581P.
 PR 23-MAY-1997; 97US-0047582P.
 PR 23-MAY-1997; 97US-0047583P.
 PR 23-MAY-1997; 97US-0047584P.
 PR 23-MAY-1997; 97US-0047585P.
 PR 23-MAY-1997; 97US-0047586P.
 PR 23-MAY-1997; 97US-0047587P.
 PR 23-MAY-1997; 97US-0047588P.
 PR 23-MAY-1997; 97US-0047589P.
 PR 23-MAY-1997; 97US-0047590P.
 PR 23-MAY-1997; 97US-0047592P.
 PR 23-MAY-1997; 97US-0047593P.
 PR 23-MAY-1997; 97US-0047594P.
 PR 23-MAY-1997; 97US-0047595P.
 PR 23-MAY-1997; 97US-0047596P.
 PR 23-MAY-1997; 97US-0047597P.
 PR 23-MAY-1997; 97US-0047598P.
 PR 23-MAY-1997; 97US-0047599P.
 PR 23-MAY-1997; 97US-0047600P.
 PR 23-MAY-1997; 97US-0047601P.
 PR 23-MAY-1997; 97US-0047612P.
 PR 23-MAY-1997; 97US-0047613P.
 PR 23-MAY-1997; 97US-0047614P.
 PR 23-MAY-1997; 97US-0047615P.
 PR 23-MAY-1997; 97US-0047617P.
 PR 23-MAY-1997; 97US-0047618P.
 PR 23-MAY-1997; 97US-0047632P.
 PR 23-MAY-1997; 97US-0047633P.
 PR 06-JUN-1997; 97US-0048964P.
 PR 06-JUN-1997; 97US-0048974P.
 PR 13-JUN-1997; 97US-0049610P.
 PR 08-JUL-1997; 97US-0051926P.
 PR 16-JUL-1997; 97US-0052874P.
 PR 18-AUG-1997; 97US-0055724P.
 PR 22-AUG-1997; 97US-0056630P.
 PR 22-AUG-1997; 97US-0056631P.
 PR 22-AUG-1997; 97US-0056632P.
 PR 22-AUG-1997; 97US-0056636P.

PR 22-AUG-1997; 97US-0056637P.
 PR 22-AUG-1997; 97US-0056662P.
 PR 22-AUG-1997; 97US-0056664P.
 PR 22-AUG-1997; 97US-0056845P.
 PR 22-AUG-1997; 97US-0056862P.
 PR 22-AUG-1997; 97US-0056864P.
 PR 22-AUG-1997; 97US-0056872P.
 PR 22-AUG-1997; 97US-0056874P.
 PR 22-AUG-1997; 97US-0056875P.
 PR 22-AUG-1997; 97US-0056876P.
 PR 22-AUG-1997; 97US-0056877P.
 PR 22-AUG-1997; 97US-0056878P.
 PR 22-AUG-1997; 97US-0056879P.
 PR 22-AUG-1997; 97US-0056880P.
 PR 22-AUG-1997; 97US-0056881P.
 PR 22-AUG-1997; 97US-0056882P.
 PR 22-AUG-1997; 97US-0056884P.
 PR 22-AUG-1997; 97US-0056886P.
 PR 22-AUG-1997; 97US-0056887P.
 PR 22-AUG-1997; 97US-0056888P.
 PR 22-AUG-1997; 97US-0056889P.
 PR 22-AUG-1997; 97US-0056892P.
 PR 22-AUG-1997; 97US-0056893P.
 PR 22-AUG-1997; 97US-0056894P.
 PR 22-AUG-1997; 97US-0056903P.
 PR 22-AUG-1997; 97US-0056908P.
 PR 22-AUG-1997; 97US-0056909P.
 PR 22-AUG-1997; 97US-0056910P.
 PR 05-SEP-1997; 97US-0056911P.
 PR 05-SEP-1997; 97US-0057650P.
 PR 05-SEP-1997; 97US-0057669P.
 PR 12-SEP-1997; 97US-0057761P.
 PR 09-OCT-1997; 97US-0058785P.
 PR 06-MAR-1998; 98WO-US004493.
 PR 08-SEP-1998; 98US-00149476.
 PR 17-MAR-2000; 2000US-0190068P.
 XX
 PA (RUBE/) RUBEN S M.
 PA (ROSE/) ROSEN C A.
 PA (SOPP/) SOPPET D R.
 PA (CART/) CARTER K C.
 PA (BEDN/) BEDNARIK D P.
 PA (ENDR/) ENDRESS G A.
 PA (YUGG/) YU G.
 PA (NLJJ/) NI J.
 PA (FENG/) FENG P.
 PA (YOUN/) YOUNG P E.
 PA (GREE/) GREENE J M.
 PA (FERR/) FERRIE A M.
 PA (DUAN/) DUAN D R.
 PA (HUJJ/) HU J.
 PA (FLOR/) FLORENCE K A.
 PA (OLSE/) OLSEN H S.
 PA (FISC/) FISCHER C L.
 PA (EBNE/) EBNER R.
 PA (BREW/) BREWER L A.
 PA (MOOR/) MOORE P A.
 PA (SHIY/) SHI Y.
 PA (LAFI/) LAFLEUR D W.
 PA (LIYY/) LI Y.
 PA (ZENG/) ZENG Z.
 PA (KYAW/) KYAW H.
 XX
 PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
 PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
 PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
 PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
 XX
 DR WPI; 2003-521800/49.
 DR P-PSDB; ABO34549.
 XX
 PT New genes and its encoded prostate cancer antigen proteins, useful for

PR 22-AUG-1997; 97US-0056881P.
 PR 22-AUG-1997; 97US-0056882P.
 PR 22-AUG-1997; 97US-0056884P.
 PR 22-AUG-1997; 97US-0056886P.
 PR 22-AUG-1997; 97US-0056887P.
 PR 22-AUG-1997; 97US-0056888P.
 PR 22-AUG-1997; 97US-0056889P.
 PR 22-AUG-1997; 97US-0056892P.
 PR 22-AUG-1997; 97US-0056893P.
 PR 22-AUG-1997; 97US-0056894P.
 PR 22-AUG-1997; 97US-0056903P.
 PR 22-AUG-1997; 97US-0056908P.
 PR 22-AUG-1997; 97US-0056909P.
 PR 22-AUG-1997; 97US-0056910P.
 PR 22-AUG-1997; 97US-0056911P.
 PR 05-SEP-1997; 97US-0057650P.
 PR 05-SEP-1997; 97US-0057669P.
 PR 12-SEP-1997; 97US-0057761P.
 PR 12-SEP-1997; 97US-0058785P.
 PR 09-OCT-1997; 97US-0061660P.
 PR 06-MAR-1998; 98WO-US004493.
 PR 08-SEP-1998; 98US-00149476.
 PR 17-MAR-2000; 2000US-0190068P.
 PR 16-MAR-2001; 2001US-00809331.

XX (RUBE//) RUBEN S M.
 PA (ROSE//) ROSEN C A.
 PA (SOPP//) SOPPET D R.
 PA (CART//) CARTER K C.
 PA (BEDN//) BEDNARIK D P.
 PA (ENDR//) ENDRESS G A.
 PA (YUGG//) YU G.
 PA (NIJJ//) NI J.
 PA (FENG//) FENG P.
 PA (YOUN//) YOUNG P E.
 PA (GREEN//) GREENE J M.
 PA (FERR//) FERRIE A M.
 PA (DUAN//) DUAN D R.
 PA (HUJJ//) HU J.
 PA (FLOR//) FLORENCE K A.
 PA (OLSE//) OLSEN H S.
 PA (FISC//) FISCHER C L.
 PA (EBNE//) EBNER R.
 PA (BREW//) BREWER L A.
 PA (MOOR//) MOORE P A.
 PA (SHIY//) SHI Y.
 PA (LAFLE//) LAFLEUR D W.
 PA (LIYY//) LI Y.
 PA (ZENG//) ZENG Z.
 PA (KYAW//) KYAW H.

XX Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
 PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
 PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
 PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;

XX WPI: 2003-898535/82.
 DR P-PSDB; ADI23210.

XX New nucleic acid molecule, useful for preparing a medicament for
 PT diagnosing, preventing, treating or ameliorating a medical condition
 FT e.g., cancer.

XX Claim 1; SEQ ID NO 186; 256pp; English.

XX The invention describes an isolated nucleic acid comprising a sequence
 CC having 95 % identity with: a polynucleotide fragment of a sequence not
 CC given in the specification, or its allelic variant; a polynucleotide
 CC fragment of the cDNA sequence; a polynucleotide sequence encoding a
 CC polypeptide, or its fragment, domain, epitope or species homologue; or a
 CC polynucleotide that hybridises under stringent conditions to any one of
 CC the sequences of (a)-(c). The nucleic acid is useful for preparing a
 CC medicament for diagnosing, preventing, treating or ameliorating a medical

CC condition e.g., cancer. The sequence encodes a novel human secreted
 CC protein of the invention.

XX SQ Sequence 1212 BP; 363 A; 241 C; 307 G; 300 T; 0 U; 1 Other;
 Query Match 2.9%; Score 66; DB 10; Length 1212;
 Best Local Similarity 70.7%; Pred. No. 0.00024;
 Matches 87; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 2120 GCCTTTGCTTTTACCACCTCTTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCT 2179
 |||||
 Db 1086 GCATTGCTTTTAAACCATTTCTTTTAAATAAATAAAGTAATAAAGCTAGTT 1145
 |||||
 QY 2180 GNTCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2239
 |||||
 Db 1146 CTATTGAAATGCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1205
 |||||

QY 2240 AAA 2242
 |||||
 Db 1206 AAA 1208

RESULT 1035

ADH73903

ID ADH73903 standard; cDNA; 1212 BP.

XX AC ADH73903;

XX DT 25-MAR-2004 (first entry)

XX DE Human secreted protein cDNA #176.

XX KW human; secreted protein; cancer; haematopoietic disorder;
 KW endocrine disorder; immune system disease; inflammatory disorder; ss;
 KW gene.

XX OS Homo sapiens.

XX PN US2003225248-A1.

XX PD 04-DEC-2003.

XX 10-JUN-2002; 2002US-00164861.

XX 07-MAR-1997; 97US-0038621P.

PR 07-MAR-1997; 97US-0040161P.

PR 07-MAR-1997; 97US-0040162P.

PR 07-MAR-1997; 97US-0040163P.

PR 07-MAR-1997; 97US-0040333P.

PR 07-MAR-1997; 97US-0040334P.

PR 07-MAR-1997; 97US-0040336P.

PR 07-MAR-1997; 97US-0040626P.

PR 11-APR-1997; 97US-0043311P.

PR 11-APR-1997; 97US-0043312P.

PR 11-APR-1997; 97US-0043313P.

PR 11-APR-1997; 97US-0043314P.

PR 11-APR-1997; 97US-0043315P.

PR 11-APR-1997; 97US-0043568P.

PR 11-APR-1997; 97US-0043569P.

PR 11-APR-1997; 97US-0043576P.

PR 11-APR-1997; 97US-0043578P.

PR 11-APR-1997; 97US-0043580P.

PR 11-APR-1997; 97US-0043669P.

PR 11-APR-1997; 97US-0043670P.

PR 11-APR-1997; 97US-0043671P.

PR 11-APR-1997; 97US-0043672P.

PR 11-APR-1997; 97US-0043674P.

PR 23-MAY-1997; 97US-0047492P.

PR 23-MAY-1997; 97US-0047500P.

PR 23-MAY-1997; 97US-0047501P.

PR 23-MAY-1997; 97US-0047502P.

PR 23-MAY-1997; 97US-0047503P.

PR 23-MAY-1997; 97US-0047581P.

```
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047616P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 23-MAY-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 06-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057659P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
PR 06-MAR-1998; 98US-0004493.
PR 08-SEP-1998; 98US-00149476.

XX (HUMA-) HUMAN GENOME SCI INC.
XX Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP,
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
PI Duan R, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX WPI; 2004-131264/13.
DR P-PSDB; ADH74212.
XX Isolated nucleic acid molecules encoding human secreted proteins, useful
PT for preventing, diagnosing and treating disorders associated with
PT aberrant expression and activity.
XX Claim 3; SEQ ID NO 186; 142pp; English.
XX The invention relates to isolated nucleic acid molecules and the human
CC secreted proteins (SPs) they encode. The proteins and nucleic acids may
CC be used in the prevention, diagnosis and treatment of diseases associated
CC with inappropriate SP expression e.g. cancer, haematopoietic disorders,
CC endocrine disorders, diseases of the immune system, inflammatory
CC disorders and many others. Full details of disorders that may be
CC prevented, diagnosed and/or treated by the above methods are given in the
CC specification. The nucleic acid molecules may be used to produce their
CC proteins. The nucleic acid and it's complementary sequences may also be
CC used as DNA probes in diagnostic assays to detect and quantitate the
CC presence of similar nucleic acids in samples, and therefore which
CC patients may be in need of restorative therapy. The SPs may also be used
CC as antigens in the production of antibodies against the proteins and in
CC assays to identify modulators of SP expression and activity. The anti-SP
CC antibodies and antagonists may also be used to down regulate expression
CC and activity. The anti-SP antibodies may also be used as diagnostic
CC agents for detecting the presence of the proteins in samples (e.g. by
CC enzyme linked immunosorbant assay (ELISA)). The present sequence
CC represents a human secreted protein cDNA.
XX
SQ Sequence 1212 BP; 363 A; 241 C; 307 G; 300 T; 0 U; 1 Other;
Query Match 2.9%; Score 66; DB 12; Length 1212;
Best Local Similarity 70.7%; Pred. No. 0.00024;
Matches 87; Conservative 0; Mismatches 36; Indels 0; Gaps 0;
QY 2120 GCCTTTGCTTTACCACTCTTCTTTTATCTTTATTAATAAAATGTTGTCTCCACACT 2179
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1086 GCATTTGCTTTTAAACCACTTCTTTTGTAAATAAATAAGTAAATAAGCTAGTT 1145
QY 2180 GNCCTCCAAAAA 2239
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1146 CTATTGAAATGCACAAAAA 1205
QY 2240 AAA 2242
Db |||||
1206 AAA 1208
RESULT 1036
ABX71274
ID ABX71274 standard; cDNA; 1447 BP.
XX
AC ABX71274;
XX
DT 14-APR-2003 (first entry)
XX Human brain-derived cDNA from clone DKFZphbr2_78n23.
XX Human; gene; gene therapy; vaccine; disease treatment; detection; ss.
XX Homo sapiens.
XX WC200112659-A2.
XX
XX 22-FEB-2001.
```

XX 18-AUG-2000; 2000WO-IB001496.
 XX 18-AUG-1999; 99US-0149499P.
 PR 28-SEP-1999; 99US-0156503P.
 XX (GEHU-) GERMAN HUMAN GENOME PROJECT.
 XX Wiemann S;
 PI WPI; 2001-327840/34.
 DR P-PSDB; ABUS2772.
 XX Nucleic acids having the sequences of clones isolated from libraries of
 PT different human tissues, useful in recombinant DNA methodologies.
 XX Claim 1; Page 334; 1095pp; English.
 XX This invention describes novel polynucleotides and polypeptides isolated
 CC from human cDNA libraries which can be used for gene therapy or in
 CC vaccines. The polynucleotides of the invention and antibodies encoded by
 CC them may be used in the prevention, diagnosis and treatment of diseases
 CC associated with inappropriate polypeptide expression. The products of the
 CC invention may also be used to identify modulators of expression and
 CC activity and to down regulate expression and activity. The antibodies of
 CC the invention may also be used as diagnostic agents for detecting the
 CC presence of polypeptides in samples. This sequence encodes a polypeptide
 CC described in the disclosure of the invention
 XX Sequence 1447 BP; 384 A; 376 C; 397 G; 290 T; 0 U; 0 Other;
 SQ
 Query Match 2.9%; Score 66; DB 5; Length 1447;
 Best Local Similarity 68.7%; Pred. No. 0.00025;
 Matches 90; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
 Qy 2112 CAATGATCGCTTTCCTTACACCTCTTCTTTTATCTTATTAATAAATGTTGCT 2171
 Db 1311 CATGATAATTTTGTCTTCTCCCTGTGTGATTTTGCCATCAAAATAAATTTGAGACT 1370
 Qy 2172 CCACCATGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2231
 Db 1371 CGTTAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAAGNA 1430
 Qy 2232 AAAAAAATAAAAA 2242
 Db 1431 AAAAAAATAAAAA 1441
 RESULT 1037
 ID AAQ50573
 AC AAQ50573 standard; cDNA to mRNA; 1453 BP.
 XX AAQ50573;
 XX 25-MAR-2003 (revised)
 DT 24-MAY-1994 (first entry)
 XX Asparaginylendopeptidase clone 104.
 XX Asparaginylendopeptidase; Canavalia ensiformis; seed; L-asparagine;
 KW primer; PCR; protein fragmentation; peptide synthesis; ss.
 XX Canavalia ensiformis.
 XX Key Location/Qualifiers
 FH CDS 3..1094
 FT /*tag= a
 XX JP05276960-A.
 XX 26-OCT-1993.
 XX 07-AUG-1992; 92JP-00231602.

XX 07-FEB-1992; 92JP-00056023.
 PR (TAKI) TAKARA SHUZO CO LTD.
 XX WPI; 1993-373587/47.
 DR P-PSDB; AAR43038.
 XX New gene for encoding asparaginyl endo-peptidase - comprises 8 specified
 PT DNA sequences.
 XX Disclosure; Page 22-24; 35pp; Japanese.
 XX A gene encoding asparaginylendopeptidase is claimed. 8 DNA sequences are
 CC given (AAQ50559-66). The enzyme is a protease derived from a seed of
 CC Canavalia ensiformis which selectively hydrolyses C-terminus amide bond
 CC of L-asparagine residue (see AAR43033 and AAR43041). The enzyme is useful
 CC for protein fragmentation and enzymatic peptide synthesis. The primers
 CC given in AAQ50567-68, AAQ50576-77 and AAQ50583-90 were used in the
 CC isolation of the fragments given in AAQ50569-75 and AAQ50578-79, by PCR.
 CC (Updated on 25-MAR-2003 to correct PA field.)
 XX Sequence 1453 BP; 480 A; 252 C; 335 G; 386 T; 0 U; 0 Other;
 SQ
 Query Match 2.9%; Score 66; DB 2; Length 1453;
 Best Local Similarity 61.4%; Pred. No. 0.00025;
 Matches 105; Conservative 0; Mismatches 66; Indels 0; Gaps 0;
 Qy 2072 TCTAGTCCCTCAAGTCTCGTGACACATAATCATTCATCCATCCATGATCGCTTTCCTTA 2131
 Db 1275 TCTATTATTTCTATTGAGAGTGGTTAGGAGAGAATGCATATATCGATCAGCTGATATAA 1334
 Qy 2132 CCACCTCTTCTCTTTTCTTATTATAAATAATGTTGTCCTCCACACGTGCTCCCAAAA 2191
 Db 1335 ATGCAGTGCCTTTTCATAAATAAGTAATTAAGTATTAGTCTATTAAAAAATAAAAA 1394
 Qy 2192 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
 Db 1395 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1445
 RESULT 1038
 ID ADQ25305
 AC ADQ25305 standard; DNA; 1585 BP.
 XX ADQ25305;
 XX 26-AUG-2004 (first entry)
 DT Human soft tissue sarcoma-upregulated DNA - SEQ ID 8125.
 DE soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human;
 KW ds.
 XX Homo sapiens.
 OS WO2004048938-A2.
 PN 10-JUN-2004.
 PD 26-NOV-2003; 2003WO-US038193.
 PF 26-NOV-2002; 2002US-0429739P.
 XX (PROT-) PROTEIN DESIGN LABS INC.
 XX Aziz N, Ginsburg WM, Zlotnik A;
 XX WPI; 2004-441208/41.
 XX Early detection of soft tissue sarcoma comprises determining expression
 PT of a gene in a first soft tissue sample and a normal soft tissue sample
 PT and comparing the gene expression, also useful in treating soft tissue

```
PT sarcoma.
XX
PS Example 2; SEQ ID NO 8125; 210pp; English.
XX
CC The invention relates to a novel method for detecting soft tissue sarcoma
CC which comprises obtaining a first soft tissue sample from an individual
CC and a normal soft tissue sample from the same or different individual,
CC determining the expression of a gene in both samples and comparing the
CC expression of the gene in both soft tissue samples, where a higher level
CC of protein expression in the first soft tissue sample indicates the
CC presence of soft tissue sarcoma. The method of the invention has
CC cytostatic applications and may be useful for detecting soft tissue
CC sarcoma, possibly via gene therapy or vaccine production. The nucleic
CC acid sequences may be useful in diagnostic and screening applications.
CC The current sequence is that of a human soft tissue sarcoma-upregulated
CC DNA of the invention. The current sequence is not shown within the
CC specification per se but was submitted in CD format by the inventor.
XX
SQ Sequence 1585 BP; 471 A; 321 C; 440 G; 337 T; 0 U; 16 Other;
Query Match 2.9%; Score 66; DB 12; Length 1585;
Best Local Similarity 68.7%; Pred. No. 0.00026;
Matches 90; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
QY 2112 CAATGATCGCTTGGCTTTACCACTCTTCTCTTTATCTTATTAATAAATAATCTTGGTCT 2171
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1430 CAATTTCTATATCGCTATTAACTTTTCTTTTCTTAAATAAATAAATAAATAA 1489
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2172 CCACCACTGNTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2231
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1490 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1549
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2232 AAAAAAAAAA 2242
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1550 AAAAAAAAAA 1560
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
RESULT 1039
AAC77949
ID AAC77949 standard; cDNA to mRNA; 1640 BP.
XX
AC AAQ50575;
XX
DT 25-MAR-2003 (revised)
DT 24-MAY-1994 (first entry)
XX
DE Asparaginylendopeptidase clone ASN-1.
XX
KW Asparaginylendopeptidase; Canavalia ensiformis; seed; L-asparagine;
KW primer; PCR; protein fragmentation; peptide synthesis; ss.
XX
OS Canavalia ensiformis.
XX
XX JP05276960-A.
XX
XX 26-OCT-1993.
XX
PF 07-AUG-1992; 92JP-00231602.
XX
PR 07-FEB-1992; 92JP-00056023.
XX
PA (TAKI ) TAKARA SHUZO CO LTD.
XX
DR WPI; 1993-373587/47.
XX
PT New gene for encoding asparaginyl endo-peptidase - comprises 8 specified
PT DNA sequences.
XX
PS Disclosure; Page 26; 35pp; Japanese.
XX
CC A gene encoding asparaginylendopeptidase is claimed. 8 DNA sequences are
CC given (AAQ50559-66). The enzyme is a protease derived from a seed of
CC Canavalia ensiformis which selectively hydrolyses C-terminus amide bond
CC
```

```
CC of L-asparagine residue (see AAR43033 and AAR43041). The enzyme is useful
CC for protein fragmentation and enzymatic peptide synthesis. The primers
CC given in AAQ50567-68, AAQ50576-77 and AAQ50583-90 were used in the
CC isolation of the fragments given in AAQ50569-75 and AAQ50578-79, by PCR.
CC (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 1640 BP; 533 A; 288 C; 383 G; 436 T; 0 U; 0 Other;
Query Match 2.9%; Score 66; DB 2; Length 1640;
Best Local Similarity 61.4%; Pred. No. 0.00026;
Matches 105; Conservative 0; Mismatches 66; Indels 0; Gaps 0;
QY 2072 TCTAGTCTCCTCAAGTGTGTCGACACATAATCAATCCATCCATGATCCCTTTGCTTAA 2131
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1462 TCTATTATTCTTATCTTATTAATAAATAATGTTGGTCTCCACCACCTGCTCCCAAAA 1521
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2132 CCACCTCTTCTCTTTTATCTTATTAATAAATAATGTTGGTCTCCACCACCTGCTCCCAAAA 2191
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1522 ATGCAGTGTCTTTTTCATAAATAATGAATTAAGTATTAGTCTATTAAAAAATAAATAA 1581
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2192 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1582 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1632
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
RESULT 1040
AAC77949
ID AAC77949 standard; cDNA; 1793 BP.
XX
AC AAC77949;
XX
DT 08-FEB-2001 (first entry)
XX
DE Human cancer associated gene sequence SEQ ID NO:343.
XX
KW Human; cancer associated gene; cancer antigen; detection; cancer;
KW diagnosis; cytostatic; proliferative; cancer antigen; immunomodulator;
KW anti-diabetic; antiasthmatic; antirheumatic; antithrombotic; antiviral;
KW anti-inflammatory; antithyroid; antiallergic; antibacterial; cardiant;
KW dermatological; neuroprotective; thrombolytic; coagulant; nootropic;
KW vasotropic; antipsoriatic; angiogenic; gene therapy; inflammation;
KW immune disorder; haematopoietic cell disorder; autoimmune disorder;
KW allergic reaction; graft versus host disease; organ rejection;
KW haemostatic; thrombolytic; cardiovascular disorder; infection;
KW neurological disease; drug screening; ss.
XX
OS Homo sapiens.
XX
XX WO200053350-A1.
XX
XX 21-SEP-2000.
XX
XX 08-MAR-2000; 2000WO-US005882.
XX
XX 12-MAR-1999; 99US-0124270P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Ruben SM;
XX
XX WPI; 2000-587533/55.
XX
XX P-PSDB; AAB43740.
XX
XX Novel isolated nucleic acids comprising sequences encoding peptides
XX useful for treating or diagnosing e.g. cancer.
XX
XX Claim 1; Page 894; 2352pp; English.
XX
XX AAC77607 to AAC78448 encode the human cancer associated proteins given in
XX AAB43398 to AAB44239. The proteins can have activities based on the
XX tissues and cells the genes are expressed in. Example of activities
XX include: cytostatic; proliferative; vulnary; immunomodulator;
XX antidiabetic; antiasthmatic; antirheumatic; antiarthritic;
```


CC antiinflammatory; antithyroid; antiallergic; antibacterial; antiviral;
 CC dermatological; neuroprotective; cardiac; thrombolytic; coagulant;
 CC nootropic; vasotropic; antipsoriatic and antiangiogenic. The
 CC polynucleotides and polypeptides can be used for preventing, treating or
 CC ameliorating medical conditions and diagnosing pathological conditions.
 CC polynucleotides, polypeptides, antibodies, agonists and antagonists from
 CC the present invention may be used to treat immune disorders by activating
 CC or inhibiting the proliferation, differentiation or mobilisation of
 CC immune cells, to treat disorders of haematopoietic cells, autoimmune
 CC disorders, allergic reactions, graft versus host disease and organ
 CC rejection, modulate haemostatic or thrombolytic activity, modulate
 CC inflammation, cancers, cardiovascular disorders, neurological disease and
 CC bacterial or viral infections. The peptides, nucleotides, antibodies,
 CC agonists and antagonists may be also be used in drug screens. AAC78449 to
 CC AAC78457 and AAB44240 represent sequences used in the exemplification of
 CC the present invention

SQ Sequence 1793 BP; 514 A; 394 C; 469 G; 409 T; 0 U; 7 Other;

Query Match 2.9%; Score 66; DB 3; Length 1793;
 Best Local Similarity 66.7%; Pred. No. 0.00027;
 Matches 90; Conservative 2; Mismatches 43; Indels 0; Gaps 0;
 QY 2108 CATCAATGATCGCTTTCCTTTACCACTCTTCTTTTATCTTATTAATAAATGTG-2167
 DB 1646 CCTCTGTGATGCTCTGCTCCCAACCATTTGACTCTTACAAAGAAATAAATA 1705
 QY 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
 DB 1706 TTAAGCTTCMAWAGCTGNAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1765
 QY 2228 AAAAAAAAAAAAAA 2242
 DB 1766 AAAAAAAAAAAAAA 1780

RESULT 1041

AAQ50579
 ID AAQ50579 standard; cDNA to mRNA; 1910 BP.

AC AAQ50579;
 XX
 XX 25-MAR-2003 (revised)
 DT 24-MAY-1994 (first entry)
 XX
 DE Asparaginylendopeptidase ASN.
 XX
 KW Asparaginylendopeptidase; Canavalia ensiformis; seed; L-asparagine;
 KW primer; PCR; protein fragmentation; peptide synthesis; ss.

XX Canavalia ensiformis.

Key Location/Qualifiers
 CDS 229..1551
 FT /*tag= a

JP05276960-A.

26-OCT-1993..

07-AUG-1992; 92JP-00231602.

07-FEB-1992; 92JP-00056023.

(TAKI) TAKARA SHUZO CO LTD.

WPI; 1993-373587/47.

P-PSDB; AAR43040.

XX New gene for encoding asparaginyl endo-peptidase - comprises 8 specified
 PT DNA sequences.

PS Disclosure; Page 27-29; 35pp; Japanese.

XX A gene encoding asparaginylendopeptidase is claimed. 8 DNA sequences are
 CC given (AAQ50559-66). The enzyme is a protease derived from a seed of
 CC Canavalia ensiformis which selectively hydrolyses C-terminus amide bond
 CC of L-asparagine residue (see AAR43033 and AAR43041). The enzyme is useful
 CC for protein fragmentation and enzymatic peptide synthesis. The primers
 CC given in AAQ50567-68, AAQ50576-77 and AAQ50583-90 were used in the
 CC isolation of the fragments given in AAQ50569-75 and AAQ50578-79, by PCR.
 CC (Updated on 25-MAR-2003 to correct PA field.)

SQ Sequence 1910 BP; 591 A; 339 C; 464 G; 516 T; 0 U; 0 Other;

Query Match 2.9%; Score 66; DB 2; Length 1910;
 Best Local Similarity 61.4%; Pred. No. 0.00028;
 Matches 105; Conservative 0; Mismatches 66; Indels 0; Gaps 0;
 QY 2072 TCTAGGTCCTCAAGTCCTCGACACATAATCATTCCATCCATGATCGCTTTCCTTA 2131
 DB 1732 TCTATTATTCTTATTTAGAGTGGTTAGGAGAGATGTCATATATCGATCAGGTATATAA 1791
 QY 2132 CCACCTCTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCTGCTCCCAAAA 2191
 DB 1792 ATGCAGTCCCTTTTCATATAAATAAGTAATTAGTATTAGTCTATTAAAAA 1851
 QY 2192 AA 2242
 DB 1852 AA 1902

RESULT 1042

AAAL62477
 ID AAL62477 standard; DNA; 2291 BP.

AC AAL62477;

XX 06-OCT-2003 (first entry)

DE Human oxidase DNA.

XX Human; haematologic disorder; haematopoiesis; anaemia; chronic infection;
 KW malaria; trypanosomiasis; marrow deficiency; renal failure; thalassaemia;
 KW polycythaemia; infectious mononucleosis; IM; leukaemia; Ewing's sarcoma;
 KW Wilm's tumour; cancer; retinoblastoma; haemophilia; thrombosis; virucide;
 KW lead poisoning; chemical injury; disseminated intravascular coagulation;
 KW hyperplenism; antibody-mediated disorder; protozoacide; gene therapy;
 KW erythroblastosis; nephrotropic; oxidase; ds.

XX Homo sapiens.

Key Location/Qualifiers
 CDS 223..1890
 FT /*tag= a
 FT /product= "Human oxidase"

WO2003051180-A2.

26-JUN-2003.

17-DEC-2002; 2002WO-US040194.

17-DEC-2001; 2001US-0341606P.

(MILL-) MILLENNIUM PHARM INC.

Carroll JM, Healy A;

WPI; 2003-523489/49.

P-PSDB; AAO30989.

XX Identifying a compound useful for treating a hematologic disorder, e.g.
 PT anemia, comprises assaying the ability of the compound to modulate 252,
 PT 304, 1980, 14717, 9941, 19310 or 17832 nucleic acid expression or
 PT polypeptide activity.

CC expression of the gene in both soft tissue samples, where a higher level
CC of protein expression in the first soft tissue sample indicates the
CC presence of soft tissue sarcoma. The method of the invention has
CC cytosstatic applications and may be useful for detecting soft tissue
CC sarcoma, possibly via gene therapy or vaccine production. The nucleic
CC acid sequences may be useful in diagnostic and screening applications.
CC The current sequence is that of a human soft tissue sarcoma-upregulated
CC DNA of the invention. The current sequence is not shown within the
CC specification per se but was submitted in CD format by the inventor.
XX

SQ Sequence 2988 BP; 704 A; 834 C; 801 G; 649 T; 0 U; 0 Other;

	Query Match	2.9%	Score 66	DB 12	Length 2988
	Best Local Similarity	73.0%	Pred. No. 0.00032		
	Matches 84	Conservative 0	Mismatches 31	Indels 0	Gaps 0
Qy	2128	TTTACCACTCTTTCCTTTTATCTATTAAATAAAATGTTGGTCTCCACCACTGNCCTCCCA	2187		
Db	2855	TTTCCTTTTTTTTTTCTTTTGTCTACTGCAACGATGCTATATAAATGCTCTTATCAAA	2914		
Qy	2188	AA	2242		
Db	2915	AA	2969		

RESULT 1045
AAZ52568
ID AAZ52568 standard; cDNA; 3116 BP.
XX
AC AAZ52568;

29-FEB-2000	(first entry)
Human secreted protein clone y118_1	nucleotide sequence SEQ ID NO:187.

Human; secreted protein; immunostimulatory; haemostatic; cytokine;
proliferative; differentiative; chemotactic; chemokinetic; vaccine;
thrombolytic; antiinflammatory; cytostatic; immunosuppressive;
gene therapy; ss.

XX	Homo sapiens.	
OS		
PN		
XX	WO9958642-A2.	
XX		
PD	18 - NOV-1999 .	
XX		
XX		99WO-US010843 .
XX		
PR	14-MAY-1998;	98US-0085472P.
PR	17-AUG-1998;	98US-0096824P.
PR	11-SEP-1998;	98US-0099843P.
PR	11-SEP-1998;	98US-0099950P.
PR	15-SEP-1998;	98US-0100424P.
PR	29-SEP-1998;	98US-0103229P.
PR	09-OCT-1998;	98US-0103615P.
PR	11-DEC-1998;	98US-0111799P.
PR	14-DEC-1998;	98US-0112159P.
PR	31-DEC-1998;	98US-0114415P.
PR	10-FEB-1999;	99US-00248059.
PR	06-APR-1999;	99US-00287150.
PR	13-MAY-1999;	99US-00311021.
XX		
PA	(GEMY) GENETICS INST INC.	

Wong GG, Clark HF, Fechtel K, Agostino MJ;
PI
XX
XX
DR WPI; 2000-053095/04.
DR P-PSDB; AAY73483.
XX
XX
PT Novel polynucleotides and proteins having biological activities which
PT make them suitable for treating, preventing or ameliorating medical
PT conditions in humans or animals.
XX

Claim 196; Page 699-700; 730pp; English.

The present invention describes human secreted proteins encoded by polynucleotides obtained from adult testes, foetal brain, adult brain, brain (foetal and adult), foetal kidney, adult spleen, and adult thymus cDNA libraries. The polynucleotides and proteins are predicted to have biological activities which would make them suitable for treating, preventing or ameliorating medical conditions in humans and animals. Suggested activities include nutritional activity, cytokine and cell proliferation/differentiation activity, immune stimulating (e.g. as vaccines) or suppressing activity, haematopoiesis regulating activity, tissue growth activity, activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, receptor/ligand activity, anti-inflammatory activity, cadherin/tumour invasion suppressor activity, and tumour inhibition activity. The polynucleotides are also stated to be useful for gene therapy. Therapeutic compositions are also presently valuable for veterinary applications. AA252475 to AA252581 encode human secreted proteins, and AA773390 to AA773500 represent human secreted proteins, given in the present invention

Sequence 3116 BP; 1062 A; 444 C; 526 G; 1084 T; 0 U; 0 Other

Query Match	2.9%;	Score 66;	DB 3;	Length 3116;
Best Local Similarity	78.8%;	Pred. No. 0.00032;		
Matches	78;	Conservative 0;	Mismatches 21;	Indels 0; Gaps 0;
Qy	2144	TTTATCTTATTAATAAAATGTTGGTCTCCACACACTGNCCTCCAAAAA	AAAAAAAAAAAAAAAA	2203
Db	2986	TTTTCTCAAGAATAAAAAAATGTTCTTGCCCTTGATCTACTGCAAAAA	AAAAAAAAAAAAAAAA	3045
Qy	2204	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	AAAAAAAA	2242
Db	3046	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	AAAAAAAA	3084

RESULT 1046
ADQ22371
ID ADQ22371 standard; DNA; 4824 BP.
XX
XX
AC AC
ADQ22371;
XX
DT 26-AUG-2004 (first entry)
XX
XX
DE Human soft tissue sarcoma-upregulated DNA - SEQ ID 5191.
XX
XX
KW soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human;
KW db.
XX
XX
OS Homo sapiens.
XX
XX
PN WC2004048938-A2.
XX
XX
10-JUN-2004.
XX
XX
26-NOV-2003; 2003WO-US038193.
PF
PF
XX
XX
26-NOV-2002; 2002US-0429739P.
PR
XX
XX
(PROT-) PROTEIN DESIGN LABS INC.
PA
XX
XX
Aziz N, Ginsburg WM, Zlotnik A;
PI
XX
XX
WPI: 2004-441208/41.
DR

PT Early detection of soft tissue sarcoma comprises determining expression
PT of a gene in a first soft tissue sample and a normal soft tissue sample
PT and comparing the gene expression, also useful in treating soft tissue
XX sarcoma.
XX
PS Example 2; SEQ ID NO 5191; 210pp; English.
PS
XX
XX The invention relates to a novel method for detecting soft tissue sarcoma
CC which comprises obtaining a first soft tissue sample from an individual
CC

XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
PA
XX
XX
XX Lee J, Lillie J;
XX
XX WPI; 2001-611502/70.
DR
XX
XX Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
PT cancer cells as compared to their normal non-cancerous ovarian cells are
PT used to characterize stage, grade, histological type of ovarian cancer.
XX
XX Disclosure; SEQ ID NO 11292; 106pp; English.
PS
XX
XX The invention relates to nucleic acid markers which are overexpressed in
CC ovarian cancer cells as compared to their expression in normal (i.e. non-
CC cancerous) ovarian cells. The invention also relates to polypeptides
CC encoded by the markers, antibodies that selectively bind to the
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk
CC of developing ovarian cancer involving inhibiting expression of a gene
CC corresponding to a marker of the invention and a method of treating a

XX
----- (CONT.)

PA (MILL-) N

PA (MILL-) N

PI Lee J, Lillie J;
 XX WPI; 2001-611502/70.
 XX
 PT Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
 PT cancer cells as compared to their normal non-cancerous ovarian cells are
 PT used to characterize stage, grade, histological type of ovarian cancer.
 XX
 XX
 XX Disclosure; SEQ ID NO 5000; 106pp; English.
 XX
 CC The invention relates to nucleic acid markers which are overexpressed in
 CC ovarian cancer cells as compared to their expression in normal (i.e. non-
 CC cancerous) ovarian cells. The invention also relates to polypeptides
 CC encoded by the markers, antibodies that selectively bind to the
 CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk
 CC of developing ovarian cancer involving inhibiting expression of a gene
 CC corresponding to a marker of the invention and a method of treating a
 CC patient afflicted with ovarian cancer comprising providing to cells of
 CC the patient an antisense oligonucleotide complementary to a marker of the
 CC invention. The markers are useful for assessing if a patient is afflicted
 CC with ovarian cancer, which involves comparing the level of expression of
 CC a marker in a patient sample and a normal level of expression of the
 CC marker in a control non-ovarian cancer sample. A difference between the
 CC expression levels indicates ovarian cancer. The level of expression of a
 CC marker corresponds to a secreted protein or to a transcribed
 CC polynucleotide or its portion. The level of expression of the marker is
 CC assessed by detecting the presence in the sample, a protein or protein
 CC fragment corresponding to the marker. The presence of protein or protein
 CC fragment is detected using an antibody that specifically binds with the
 CC protein or protein fragment. Alternatively, the level of expression of
 CC the marker is assessed by detecting the presence of a transcribed
 CC polynucleotide which anneals with the marker or anneals with a portion of
 CC the polynucleotide comprising the marker, under stringent conditions. The
 CC marker is also used for monitoring the progression of ovarian cancer in a
 CC patient which involves detecting expression of the marker in a patient
 CC sample at a first point in time, repeating the method at a subsequent
 CC time and comparing the level of expression. The method is carried out
 CC using an ovarian tissue sample. A composition comprising a marker,
 CC polypeptide or antibody of the invention is used to treat ovarian cancer.
 CC This sequence represents a human ovarian cancer DNA marker of the
 CC invention.
 XX
 SQ Sequence 216 BP; 56 A; 14 C; 18 G; 105 T; 0 U; 23 Other;
 Query Match 2.9%; Score 65.8; DB 5; Length 216;
 Best Local Similarity 56.1%; Pred. No. 0.00015;
 Matches 97; Conservative 0; Mismatches 76; Indels 0; Gaps 0;
 Qy 2070 TTCTAGTCTCTCAAGTCTCTGTGACATATCATATTCATCCATGATCGCTTTGGTT 2129
 Db 214 TTTTCTTCTTAAATAAANNCNNCNAATAATAAANNCCTTCGNTNATTTTNNATN 155
 Qy 2130 TACCACCTCTTCTCTTTATCTATTATAAATAATGTTGTTCTCCACCTGCTCCCAA 2189
 Db 154 NAAGTTTCTTTTNTTATTCNANTNAAATAATTTTTTTTNTTNTTNTTAAAAA 95
 Qy 2190 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2242
 Db 94 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 42
 RESULT 1049
 AAI83087
 ID AAI83087 standard; cDNA; 391 BP.
 XX
 AC AAI83087;
 XX
 XX 06-NOV-2001 (first entry)
 DT
 XX Human polynucleotide SEQ ID NO 3147.
 XX
 XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
 XX
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 XX nervous system disorders; arthritis; inflammation; ss.
 OS Homo sapiens.
 XX WO200164835-A2.

KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 KW nervous system disorders; arthritis; inflammation; ss.
 XX Homo sapiens.
 XX WO200164835-A2.
 PN
 XX 07-SEP-2001.
 PD
 XX 26-FEB-2001; 2001WO-US004927.
 PF
 XX 28-FEB-2000; 2000US-00515126.
 PR
 XX 18-MAY-2000; 2000US-00577409.
 PR
 XX (HYSE-) HYSEQ INC.
 PA
 XX Tang YT, Liu C, Drmanac RT;
 PI
 XX WPI; 2001-514838/56.
 DR
 XX P-PSDB; AAO03156.
 DR
 XX Isolated nucleic acids and polypeptides, useful for preventing diagnosing
 PT and treating e.g. leukemia, inflammation and immune disorders.
 PT
 XX Claim 1; SEQ ID NO 3147; 1399pp + Sequence Listing; English.
 PS
 XX The invention relates to human polynucleotides (AAI79941-AAI93841) and
 CC the encoded proteins (AAO00010-AAO13910) that exhibit activity relating to
 CC cytokine, cell proliferation or cell differentiation or which may induce
 CC production of other cytokines in other cell populations. The
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
 CC peptide therapy. The polypeptides have various cytokine-like activities,
 CC e.g. stem cell growth factor activity, haematopoiesis regulating
 CC activity, tissue growth factor activity, immunomodulatory activity and
 CC activin/inhibin activity and may be useful in the diagnosis and/or
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
 CC inflammation. Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 391 BP; 178 A; 69 C; 59 G; 85 T; 0 U; 0 Other;
 Query Match 2.9%; Score 65.8; DB 4; Length 391;
 Best Local Similarity 84.9%; Pred. No. 0.00019;
 Matches 73; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
 Qy 2155 AATAAAAATGTTGTTCTCCACCTGCTCCCAAAAAAATAAATAAATAAATAA 2214
 Db 188 AAAAAAATTTTTTTTTTCCCTCCCTAAAAAATAAATAAATAAATAAATAA 247
 Qy 2215 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2240
 Db 248 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 273
 RESULT 1050
 AAI85290
 ID AAI85290 standard; cDNA; 398 BP.
 XX
 AC AAI85290;
 XX
 XX 06-NOV-2001 (first entry)
 DT
 XX Human polynucleotide SEQ ID NO 5350.
 XX
 XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 XX nervous system disorders; arthritis; inflammation; ss.
 XX Homo sapiens.
 OS
 XX WO200164835-A2.
 PN


```
XX
DR WPI; 2001-611502/70.
XX
PT Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
PT cancer cells as compared to their normal non-cancerous ovarian cells are
PT used to characterize stage, grade, histological type of ovarian cancer.
XX
PS Disclosure; SEQ ID NO 11478; 106pp; English.
XX
CC The invention relates to nucleic acid markers which are overexpressed in
CC ovarian cancer cells as compared to their expression in normal (i.e. non-
CC cancerous) ovarian cells. The invention also relates to polypeptides
CC encoded by the markers, antibodies that selectively bind to the
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk
CC of developing ovarian cancer involving inhibiting expression of a gene
CC corresponding to a marker of the invention and a method of treating a
CC patient afflicted with ovarian cancer comprising providing to cells of
CC the patient an antisense oligonucleotide complementary to a marker of the
CC invention. The markers are useful for assessing if a patient is afflicted
CC with ovarian cancer, which involves comparing the level of expression of
CC a marker in a patient sample and a normal level of expression of the
CC marker in a control non-ovarian cancer sample. A difference between the
CC expression levels indicates ovarian cancer. The level of expression of a
CC polynucleotide or its portion. The level of expression of the marker is
CC assessed by detecting the presence in the sample, a protein or protein
CC fragment corresponding to the marker. The presence of protein or protein
CC fragment is detected using an antibody that specifically binds with the
CC protein or protein fragment. Alternatively, the level of expression of
CC the polynucleotide which anneals with the marker or anneals with a portion of
CC the polynucleotide comprising the marker, under stringent conditions. The
CC marker is also used for monitoring the progression of ovarian cancer in a
CC patient which involves detecting expression of the marker in a patient
CC sample at a first point in time, repeating the method at a subsequent
CC time and comparing the level of expression. The method is carried out
CC using an ovarian tissue sample. A composition comprising a marker,
CC polypeptide or antibody of the invention is used to treat ovarian cancer.
CC This sequence represents a human ovarian cancer DNA marker of the
CC invention.
XX
SQ Sequence 608 BP; 178 A; 42 C; 55 G; 211 T; 0 U; 122 Other;
XX
Query Match 2.9%; Score 65.8; DB 5; Length 608;
Best Local Similarity 68.3%; Pred. No. 0.00021;
Matches 82; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
XX
QY 2123 TTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTGGTCTCCACACTGNC 2182
Db 214 TTTTCCCCCNAATTTTTTTTTTTTTTTTNAAAAAAAAAANNNNNNTTTNAA 155
XX
QY 2183 TCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 154 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 95
XX
RESULT 1055
ADI72448/c
ID ADI72448 standard; DNA; 608 BP.
XX
AC ADI72448;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human ovarian cancer DNA marker #5190.
XX
KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.
XX
OS Homo sapiens.
XX
FN WO200170979-A2.
XX
PD 27-SEP-2001.
XX
XX
21-MAR-2001; 2001WO-US009126.
XX
21-MAR-2000; 2000US-0191031P.
25-MAY-2000; 2000US-0207124P.
PR 15-JUN-2000; 2000US-0211940P.
PR 07-JUL-2000; 2000US-0216820P.
PR 25-JUL-2000; 2000US-0220661P.
PR 21-DEC-2000; 2000US-0257672P.
XX
(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
Lee J, Lillie J;
PI
WPI; 2001-611502/70.
XX
Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
PT cancer cells as compared to their normal non-cancerous ovarian cells are
PT used to characterize stage, grade, histological type of ovarian cancer.
XX
PS Disclosure; SEQ ID NO 5190; 106pp; English.
XX
CC The invention relates to nucleic acid markers which are overexpressed in
CC ovarian cancer cells as compared to their expression in normal (i.e. non-
CC cancerous) ovarian cells. The invention also relates to polypeptides
CC encoded by the markers, antibodies that selectively bind to the
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk
CC of developing ovarian cancer involving inhibiting expression of a gene
CC corresponding to a marker of the invention and a method of treating a
CC patient afflicted with ovarian cancer comprising providing to cells of
CC the patient an antisense oligonucleotide complementary to a marker of the
CC invention. The markers are useful for assessing if a patient is afflicted
CC with ovarian cancer, which involves comparing the level of expression of
CC a marker in a patient sample and a normal level of expression of the
CC marker in a control non-ovarian cancer sample. A difference between the
CC expression levels indicates ovarian cancer. The level of expression of a
CC polynucleotide or its portion. The level of expression of the marker is
CC assessed by detecting the presence in the sample, a protein or protein
CC fragment corresponding to the marker. The presence of protein or protein
CC fragment is detected using an antibody that specifically binds with the
CC protein or protein fragment. Alternatively, the level of expression of
CC the polynucleotide which anneals with the marker or anneals with a portion of
CC the polynucleotide comprising the marker, under stringent conditions. The
CC marker is also used for monitoring the progression of ovarian cancer in a
CC patient which involves detecting expression of the marker in a patient
CC sample at a first point in time, repeating the method at a subsequent
CC time and comparing the level of expression. The method is carried out
CC using an ovarian tissue sample. A composition comprising a marker,
CC polypeptide or antibody of the invention is used to treat ovarian cancer.
CC This sequence represents a human ovarian cancer DNA marker of the
CC invention.
XX
SQ Sequence 608 BP; 178 A; 42 C; 55 G; 211 T; 0 U; 122 Other;
XX
Query Match 2.9%; Score 65.8; DB 5; Length 608;
Best Local Similarity 68.3%; Pred. No. 0.00021;
Matches 82; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
XX
QY 2123 TTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTGGTCTCCACACTGNC 2182
Db 214 TTTTCCCCCNAATTTTTTTTTTTTTTTTNAAAAAAAAAANNNNNNTTTNAA 155
XX
QY 2183 TCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 154 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 95
XX
RESULT 1056
AAA60768
ID AAA60768 standard; cDNA; 638 BP.
XX
```


AC AAA60768;
 DT 27-OCT-2000 (first entry)
 XX
 DE
 XX
 XX
 XX
 KW SENR; sensory epithelium neuroepitide-like receptor; urotensin II;
 KW diagnosis; G protein-coupled receptor; hypertension; GPR14; hormone;
 KW kidney disease; regulator; central function; circulatory function;
 KW heart function; immune system function; digestive function;
 KW metabolic function; genital function; ss.
 XX
 XX
 OS Sus scrofa.
 XX
 XX WO200032627-A1.
 PN
 XX
 XX 08-JUN-2000.
 PD
 XX
 XX 29-NOV-1999; 99WO-JP006649.
 PF
 XX 30-NOV-1998; 98JP-00338984.
 PR
 XX 04-FEB-1999; 99JP-00026848.
 PR
 XX 26-AUG-1999; 99JP-00239367.
 XX
 XX (TAKE) TAKEDA CHEM IND LTD.
 PA
 XX
 XX Mori M, Abe M, Shimomura Y, Sugo T, Kitada C;
 PI
 XX
 XX WPI; 2000-412287/35.
 DR
 XX
 XX Urotensin peptides which are ligands for sensory epithelium neuroepitide-
 PT like receptor (SENR) for diagnosis and treatment of hypertension.
 PT
 XX
 XX Claim 8; Page 132; 147pp; Japanese.
 PS
 XX
 XX The present invention provides peptides which are ligands for sensory
 CC epithelium neuroepitide-like receptor (SENR), and their amides, esters
 CC and salts. SENR is a G-protein coupled receptor protein (also known as
 CC GPR14), and the peptides which are ligands for it are forms of the
 CC peptide hormone urotensin II. The peptides can be used in the treatment
 CC and diagnosis of hypertension and kidney disease, and the development of
 CC drugs which are regulators of central functions, circulatory functions,
 CC heart functions, immune system functions, digestive functions, metabolic
 CC functions and genital functions. The present sequence represents a
 CC specifically claimed pig SENR ligand nucleotide sequence, from the
 CC present invention
 XX
 XX Sequence 638 BP; 245 A; 144 C; 124 G; 125 T; 0 U; 0 Other;
 SQ
 Query Match 2.9%; Score 65.8; DB 3; Length 638;
 Best Local Similarity 74.5%; Pred. No. 0.00022;
 Matches 82; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
 Qy 2133 CACTCTTTCTTTATCTATTATAAAAAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2192
 Db 499 CTCTGTTTCACTATTATCTGGAATAAACCCTTTGTGTTGGCCAAAAA 558
 Qy 2193 AAAAAA 2242
 Db 559 AAAAAA 608
 Qy 2193 AAAAAA 2242
 Db 559 AAAAAA 608
 RESULT 1057
 ABK50021
 ID ABK50021 standard; cDNA; 638 BP.
 XX
 AC ABK50021;
 AC
 DT 07-OCT-2002 (first entry)
 DT
 XX Pig sensory epithelium neuroepitide-like receptor (SENR) cDNA #1.
 DE
 XX SENR; Sensory epithelium neuroepitide-like receptor; pig; fear;
 KW

attention deficit disorder; narcolepsy; anxiety; depression; insomnia;
 schizophrenia; G protein-coupled; receptor; gene; ss.
 KW
 XX
 OS Sus scrofa.
 XX
 XX WO200214513-A1.
 PN
 XX
 XX 21-FEB-2002.
 PD
 XX
 XX 10-AUG-2001; 2001WO-JP006899.
 PF
 XX
 XX 10-AUG-2000; 2000JP-00247968.
 PR
 XX
 XX (TAKE) TAKEDA CHEM IND LTD.
 PA
 XX
 XX Matsumoto Y, Watanabe T, Takahashi H, Mori M;
 PI
 XX
 XX WPI; 2002-329576/36.
 DR
 XX
 XX Polypeptide GPR12 with ligand activity to sensor epithelium neuroepitide-
 PT like receptor, useful e.g. in treating attention deficit disorder or
 PT narcolepsy, or for screening drug candidates for these indications and
 PT for anxiety.
 XX
 XX Disclosure; Page 269; 290pp; Japanese.
 PS
 XX
 XX This invention relates to an anti-attention deficit disorder or anti-
 CC narcolepsy agent containing a polypeptide with a sequence identical or
 CC substantially similar to a fully defined 12 amino acid sequence given in
 CC the specification, and its amide, ester or their salt. The peptides have
 CC ligand activity to sensory epithelium neuroepitide-like receptor (SENR)
 CC protein. The invention also includes a method for diagnosing attention
 CC deficit disorder, narcolepsy, anxiety, depression, insomnia,
 CC schizophrenia or fear. The polypeptides of the invention, their precursor
 CC proteins and their encoding DNAs are useful in treating attention deficit
 CC disorder or narcolepsy, or for screening drug candidates for these
 CC indications and for anxiety, depression, insomnia, schizophrenia or fear.
 CC They are also useful for gene therapy. The polypeptide is a G protein-
 CC coupled receptor protein, with ligand activity to sensor epithelium
 CC neuroepitide-like receptor. The present sequence represents a pig sensory
 CC endothelium neuroepitide-like receptor cDNA of the invention
 XX
 XX Sequence 638 BP; 245 A; 144 C; 124 G; 125 T; 0 U; 0 Other;
 SQ
 Query Match 2.9%; Score 65.8; DB 6; Length 638;
 Best Local Similarity 74.5%; Pred. No. 0.00022;
 Matches 82; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
 Qy 2133 CACTCTTTCTTTATCTATTATAAAAAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2192
 Db 499 CTCTGTTTCACTATTATCTGGAATAAACCCTTTGTGTTGGCCAAAAA 558
 Qy 2193 AAAAAA 2242
 Db 559 AAAAAA 608
 RESULT 1058
 ADN05332
 ID ADN05332 standard; cDNA; 711 BP.
 XX
 AC ADN05332;
 AC
 DT 01-JUL-2004 (first entry)
 DT
 XX Antipsoriatic cDNA sequence #88.
 DE
 XX ds; gene; antipsoriatic; gene therapy; psoriasis; diagnosis.
 KW
 XX Homo sapiens.
 OS
 XX WO2004028479-A2.
 PN
 XX

PD 08-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030907.
XX
PR 25-SEP-2002; 2002US-0414006P.
XX
PA (GETH) GENENTECH INC.
XX
PI Bodary S, Clark H, Jackman J, Schoenfeld J, Williams PM, Wood WI;
PI Wu TD;
XX
XX WPI; 2004-305105/28.
DR P-PSDB; ADN05332.
DR
XX New PRO nucleic acid or polypeptide, useful for preparing a
PT pharmaceutical composition for diagnosing or treating psoriasis in a
PT mammal.
XX
PS Claim 1; SEQ ID NO 1726; 3069pp; English.
XX
XX The invention relates to novel polynucleotide and polypeptides for
CC treating psoriasis or a sequence having at least 80% identity to the
CC above sequences. The nucleic acid is useful for preparing a composition
CC for diagnosing or treating psoriasis in a mammal. This sequence
CC corresponds to one of the polynucleotides of the invention.
XX
XX Sequence 711 BP; 172 A; 210 C; 215 G; 114 T; 0 U; 0 Other;
SQ
Query Match 2.9%; Score 65.8; DB 12; Length 711;
Best Local Similarity 67.9%; Pred. No. 0.00022;
Matches 91; Conservative 0; Mismatches 43; Indels 0; Gaps 0;
QY 2109 ATCAATGATGCGCTTGGCTTTTACCACCTCTTCTTATTTATTAATAAATGTTGG 2168
Db 572 AACGAGCCCTGCTCTCGACTTCTTCTTAGCTTCATGTGAATAAAGCTATTCTGG 631
QY 2169 TCTCCACCTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2228
Db 632 TCTCTCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 691
QY 2229 AAAAAAATAAAAAA 2242
Db 692 AAAAAAATAAAAAA 705
RESULT 1059
ADQ23192
ID ADQ23192 standard; DNA; 1383 BP.
XX
AC ADQ23192;
XX
DT 26-AUG-2004 (first entry)
XX
DE Human soft tissue sarcoma-upregulated DNA - SEQ ID 6012.
XX
KW soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human;
KW ds.
XX
OS Homo sapiens.
XX
PN WO2004048938-A2.
XX
PD 10-JUN-2004.
XX
PF 26-NOV-2003; 2003WO-US038193.
XX
PR 26-NOV-2002; 2002US-0429739P.
XX
PA (PROT-) PROTEIN DESIGN LABS INC.
XX
XX Aziz N, Ginsburg WM, Zlotnik A;
PI WPI; 2004-441208/41.
DR

XX
PT Early detection of soft tissue sarcoma comprises determining expression
PT of a gene in a first soft tissue sample and a normal soft tissue sample
PT and comparing the gene expression, also useful in treating soft tissue
PT sarcoma.
XX
PS Example 2; SEQ ID NO 6012; 210pp; English.
XX
CC The invention relates to a novel method for detecting soft tissue sarcoma
CC which comprises obtaining a first soft tissue sample from an individual
CC and a normal soft tissue sample from the same or different individual,
CC determining the expression of a gene in both samples and comparing the
CC expression of the gene in both soft tissue samples, where a higher level
CC of protein expression in the first soft tissue sample indicates the
CC presence of soft tissue sarcoma. The method of the invention has
CC cytostatic applications and may be useful for detecting soft tissue
CC sarcoma, possibly via gene therapy or vaccine production. The nucleic
CC acid sequences may be useful in diagnostic and screening applications.
CC The current sequence is that of a human soft tissue sarcoma-upregulated
CC DNA of the invention. The current sequence is not shown within the
CC specification per se but was submitted in CD format by the inventor.
XX
SQ Sequence 1383 BP; 357 A; 253 C; 528 G; 223 T; 0 U; 22 Other;
Query Match 2.9%; Score 65.8; DB 12; Length 1383;
Best Local Similarity 77.5%; Pred. No. 0.00028;
Matches 79; Conservative 0; Mismatches 23; Indels 0; Gaps 0;
QY 2141 CTTTATCTTATTATAAATAATGTTGCTCTCCACCTGCTCCCAAAAAAATAAAAAA 2200
Db 1225 CCGTGACCTCAATACATAAATGATCCCTCCCAAAAAAATAAAAAAATAAAAAA 1284
QY 2201 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
Db 1285 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1326
RESULT 1060
ADC38959
ID ADC38959 standard; cDNA; 1475 BP.
XX
AC ADC38959;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding a secreted protein #104.
XX
KW ss; gene; immune disorder; severe combined immunodeficiency; SCID;
KW autoimmune disorder; multiple sclerosis; systemic lupus erythematosus;
KW rheumatoid arthritis; allergic reaction; asthma; myeloid cell deficiency;
KW lymphoid cell deficiency; osteoporosis; osteoarthritis;
KW peripheral nervous system disease; peripheral neuropathy;
KW Alzheimer's disease; Parkinson's disease; coagulation disorder;
KW inflammatory disease; systemic inflammatory response syndrome; SIRS;
KW hyperaemia-reperfusion injury; Crohn's disease; anaphylaxis;
KW hypersensitivity; regeneration; neural cell proliferation; fertility;
KW tumour; chemokine; human; secreted protein.
XX
OS Homo sapiens.
XX
PN US2002193567-A1.
XX
PD 19-DEC-2002.
XX
PF 02-APR-2002; 2002US-00114893.
XX
PR 11-AUG-1995; 95US-00514014.
PR 05-APR-1996; 96US-00628364.
PR 07-APR-1996; 96US-00635311.
PR 17-JUN-1996; 96US-00659224.
PR 17-JUN-1996; 96US-00664596.
PR 09-JUL-1996; 96US-00677231.
PR 26-JUL-1996; 96US-00686878.

PR 23-AUG-1996; 96US-00701819.
 PR 27-SEP-1996; 96US-00721488.
 PR 27-SEP-1996; 96US-00721798.
 PR 27-SEP-1996; 96US-00721923.
 PR 27-SEP-1996; 96US-00721926.
 PR 25-OCT-1996; 96US-00738367.
 PR 30-OCT-1996; 96US-00739775.
 PR 13-JAN-1997; 97US-00783395.
 PR 10-APR-1997; 97US-00833823.
 PR 02-JUN-1997; 97US-00867677.
 PR 05-SEP-1997; 97US-00924838.
 PR 06-OCT-1999; 99US-00413232.
 XX (GENY) GENETICS INST INC.
 XX
 PI Jacobs K, McCoey JM, Lavallie ER, Collins-Racie LA, Evans C;
 PI Merberg D, Treacy M, Bowman MR, Spaulding V, Carlin-Duckett M;
 PI Kelleher K;
 XX
 DR WPI; 2003-657236/62.
 DR P-PSDB; ADC38960.
 XX
 PT Proteins AZ3021 encoded by clone AZ3021 from human adult colon, and
 PT BDI2716 encoded by clone BDI2716 from human fetal kidney cDNA library,
 PT useful for treating e.g. multiple sclerosis and rheumatoid arthritis.
 XX
 PS Disclosure; SEQ ID NO 317; 412pp; English.
 XX
 CC The invention relates to a protein comprising fully defined AZ302 1
 CC protein or BDI27 1 6 protein. The polynucleotides are useful for
 CC expressing recombinant proteins for analysis and are also useful as
 CC chromosome markers or tags to identify chromosomes or to map related gene
 CC positions. The proteins are useful as amino acid supplement, carbon
 CC source, nitrogen source and carbohydrate source. The proteins are useful
 CC for treating various immune deficiencies and disorders (e.g. severe
 CC combined immunodeficiency (SCID)), autoimmune disorders (e.g. multiple
 CC sclerosis, systemic lupus erythematosus, rheumatoid arthritis), allergic
 CC reactions (e.g. asthma), myeloid or lymphoid cell deficiencies,
 CC osteoporosis or osteoarthritis, peripheral nervous system diseases (e.g.
 CC peripheral neuropathy, Alzheimer's disease, Parkinson's disease),
 CC coagulation disorders, inflammatory diseases (e.g. systemic inflammatory
 CC response syndrome (SIRS), ischaemia-reperfusion injury, Crohn's disease),
 CC anaphylaxis and hypersensitivity. Proteins are also useful for inducing
 CC tumour immunity, for inducing bone, cartilage, tendon, ligament and/or
 CC nerve growth or regeneration, for proliferating neural cells and for
 CC regenerating nerve and brain tissue, for inducing fertility and for
 CC inhibiting tumour growth. Proteins are also useful as chemokine for
 CC mammalian cells (e.g., monocytes, fibroblasts, neutrophils), and also
 CC useful as inhibitors of receptor/ligand interactions. The present
 CC sequence represents cDNA encoding a human secreted protein.
 XX
 SQ Sequence 1475 BP; 481 A; 259 C; 306 G; 427 T; 0 U; 2 Other;
 Query Match 2.9%; Score 65.8; DB 10; Length 1475;
 Best Local Similarity 76.0%; Pred. No. 0.00028;
 Matches 79; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
 OY 2139 TTCTTTTATCTATTATAAATAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2198
 DB 1365 TTATCTTTTCTACATTAATAATATTTTCTCTNNAAAAA 1424
 OY 2199 AAAAAA 2242
 DB 1425 AAAAAA 1468
 RESULT 1061
 ID AAF21664
 XX AAF21664 standard; DNA; 1635 BP.
 AC AAF21664;
 XX
 DT 27-MAR-2001 (first entry)

XX Human breast and ovarian cancer associated antigen gene SEQ ID 51.
 DE
 XX
 KW Human; breast cancer; ovarian cancer; cytostatic; immunosuppressive;
 KW neotropic; neurprotection; antiviral; antiallergic; hepatotropic;
 KW antidiabetic; antiinflammatory; antitumor; vulnary; anticonvulsant;
 KW antibacterial; antifungal; antiparasitic; cardiac; immune disorder;
 KW Addison's disease; allergy; autoimmune haemolytic anaemia;
 KW autoimmune thyroiditis; diabetes mellitus; Crohn's disease;
 KW multiple sclerosis; rheumatoid arthritis; ulcerative colitis;
 KW cardiovascular disorder; wound healing; neurological disease; ds.
 XX
 OS Homo sapiens.
 XX
 FN WO200055173-A1.
 XX
 PD 21-SEP-2000.
 XX
 PF 08-MAR-2000; 2000WO-US005881.
 XX
 PR 12-MAR-1999; 99US-0124270P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Ruben SM;
 XX
 DR WPI; 2000-611515/58.
 DR P-PSDB; AAB58761.
 XX
 PT New human breast and ovarian cancer associated gene sequences and the
 PT polypeptides encoded by these genes, useful in the prevention, treatment
 PT and diagnosis of cancer, immune disorders, cardiovascular disorders and
 PT neurological diseases.
 XX
 PS Claim 1; Page 517-518; 1299pp; English.
 XX
 CC Sequences AAF21614 - AAF22031 represent DNA sequences encoding human
 CC proteins AAB58711 - AAB59128. The DNA and protein sequences are
 CC associated with breast and ovarian cancer. Included in the invention are
 CC sequences AAF22032 - AAF22040 and AAB59129 which are used in the
 CC isolation and characterisation of the DNA and protein sequences of the
 CC invention. The breast and ovarian cancer associated DNA, protein, agonist
 CC or antagonist sequences exhibit cytostatic; immunosuppressive; neotropic;
 CC neuroprotective; antiviral; antiallergic; hepatotropic; antidiabetic;
 CC antifungal; antiparasitic and vulnary; anticonvulsant; antibacterial;
 CC protein sequences are used in the diagnosis of cancer, particularly
 CC breast and ovarian cancer. The nucleic acid sequences, proteins, agonists
 CC and agonists may also be used in the diagnosis, prevention and treatment
 CC of immune disorders e.g. Addison's disease, allergies, autoimmune
 CC haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
 CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis;
 CC cardiovascular disorders such as myocardial ischaemia; wound healing;
 CC neurological diseases such as cerebral anoxia and epilepsy; and
 CC infectious diseases
 XX
 SQ Sequence 1635 BP; 404 A; 485 C; 486 G; 256 T; 0 U; 4 Other;
 Query Match 2.9%; Score 65.8; DB 3; Length 1635;
 Best Local Similarity 72.0%; Pred. No. 0.00029;
 Matches 85; Conservative 0; Mismatches 33; Indels 0; Gaps 0;
 OY 2125 TGCTTTTACCCTCTTTCTTTTATTTATTAATAAATGTTGGTCTCCACCACTGCTC 2184
 DB 1482 TCCCTTCCCATGCTTCTTGGCTGATGACATTAAGCTTGTTCAGTCAGTAAAAA 1541
 OY 2185 CCRAAAAAA 2242
 DB 1542 AAAAAA 1599
 RESULT 1062
 ID AAA77670

PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 21-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828566.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-466355/44.
 DR P-PSDB; ABO25091.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 PT
 XX
 PS Claim 2; Fig 501; 659pp; English.
 XX
 CC The invention relates to an isolated nucleic acid comprising at least 80%
 CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
 CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
 CC extracellular domain (with or without its associated signal peptide),
 CC which comprises any of the 275 120-850 residue amino acid sequences,
 CC given in the specification; (b) comprising any of the 275 300-3500
 CC nucleotide sequences, given in the specification; or (c) comprising the
 CC full-length coding sequence of the nucleotide sequences given in the
 CC specification, or of the DNA deposited under any of the American Type
 CC Culture Collection (ATCC) Accession Numbers listed in the specification.
 CC Also included are a vector comprising the novel nucleic acid, a host cell
 CC comprising the vector, producing a PRO polypeptide, the isolated PRO
 CC polypeptides detailed above, a chimaeric molecule comprising the PRO
 CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
 CC antibody, detecting a PRO polypeptide in a sample suspected of containing
 CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a
 CC PRO polypeptide, modulating at least one biological activity of a cell
 CC expressing a PRO polypeptide, stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
 CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
 CC modulating the uptake of glucose or FFA by skeletal muscle cells or
 CC adipocyte cells, stimulating the proliferation or differentiation of
 CC chondrocyte cells (or proliferation of or gene expression in pericyte
 CC cells), stimulating the proliferation of inner ear utricular supporting
 CC cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
 CC binding of A-1-lymphocyte cells, or of endothelial cells), inhibiting the
 CC cells, detecting the presence of a tumour in a mammal and an
 CC oligonucleotide probe derived from any of the nucleotide sequences given
 CC in the specification. The polynucleotide is useful in molecular biology,
 CC including uses as hybridisation probes, in chromosome and gene mapping,
 CC in generating antisense RNA and DNA, and in gene therapy. The
 CC polynucleotide may also be used in preparing PRO polypeptides by
 CC recombinant techniques, and in generating either transgenic animals or
 CC knock-out animals which, in turn, are useful in the development and
 CC screening of therapeutically useful reagents. The PRO polypeptide or the
 CC antibody is used in preparing a medicament for treating a condition
 CC responsive to the polypeptide or antibody, such as tumours, and in
 CC various diagnostic assays. The present sequence encodes a PRO polypeptide
 XX
 SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.8; DB 8; Length 1883;
 Best Local Similarity 62.0%; Pred. No. 0.0003;
 Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;